		NO.HFW-H(DRUGS)279/0 ILY WELFARE DEPARTMENT,H	IIMACI			
	having license No. FORM25:M	ts Approved to be Manufactured by INB/07/642 AND MB/07/643 28:S-MB/07/643 For the per ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	iod from 01.	n Blotec 12.2022 to 30.	n PVt. 11.2027	Lta.
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
1	Thiamine HCl, Riboflavin,	Each Hard Gelatin capsule contains:-				
	Pyridoxine HCl,	Thiamine HCl	IP	10	mg	
	Niacinamide, Folic Acid,	Riboflavin	IP	10	mg	
	Cyanocobalamin,	Pyridoxine HCl	IP	3	mg	
	Calcium Pantothenate &	Niacinamide	IP	50	mg	9/21/2015
	Vitamin C Capsule	Folic Acid	IP	1000	mcg	5/21/2015
		Cyanocobalamin	IP	5	mcg	
		Calcium Pantothenate	IP	12.5	mg	
		Vitamin C	IP	150	mg	
		Approved Colour used in Capsule shell				
2	Vitamin A, Vitamin E,	Each hard gelatin Capsule contains :-				
	Vitamin C, Zinc Oxide	Vitamin A (as acetate)	IP	5000	IU	
	Cupric Oxide & sodium	Vitamin E (as acetate)	IP	30	mg	
	Selenate Capsule	Ascorbic Acid	IP	60	mg	
	-	Cupric Oxide				
		eq. to Copper		2	mg	0/21/2015
		Sodium Selenate				9/21/2015
		eq to Selenium		40	mcg	
		Zinc Oxide	IP			
		Eq. to Zinc		40	mg	
		Excipients		q.s		
		Approved Colour used in Capsule shell				
3	Sildenafil Citrate	Each Filmcoated tablet contains:-		I		
3	Tablets IP	sildenafil Citrate	IP			
	Tablets IF	Eq. to sildenafil	п	50	mg	9/21/2015
		Excipients			mg	9/21/2015
		Approved colour used in Coating		q.s		
		Approved colour used in coaulig				
	Betamethasone Valerate,	Each Gram Contains				
	Gentamycin Sulphate,	Betamethasone Valerate	IP	0.61	mg	
	Tolnaftate &	Gentamycin Sulphate	IP			
	Iodochlorohydroxyquinoline	eq. to Gentamycin		1	mg	9/21/2015
	Cream	Tolnaftate	IP	10	mg	,,_,,_,,
		Iodochlorohydroxyquinoline	IP	10	mg	
		Chlorocresol(As Preservative)	IP	1	mg	
		In Cream base		q.s		
5	Folic Acid Tablets IP	Each Uncoated tablet contains:-				
		Folic Acid	IP	5	mg	0.01.001-
		Excipients		q.s	-0	9/21/2015
		Approved colour used in Tablets		1		
6	L-Ornithine - L-Aspartate &	Each Enteric coated tablet contains:-		150	$\left - \right $	
	Pancreatin Tablets	L-Ornithine - L-Aspartate	m	150	mg	-
		Pancreatin	IP	100	mg	
		Excipients		q.s		
		Approved colour used in Coating				

	List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/ LY WELFARE DEPARTMENT, ts Approved to be Manufactured NB/07/642 AND MB/07/643 28:S-MB/07/643 For the p	HIMACI by : Boffi period from 01.	n Biotecl	h Pvt.	
S. No.	PACK SI DOSAGE FORM, GENERIC NAME/BRAND NAME	ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
7	Doxylamine succinate,	Each Filmcoated tablet contains:-				ONDATED
	Pyridoxine HCl &	Doxylamine succinate	USP	10	mg	
	Folic Acid Tablets	Pyridoxine HCl	IP	10	mg	0/01/0015
		Folic Acid	IP	5	mg	9/21/2015
		Excipients		q.s		
		Approved colour used in Coating				
8	Diacerin	Each hard geletin capsule contains:-				
0	Capsule IP	Diacerin	IP	50	mσ	
	Capsule II	Excipients	- 11		mg	9/21/2015
		Approved colour used in empty capsule	shell	qs		
				1		
9	Hydroxyzine Hydrochloride	Each film coated tablet contains:				
	Tablets IP	Hydroxyzine Hydrochloride	IP	25	mg	9/21/2015
		Excipients			q.s.	9/21/2015
		Colour: Approved colour used				
10	Cataliani da Stanara	Catalantia	ID	10/	(
10	Cetrimide Shampoo	Cetrimide	IP	1%	w/v	
		Medicated Shampoo Foam base Perfume		qs		9/21/2015
	Medicated Shampoo Foam base FOR VETERINARY USE ONLY	Periume		q.s		
11	Clobetasol Propionate,	Clobetasol Propionate	BP	0.025%	w/v	
	Ofloxacin,	Ofloxacin	IP	0.1%	w/v	
	Miconazole Nitrate &	Miconazole Nitrate	IP	2%	w/v	9/21/2015
	Zinc Sulphate Lotion	Zinc Sulphate	IP	3%	w/v	
	FOR VETERINARY USE ONLY	In Lotion Base		q.s		
12	Permethrin & Coal Tar	Permethrin		1%	w/v	
	Shampoo	Coal Tar IP"66"	IP	0.5%	w/v	9/21/2015
	Medicated Shampoo Foam base	Medicated Shampoo Foam base		qs		
	FOR VETERINARY USE ONLY	Perfume		q.s		
13	Ketoconazole &	Ketoconazole	IP	2%	w/v	
	Chlorhexidine Gluconate	Chlorhexidine Gluconate Solution	IP	4%	w/v	
	Shampoo	Eq. to Chlorhexidine Gluconate		0.8%	W/V	0/21/2015
		Medicated Shampoo Foam base		qs		9/21/2015
		Perfume		q.s		
	FOR VETERINARY USE ONLY	Approved Colour used				
14	Miconazole Nitrate &	Missenarala Niturta	TD	20/		
14	Miconazole Nitrate & Chlorhexidine Gluconate	Miconazole Nitrate Chlorhexidine Gluconate Solution	IP ID	2%	W/V	
			IP	2%	W/V	
	Shampoo	Eq. to Chlorhexidine Gluconate Medicated Shampoo Foam base		0.4%	w/v	9/21/2015
		Perfume		qs		
	FOR VETERINARY USE ONLY	Approved Colour used		q.s		
				1		
15	Cypermethrin Shampoo	Cypermethrin		1%	w/v	
		Medicated Shampoo Foam base		qs		9/21/2015
		Perfume			1	

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/0' ILY WELFARE DEPARTMENT,H ts Approved to be Manufactured by INB/07/642 AND MB/07/643 28:S-MB/07/643 For the per ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	IMACI y:Boffi iod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
16	Diclofenac Gel BP	Composition Diclofenac Diethylamine eq. to Diclofenac Sodium Preservative:-	BP	1.16% 1%	w/w w/w	9/21/2015
		Methyl Paraben Sodium Propyl Paraben Sodium In Gel base	IP IP	0.15% 0.1% q.s	w/w w/w	<i>)</i> /21/2013
17	Aceclofenac Tablets IP	Each Filmcoated Tablets Contains:- Aceclofenac Excipients Approved Colour used in Coating	IP	100 q.s	mg	9/21/2015
18	Aceclofenac Sustained Release Tablets	Each Sustained Release Film coated table Aceclofenac Excipients Approved colour used in Tablets	t contains IP	200 q.s	mg	9/21/2015
19	Ginseng Powder, Vitamin A, Vitamin E , Vitamin D3, Thiamine HCl, Riboflavin, Pyridoxine HCl, Niacinamide, Folic Acid, Cyanocobalamin, Calcium Pantothenate, Vitamin C, Zinc Sulphate, Manganese Sulphate , Dibasic calcium Phosphate, Dried Ferrous Sulphate, Light magnesium Oxide & Copper sulphate Capsule	Each Hard Gelatin capsule contains:- Ginseng Powder Vitamin A(as Acetate) Vitamin E (as Acetate) Vitamin D3 Thiamine Mononitrate Riboflavin Pyridoxine HCl Niacinamide Folic Acid Cyanocobalamin Calcium Pantothenate Vitamin C Zinc Sulphate Manganese Sulphate Dried Ferrous Sulphate Light magnesium Oxide Copper sulphate(anhydrous) Dibasic calcium Phosphate Approved Colour used in Capsule shell	JP IP IP IP IP IP IP IP IP IP IP IP IP IP	$\begin{array}{c} 200\\ 2500\\ 10\\ 200\\ 2\\ 1.5\\ 25\\ 0.1\\ 1\\ 5\\ 50\\ 1\\ 2\\ 30\\ 10\\ 1\\ 25\\ \end{array}$	mg IU mg mg	9/21/2015
20	Clobetasol Propionate & Salicylic Acid Lotion	Clobetasol Propionate Salicylic Acid In a Lotion Base	IP IP	0.05%	w/v w/v	9/21/2015
21	Pantoprazole Sodium & Itopride HCl Capsule	Each Hard Gelatin capsule contains:- Pantoprazole Sodium eq. to Pantoprazole (As Enteric Coated Pellets) Itopride HCl (As Sustained Release Pellets) Excipients Approved Colour used in Capsule shell		40 150 qs	mg mg	9/21/2015
22	Paracetamol Tablets IP	Each Uncoated tablet contains:- Paracetamol Excipients Approved colour used in tablets	IP	125 q.s	mg	9/21/2015

NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945

	S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
--	--------	---	-------------	-------------------	----------	------	----------------------

23	Calamine,	Calamine	IP	8%	w/v	
	Diphenhydramine HCl &	Diphenhydramine HCl	IP	1%	w/v	9/21/2015
	Camphor Lotion	Camphor	BP	0.1%	w/v	9/21/2015
		In a Lotion Base		q.s		
24	Ivermectin Tablets IP	Each Uncoated tablet contains:-				
		Ivermectin	IP	6	mg	9/21/2015
		Excipients		q.s		9/21/2013
		Approved colour used in Tablets				
25	Ivermectin Tablets IP	Each Uncoated tablet contains:-				
		Ivermectin	IP	12	mg	9/21/2015
		Excipients		q.s		9/21/2015
		Approved colour used in Tablets				
26	Cefixime Tablets	Each film coated tablet contains:				
	IP	Cefixime	IP			
		Eq. to anhydrous Cefixime		200	mg	9/21/2015
		Excipients			q.s.	
		Colour: Approved colour used				
27	Cetrimide Cream IP	Cetrimide	IP	1%	W/W	
		Chlorocresol(As a Preservative)	IP	0.1%	w/w	0/01/0015
		Cream Base		q.s		9/21/2015
28	Cefixime Dispersible	Each Uncoated Dispersible tablet Contain	is:-			
	Tablets IP	Cefixime	IP			
		Eq.to Anhydrous Cefixime		100	mg	9/21/2015
		Excipients		q.s		
		Approved colour used in Tablets				

29	Thiamine HCl, Riboflavin,	Each Hard Gelatin capsule contains:-				
2)	Pyridoxine HCl,	Thiamine HCl	IP	10	mg	
					U	
	Niacinamide, Folic Acid,	Riboflavin	IP	10	mg	
	Cyanocobalamin,	Pyridoxine HCl	IP	3	mg	
	Calcium Pantothenate,	Niacinamide	IP	50	mg	
	Zinc Sulphate,	Folic Acid	IP	1000	mcg	
	Manganese Sulphate &	Cyanocobalamin	IP	5	mcg	9/21/2015
	Dibasic calcium Phosphate	Calcium Pantothenate	IP	12.5	mg	9/21/2013
	Capsule	Zinc Sulphate	IP	20	mg	
		Manganese Sulphate	BP	10	mg	
		Dibasic calcium Phosphate	IP			
		eq. to calcium &		93.6	mg	
		eq. to Phosphorus		72.8	mg	
		Approved Colour used in Capsule shell				

30	Lignocaine Gel IP	Composition				
		Lignocaine HCl	IP			9/21/2015
		Eq. to. Anhydrous Lignocaine Hcl		2%	w/w	9/21/2013
		In Gel base		q.s		

31	Enrofloxacin Tablets	Each Uncoated tablet contains:-				
		Enrofloxacin	IP	50	mg	9/21/2015
	(FOR ANIMAL USE ONLY)	Excipients		q.s		9/21/2013
	(NOT FOR HUMAN USE)	Approved colour used in Tablets				

	List of Retention Produc	NO.HFW-H(DRUGS)279/ ILY WELFARE DEPARTMENT ts Approved to be Manufactured INB/07/642 AND MB/07/643 28:S-MB/07/643 For the	,HIMACI by : Boffi	n Biotecl	h Pvt.	
	0	ZE AS PER SCHEDULE-P-1 OF DRUGS & COSME				
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
32	Enrofloxacin Tablets	Each Uncoated tablet contains:-			, ,	
32	Emonoxaem Tablets	Enrofloxacin	IP	150	ma	
	(FOR ANIMAL USE ONLY)		Ir		mg	9/21/2015
	(FOR ANIMAL USE ONLY) (NOT FOR HUMAN USE)	Excipients Approved colour used in Tablets		q.s		
		**		L		
33	Praziquantel,	Each Uncoated tablet contains:-				
	Pyrantel Embonate &	Praziquantel	IP	50	mg	
	Febantel Tablets	Pyrantel Embonate	IP	144	mg	9/21/2015
		Febantel	BP	150	mg	9/21/2015
	(FOR ANIMAL USE ONLY)	Excipients		q.s		
	(NOT FOR HUMAN USE)	Approved colour used in Tablets				<u> </u>
34	Diclofenac Diethylamine,	Composition			· · · ·	
54	Menthol, Linseed Oil,	Diclofenac Diethylamine	BP	1.16%	w/w	
	Methyl salicylate &	Eq. to Diclofenac Sodium	Dr	1.10%	w/w w/w	
	Benzyl Alcohol Oil	1	IP	1%		
	Benzyi Alconol Oli	Methyl salicylate	IP IP	5%	w/w w/w	9/21/2015
		Menthol				9/21/2015
		Linseed Oil	BP	3%	w/w	
		Benzyl alcohol	IP	1.0%	w/w	
		(As a Preservative) In Oil base		q.s		
		in On base		4 .5		
35	Sulfaguanidine Tablets	Each Uncoated Tablet Contains:-				
		Sulfaguanidine	BP	500	mg	9/21/2015
		Excipients		qs		9/21/2013
		Approved colour used in Tablets				
26	Cafining Dispersible	Each Un-Coated Dispersible tablet Con	ntoino		<u> </u>	
36	Cefixime Dispersible Tablets IP	^				
	Tablets IP	Cefixime	IP	200		0/01/0015
		Eq.to Anhydrous Cefixime		200	mg	9/21/2015
		Excipients		q.s		
		Approved colour used in Tablets				
37	Methylcobalamin,	Each Filmcoated Tablet Contains:-				
	Vit.B1, Vit.B6	Methylcobalamin	IP	500	mcg	
	Folic Acid, Nicotinamide,	Thiamine HCl	IP	10	mg	
	& Calcium Pantothenate,	Pyridoxine HCl	IP	3	mg	
	Tablets	Folic Acid	IP	1.5	mg	9/21/2015
		Nicotinamide	IP	45	mg	
		Calcium Pantothenate	IP	50	mg	
		Excipients		20	qs	
		Colour : Approved Colour Used			4 5	
38	Sildenafil Citrate	Each Filmcoated tablet contains:-				
	Tablets IP	sildenafil Citrate	IP			
		Eq. to sildenafil		100	mg	9/21/2015
		Excipients		q.s		
		Approved colour used in Coating				

	List of Retention Product	NO.HFW-H(DRUGS)279/0 LY WELFARE DEPARTMENT, ts Approved to be Manufactured by NB/07/642 AND MB/07/643 28:S-MB/07/643 For the per	HIMACI y : Boffi	n Biotecl	h Pvt.	
		ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC				
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
39	Lactic Acid Bacillus,	Each hard geletin capsule contains:-				
	Vitamin B1, Vitamin B2,	Lactic Acid bacillus		1000 lac	sporon ges	
	Vitamin B6,Cynocobalamin,	Riboflavin	IP	10	mg	
	Folic Acid ,Niacinamide,	Pyridoxine Hcl	IP	3	mg	
	Calcium Pantothenate,	Thiamine Hcl	IP	10	mg	
	Vitamin C&ZincSulphate	Cynocobalamin	IP	10	mcg	
	Capsules	Folic Acid	IP	1500	mcg	12/1/2017
	(For Therapeutic Use)	Niacinamide	IP	75	mg	
		Calcium Pantothenate	IP	20	mg	
		Vitamin C	IP	75	mg	
		Zinc Sulphate monohydrate	IP	61.8	mg	
		Excipients		qs		
		Approved colour used in empty capsule s	hell			
40	Indomethacin Capsules IP	Each hard geletin capsule contains:-				
		Indomethacin	IP	25	mg	12/1/2017
		Excipients		q.s		, _, _ • - •
		Approved colour used in empty capsule s	hell			
41	Ferrous Fumarate, Folic Acid,	Each hard geletin capsule contains:-				
41	Vitamin B12,Zinc,Copper &	Ferrous Fumarate	IP	125	ma	
	Manganese Capsules	Folic Acid	IP IP	125	mg	
	Wanganese Capsules	Vitamin B12	IP	5	mg mcg	
		Zinc Sulphate monohydrate	IP	2.5	mg	12/1/2017
		Copper Suphate	IP	2.5	mg	
		Manganese Sulphate	IP	2.5	mg	
		Excipients		qs		
		Approved colour used in empty capsule s	hell			
42	Ferrous Sulphate &	Each hard geletin sustained releasecapsul	e contains	·-		
72	Foilc acid Capsules	Dried Ferrous Sulphate	IP	150	mg	
	i one acia cupsules	(In Time Release Form)		150	mg	
		Folic Acid	IP	500	mcg	12/1/2017
		Excipients		qs	8	
		Approved colour used in empty capsule s	hell	-		
		· · · · ·		·		
43	Ferrous Fumarate, Folic Acid,	Each hard geletin capsule contains:-				
	Vitamin B12,Zinc,Copper&	Ferrous Fumarate	IP	304	mg	
	Manganese Capsules	Eq. to Elemental Iron		100	mg	
		Folic Acid	IP	1.5	mg	
		Vitamin B12	IP	10	mcg	
		Zinc Sulphate monohydrate	IP			12/1/2017
		Eq. to elemental zinc		15	mg	
		Copper Suphate	IP	2.5	mg	
		Manganese Sulphate	IP	2.5	mg	
		Excipients	1 11	qs		
		Approved colour used in empty capsule s	hell		L	
44	Diphenhydramine HCl	Each hard geletin capsule contains:-	1	1		
44	Capsules	Diphenhydramine HCl	IP	25	ma	
	Capsulos	Excipients	щ		mg	12/1/2017
			hall	q.s		
		Approved colour used in empty capsule s	nell			

	NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945									
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED				
45	Gentamycin cream IP	Gentamycin sulphate	IP							
		eq. to Gentamycin Gentamycin Base (1000 units per gm)		0.10%	w/w	12/1/2017				
		Water Miscible Base		q.s						
46	Ciprofloxacin Hcl,	Ciprofloxacin Hcl	IP	4 .5						
	Fluocinolone,	eq to Ciprofloxacin		0.50%	w/w					
	Clotrimazole Cream	Fluocinolone Acetonide	IP	0.025%	w/w					
		Clotrimazole	IP	1.00%	w/w	10/1/0015				
		Preservative:				12/1/2017				
		Sodium Methyl Paraben	IP	0.20%	\mathbf{W}/\mathbf{W}					
		Sodium Propyl Paraben	IP	0.10%	\mathbf{W}/\mathbf{W}					
		Cream Base		q.s						
47	Neomycin Sulphate Cream IP	Neomycin Sulphate	IP	0.50%	w/w					
		(3500 Units Per Gm)				12/1/2017				
		Suitable Cream Base		q.s						
			1	1						
48	Vitamin B1, Vitamin B2,	Each hard geletin capsule contains:-								
	Vitamin B6,Nicotinamide,	Thiamine Hcl	IP	10	mg					
	Folic Acid,	Riboflavin	IP	10	mg					
	Calcium pantothenate,	Pyridoxine Hcl	IP	3	mg					
	Cynocobalamin&L-lysine	Nicotinamide	IP	50	mg	12/1/2017				
	monohydrochloride Capsules	Folic Acid	IP	1000	mcg	12/1/2017				
		Calcium Pantothenate	IP	20	mg					
		L-lysine Monohydrochloride Cynocobalamin	USP IP	150 5	mg					
		Excipients	IP	-	mcg					
		Approved colour used in empty capsule si	hall	qs						
		Approved colour used in empty capsule si	lieli							
49	Nitrofurazone cream USP	Nitrofurazone	USP	0.20%	w/w					
12		Cream base	0.01	q.s	,	12/1/2017				
				4.~						
50	Caliavilia A aid Com	Each Corn Cap is Filled With Ointment								
50	Salicylic Acid Corn Caps	Salicylic Acid	IP	45.00%	w/w	12/1/2017				
	Caps	Ointment Base		45.00%	w/w					
			qs							
51	Salicylic Acid Corn	Each Corn Cap is Filled With Ointment				12/1/2017				
	Caps	Salicylic Acid	IP	50.00%	w/w	12, 1, 2017				
		Ointment Base	qs							
52	Lycopene,	Each Hard Gelatin capsule contains:-								
	Vitamin A,	Lycopene 10%	USP	2	mg					
	Vitamin C,	Vitamin A(as Acetate) powder form	IP	2500	IU					
	Zinc Sulphate &	Vitamin C	IP	50	mg					
	Selenium Capsule	Zinc Sulphate	IP	27.45	mg	12/1/2017				
		Sodium Selenate			-0					
		Eq. to Selenium		70	mcg					
		Excipients	1	qs	0					
		Approved Colour used in Capsule shell	•		•					

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/0 ILY WELFARE DEPARTMENT, ts Approved to be Manufactured by NB/07/642 AND MB/07/643 28:S-MB/07/643 For the per ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	HIMACI y : Boffi riod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
53	Lactobacillus Sporogenes, Fungal Diastase,Papain,	Each hard geletin capsule contains:- Lactobacillus Sporogenes		40x10^6		
	simethicone, Vitamin B1,	Fungal Diastase(1:800)	IP	25	mg	
	Vitamin B2, Vitamin B6	Papain	IP	20	mg	0
	Niacinamide,Folic Acid,	Simethicone	IP	40	mg	
	D-panthenol Capsules	Vitamin B1	IP	1	mg	10/1/2015
		Vitamin B2	IP	2.5	mg	12/1/2017
		Vitamin B6	IP	0.5	mg	
		Niacinamide	IP	15	mg	
		Folic Acid	IP	75	mcg	
		D-panthenol	IP	1	mg	
		Excipients Approved colour used in empty capsule s	hell	qs		
54	Artesunate Tablets	Each Uncoated tablet Contains:-				
54	Artesuliate Tablets	Artesunate	IP	50	ma	
		Excipients	п		mg	12/1/2017
		Approved colour used in Tablets		q.s		
		Approved colour used in Tablets				
55	Piracetam Tablets	Each Film coated Tablet Contains:-	1			
55	r liacetani Tablets	Piracetam	IP	1200	ma	
			IP		mg	12/1/2017
		Excipients Approved colour used in Coating		q.s		
		Approved colour used in Coating				
56	Mintagonina Tablata ID	Each un coated Tablet Contains:-	1			
56	Mirtazapine Tablets IP		IP	7.5		
		Mirtazapine Excipients	IF		mg	12/1/2017
		Approved colour used in Tablet		q.s		
		Approved colour used in Tablet				
57	Mirtazapine Tablets IP	Each un coated Tablet Contains:-	1			
57		Mirtazapine	IP	15	mg	
		Excipients		q.s	mg	12/1/2017
		Approved colour used in Tablet		q .5		
		rippioved colour used in Tublet				
58	Dothiepin Hcl Tablets IP	Each Film coated Tablet Contains:-				
50	2 sunopin nor ruototo n	Dothiepin Hcl	IP	25	mg	
		Excipients		q.s	mg	12/1/2017
		Approved colour used in Coating		4.5		
L	1	rpio rea consul used in couning	L	L	I	
59	Dothiepin Hcl Tablets IP	Each Film coated Tablet Contains:-				
57	2 sanophi noi rubicts n	Dothiepin Hcl	IP	75	mg	
		Excipients		q.s	1116	12/1/2017
		Approved colour used in Coating	1	4.5		
L		rippiorea colour usea in Coaulig	I	L		
60	Haloperidol Tablets IP	Each un coated Tablet Contains:-				
00		Haloperidol	IP	10	mg	
		Excipients			mg	12/1/2017
		Approved colour used in Tablet	1	q.s		
61 Paroxetine sustained Release Each Enteric coated Sustained Release Tablet Contains:-						
01	Tablets IP	Paroxetine Hcl IP				
	1 autors Ir		11'	25	ma	12/1/2017
		Eq. to Paroxetine		-	mg	12/1/2017
		Excipients Approved colour used in Coating		q.s		
L		Approved colour used in Coauling	I	L		

	HEALTH AND FAMI List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/ LY WELFARE DEPARTMENT ts Approved to be Manufactured NB/07/642 AND MB/07/643 28:S-MB/07/643 For the J ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	HIMACI by : Boffi period from 01.	n Biotec	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
62	Escitalopram Oxalate	Each Film coated Tablet Contains:-				
	Tablets IP	Escitalopram Oxalate	IP			
		Eq. to Escitalopram		10	mg	12/1/2017
		Excipients		q.s		
		Approved colour used in Coating				
63	Escitalopram Oxalate	Each Film coated Tablet Contains:-				
	Tablets IP	Escitalopram Oxalate	IP			
		Eq. to Escitalopram		20	mg	12/1/2017
		Excipients		q.s		
		Approved colour used in Coating				-
64	Clobetasol Propionate,	Clobetasol Propionate	IP	0.05%	w/w	
	Gentamycin,miconazole	Gentamycin Sulphate	IP			
	Nitrate Cream	eq. to Gentamycin		0.10%	w/w	12/1/2017
		miconazole Nitrate	IP	2.00%	w/w	
		Cream Base		q.s		
				-		
65	Vitamin B1, Vitamin B2,	Each hard geletin capsule contains:-				
	Vitamin B6,Niacinamide&	Vitamin B1	IP	1	mg	
	Di-Calcium Phosphate	Vitamin B2	IP	1	mg	
	capsules (for prophylatic use)	Vitamin B6	IP	0.65	mg	12/1/2017
		Niacinamide	IP	15	mg	12/1/2017
		Di-calcium Phosphate	IP	50	mg	
		Excipients		q.s		
		Approved colour used in empty capsule	e shell			
66	Nimesulide Tablets	Each un coated Tablet Contains:-		1		
00	(in Betacyclodextrine)Tablets	Nimesulide	BP	200	ma	
	(III Betacyclouextime) rabiets	(in Betacyclodextrine)	DI	200	mg	12/1/2017
		Excipients	-			12/1/2017
		Approved colour used in Tablet		q.s		
		Approved colour used in Tablet				
67	Paroxetine sustained Release	Each Enteric coated Sustained Release Tab	olet Contains	·-		
57	Tablets IP	Paroxetine Hcl	IP			
		Eq. to Paroxetine		12.5	mg	12/1/2017
		Excipients		q.s	mg	
		Approved colour used in Coating		-		
68	Flupentixol & Melitracen	Each Film coated Tablet Contains:-				
	Tablets	Flupentixol Dihydrochloride	BP			
		Eq.to Flupentixol		0.5	mg	
		Melitracen Hcl				12/1/2017
		Eq. to Melitracen		10	mg	
		Excipients		q.s		
		Approved colour used in Coating		4.5		

	List of Retention Product having license No. FORM25:MI	NO.HFW-H(DRUGS)279/0 LY WELFARE DEPARTMENT, J IS Approved to be Manufactured b NB/07/642 AND MB/07/643 28:S-MB/07/643 For the pe ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	HIMACI y : Boffi riod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATEE
69	Vitamin A, Vitamin B1,	Each hard geletin capsule contains:-				
	Vitamin B2, Vitamin B6,	Vitamin A(as Acetate)	IP	5000	IU	
	Vitamin B12, Vitamin C,	Thiamine Hcl	IP	10	mg	
	Vitamin E, Vitamin D3,	Riboflavin	IP	10	mg	
	Niacinamide,folic acid,	Pyridoxine Hcl	IP	2	mg	
	Calcium D-Pantothenate,	Cynocobalamin	IP	7.5	mcg	
	Biotin, Manganese, Copper,	Ascorbic Acid(coated)	IP	50	mg	
	Magnesium, Iodine, Selenium,	Vitamin D3	IP	400	IU	
	-	Vitamin E(as Acetate)	IP	25	IU	
	Capsules	Niacinamide	IP	50	mg	
	(For Therapeutic Use)	Folic Acid	IP	1	mg	
		Calcium D-pantothenate	IP	10	mg	
		Biotin	BP	150	mcg	12/1/201
		Zinc(as Zinc Sulphate Monohydrate)	IP	63	mg	
		Magnesium(as Magnesium Hydroxide)	IP	30	mg	
		Manganese(as Manganese Sulphate)	USP	2.8	mg	
		Copper(as Copper Sulphate)	IP	2	mg	
		Potassium Iodide	IP			
		Eq to Iodine		150	mcg	
		Selenium(as Sodium Selenate)		60	mcg	
		Chromium(as Chromium Picolinate)	USP	65	mcg	
		Sodium Molybdate Dihydrate	BP			
		Eq to Molybdenum		25	mcg	
		Excipients		qs		
		Approved colour used in empty capsule	· ·			
70	Salicylic Acid Corn caps	Salicylic Acid	IP	40.00%	w/w	12/1/201
		Excipients	qs			
71	Levofloxacin & Ornidazole	Each Film Coated Tablet Contains:-				
	Tablets	Levofloxacin Hemihydrate				
		Eq.to Levofloxacin	IP	250	mg	12/1/201
		Ornidazole	IP	500	mg	12/1/2017
		Excipients		q.s		
		Approved colour used in Coating				
72	Ofloxacin & Tinidazole	Each Film Coated Tablet Contains:-				
	Tablets	Ofloxacin	IP	200	mg	
		Tinidazole	IP	600	mg	12/1/201
		Excipients		q.s		
		Approved colour used in Coating				
73	Thiamine mononitrate,	Each Film coated Tablet Contains:-				
	Riboflavin, Nicotinic Acid,	Thiamine mononitrate	IP	10	mg	
	Pyridoxine Hcl,	Riboflavin	IP	10	mg	
	Cyanocobalamin, Niacinamide,	Nicotinic Acid	IP	25	mg	
	Calcium Pantothenate, Biotin,	Pyridoxine Hcl	IP	3	mg	
	Folic Acid & Vitamin C	Cyanocobalamin	IP	15	mcg	
	Tablets	Niacinamide	IP	75	mg	12/1/201
		Calcium Pantothenate	IP	50	mg	
		Biotin	BP	260	mcg	
		Folic acid	IP	1.5	mg	
		vitamin C	IP	150	mg	
		Excipients	1 I	q.s	-	
	1	Approved colour used in Coating	1	1 -		

	HEALTH AND FAMI List of Retention Product having license No. FORM25:MP	NO.HFW-H(DRUGS)279/0 LY WELFARE DEPARTMENT, s Approved to be Manufactured b NB/07/642 AND MB/07/643 28:S-MB/07/643 For the p TE AS PER SCHEDULE-P-1 OF DRUGS & COSMETI	HIMACI by : Boffi eriod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
				•		
74	Amoxycillin & Potassium	Each Uncoated dispersible Tablet Conta				
	Clavulanate Dispersible	Amoxycillin Tryhydrate	IP			
	Tablets	Eq. to Amoxycillin	m	200	mg	12/1/2017
		Potassium Clavulanate Diluted	IP	20.5		
		Eq to Clavulanic acid		28.5	mg	
		Excipients		q.s		
75	Amoxycillin & Potassium	Each Film coated Tablet Contains:-				
10	Clavulanate Tablets IP	Amoxycillin Tryhydrate	IP			
		Eq. to Amoxycillin		500	mg	
		Potassium Clavulanate Diluted	IP		0	12/1/201
		Eq to Clavulanic acid		125	mg	
		Excipients		q.s	Ū	
		Approved colour used in Coating				
76	Amoxycillin & Potassium	Each Film coated Tablet Contains:-				
	Clavulanate Tablets IP	Amoxycillin Tryhydrate	IP			
		Eq. to Amoxycillin		250	mg	4/10/202
		Potassium Clavulanate Diluted	IP	105		4/12/202
		Eq to Clavulanic acid		125	mg	
		Excipients Approved colour used in Coating		q.s		
		Approved colour used in coating				
77	Fluocinolone Acetonide,	Fluocinolone Acetonide	IP	0.01%	w/w	
	Neomycin Sulphate &	Neomycin Sulphate	IP			
	Clotrimazole Cream	eq. to Neomycin		0.35%	w/w	12/1/201
		Clotrimazole	IP	1.00%	w/w	12/1/201
		Chlorocresol(as Preservative)	IP	0.10%	w/w	
		Cream Base		q.s		
78	Thiamine mononitrate,	Each hard geletin capsule contains:-				
	Riboflavin,Pyridoxine Hcl,	Thiamine mononitrate	IP	10	mg	
	Cyanocobalamin,Niacinamide,	Riboflavin	IP	10	mg	
	Calcium Pantothenate, Biotin,	Pyridoxine Hcl	IP	3	mg	
	Folic Acid & Vitamin C, Zinc Sulphate Capsules	Cyanocobalamin Niacinamide	IP IP	15	mcg	
	(For Therapeutic Use)	Calcium Pantothenate	IP	100 50	mg mg	12/1/201
	(1%) Therapeutic Use)	Biotin	BP	100	mcg	12/1/201
		Folic acid	IP	1.5	mg	
		vitamin C	IP	1.5	mg	
		Zinc Sulphate Monohydrate	IP	41.4	mg	
		Excipients		q.s	0	
		Approved colour used in empty capsule	shell	1		
79	Amoxycillin Trihydrate,	Each hard geletin capsule contains:-		Ī		
	Cloxacillin Sodium&	Amoxycillin Tryhydrate	IP			
	Lactic Acid bacillus Capsules	Eq.to Amoxycillin		250	mg	
		Cloxacillin Sodium	IP			10/1/201
		Eq.to Cloxacillin		250	mg	12/1/201
		Lactic Acid Bacillus		60	million spores	
		Excipients		qs		
		Approved colour used in empty capsule			-	

	HEALTH AND FAMI List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/0 LY WELFARE DEPARTMENT, I ts Approved to be Manufactured b NB/07/642 AND MB/07/643 28:S-MB/07/643 For the pc ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	HIMACI y : Boffi eriod from 01.	n Biotec	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
80	Ampicillin Trihydrate,	Each hard geletin capsule contains:-				
	Cloxacillin Sodium &	Ampicillin Trihydrate	IP			
	Lactic Acid bacillus Capsules	Eq.to Ampicillin		250	mg	
		Cloxacillin Sodium	IP			12/1/2017
		Eq.to Cloxacillin		250	mg	12/1/2017
		Lactic Acid Bacillus		60	million spores	
		Excipients		qs	spores	
		Approved colour used in empty capsule	shell	-		
81	Roxithromycin & Ambroxol	Each Film coated Tablet Contains:-				
	HCl Tablets	Roxithromycin	IP	150	mg	
		Ambroxol Hcl	IP	60	mg	12/1/2017
		Excipients		q.s		
		Approved colour used in Coating				
82	Diclofenac Potassium	Each Film Coated Tablet Contains:-				
	Tablets	Diclofenac Potassium	BP	50	mg	12/1/2017
		Excipients		q.s		12,1,201,
		Approved colour used in Coating				
02	C D		LICD	1.000/		
83	Gamma Benzene	Gamma Benzene Hexachloride	USP	1.00%	w/v	12/1/2017
	Hexachloride Lotion USP	Emulsion Base				12/1/2017
		Emuision Base		q.s		
84	Salicylic Acid,&Lanoline	Each Corn Cap is Filled With Ointment				
	Corn Caps	Salicylic Acid	IP	50.00%	w/w	
	Ĩ	Lanoline		10.00%	w/w	12/1/2017
		Paraffin Base	qs			
07				1		
85	Doxylamine Succinate,	Each Enteric Coated Tablet Contains:-	LICD	20		
	Pyridoxine HCl & Folic Acid	Doxylamine Succinate	USP	20	mg	
	Tablets	Pyridoxine HCl Folic Acid	IP	20 5	mg	12/1/2017
		Excipients	IP		mg	
		Approved colour used in Coating				
86	Paracetamol	Each Uncoated tablet contains:				
	Cetirizine HCl &	Paracetamol	IP	500	mg	
	Phenylephrine HCl	Cetirizine HCl	IP	5	mg	12/1/2017
	Tablets	Phenylephrine HCl	IP	5	mg	12/1/2017
		Excipients		q.s.		
		Colour:Approved colour used				
87	Trimethoprim &	Each Uncoated Bolus contains:-		İ		
	Sulphamethoxazole Bolus	Trimethoprim	IP	200	mg	
	(For animal use only)	Sulphamethoxazole	IP	1	gm	12/1/2017
	(Not for human use)	Excipients		q.s		
	· · ·	Approved colour used in Bolus				
88	Trimethoprim &	Each Uncoated Bolus contains:-				
	Sulphamethoxazole Bolus	Trimethoprim	IP	400	mg	
	(For animal use only)	Sulphamethoxazole	IP	2	gm	12/1/2017
	(Not for human use)	Excipients		q.s		

	List of Retention Product	NO.HFW-H(DRUGS)279/(LY WELFARE DEPARTMENT, ts Approved to be Manufactured I	HIMACI by : Boffi	n Biotec	h Pvt.	
		NB/07/642 AND MB/07/643 28:S-MB/07/643 For the p ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET		12.2022 to 30.	11.2027	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
89	Salicylic Acid,Lactic acid &	Salicylic Acid	IP	1.50%	w/w	
	Triclosan Cream	Lactic acid	IP	8.00%	W/W	12/1/2017
		Triclosan	BP	0.10%	W/W	12/1/2017
		In Cream Base		q.s		
90	Isoxsuprine HCl (SR)Tablets	Each Sustained Released Tablet Contain	ns:-			
		Isoxsuprine HCl	IP	40	mg	12/1/2017
		Excipients		q.s		12/1/2017
		Approved colour used in Coating				
91	Clotrimazole Lotion USP	Clotrimazole	IP	1%	w/v	
		Chlorocresol(As Preservative)	IP	0.1%	w/v	12/1/2017
		Lotion Base		q.s		
92	Nimesulide Tablets	Each un coated DispersibleTablet Conta	uns:-			
	(in Betacyclodextrine)	Nimesulide	BP	100	mg	
	Tablets	(in Betacyclodextrine)				11/30/2012
		Excipients		q.s		
		Approved colour used in Tablet				
	-	-				
93	Rosiglitazone	Each Film Coated Tablet Contains:-				
	Tablets	Rosiglitazone maleate				
		Eq. to Rosiglitazone		2	mg	11/30/2012
		Excipients		q.s		
		Approved colour used in Coating				
94	Ofloxacin Tablets IP	Each Film Coated Tablet Contains:-				
		Ofloxacin	IP	300	mg	11/30/2012
		Excipients		q.s		11/30/2012
		Approved colour used in Coating				
r						
95	Vitamin A, Vitamin E	Each hard geletin capsule contains:-				
	Vitamin C,Vitamin B1,	Vitamin A(as Acetate)	IP	2500	IU	
	Vitamin B2, Vitamin B6,	Vitamin E	IP	10	mg	
	Nicotinamide,	Vitamin C	IP	50	mg	
	Folic Acid, Vitamin D3	Vitamin B1	IP	2	mg	
	Calcium Pantothenate,Zinc,	Vitamin B2	IP	3	mg	
	Selenium, Chromium, Copper,	Vitamin B6	IP	1	mg	
	Manganese, Phosphorous,	Vitamin D3	IP	200	IU	
	Iodine& Potassium Capsules	Nicotinamide	IP	20	mg	
	(For Therapeutic Use)	Folic Acid	IP	0.3	mg	
		Copper(as Copper Sulphate)	IP	0.5	mg	11/30/2012
		Manganese(as manganese sulphate)	USP	0.5	mg	11/30/2012
		Zinc(as Zinc Sulphate)	IP	10	mg	
		Di-Basic calcium Phosphate	IP	75	mg	
		Eq.to Calcium Phosphorus		58	mg	
		Potassium Iodate	IP			
		Eq.to iodine		0.1	mg	
		Calcium D-Pantothenate	IP	5	mg	-
		Potassium Sulphate	IP			
		Eq.to Potassium		2	mg	
		Excipients		qs		
		Approved colour used in empty capsule	shell			

NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH

List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

	PACK SIZ	E AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	ACT 1945			
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	-					
96	Ciprofloxacin Cream	Ciprofloxacin Hcl	IP			
				0 500/	1	11/20/2012

		eq.to Ciprofloxacin	0.50%	\mathbf{W}/\mathbf{W}	11/30/2012
		In Cream Base	q.s		
-					

IP

Gentamicin sulphate

97 Gentamicin cream IP

)		Ochtainieni Sulphate				1
		eq. to Gentamycin		0.30%	\mathbf{W}/\mathbf{W}	11/30/2012
		In Cream Base		q.s		
98	Vitamin A, Vitamin E	Each hard geletin capsule contains:-				
	Vitamin C,Vitamin B1,	Vitamin A(as Acetate)	IP	5000	IU	
	Vitamin B2, Vitamin B6	Vitamin E(Tocopheryl Acetate)	IP	25	IU	
	Vitamin B12, Nicotinamide	Vitamin C(Coated)	IP	50	mg	
	Folic Acid,	Vitamin B1	IP	10	mg	
	Calcium Pantothenate, Zinc,	Vitamin B2	IP	10	mg	
	Selenium, Chromium Capsules	Vitamin B6	IP	3	mg	
	(For Therapeutic Use)	Vitamin B12	IP	5	mcg	11/30/2012
		Nicotinamide	IP	50	mg	11/30/2012
		Folic Acid	IP	1	mg	
		Calcium D-Pantothenate	IP	12.5	mg	
		Zinc(as Zinc Sulphate Monohydrate)	IP	2.5	mg	
		Selenium(as Sodium Selenate)		60	mcg	
		Chromium(as Chromium Picolinate)		65	mcg	
		Excipients		qs		
		Approved colour used in empty capsule	shell			
99	Carbonyl Iron,	Each hard geletin capsule contains:-				
	Cyanocobalamin,	Carbonyl Iron		100	mg	

99	Carbonyi Iron,	Each nard geletin capsule contains:-				
	Cyanocobalamin,	Carbonyl Iron		100	mg	
	Foilc acid,Zinc Sulphate &	Cynocobalamin	IP	15	mcg	
	Ascorbic Acid Capsules	Zinc Sulphate Monohydrate	IP	61.8	mg	11/30/2012
		Folic Acid	IP	500	mcg	11/30/2012
		Ascorbic Acid(Coated)	IP	50	mg	
		Excipients		qs		
		Approved colour used in empty capsule	shell			

100	Betacarotine, Vitamin A,	Each hard geletin capsule contains:-				
	Vitamin E, Vitamin C, Copper,	Betacarotine 20% Dispersion	BP	10	mg	
	Manganese,Zinc&	Vitamin A	IP	5000	IU	
	Selenium Capsules	Vitamin E(Tocopheryl Acetate)	IP	10	IU	
	(For Therapeutic Use)	Vitamin C	IP	25	mg	
		Copper (as Cupric Oxide)	BP	500	mcg	11/30/2012
		Manganese(as Mangnese Sulphate)	IP	500	mcg	
		Zinc(as Zinc Sulphate Monohydrate)	IP	5	mg	
		Selenium(as Sodium Selenate)		50	mcg	
		Excipients		qs		
		Approved colour used in empty capsule s	hell			
101	Diclofenac Sodium	Each Filmcoated Tablet contains:-				
	Tablets IP	Diclofenac Sodium	IP	50	mg	1/31/2013
	(Not for Veterinary Use)	Excipients		q.s		1/31/2013
		Approved colour used in Coating				

	List of Retention Product having license No. FORM25:N	NO.HFW-H(DRUGS)279/ ILY WELFARE DEPARTMENT, ets Approved to be Manufactured I MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the p IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	HIMACH by:Boffin eriod from 01.1	n Biotec	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
102	Diclofenac Sodium &	Each Uncoated Tablet Contains:-				
	Paracetamol Tablets IP	Diclofenac Sodium	IP	50	mg	
	(Not for Veterinary Use)	Paracetamol	IP	325	mg	1/31/2013
		Excipients		q.s		
		Approved colour used in Tablets				
103	Cetirizine Hydrochloride	Each Uncoated Tablet Contains:-				
105	Tablets IP	Cetirizine Hydrochloride	IP	10	mg	
		Excipients		q.s	mg	1/31/2013
		Approved colour used in Tablets		4.5		
104	Cefixime	Each Uncoated tablet Contains:-				
	Tablets IP	Cefixime	IP			
		Eq.to Anhydrous Cefixime	1	200	mg	1/31/2013
		Excipients		q.s	Ū	
		Approved colour used in Tablets				
	1			1		
105	Mometasone Furoate	Mometasone Furoate	IP	0.1%	w/w	1/31/2013
	Cream IP	Cream base		q.s		
106	Aceclofenac	Each Filmcoated tablet contains:-				
100	Paracetamol Tablets	Aceclofenac	IP	100	mg	
		Paracetamol	IP	325	mg	1/31/2013
		Excipients		q.s	0	
		Approved colour used in Tablets				
107	Clindamycin Phosphate	Clindamycin Phosphate	IP			
	Gel USP	Eq. to Clindamycin		1%	w/w	3/26/2013
		Gel base		q.s		
100	A '11' T '1 1 4					
108	Amoxycillin Trihydrate	Each Un- coated Dispersible tablet Con		-		
	Dispersible Tablets IP	Amoxycillin Trihydrate eq. to Amoxycillin	IP	250		3/26/2013
		Approved Colour used in tablets		230	mg	
		Approved Colour used in tablets				
109	Ketoconazole &	Ketoconazole	IP	2%	w/v	
107	Prepared Coal tar	Prepared coal Tar	IP(1966)	2%	w/v	
	Solution	Sampoo Base		q.s		3/26/2013
		Approved Colour(s) Only may be used		1		
			·			
110	Clotrimazole Cream IP	Clotrimazole	IP	1%	w/w	
		Chlorocresol(As a Preservative)	IP	0.1%	w/w	6/25/2013
		Cream Base		q.s		0/25/2015
111	Clobatagal Drawiswetz	Clabotagel Dramion - +-	LICD	0.050/	····	
111	Clobetasol Propionate,	Clobetasol Propionate	USP	0.05%	w/w	
	Miconazole Nitrate,	Miconazole Nitrate	IP	2%	w/w	
	Neomycin Sulphate,	Neomycin Sulphate	IP	0.5%	····	
	Zinc Sulphate Cream	eq. to Neomycin Zinc Sulphate	IP	0.5%	w/w	8/14/2013
		Chlorocresol	IP IP	0.1%	w/w w/w	
		(As Preservative)	11*	0.1%	W/W	
		In cream Base		٥٩		
	1	in crouin Duoc	1	q.s	1	

	HEALTH AND FAMI List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/ LY WELFARE DEPARTMENT IS Approved to be Manufactured NB/07/642 AND MB/07/643 28:S-MB/07/643 For the p ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	HIMACI, by : Boffi period from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
112	Hydroquinone Cream USP	Hydroquinone	USP	4%	***/***	
112	Hydroquinone Cream USP	In cream Base	USF		w/w	8/14/2013
113	Hydroquinone, Tretinoin &	Hydroquinone	USP	q.s 2%	w/w	
115	Mometasone Furoate	Tretinoin	IP	0.025%	w/w w/w	
	Cream	Mometasone Furoate	IP	0.1%	w/w	8/14/2013
		In cream Base		q.s	,	
114	Xylometazoline HCl.,	Xylomatazoline HCl.	IP	0.1%	w/v	
	Nasal Solution USP.	Benzalkonium Chloride	IP	0.01%	w/v	8/14/2013
		In Solution base		q.s	, .	
117	Lornoxicam &					
115	Lornoxicam & Paracetamol Tablets	Each Film Coated Tablet Contains:- Lornoxicam		8	ma	
	ranacetamon radiets	Paracetamol	IP	8 325	mg	9/3/2013
		Excipients	112		mg	7/3/2013
		Approved colour used in Coating		q.s		
116				0.0250/		
116	Beclomethasone Dipropionate, Clotrimazole &	Beclomethasone Dipropionate Neomycin Sulphate	IP IP	0.025%	w/w	
	Neomycin Sulphate Cream	eq.to Neomycin	11	0.5%	w/w	
	Neomychi Sulphate Cream	Clotrimazole	IP	1%	w/w w/w	10/21/201
		Chlorocresol(As Preservative)	IP	0.1%	w/w w/w	
		In cream Base	п	q.s	w/w	
117	Clobetasol Propionate,	Clobetasol Propionate	USP	0.05%	w/w	
	Neomycin Sulphate &	Neomycin Sulphate	IP	0.5%	w/w	10/21/201
	Miconazole Nitrate Cream	Miconazole Nitrate	IP	2%	w/w	
		In a Cream Base				
118	Diclofenac Diethylamine,	Diclofenac Diethylamine	BP	1.16%	w/w	
	Oleum Lini, Methylaslicylate,	eq. to Dicflofenac Sodium		1%	w/w	
	& Menthol Gel	Oleum Lini	BP	3%	w/w	
		Menthol	IP	5%	W/W	10/21/201
		Methyl salicylate	IP	10%	w/w	
		Benzyl Alcohol(As Preservative)	IP	0.1%	w/w	
		In Gel Base		q.s		
119	Povidone Iodine Ointment	Povidone Iodine	IP	5%	w/w	
	USP	eq. to Available Iodine (0.5% w/w)		570		10/21/201
,	0.51	Water Soluble Ointment Base				
			_	_		
120	Povidone Iodine,	Povidone Iodine	IP	5%	w/w	
120	Metronidazole &	eq. to Available Iodine (0.5% w/w)		5%	w/w	
120		eq. to Available Iodine (0.5% w/w) Metronidazole Benzoate	IP IP			10/21/201
120	Metronidazole &	eq. to Available Iodine (0.5% w/w) Metronidazole Benzoate eq. to Metronidazole	IP	1%	w/w	10/21/201
120	Metronidazole &	eq. to Available Iodine (0.5% w/w) Metronidazole Benzoate eq. to Metronidazole Aloe Vera				10/21/201
120	Metronidazole &	eq. to Available Iodine (0.5% w/w) Metronidazole Benzoate eq. to Metronidazole	IP	1%	w/w	10/21/201
	Metronidazole & Aloe Vera Ointment Silver Sulfadiazine &	eq. to Available Iodine (0.5% w/w) Metronidazole Benzoate eq. to Metronidazole Aloe Vera Water Soluble Ointment Base Silver Sulfadiazine	IP	1%	w/w	10/21/201
120	Metronidazole & Aloe Vera Ointment Silver Sulfadiazine &	eq. to Available Iodine (0.5% w/w) Metronidazole Benzoate eq. to Metronidazole Aloe Vera Water Soluble Ointment Base	IP IP	1% 1.5%	w/w w/w	
	Metronidazole & Aloe Vera Ointment Silver Sulfadiazine &	eq. to Available Iodine (0.5% w/w) Metronidazole Benzoate eq. to Metronidazole Aloe Vera Water Soluble Ointment Base Silver Sulfadiazine	IP IP USP	1% 1.5%	w/w w/w	10/21/201

	List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/ LY WELFARE DEPARTMENT, ts Approved to be Manufactured I NB/07/642 AND MB/07/643 28:S-MB/07/643 For the p ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	HIMACI by:Boffi period from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
122	Clotrimazole & Beclomethasone Dipropionate Lotion	Clotrimazole Beclomethasone Dipropionate Lotion Base	IP IP	1% 0.025% q.s	w/w w/w	12/26/2013
123	Pantoprazole & Domperidone Capsule IP	Each hard geletin capsule contains:- Pantoprazole Sodium eq.to Pantoprazole (As enteric coated Pellets) Domperidone (Sustained release Pellets) Excipients Approved colour used in empty capsule	IP IP IP	40 30 qs	mg mg	4/9/2014
124	Diclofenac Diethylamine, Oleum Lini, Methylaslicylate, & Menthol Gel (NOT FOR VETERINARY USE)	Diclofenac Diethylamine eq. to Dicflofenac Sodium Oleum Lini Menthol Methyl salicylate Benzyl Alcohol(As Preservative) In Gel Base	BP BP IP IP IP IP	1.16% 1% 3% 0.5% 10% 0.1% q.s	w/w w/w w/w w/w w/w	4/9/2014
125	Beclomethasone Dipropionate, Neomycin Sulphate Cream	Beclomethasone Dipropionate Neomycin Sulphate eq.to Neomycin Chlorocresol(As Preservative) In cream Base	IP IP IP	0.025% 0.5% 0.1% q.s	w/w w/w w/w	4/9/2014
126	Miconazole Nitrate, Flucinolone Acetonide & Neomycin Cream	Miconazole Nitrate Fluocinolone Acetonide Neomycin Sulphate eq. to Neomycin Chlorocresol(As Preservative) In Cream base	IP IP IP IP IP	2% 0.01% 0.5% 0.1% q.s	w/w w/w w/w w/w	4/9/2014
127	Levocetirizine Tablets IP	Each Film Coated Tablet Contains:- Levocetirizine Hydrochloride Excipients Approved colour used in Coating	IP	5 q.s	mg	5/27/2014
128	Levocetirizine & Montelukast Tablets IP	Each Film Coated Tablet Contains:- Levocetirizine HCl. Montelukast Sodium Eq. to Montelukast Excipients Approved colour used in Coating	IP IP	5 10 q.s	mg mg	5/27/2014
129	Diclofenac Potassium, Paracetamol & Chlorzoxazone Tablets (Not for Veterinary Use)	Approved colour used in Coating Each Uncoated Tablet contains:- Diclofenac Potassium paracetamol Chlorzoxazone Excipients Approved colour used in Tablets.	BP IP USP	50 325 250 q.s	mg mg mg	5/27/2014

	NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945									
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED				
130	Deflazacort Tablets	Each Uncoated tablet contains:-	1							
150	Denazacont Tablets	Deflazacort	1	6	mg					
		Excipients		q.s	mg	5/27/2014				
		Approved colour used in Tablets		q .5						
131	Calcium Citrate,	Each Film Coated Tablet Contains:-		1						
151	Magnesium Hydroxide,	Calcium citrate	USP	1000	mg					
	Zinc Sulphate &	Magnesium Hydroxide	IP	1000	mg					
	Vitamin D3 Tablets	eq. to Magnesium	- 11	100	mg					
	Vitaliili D5 Tablets	Zinc Sulphate Monohydrate	IP	100	mg	5/27/2014				
		eq. to Zinc		4	mg	5/2//201				
		Vitamin D3	IP	200	IU					
		Excipients		q.s	10					
		Approved colour used in Coating		4						
122	Telmisartan &	Each Uncoated Tablet contains:-		1						
132			т	40						
	Hydrochlorothiazide Tablets IP	Telmisartan Hydrochlorothiazide	IP IP	40	mg	5/27/2014				
	Tablets IP	Excipients	IP		mg	5/27/2014				
		Approved colour used in Tablets.		q.s						
				1						
133	Calcium with	Each Film Coated Tablet Contains:-								
	& Vitamin D3 Tablets IP	Calcium Carbonate		1.25	gm					
		From an organic Source (Oyster Shell)		500		E 10 E 10 0 1				
		eq. to Elemental Calcium	ID	500	mg	5/27/2014				
		Vitamin D3	IP	250	IU					
		Excipients Approved colour used in Coating		q.s						
134	Amlodipine &	Each Uncoated Tablet Contains:-								
	Atenolol Tablets IP	Amlodipine Besilate	IP							
		eq. to Amlodipine		5	mg	5/27/2014				
		Atenolol	IP	50	mg	5/2//201				
		Excipients		q.s						
		Approved colour used in Tablets								
135	Pantoprazole	Each Enteric Coated Tablet contains:-								
	Tablets IP	Pantoprazole Sodium	IP							
		eq. to pantoprazole		40	mg	5/27/2014				
		Excipients		q.s						
		Approved colour used in Coating								
136	Paracetamol,	Each Uncoated Tablet Contains:-								
100	Phehylephrine HCl.,	Paracetamol	IP	325	mg					
	Chlorpheniramine,	Phenylephrine Hydrochloride	IP	5	mg					
	Meleate & Caffeine	Chlorpheniramine Meleate	Ip	4	mg	5/27/2014				
	anhydrous Tablets.	Caffeine Anhydrous	IP	25	mg					
		Excipients	1	q.s						
	1	Approved colour used in Tablets	1		1					

_

	List of Retention Product having license No. FORM25:N	NO.HFW-H(DRUGS)279/ ILY WELFARE DEPARTMENT cts Approved to be Manufactured MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the EZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	,HIMACI by : Boffi period from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
137	Aceclofenac &	Each Uncoated Tablet Contains:-				
	Paracetamol Tablets	Aceclofenac	IP	100	mg	
		Paracetamol	IP	325	mg	5/27/2014
		Excipients		q.s		
		Approved colour used in Tablets				
138	Paracetamol	Each Uncoated tablet contains:-			<u> </u>	
130	Tablets IP	Paracetamol	IP	650	ma	
	Tablets IF	Excipients	11		mg	7/14/2014
		Approved colour used in tablets	-	q.s		
		Approved colour used in tablets				
139	Paracetamol	Each Uncoated tablet contains:-				
	Tablets IP	Paracetamol	IP	500	mg	7 /14/2011
		Excipients		q.s	Ő	7/14/2014
		Approved colour used in tablets		1		
140	Erythromycin stearate	Each Film Coated Tablet Contains:-				
	& Bromhexine HCl	Erythromycin stearate	IP			
	Tablets	eq to Erythromycin		250	mg	7/14/2014
		Bromhexine HCl	IP	8	mg	//14/2014
		Excipients		q.s		
		Approved colour used in Coating				
141	Erythromycin stearate	Each Film Coated Tablet Contains:-				
141	& Bromhexine HCl	Erythromycin stearate	IP			
	Tablets	eq to Erythromycin		500	mg	
	i dolotis	Bromhexine HCl	IP	8	mg	7/14/2014
		Excipients		q.s	mg	
		Approved colour used in Coating		1		
	Diethyl Carbamazine	Each Film Coated Tablet Contains:-				
	Citrate & Levocetirizine	Diethyl Carbamazine Citrate	IP	100	mg	
	HCl tablets	Levocetirizine HCl	IP	2.5	mg	7/14/2014
		Excipients		q.s		
		Approved colour used in Coating	_		┝──┨	
143	Azithromycin	Each Film Coated Tablet Contains:-				
	Tablets IP	Azithromycin	IP	0.50		- (1.4/2.0.1.)
		eq. to anhydrous Azithromycin		250	mg	7/14/2014
		Excipients		q.s		
144	A 1/1 1	Approved colour used in Coating				
144	Azithromycin	Each Film Coated Tablet Contains:-	m			
	Tablets IP	Azithromycin	IP	500	ma	7/14/2014
		eq. to anhydrous Azithromycin Excipients		500	mg	//14/2014
		Approved colour used in Coating		q.s	╞──┨	
145	Rabeprazole Sodium	Each hard geletin capsule contains:-			┝──┨	
175	& Domperidone	Rabeprazole Sodium	IP	20	mg	
	Capsule	(As enteric coated pellets)		20	mg	
	Capbule	Domperidone	IP	30	mg	7/14/2014
		(As Sustained release pellets)		50	mg	,, 17, 2014
		(115 Sustaniou release penets)				
		Excipients		qs		

		MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the per SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC		12.2022 to 30.	11.2027	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
146	Omeprazole	Each hard geletin capsule contains:-				
	Capsule IP	Omeprazole	IP	20	mg	
		As enteric coated pellets				7/14/2014
		Excipients		qs		
		Approved colour used in empty capsule s	shell			
147	Omeprazole &	Each hard geletin capsule contains:-				
147	Domperidone	Omeprazole	IP	20	mg	
	Capsule IP	(As enteric coated pellets)		20	mg	
	Cupbule II	Domperidone	IP	10	mg	7/14/2014
		(As pellets)		10	mg	
		Excipients		qs		
		Approved colour used in empty capsule s	hell	45		
148	Carbonyl Iron,	Each hard gelatin capsule Contains:-				
	Zinc Sulphate &	Carbonyl Iron				
	Folic Acid Capsules	Eq. to Elemental Iron		100	mg	
		Zinc Sulphate Monohydrate	IP	61.8	mg	7/14/2014
		Eq. to Elemental Zinc 22.5mg)				//1//201
		Folic Acid	IP	0.5	mg	
		Excipients		q.s		
		Approved colour used in Capsule shell				
149	Amoxycillin	Each Uncoated tablet contains:-				
	Tablets BP vet	Amoxycillin Trihydrate	IP			
		eq. to Amoxycillin		1500	mg	7/14/2014
	(For animal use only)	Excipients		q.s	0	
	(Not for human use)	Approved colour used in Tablets		-		
150	Albendazole Bolus	Each Uncoated Bolus contains:-				
		Albendazole	IP	3	gm	7/14/2014
	(For animal use only)	Excipients		q.s		
	(Not for human use)	Approved colour used in Bolus				
151	Albendazole &	Each Uncoated Bolus contains:-				
	Ivermectin Bolus	Albendazole	IP	3	gm	
		Ivermectin	IP	100	mg	7/14/2014
	(For animal use only)	Excipients		q.s	8	
	(Not for human use)	Approved colour used in Bolus		1		
152	Ciprofloxacin &	Each Uncoated Bolus contains:-				
	Tinidazole Bolus	Ciprofloxacin HCl	IP			
		eq. to Ciprofloxacin		1500	mg	7/14/2014
		Tinidazole Bolus	IP	1800	mg	
	(For animal use only)	Excipients		q.s		-
	(Not for human use)	Approved colour used in Bolus				
	Enrofloxacin Bolus	Each Uncoated Bolus contains:-				
153						
153	Linonoxaciii Dolus	Enrofloxacin	IP(Vet.)	1500	mg	- /1 + /= 0 :
153	(For animal use only)		IP(Vet.)	1500 q.s	mg	7/14/2014

HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945									
				8					
54	Fenbendazole Bolus	Each Uncoated Bolus contains:-							
		Fenbendazole	IPvet	3	gm	7/14/2014			
	(For animal use only)	Excipients		q.s		//14/201			
	(Not for human use)	Approved colour used in Bolus							
55	Fenbendazole &	Each Uncoated Bolus contains:-							
	Ivermectin Bolus	Fenbendazole	IPvet	3	gm				
		Ivermactin	IP	100	mg	7/14/201			
	(For animal use only)	Excipients		q.s					
	(Not for human use)	Approved colour used in Bolus							
56	Levamisole HCl &	Each Uncoated Bolus contains:-							
50	Oxyclozanide Bolus	Levamisole HCl &	IP	2	am				
	Oxyclozanide Bolus			4	gm	7/14/201			
	(For animal use only)	Oxyclozanide Bolus	IP vet	-	gm	//14/201			
	(Not for human use)	Excipients Approved colour used in Bolus		q.s					
	(Not for numan use)	Approved colour used in Bolus							
57	Meloxicam &	Each Uncoated Bolus contains:-							
0.	Paracetamol Bolus	Meloxicam	BP	100	mg				
		Paracetamol	IP	1500	mg	7/14/201			
	(For animal use only)	Excipients			0				
	(Not for human use)	Approved colour used in Bolus		q.s					
58	Nimesulide &	Each Uncoated Bolus contains:-							
	Paracetamol Bolus	Nimesulide	BP	400	mg				
		Paracetamol	IP	1500	mg	7/14/201			
	(For animal use only)	Excipients		q.s					
	(Not for human use)	Approved colour used in Bolus							
59	Norfloxacin &	Each Uncoated Bolus contains:-		1000					
	Tinidazole Bolus	Norfloxacin	IP	1200	mg				
		Tinidazole	IP	1800	mg	7/14/201			
	(For animal use only)	Excipients		q.s					
	(Not for human use)	Approved colour used in Bolus							
60	Sulphadimidine	Each Uncoated tablet contains:-							
60	Tablets BP vet	Sulphadimidine	BP	0.5	am				
	(For animal use only)	Excipients	Dr		gm	7/14/201			
	(Not for human use)	Approved colour used in Tablets		q.s					
		reproved colour used in Tablets		1					
61	Sulphadimidine	Each Uncoated tablet contains:-							
51	Tablets BP vet	Sulphadimidine	BP	5	gm				
	(For animal use only)	Excipients		q.s	5	7/14/2014			
	(Not for human use)	Approved colour used in Tablets		4.5					

162	Rabeprazole Sodium	Each Enteric Coated tablet Contains:-				
	Tablets IP	Rabeprazole Sodium	IP	20	mg	9/1/2014
		Excipients		q.s		9/1/2014
		Approved colour used in Coating				

	List of Retention Produc having license No. FORM25:N	NO.HFW-H(DRUGS)279/0 ILY WELFARE DEPARTMENT, J its Approved to be Manufactured b 1NB/07/642 AND MB/07/643 28:S-MB/07/643 For the pe IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETI	HIMACI y:Boffi riod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
163	Rabeprazole Sodium &	Each Enteric Coated tablet Contains:-				
	Domperidone	Rabeprazole Sodium	IP	20	mg	
	Tablets	Domperidone	IP	10	mg	9/1/2014
		Excipients		q.s		
		Approved colour used in Coating				
164	Pantoprazole &	Each Enteric Coated tablet Contains:-				
101	Domperidone Tablets	Pantoprazole Sodium	IP			
		eq. to Pantoprazole		40	mg	
		Domperidone	IP	10	mg	9/1/2014
		Excipients		q.s		
		Approved colour used in Coating		4 15		
	1			1		
165	Ofloxacin &	Each Film Coated tablet Contains:-				
	Ornidazole Tablets IP	Ofloxacin	IP	200	mg	
		Ornidazole	IP	500	mg	9/1/2014
		Excipients		q.s		
		Approved colour used in Coating				
166	Ofloxacin Tablets IP	Each Film Coated tablet Contains:-				
100	Offoxacili Tablets IF	Ofloxacin	IP	400	ma	
		Excipients	Ir		mg	9/1/2014
		Approved colour used in Coating		q.s		
167	Ofloxacin Tablets IP	Each Film Coated tablet Contains:-				
107		Ofloxacin	IP	200	mg	
		Excipients		q.s	8	9/1/2014
		Approved colour used in Coating		-1		
168	Levofloxacin	Each Film Coated tablet Contains:-				
	Tablets IP	Levofloxacin Hemihydrate	IP			
		eq. to Levofloxacin		250	mg	9/1/2014
		Excipients		q.s		
		Approved colour used in Coating				
169	Levofloxacin	Each Film Coated tablet Contains:-				
	Tablets IP	Levofloxacin Hemihydrate	IP			
		eq. to Levofloxacin		500	mg	9/1/2014
		Excipients		q.s		
		Approved colour used in Coating				
170	Glimepiride &	Each Uncoated tablet Contains:-				
	Metformin HCl.	Glimepiride	IP	2	mg	
	Pioglitazone Tablets	Metformin Hcl.	IP	500	mg	a (
	Note:- Package insert	Pioglitazone HCl.	IP			9/1/2014
	as per notification of	eq. ot Pioglitazone		15	mg	
	Ministry of Health & Family	Excipients		q.s		
	Welfare No.GSR520(E)	Approved colour used in Tablets				
171	Glimepiride &	Each Uncoated tablet Contains:-				
. / 1	Metformin HCl.	Glimepiride	IP	1	mg	
	Pioglitazone Tablets	Metformin Hcl.	IP	500	mg	
	Note:- Package insert	Pioglitazone HCl.	IP	500	mg	9/1/2014
	as per notification of	eq. ot Pioglitazone	ш	15	mg	2/1/2014
	Ministry of Health & Family	Excipients		q.s	mg	-
	Welfare No.GSR520(E)	Approved colour used in Tablets	1	4.5		

	NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945									
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED				
172	Glimepiride &	Each Uncoated tablet Contains:-								
	Metformin HCl.	Glimepiride	IP	1	mg					
	Tablets	Metformin Hcl.	IP	500	mg	9/1/2014				
		Excipients		q.s	0					
		Approved colour used in Tablets		1						
173	Glimepiride &	Each Uncoated tablet Contains:-								
	Metformin HCl.	Glimepiride	IP	2	mg					
	Tablets	Metformin Hcl.	IP	500	mg	9/1/2014				
		Excipients		q.s						
		Approved colour used in Tablets								
174	Clobetasol Propionate	Clobetasol Propionate	IP	0.05%	W/W					
	Cream IP	Preservatives:-								
		Methyl Paraben	IP	0.08%	\mathbf{W}/\mathbf{W}	9/1/2014				
		Propyl Paraben	IP	0.04%	w/w					
		In Cream base		q.s						
175	Cinnarizine Tablets IP	Each Filmcoated tablet Contains:-								
		Cinnarizine	IP	25	mg	9/1/2014				
		Excipients		q.s		<i>)/1/201</i> 4				
		Approved colour used in Tablets								
	•			1						
176	Ciprofloxacin	Each Film Coated tablet Contains:-								
	Tablets IP	Ciprofloxacin HCl.	IP							
		eq. to Ciprofloxacin		250	mg	9/1/2014				
		Excipients		q.s						
		Approved colour used in Coating								

177	Ciprofloxacin	Each Film Coated tablet Contains:-				
	Tablets IP	Ciprofloxacin HCl.	IP			
		eq. to Ciprofloxacin		500	mg	9/1/2014
		Excipients		q.s		
		Approved colour used in Coating				
178	Aceclofenac,	Each Uncoated tablet Contains:-				
	Paracetamol &	Aceclofenac	IP	100	mg	9/1/2014
	Chlorzoxazone Tablets	Paracetamol	IP	325	mg	
		Chlorzoxazone	USP	250	mg	9/1/2014
		Excipients		q.s		
		Approved colour used in Tablets				
179	Aciclovir Tablets IP	Each Uncoated tablet Contains:-				
		Aciclovir	IP	200	mg	9/1/2014
		Excipients		q.s		9/1/2014
		Approved colour used in Tablets				
180	Aciclovir Tablets IP	Each Uncoated tablet Contains:-				
		Aciclovir	IP	400	mg	9/1/2014
		Excipients		q.s		9/1/2014
		Approved colour used in Tablets				

PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945								
8. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATED		
181	Atenolol Tablets IP	Each Uncoated tablet Contains:-						
		Atenolol	IP	50	mg	0/1/0014		
		Excipients		q.s		9/1/2014		
		Approved colour used in Tablets						
182	Aciclovir Tablets IP	Each Uncoated tablet Contains:-						
		Aciclovir	IP	800	mg	9/1/2014		
		Excipients		q.s		9/1/2014		
		Approved colour used in Tablets						
183	Amlodipine Tablets IP	Each Uncoated tablet Contains:-						
		Amlodipine Besilate	IP					
		eq. to Amlodipine		5	mg	9/1/2014		
		Excipients		q.s				
		Approved colour used in Tablets						
184	Mupirocin Ointment IP	Mupirocin	IP	2%	w/w	0.11.10.0.1.1		
		Ointment Base		q.s		9/1/2014		
185	Ofloxacin &	Each Filmcoated tablet Contains:-						
	Cefixime Tablets	Ofloxacin	IP	200	mg			
		Cefixime	IP			10/1/2014		
		eq. to anhydrous Cefixime		200	mg	10/1/201		
		Excipients		q.s				
		Approved colour used in Coating						
186	Gliclazide(MR) &	Each Uncoated tablet Contains:-						
	Metformin HCl.(ER)	Gliclazide(MR)	IP	80	mg			
	Tablets	Metformin HCl.(ER)	IP	500	mg	10/1/2014		
		Excipients		q.s				
		Approved colour used in Tablets						
187	Levocetirizine Tablets IP	Each Uncoated tablet Contains:-						
		Levocetirizine HCl.	IP	5	mg	10/1/201		
		Excipients		q.s		10/1/2014		
		Approved colour used in Tablets						
188	Glibenclamide &	Each Uncoated tablet Contains:-						
	Metformin HCl.	Glibenclamide	IP	5	mg			
	Tablets	Metformin HCl.	IP	500	mg	10/1/2014		
		Excipients		q.s				
		Approved colour used in Tablets						
189	Diltiazem Tablets IP	Each Uncoated tablet Contains:-						
- 57	- malen fueles fi	Diltiazem HCl.	IP	30	mg			
		Excipients		q.s	8	10/1/2014		
		Approved colour used in Tablets		-				
100	Diltiogon Tableta D	Each Upperstad tablet Container						
190	DiltiazemTablets IP	Each Uncoated tablet Contains:- Diltiazem HCl.	IP	60	ma			
		Excipients	Ir		mg	10/1/2014		
		Approved colour used in Tablets		q.s				

	List of Retention Produc	NO.HFW-H(DRUGS)279/ ILY WELFARE DEPARTMENT, ts Approved to be Manufactured	HIMACI by : Boffi	n Biotecl	h Pvt.	
		INB/07/642 AND MB/07/643 28:S-MB/07/643 For the p ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET		12.2022 to 30.	11.2027	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
191	Cinnarizine Tablets IP	Each Uncoated tablet Contains:-				
		Cinnarizine	IP	25	mg	10/1/2014
		Excipients		q.s		10/1/2014
		Approved colour used in Coating				
102	Atenolol Tablets IP	Each Unseeded to black Country's an	1	1		
192	Atenoiol Tablets IP	Each Uncoated tablet Contains:- Atenolol	тр	25		
		Excipients	IP	25	mg	10/1/2014
		Approved colour used in Tablets		q.s		
		rippioved colour used in Tublets				
193	Amitripthyline Tablets IP	Each Filmcoated tablet Contains:-				
		Amitriptyline HCl.	IP	10	mg	10/1/2014
		Excipients		q.s		10/1/2014
		Approved colour used in Coating				
194	Amitripthyline Tablets IP	Each Filmcoated tablet Contains:-				
		Amitriptyline HCl.	IP	25	mg	10/1/2014
		Excipients		q.s		10/1/2014
		Approved colour used in Coating				
			-			
195	Amlodipine Tablets IP	Each Uncoated tablet Contains:-				
		Amlodipine Besilate	IP			10/1/0011
		eq. to Amlodipine		2.5	mg	10/1/2014
		Excipients		q.s		
		Approved colour used in Tablets				
196	Simvastatin Tablet BP	Each Uncoated tablet contains:-				
		Simvastatin	BP	10	mg	
		Excipients		qs	0	10/29/2014
		Approved colour used in Tablet				
197	Metformin	Each Uncoated Tablets Contains:-				
	Hydrochloride Tablets IP	Metformin Hydrochloride	IP	500	mg	10/29/2014
		Excipients		qs		10/29/201-
		Approved colour used in Tablets				
109	Losartan Potassium	Each Film ageted Tableta Container				
198	Losartan Potassium Tablets IP	Each Film coated Tablets Contains:- Losartan Potassium	т	25		
	I ablets IP		IP	25	mg	10/29/2014
		Excipients Approved colour used in Coating	-	q.s		
199	Losartan Potassium	Each Film coated Tablets Contains:-				
177	Tablets IP	Losartan Potassium	IP	50	mg	
		Excipients	11		mg	10/29/2014
		Approved colour used in Coating	+	q.s		
200	Losartan Potassium &	Each Filmcoated Tablets Contains:-				
	Hydrochlorothiazide Tablets	Losartan Potassium	IP	50	mg	
	IP.	Hydrochlorothiazide	IP	12.5	mg	10/29/2014
		Excipients		q.s	8	
		Approved colour used in Coating	+	7.5		
201	Glimepiride Tablet IP	Each Uncoated Tablets Contains:-				
	T ST ST ST ST	Glimepiride	IP	1	mg	10/20
		Excipients		q.s	0	10/29/2014
		Approved colour used in Tablet		-	1	

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/ ILY WELFARE DEPARTMENT its Approved to be Manufactured INB/07/642 AND MB/07/643 28:S-MB/07/643 For the p IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	HIMACI by : Boffi period from 01.	n Biotec	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
202	Glimepiride Tablet IP	Each Uncoated Tablets Contains:-				
		Glimepiride	IP	2	mg	10/29/2014
		Excipients		q.s		10/29/2014
		Approved colour used in Tablet				
202				1		
203	Atorvastatin Calcium	Each Uncoated tablet contains:-	ID			
	Tablets IP	Atorvastatin Calcium	IP	20		10/29/2014
		eq. to Atorvastatin		20	mg	10/29/2014
		Excipients Approved colour used in tablets		q.s		
		Approved colour used in tablets				
204	Atorvastatin Calcium	Each Uncoated tablet contains:-				
	Tablets IP	Atorvastatin Calcium	IP			
		eq. to Atorvastatin		5	mg	10/29/2014
		Excipients		q.s	0	
		Approved colour used in tablets				
		▲ ▲ ▲				
205	Atorvastatin Calcium	Each Uncoated tablet contains:-				
	Tablets IP	Atorvastatin Calcium	IP			
		eq. to Atorvastatin		10	mg	10/29/2014
		Excipients		q.s		
		Approved colour used in tablets				
			-			
206		Each hard gelatin capsule contains:		• •		
	Itopride Hydrochloride(SR)	Rabeprazole Sodium	IP	20	mg	
	Capsules	(As Enteric coated Pellets)		1.50		10/20/2014
		Itopride Hydrochloride		150	mg	10/29/2014
		(As Sustained release pellets)				
		Excipients Approved colour used in Empty cap. Sh	20110	q.s		
		Approved colour used in Empty cap. Si	lells			
207	Voglibose	Each Uncoated tablet contains:-				
207	Tablets IP	Voglibose	IP	0.2	mg	
		Excipients		q.s	8	11/13/2014
		Approved colour used in tablets		-1		
		• • •		·		
208	Voglibose	Each Uncoated tablet contains:-				
	Tablets IP	Voglibose	IP	0.3	mg	11/13/2014
		Excipients		q.s		11/13/2014
		Approved colour used in tablets				
209	Voglibose & Metformin	Each Uncoated tablet contains:-				
	Tablets	Voglibose	IP	0.2	mg	
		Metformin	IP	500	mg	11/13/2014
		Excipients		q.s		
		Approved colour used in tablets				

	List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/0 LY WELFARE DEPARTMENT, Approved to be Manufactured b NB/07/642 AND MB/07/643 28:S-MB/07/643 For the pc EAS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	HIMACI y:Boffi riod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
210	Methylcobalamin,	Each Filmcoated Tablet Contains:-				
	Vit.A, Vit.D3, Vit.E, Vit.B1,	Methylcobalamin	IP	500	mcg	
	Riboflavin, B6.,	Vit.A (Acetate)	IP	5000	IU	
	Niacinamide,	Vit.D3	IP	400	IU	
	Calcium Pantothenate,	Vit.E (50%)	IP	25	IU	
	Vit.C, Folic Acid, Biotin,	Vit.B1	IP	10	mg	
	L-Glutamic Acid,	Riboflavin	IP	10	mg	
	DI-Methionine,	Vit.B6	IP	3	mg	
	Magnesium Oxide	Niacinamide	IP	50	mg	
	manganese, Copper,	Calcium Pantothenate	IP	12.5	mg	
	Zinc, Chromium,	Vit. C (Coated)	IP	100	mg	
	Selenium Tablets	Folic Acid	IP	1500	mcg	
		Biotin	BP	60	mcg	
		L-Glutamic Acid	IP	100	mg	11/13/2014
		DI-Methionine	IP	25	mg	
		Magnesium Oxide	IP	30	mg	
		Manganese Sulphate	IP		Ū	
		eq. to Manganese		2.5	mg	
		Copper Sulphate Anhydrous	BP	2.5	mg	
		Zinc Sulphate Monohydrate	IP		0	
		eq.to Zinc		22.5	mg	
		Chromium Picolenate	BP		0	
		eq. to Chromium		100	mcg	
		Sodium Selenite	IP			
		eq. to Selenium		60	mcg	
		Excipient	IP	q.s	meg	
		Approved colour used in Coating.		4.5		
		ripproved colour used in country.				
211	Metformin(SR) &	Each Uncoated tablet contains:-				
	Voglibose Tablets	Voglibose	IP	0.3	mg	
		Metformin (SR)	IP	500	mg	11/13/2014
		Excipients		q.s	8	
		Approved colour used in Tablet		-1·		
	I	- rr-				
212	Clopidogrel Bisulphate	Each Filmcoated Tablet Contains:-				
	Tablets IP	Clopidogrel Bisulphate	IP			
		Eq. to Clopidogrel		75	mg	11/13/2014
		Excipients			8	
				-1-5		
		Approved colour used in Coating		q.s		L

213	Betahistine	Each Uncoated Tablets Contains:-				
	Hydrochloride Tablets IP	Betahistine Hydrochloride	IP	8	mg	11/13/2014
		Excipients		qs		11/13/2014
		Approved colour used in Tablets				
214	Betahistine	Each Uncoated Tablets Contains:-				
	Hydrochloride Tablets IP	Betahistine Hydrochloride	IP	16	mg	11/13/2014
		Excipients		qs		11/13/2014
		Approved colour used in Tablets				
		Approved colour used in Tablets				

S.No. DOSNGE FORM, GENERIC NAME/BRAND NAME COMPOSITION secure current current current current current current current current current current current ploit APPROVE Current curent curent current current current current current current current		List of Retention Product having license No. FORM25:N	NO.HFW-H(DRUGS)279/07 ILY WELFARE DEPARTMENT,H ets Approved to be Manufactured by 1NB/07/642 AND MB/07/643 28:S-MB/07/643 For the per IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	IMACI 7 : Boffi iod from 01.	n Biotecl	h Pvt.	
Benototiamine, Vit.B6, Biotin & Folic Acid Alpha Lipoic Acid USP 200 mg Gapsules Wit B6 IP 3 mg Biotin BP 5 mg Parcetamol, IP 1.5 mg Excipients 9.8 9.8 12/15/201 Approved colour used in Tablet IP 3.2 mg Paracetamol, IP 3.25 mg Diclofenac Potassium & Serratiopeptidase IP 10 mg Serratiopeptidase IP 10 mg 12/15/201 Elevipents 9.8 IP 10 mg 12/15/201 Elevipents 9.8 IP 10 mg 12/15/201 Paracetamol, IP 3.0 mg 12/15/201 Seratiopeptidase IP 10 mg 12/15/201 Eckorip	S. No.	DOSAGE FORM, GENERIC		SPECIFI	QUANTITY	UNIT	APPROVED ON DATED
Biotin & Folic Acid CapsulesBenfottiaminei50mg p 3i1/13/201CapsulesVi B6IP3mg BiotinBP5mg mg Folic AcidIP1.5mg mg mgi1/13/201216Ramipril Tablets IPEach Uncoated tablet contains:- RamiprilIP2.5mg mg Excipients12/15/201217Ramipril Tablets IPEach Uncoated tablet contains:- RamiprilIP5mg mg Excipients12/15/201218Paracetamol, Diclofenac Potassium & Serratiopeptidase TabletsIP50mg mg Serratiopeptidase Tablets12/15/201218Paracetamol, Diclofenac Potassium & ExcipientsIP10mg mg Serratiopeptidase Tablets12/15/201219Metoprolol Tablets IPEach Uncoated tablet contains:- Diclofenac PotassiumIP10mg mg mg12/15/201220Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP25mg mg mg12/15/201221Diclofenac Sodium Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP25mg mg mg12/15/201221Diclofenac Sodium Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP50mg mg mg221Diclofenac Sodium Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP50mg mg mg221Diclofenac Sodium Tablets IPEach Entericocated tablet contai		Alpha Lipoic Acid,	Methylcobalamin	IP	1500	mcg	
CapsulesVit B6IP3mgBiotinBP5mgFolic AcidIP1.5mgApproved colour used in Cap. Shell.IP1.5mg216Ramipril Tablets IPEach Uncoated tablet contains:-IP2.5mgExcipientsq.sq.s12/15/201Approved colour used in TabletIP5mg217Ramipril Tablets IPEach Uncoated tablet contains:-IP1218Paracetamol,IP10mg12/15/201Diclofenac Potassium & Serratiopeptidase TabletsEach Filmcoated tablet contains:-IP1218Paracetamol,IP3225mg12/15/201Diclofenac Potassium & Serratiopeptidase TabletsSerratiopeptidaseIP10mg219Metoprolol Tablets IPEach Uncoated tablet contains:-IP10mg210Metoprolol Tablets IPEach Uncoated tablet contains:-IP12/15/201220Metoprolol Tablets IPEach Uncoated tablet contains:-IP12/15/201221Diclofenac Sodium Tablets IPEach Entericcoated tablet contains:-IP12/15/201222Ondansetron Tablets IPEach Entericcoated tablet contains:-IP10223Metoprolol Tablets IPEach Entericcoated tablet contains:-IP10224Diclofenac Sodium Tablets IPEach Entericcoated tablet contains:-IP4225Metoprolol Tablets IPEach En		Benfotiamine, Vit.B6,	Alpha Lipoic Acid	USP	200	mg	
		Biotin & Folic Acid	Benfotiamine		50	mg	11/13/2014
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Capsules	Vit B6	IP	3	mg	11/13/2019
Approved colour used in Cap. Shell. Image: Color of the system of the syst				BP	5	mg	
216 Ramipril Tablets IP Each Uncoated tablet contains:- IP 2.5 mg 217 Ramipril Tablets IP Each Uncoated tablet contains:- IP 2.5 mg 217 Ramipril Tablets IP Each Uncoated tablet contains:- IP 5 mg 218 Paracetamol, Excipients IP 325 mg 218 Paracetamol, Each Filmcoated tablet contains:- IP 325 mg 218 Paracetamol, Each Filmcoated tablet contains:- IP 10 12/15/201 218 Paracetamol, Each Filmcoated tablet contains:- IP 10 mg 12/15/201 218 Paracetamol, Each Filmcoated tablet contains:- IP 10 mg 12/15/201 219 Metoprolol Tablets IP Each Uncoated tablet contains:- IP 25 mg 12/15/201 220 Metoprolol Tablets IP Each Uncoated tablet contains:- IP 50 mg 221 Diclofenac Sodium Each Enterciocated tablet contains:- IP 50 mg 2220 Metoprolol Tablets IP				IP	1.5	mg	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$			Approved colour used in Cap. Shell.				
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	216	Ramipril Tablets IP	Each Uncoated tablet contains:-				
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		-	Ramipril	IP	2.5	mg	10/15/001/
217 Ramipril Tablets IP Each Uncoated tablet contains:- IP 5 mg 218 Paracetamol, IP 325 mg 12/15/201 218 Paracetamol, IP 325 mg 12/15/201 Diclofenac Potassium & Serratiopeptidase Tablets Diclofenac Potassium BP 50 mg (Not for Veterinary Use) Each Filmcoated tablet contains:- IP 10 mg (Excipients q.s q.s 12/15/201 Z19 Metoprolol Tablets IP Each Uncoated tablet contains:- IP 10 mg Z20 Metoprolol Tablets IP Each Uncoated tablet contains:- IP 25 mg Z21 Diclofenac Sodium Each Uncoated tablet contains:- IP 12/15/201 Z21 Diclofenac Sodium Each Entericcoated tablet contains:- IP 12/15/201 Z22 Metoprolol Tablets IP Each Entericcoated tablet contains:- IP 12/15/201 Z21 Diclofenac Sodium Each Entericcoated tablet contains:- IP 12/15/201 Z22 Ondansetron IP 50 mg			Excipients		q.s		12/15/2014
RamiprilIP5mg g.s.Approved colour used in TabletI2/15/201218Paracetamol, Diclofenac Potassium & Serratiopeptidase TabletsEach Filmcoated tablet contains:- ParacetamolIP325mg mg mg218Paracetamol, Diclofenac Potassium & Serratiopeptidase TabletsEach Filmcoated tablet contains:- ParacetamolIP325mg mg219Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol Tablets IPII2/15/201220Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP25mg mg Paracetamol221Diclofenac Sodium Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP50mg paracetamol221Diclofenac Sodium Tablets IPEach Entericcoated tablet contains:- Metoprolol TartrateIP50mg paracetamol221Diclofenac Sodium Tablets IPEach Entericcoated tablet contains:- Diclofenac SodiumIP50mg paracetamol222Ondansetron Tablets IPEach Uncoated Tablets Contains:- Diclofenac SodiumIP4mg paracetamol222Ondansetron Tablets IPEach Uncoated Tablets Contains:- Diclofenac SodiumIP4mg paracetamol223Methylcobalamin Tablets IPEach Filmcoated Tablets Contains:- Diclofenac SodiumIP4mg paracetamol224MethylcobalaminIP100mg paracetamolI/8/2015225Methylcobalam			Approved colour used in Tablet				
RamiprilIP5mg g.s.Approved colour used in TabletI2/15/201218Paracetamol, Diclofenac Potassium & Serratiopeptidase TabletsEach Filmcoated tablet contains:- ParacetamolIP325mg mg mg218Paracetamol, Diclofenac Potassium & Serratiopeptidase TabletsEach Filmcoated tablet contains:- ParacetamolIP325mg mg219Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol Tablets IPII2/15/201220Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP25mg mg Paracetamol221Diclofenac Sodium Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP50mg paracetamol221Diclofenac Sodium Tablets IPEach Entericcoated tablet contains:- Metoprolol TartrateIP50mg paracetamol221Diclofenac Sodium Tablets IPEach Entericcoated tablet contains:- Diclofenac SodiumIP50mg paracetamol222Ondansetron Tablets IPEach Uncoated Tablets Contains:- Diclofenac SodiumIP4mg paracetamol222Ondansetron Tablets IPEach Uncoated Tablets Contains:- Diclofenac SodiumIP4mg paracetamol223Methylcobalamin Tablets IPEach Filmcoated Tablets Contains:- Diclofenac SodiumIP4mg paracetamol224MethylcobalaminIP100mg paracetamolI/8/2015225Methylcobalam	217	Ramipril Tablets IP	Each Uncoated tablet contains:-				
Excipients q.s 12/15/201 Approved colour used in Tablet 12/15/201 218 Paracetamol, Diclofenac Potassium & Serratiopeptidase Tablets Each Filmcoated tablet contains:- Paracetamol 1P 325 ng 218 Serratiopeptidase Tablets Diclofenac Potassium BP 50 ng 218 Serratiopeptidase Tablets Diclofenac Potassium BP 50 ng 218 Serratiopeptidase Tablets Q.s method 1P 10 ng (Not for Veterinary Use) Serratiopeptidase IP 10 ng 12/15/201 219 Metoprolol Tablets IP Each Uncoated tablet contains:- 1 12/15/201 220 Metoprolol Tablets IP Each Uncoated tablet contains:- 1 12/15/201 221 Diclofenac Sodium Each Entericcoated tablet contains:- 1 12/15/201 221 Diclofenac Sodium Each Entericcoated tablet contains:- 1 12/15/201 221 Diclofenac Sodium Each Entericcoated tablet contains:- 1 12/15/201 222 Ondansetron IP 4, s 4, s	217	Rumpin Tuolois II		IP	5	mg	
Approved colour used in Tablet Image: Contrains in the i			1		-		12/15/2014
Diclofenac Potassium & Serratiopeptidase Tablets (Not for Veterinary Use)ParacetamolIP325mg mg (Eq. to 2000 units of Enzymatic activity)12/15/201219Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol Tablets IPIP10mg mg (Eq. to 2000 units of Enzymatic activity)12/15/201219Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP25mg mg (IP12/15/201220Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP50mg mg (I2/15/201221Diclofenac Sodium Tablets IPEach Entericcoated tablet contains:- Metoprolol TartrateIP50mg mg (I2/15/201221Diclofenac Sodium Tablets IPEach Entericcoated tablet contains:- Metoprolol TartrateIP50mg mg (I2/15/201222Ondansetron Tablets IPEach un-coated Tablets Contains:- OndansetronIP4mg mg (I2/15/201223Methylcobalamin Tablets IPEach un-coated Tablets Contains:- (OndansetronIP4mg mg (I8/2015223Methylcobalamin Tablets IPEach Entericcoated Tablets Contains:- (IRIP1/8/2015224Methylcobalamin Tablets IPEach IIIncoated Tablets Contains:- (IRIII1/8/2015223Methylcobalamin TabletsEach Filmcoated Tablets Contains:- (IRIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII			1		4		
Diclofenac Potassium & Serratiopeptidase Tablets (Not for Veterinary Use)ParacetamolIP325mg mg (Eq. to 2000 units of Enzymatic activity)12/15/201219Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol Tablets IPIP10mg mg (Eq. to 2000 units of Enzymatic activity)12/15/201219Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP25mg mg (IP12/15/201220Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP50mg mg (I2/15/201221Diclofenac Sodium Tablets IPEach Entericcoated tablet contains:- Metoprolol TartrateIP50mg mg (I2/15/201221Diclofenac Sodium Tablets IPEach Entericcoated tablet contains:- Metoprolol TartrateIP50mg mg (I2/15/201222Ondansetron Tablets IPEach un-coated Tablets Contains:- OndansetronIP4mg mg (I2/15/201223Methylcobalamin Tablets IPEach un-coated Tablets Contains:- (OndansetronIP4mg mg (I8/2015223Methylcobalamin Tablets IPEach Entericcoated Tablets Contains:- (IRIP1/8/2015224Methylcobalamin Tablets IPEach IIIncoated Tablets Contains:- (IRIII1/8/2015223Methylcobalamin TabletsEach Filmcoated Tablets Contains:- (IRIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	210	D 1	P 1 P ¹				
Serratiopeptidase Tablets (Not for Veterinary Use) Diclofenac Potassium BP 50 mg Serratiopeptidase IP 10 mg 12/15/201 Excipients 9.8 9.8 9.8 12/15/201 Approved colour used in Coating 9.8 12/15/201 219 Metoprolol Tablets IP Each Uncoated tablet contains:- 1 1 Metoprolol Tablets IP Each Uncoated tablet contains:- 9.8 1 220 Metoprolol Tablets IP Each Uncoated tablet contains:- 9.8 1 220 Metoprolol Tablets IP Each Uncoated tablet contains:- 1 1 220 Metoprolol Tablets IP Each Uncoated tablet contains:- 1 1 221 Diclofenac Sodium Tablets 9.8 1 12/15/201 221 Diclofenac Sodium Each Entericcoated tablet contains:- 1 1 1 222 Ondansetron IP 4.9 9.8 1 12/15/201 222 Ondansetron IP 4.9 1 1 1/15/201 223 Methylcobalamin Each	218	,		ID	225		
						U	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$						U	12/15/201
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		(Not for veterinary Use)	1 1		10	mg	12/13/2014
Approved colour used in CoatingImage: Control of Co)			
219 Metoprolol Tablets IP Each Uncoated tablet contains:- IP 25 mg 219 Metoprolol Tablets IP Each Uncoated tablet contains:- IP 25 mg 220 Metoprolol Tablets IP Each Uncoated tablet contains:- IP 50 mg 220 Metoprolol Tablets IP Each Uncoated tablet contains:- IP 50 mg 221 Diclofenac Sodium Each Entericcoated tablet contains:- IP 50 mg 221 Diclofenac Sodium Each Entericcoated tablet contains:- IP 50 mg 221 Diclofenac Sodium Each Entericcoated tablet contains:- IP 50 mg 221 Diclofenac Sodium Each Entericcoated tablet contains:- IP 50 mg 222 Ondansetron IP 50 mg 12/15/201 222 Ondansetron IP 4 mg 1/8/2015 223 Methylcobalamin Each Filmcoated Tablets Contains:- IP 4 mg 223 Methylcobalamin Each Filmcoated Tablets Contains:- IP 1/8/2015			-		q.s		
Metoprolol TartrateIP25mg12/15/201Approved colour used in TabletIP25mg12/15/201220Metoprolol Tablets IPEach Uncoated tablet contains:- Metoprolol TartrateIP50mg221Diclofenac Sodium Tablets IPEach Entericcoated tablet contains:- Metoprod colour used in TabletIP50mg221Diclofenac Sodium Tablets IP (Not for Veterinary Use)Each Entericcoated tablet contains:- Diclofenac Sodium ExcipientsIP50mg222Ondansetron Tablets IP (Not for Veterinary Use)Each un-coated Tablets Contains:- OndansetronIP4mg222Ondansetron Tablets IPEach un-coated Tablets Contains:- Approved colour used in CoatingIP4mg223Methylcobalamin TabletsEach Filmcoated Tablets Contains:-IP4mg223Methylcobalamin TabletsEach Filmcoated Tablets Contains:-InI/18/2015223Methylcobalamin TabletsEach Filmcoated Tablets Contains:-InIn223Methylcobalamin TabletsEach Filmcoated Tablets Contains:-InIn233Methylcobalamin TabletsInIP1/8/2015244Intervent InterventInInIn255Intervent InterventInInIn266Intervent InterventInInIn275Intervent InterventInInIn276Intervent InterventIn </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Excipients q.s 12/15/201 Approved colour used in Tablet 12/15/201 220 Metoprolol Tablets IP Each Uncoated tablet contains:- 1 Metoprolol Tablets IP Each Uncoated tablet contains:- 1 12/15/201 220 Metoprolol Tablets IP Each Uncoated tablet contains:- 1 12/15/201 221 Diclofenac Sodium q.s q.s 1 12/15/201 221 Diclofenac Sodium Each Entericcoated tablet contains:- 1 12/15/201 221 Diclofenac Sodium IP 50 mg Tablets IP Each Entericcoated tablet contains:- 1 12/15/201 222 Ondansetron IP 50 mg Tablets IP Each un-coated Tablets Contains:- 1 12/15/201 222 Ondansetron IP 4 mg Tablets IP Each un-coated Tablets Contains:- 1 1/8/2015 223 Methylcobalamin Each Filmcoated Tablets Contains:- 1 1/8/2015 223 Methylcobalamin Each Filmcoated Tablets Contains:- 1 1/8/2015	219	Metoprolol Tablets IP					
Excipients q.s q.s Approved colour used in Tablet Image: colour description of the second secon			-	IP	25	mg	12/15/2014
220 Metoprolol Tablets IP Each Uncoated tablet contains:- IP 50 mg 221 Diclofenac Sodium Approved colour used in Tablet IP 50 mg 221 Diclofenac Sodium Each Entericcoated tablet contains:- IP 50 mg 221 Diclofenac Sodium Each Entericcoated tablet contains:- IP 50 mg 221 Diclofenac Sodium Each Entericcoated tablet contains:- IP 50 mg 222 Ondansetron IP 50 mg 12/15/201 222 Ondansetron IP 4 mg Tablets IP Each un-coated Tablets Contains:- IP 4 mg 222 Ondansetron IP 4 mg Tablets IP Each un-coated Tablets Contains:- IP 4 mg 223 Methylcobalamin Each Filmcoated Tablets Contains:- IN 1/8/2015 223 Methylcobalamin Each Filmcoated Tablets Contains:- IN IN 223 Methylcobalamin IP 1500 mcg 1/8/2015 <td></td> <td></td> <td>1</td> <td></td> <td>q.s</td> <td></td> <td>12/10/201</td>			1		q.s		12/10/201
Metoprolol TartrateIP50mgExcipientsq.sq.s12/15/201Approved colour used in Tabletq.s12/15/201221Diclofenac SodiumEach Entericcoated tablet contains:			Approved colour used in Tablet				
Excipientsq.s12/15/201Approved colour used in TabletApproved colour used in Tablet12/15/201221Diclofenac SodiumEach Entericcoated tablet contains:	220	Metoprolol Tablets IP	Each Uncoated tablet contains:-				
Excipientsq.sApproved colour used in TabletI221Diclofenac SodiumTablets IP (Not for Veterinary Use)Each Entericcoated tablet contains:-Diclofenac SodiumIPExcipientsq.sApproved colour used in CoatingIP222Ondansetron Tablets IP (Not for Veterinary Use)Each un-coated Tablets Contains:-IImage: Contains of the section of th			Metoprolol Tartrate	IP	50	mg	10/15/001
221 Diclofenac Sodium Each Entericcoated tablet contains:-			Excipients		q.s		12/13/2014
Tablets IP (Not for Veterinary Use)Diclofenac SodiumIP50mg g.s12/15/201222Ondansetron Tablets IPEach un-coated Tablets Contains:- OndansetronIP4mg g.s1/8/2015223Methylcobalamin TabletsEach Filmcoated Tablets Contains:- MethylcobalaminIP1500mcg g.s1/8/2015223Methylcobalamin TabletsEach Filmcoated Tablets Contains:- (MethylcobalaminIP1500mcg g.s1/8/2015			Approved colour used in Tablet				
Tablets IP (Not for Veterinary Use)Diclofenac SodiumIP50mg g.s12/15/201222Ondansetron Tablets IPEach un-coated Tablets Contains:- OndansetronIP4mg g.s1/8/2015223Methylcobalamin TabletsEach Filmcoated Tablets Contains:- MethylcobalaminIP1500mcg g.s1/8/2015223Methylcobalamin TabletsEach Filmcoated Tablets Contains:- (MethylcobalaminIP1500mcg g.s1/8/2015	221	Diclofenac Sodium	Each Entericcoated tablet contains:-				
(Not for Veterinary Use) Excipients q.s 12/15/201 Approved colour used in Coating q.s 1 222 Ondansetron Tablets IP Each un-coated Tablets Contains:-	221			IP	50	mσ	
Approved colour used in Coating I 222 Ondansetron Tablets IP Each un-coated Tablets Contains:- Image: Contains:- Ondansetron Tablets IP Each un-coated Tablets Contains:- Image: Contains:- Image: Contains:- 223 Methylcobalamin Tablets Each Filmcoated Tablets Contains:- Image: Contains:- Image: Contains:- 223 Methylcobalamin Tablets Each Filmcoated Tablets Contains:- Image: Contains:- Image: Contains:- 223 Methylcobalamin Tablets Each Filmcoated Tablets Contains:- Image: Contains:- Image: Contains:- 223 Methylcobalamin Image: Contains:- Image: Contains:- Image: Contains:- 23 <							12/15/2014
Tablets IP Ondansetron IP 4 mg Excipients q.s q.s 1/8/2015 Approved colour used in Coating 1 1/8/2015 223 Methylcobalamin Tablets Each Filmcoated Tablets Contains:- 1 1 Rethylcobalamin IP 1500 mcg 1/8/2015 Excipients 1 1/8/2015 1/8/2015		(-		4		
Tablets IP Ondansetron IP 4 mg Excipients q.s q.s 1/8/2015 Approved colour used in Coating 1 1/8/2015 223 Methylcobalamin Tablets Each Filmcoated Tablets Contains:- 1 1 Rethylcobalamin IP 1500 mcg 1/8/2015 Excipients 1 1/8/2015 1/8/2015	2000						
Excipients q.s 1/8/2015 Approved colour used in Coating 1/8/2015 223 Methylcobalamin Tablets Each Filmcoated Tablets Contains:- Image: Contains:- Methylcobalamin Excipients IP 1500 mcg 1/8/2015 Image: Contains:- Image: Contains:- Image: Contains:-	222			ID	-		
Approved colour used in Coating Image: Contain state s		I ablets IP		IP		mg	1/8/2015
223 Methylcobalamin Tablets Each Filmcoated Tablets Contains:- IP 1500 mcg Excipients q.s 1/8/2015			-		q.s		
TabletsMethylcobalaminIP1500mcgExcipientsq.s1/8/2015					I		
Excipients q.s 1/8/2015	223	-					
Excipients q.s		Tablets		IP	1500	mcg	1/8/2015
					q.s		1, 0, 2010

	List of Retention Product having license No. FORM25:N	NO.HFW-H(DRUGS)279/ ILY WELFARE DEPARTMENT its Approved to be Manufactured ANB/07/642 AND MB/07/643 28:S-MB/07/643 For the IZE AS PER SCHEDULE-P-1 OF DRUGS & COSME	,HIMACI by : Boffi period from 01.	n Biotec	h Pvt.	
S. No.	PACK S DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
224	Methylprednisolone	Each Uncoated Tablets Contains:-				
	Tablets IP	Methylprednisolone	IP	4	mg	1/8/2015
		Excipients		q.s		1/0/2015
		Approved colour used in Tablet				
225	Methylprednisolone	Each Uncoated Tablets Contains:-				
225	Tablets IP	Methylprednisolone	IP	16	mg	
		Excipients		q.s	mg	1/8/2015
		Approved colour used in Tablet		4 .5		
226	Enalapril Maleate	Each Uncoated tablet contains:-				
	Tablets IP	Enalapril Maleate	IP	5	mg	1/8/2015
		Excipients		q.s		
		Approved colour used in tablets				
227	Cefpodoxime Proxetil	Each Uncoated Tablets Contains:-				
	Tablets IP	Cefpodoxime Proxetil	IP			
		Eq. to Cefpodoxime		50	mg	1/8/2015
		Excipients		q.s	0	
		Approved colour used in Tablets				
220						
228	Cefpodoxime Proxetil	Each Uncoated Tablets Contains:-	ID			
	Tablets IP	Cefpodoxime Proxetil	IP	100		1/8/2015
		Eq. to Cefpodoxime Excipients		100	mg	1/0/2013
		Approved colour used in Tablets		q.s		
229	Cefpodoxime Proxetil	Each Uncoated Tablets Contains:-				
	Tablets IP	Cefpodoxime Proxetil	IP			
		Eq. to Cefpodoxime		200	mg	1/8/2015
		Excipients		q.s		
		Approved colour used in Tablets				
230	Cefixime	Each Uncoated Tablets Contains:-				
	Tablets IP	Cefixime	IP			
		Eq. to Anhydrous Cefixime		50	mg	1/8/2015
		Excipients		q.s	0	
		Approved colour used in Tablets				
221				1		
231	Cefixime	Each Uncoated Tablets Contains:-	- ID			
	Tablets IP	Cefixime Eq. to Anhydrous Cefixime	IP	100	ma	1/8/2015
		Eq. to Annydrous Cenxine Excipients		q.s	mg	1/0/2013
		Approved colour used in Tablets		q.3		
232	Telmisartan	Each Uncoated Tablets Contains:-				
232	Telmisartan Tablets IP	Each Uncoated Tablets Contains:- Telmisartan Excipients	IP	40	mg	1/8/2015

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/0 ILY WELFARE DEPARTMENT, J Its Approved to be Manufactured b INB/07/642 AND MB/07/643 28:S-MB/07/643 For the per IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	HIMACI y:Boffi riod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
233	Pioglitazone Tablets IP	Each Uncoated tablet contains:-				
	Note:- Package insert as per	Pioglitazone HCl	IP			
	notification of Ministry	eq. to Pioglitazone		15	mg	2/24/2015
	of Health & Family	Excipients		q.s		
	Welfare No.GSR520(E)	Approved colour used in tablets				
234	Pioglitazone Tablets IP	Each Uncoated tablet contains:-				
201	Note:- Package insert as per	Pioglitazone HCl	IP			
	notification of Ministry	eq. to Pioglitazone		30	mg	2/24/2015
	of Health & Family	Excipients		q.s	mg	2/2 // 2010
	Welfare No.GSR520(E)	Approved colour used in tablets		4		
235	Rosuvastatin Tablets IP	Each Uncoated Tablets Contains:-				
		Rosuvastatin Calcium	IP			
		eq. to Rosuvastatin		10	mg	2/24/2015
		Excipients		q.s		
		Approved colour used in Tablets				
236	Rosuvastatin Tablets IP	Each Uncoated Tablets Contains:-				
250	Rosuvastatini Tablets II	Rosuvastatin Calcium	IP			
		eq. to Rosuvastatin		20	mg	2/24/2015
		Excipients		q.s	mg	2/24/2015
		Approved colour used in Tablets		q .5		
237	Serratiopeptidase Tablets IP	Each Enteric coated tablets Contains:-				
		Serratiopeptidase	IP	10	mg	
		(20,000 Enzymatic Units)				2/24/2015
		Excipients	_	q.s		
		Approved Colour used in Coating				
238	Serratiopeptidase Tablets IP	Each Enteric coated tablets Contains:-				
250	Serranopeptidase Tablets II	Serratiopeptidase	IP	20	mg	
		(40,000 Enzymatic Units)		-	mg	2/24/2015
		Excipients		q.s		
		Approved Colour used in Coating		-		
239	Telmisartan &	Each Uncoated Tablet contains:-				
	Amlodipine Besilate Tablets	Telmisartan	IP	40	mg	
		Amlodipine Besilate	IP			2/24/2015
		eq. to Amlodipine		5	mg	
		Excipients		q.s		
		Approved colour used in Tablets.				
240	Nimesulide Tablets	Each Uncoated Tablets Contains:-				
	Not for Children below	Nimesulide	BP	100	mg	a /a / /a = · · -
	12years of age	Excipients	-	q.s	0	2/24/2015
		Approved Colour used in tablets				
	-		•	•		
241	Metformin Tablets IP	Each Uncoated Sustained Release Table	ts Contain			
241	Metformin Tablets IP 500mg (SR)	Metformin HCl	ts Contain IP	is:- 500	mg	2/24/2015
241					mg	2/24/2015

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/(ILY WELFARE DEPARTMENT, ts Approved to be Manufactured I INB/07/642 AND MB/07/643 28:S-MB/07/643 For the p ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	HIMACI by : Boffi eriod from 01.	n Biotecl	h Pvt.	
S. No.	PACK SI DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
242	Metformin Tablets IP	Each Uncoated Sustained Release Table	ate Contain		-	
242	1000mg (SR)	Metformin HCl	IP	1000	mg	
	rooonig (SK)	Excipients	11		mg	2/24/2015
		Approved colour used in Tablets		q.s		
243	Mefenamic Acid &	Each Uncoated Tablets Contains:-		1		
243	Dicyclomine HCl. Tablets IP	Mefenamic Acid	IP		ma	
	Dicyclollille HCI. Tablets IP	Melenaniic Acid	IF	250	mg	
		Dicyclomine HCl.	IP	10	mg	2/24/2015
		Excipients	11	q.s	mg	
		Approved Colour used in Tablets		4 .5		
		Approved Colour used in Tablets				
244	Gliclazide Tablets IP	Each Uncoated Tablets Contains:-				
		Gliclazide	IP	80	mg	0/04/0015
		Excipients		qs		2/24/2015
		Approved colour used in Tablets				
	•					
245	Dicyclomine HCl &	Each Uncoated Tablet contains:-				
	Paracetamol Tablets	Dicyclomine HCl	IP	20	mg	
		paracetamol	IP	325	mg	2/24/2015
		Excipients		q.s	0	
		Approved colour used in Tablets.		1		
216				1	1	
246	Dexamethasone Tablets IP	Each Uncoated Tablet contains:-	m	0.5		
		Dexamethasone	IP	0.5	mg	2/24/2015
		Excipients	_	q.s		
		Approved colour used in Tablets.				
247	Clopidogrel Bisulphate &	Each Filmcoated Tablets Contains:-				
	Asprin Tablets	Clopidogrel Bisulphate	IP			
		Eq. to Clopidogrel		75	mg	0/04/2016
		Asprin	IP	150	mg	2/24/2015
		Excipients		q.s		
		Approved Colour used in Coating				
248	Betamethasone Tablets IP	Each Uncoated Tablets Contains:-				
240	Detailethasone Tablets II	Betamethasone	IP	0.5	mσ	
		Excipients	11		mg	2/24/2015
		Approved colour used in Tablets		q.s		
249	Aceclofenac &	Each Filmcoated Tablets Contains:-				
	Thiocolchicoside Tablets	Aceclofenac	IP	100	mg	
		Thiocolchicoside		4	mg	2/24/2015
		Excipients		q.s		
	1	Approved colour used in Coating				
250	Aceclofenac &	Each Filmcoated Tablets Contains:-				
	Thiocolchicoside Tablets	Aceclofenac	IP	100	mg	
		Thiocolchicoside			-	2/24/2015
		Thiocolonicoside	IP	8	mg	2/24/2015
		Excipients	IP	q.s	mg	2/24/2013

	List of Retention Produce having license No. FORM253	IILY WELFARE DEPARTMENT, cts Approved to be Manufactured b MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the per SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	y:Boffi riod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
251	Calamine,Zinc Oxide,	Calamine	IP	15%	w/v	
	Bentonite, Glycerin &	Zinc Oxide	IP	5%	w/v	
	Sodium Citrate Lotion	Bentonite	IP	3%	w/v	
		Glycerin	IP	5%	w/v	2/24/2015
		Sodium Citrate	IP	0.05%	w/v	
		Lotion Base		q.s	, .	
				1		
252	Ursodeoxycholic Acid	Each Uncoated tablet contains:-				
	Tablets IP	Ursodeoxycholic Acid	IP	150	mg	3/10/2015
		Excipients		q.s		5/10/2013
		Approved colour used in tablets				
253	Ursodeoxycholic Acid	Each Uncoated tablet contains:-				
	Tablets IP	Ursodeoxycholic Acid	IP	300	mg	3/10/2015
		Excipients		q.s		0/10/2010
		Approved colour used in tablets				
254	Linezolid Tablets IP	Each Uncoated Tablets Contains:-				
234	Linezond Tablets IP	Linezolid	IP	600	ma	
			IP		mg	3/10/2015
		Excipients Approved colour used in Tablets		q.s		
		Approved colour used in Tablets				
255	Carvedilol Tablets IP	Each Uncoated Tablets Contains:-				
		Carvedilol	IP	3.125	mg	
		Excipients		q.s	0	3/10/2015
		Approved colour used in Tablets		1		
256	Calcium with	Each Uncoated Tablet Contains:-				
	& Vitamin D3 Tablets IP	Calcium Carbonate		1.25	gm	
		From an organic Source (Oyster Shell)				
		eq. to Elemental Calcium		500	mg	3/10/2015
		Vitamin D3	IP	250	IU	
		Excipients		q.s		
		Approved colour used in Tablets				
257	Acarbose Tablets IP	Each Uncoated Tablets Contains:-				
237	Acarbose Tablets If	Acarbose	IP	25	ma	
		Excipients	п		mg	3/10/2015
		Approved colour used in Tablets		qs		
		Approved colour used in Tablets				
258	Acarbose Tablets IP	Each Uncoated Tablets Contains:-				
		Acarbose	IP	50	mg	
		Excipients		qs	5	3/10/2015
		Approved colour used in Tablets		-1-		
	•	•	·			
259	Paracetamol &	Each Uncoated Tablets Contains:-				
	CaffeineTablets IP	Paracetamol	IP	325	mg	
		Caffeine (Anhydrous)	IP	25	mg	4/8/2015
		Excipients		q.s		
		Approved colour used in Tablets				
-	Paracetamol	Each Uncoated tablet contains:				

	List of Retention Product having license No. FORM25:	NO.HFW-H(DRUGS)279/(ILY WELFARE DEPARTMENT, cts Approved to be Manufactured I MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the p HZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	HIMACI by : Boffi period from 01.	n Biotec	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Cetirizine HCl &	Paracetamol	IP	325	mg	
	Phenylephrine HCl	Cetirizine HCl	IP	5	mg	4/8/2015
	Tablets	Phenylephrine HCl	IP	5	mg	4/8/2013
		Excipients		q.s.		
		Colour:Approved colour used				
261	Tizanidine HCl &	Each Uncoated Tablets Contains:-				
	Nimesulide Tablets	Tizanidine HCl	IP			
	Not for children below	Eq. to Tizanidine		2	mg	4/8/2015
	12 years of age.	Nimesulide	BP	100	mg	4/0/2015
		Excipients		q.s		
		Approved colour used in Tablets				
262	Nimesulide	Each Uncoated Tablet contains:-				
262	Nimesulide Paracetamol &	Each Uncoated Tablet contains:- Nimesulide	חת	100		
	Chlorzoxazone Tablets	paracetamol	BP IP	100 325	mg	
	Not for children below	Chlorzoxazone	USP	250	mg	4/8/2015
	12 years of age.	Excipients	USP		mg	
	12 years of age.	Approved colour used in Tablets.		q.s		
		Approved colour used in Tablets.				
263	Lactic acid Bacillus	Each Uncoated Tablets Contains:-				
	Tablets	Lactic acid Bacillus		100	Millin	4/0/2015
		Excipients		q.s	Spore	4/8/2015
		Approved colour used in Tablets				
0.64	Y (111) YY 1 1 1			1		
264	Iron(lll) Hydroxide	Each Uncoated Chewable Tablets conta				
	polymaltose Complex	Iron(111) Hydroxide polymaltose Comple	ex	100		
	& Folic Acid Tablets	Eq. To Elemental Iron	m	100	mg	4/8/2015
		Folic Acid	IP	350	mcg	
		Excipients		q.s		
		Approved colour used in Tablets				
265	Dextromethorphan HBr,	Each Uncoated Tablets Contains:-				
-55	CPM & Phenylephrine	Dextromethorphan HBr,	IP	10	mg	
	HCI I ablets	Pnenyiepnrine HCi	IP	5	mg	4/0/2015
		Chlorpheniramine Maleate	IP	2	mg	4/8/2015
		Excipients		q.s		
		Approved colour used in Tablets				
244				1	1	
266	Ciprofloxacin HCl &	Each Film coated tablet contains:-	ID			
	Tinidazole Tablets	Ciprofloxacin HCl	IP	500		
		eq. to Ciprofloxacin	m	500	mg	4/8/2015
		Tinidazole	IP	600	mg	
		Excipients	-	q.s		
267	Carbonyl Iron	Approved colour used in Coating				
267	Carbonyl Iron,	Each hard gelatin capsule Contains:-				
	Zinc Sulphate &	Carbonyl Iron		50		
	Folic Acid Capsules	Eq. to Elemental Iron	TD	50	mg	
	Fonc Acid Capsules	Zina Sulphote Manahudat				
	Fonc Acid Capsules	Zinc Sulphate Monohydrate	IP	61.8	mg	4/8/2015
	Fonc Acid Capsules	Eq. to Elemental Zinc 22.5mg)				4/8/2015
	Fonc Acid Capsules	-	IP IP	61.8 0.5 q.s	mg mg	4/8/2015

	HEALTH AND FAMI List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/07 LY WELFARE DEPARTMENT,H ts Approved to be Manufactured by NB/07/642 AND MB/07/643 28:S-MB/07/643 For the per ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	IMACI Solution : : : : : : : : : : : : : : : : : : :	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
268	Aceclofenac and Serratiopeptidase Tablets	Each Film Coated Tablet Contains:- Aceclofenac	IP	100	mg	
		Serratiopeptidase(As enteric coated granules) (30000 enzymatic units of serratiopeptida	IP se)	15	mg	4/8/2015
		Excipients Approved colour used in Coating		q.s		
269	Beclomethasone	Beclomethasone Dipropionate	IP	0.025%	w/w	
209		Clotrimazole	IP IP			
	Dipropionate & Clotrimazole Cream	Clotrimazole Chlorocresol(As Preservative)	IP IP	1%	w/w	4/8/2015
	Clotrimazole Cream	In cream Base	IP	0.1% q.s	w/w	
	r			1		
270	Clindamycin Phosphate &	Clindamycin Phosphate	BP			
	Nicotinamide Gel	Eq. to Clindamycin		1%	w/w	
		Nicotinamide	IP	4%	W/W	4/8/2015
		Gel base		q.s		
271	Urea, Lactic Acid,	Urea	IP	10%	w/w	
	Propylene Glycol &	Lactic Acid	IP	10%	w/w	
	Liquid Paraffin Cream	Propylene Glycol	IP	10%	w/w	4/8/2015
	-	Liquid Paraffin	IP	10%	w/w	
		Cream Base		qs		
272	Diclofenac Diethylamine,	Dialofance Diathylamine	BP	1 160/	***/***	
212		Diclofenac Diethylamine	ВР	1.16%	w/w	
	Oleum Lini, Methylaslicylate,	eq. to Dicflofenac Sodium	DD	1%	w/w	
	Menthol & Capsaicin Gel.	Oleum Lini	BP	3%	w/w	
		Menthol	IP	5%	w/w	4/8/2015
		Methyl salicylate	IP	10%	w/w	., 0, 2010
		Capsaicin	USP	0.025%	W/W	
		Benzyl Alcohol(As Preservative)	IP	1%	w/w	
		In Gel Base		q.s		
273	Ketoconazole Shampoo	Ketoconazole	IP	2%	w/w	
		Shampoo Base		qs		4/8/2015
		Apprpved Colour used				
274	Permethrin Lotion	Permethrin		5%	w/v	
		Formaldehyde Solution (as Preservative)	BP	0.1%	w/v	4/8/2015
		Lotion Base		q.s		
275	Permethrin Cream	Permethrin		5%	w/v	
		Formaldehyde Solution (as Preservative)	BP	0.1%	w/v	4/8/2015
		Cream Base	21	q.s	, •	
276	Loperamide Tablets IP	Each Uncoated Tablets Contains:-				
210	Loperannue Tablets IF		ID	2	ma	
		Loperamide HCl.	IP	2	mg	5/15/2015
	1	Excipients		qs		
	1	Approved colour used in Tablets		1		

		NB/07/642 AND MB/07/643 28:S-MB/07/643 For the per ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	iod from 01.			Ltd.
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
277	Levocetirizine HCl.&	Each Dispersiable tablet contains:-				
211	Montelukast Sodium	Levocetirizine HCL.	IP	2.5	mg	
	Dispersiable Tablet	Montelukast Sodium	IP	2.5	mg	
		eq. to montelukast		4	mg	5/15/2015
		Excipients		q.s	8	
		Approved Colour used in Tablets		1		
278	Fexofenadine HCl.Tablets IP	Each Filmcoated tablet contains:-				
270	rexolenadine fiel. rablets fi	Fexofenadine HCl.	IP	180	mg	
		Excipients		q.s	mg	5/15/2015
		Approved Colour used in Coating		4.5		
279	Fluconazole Tablet IP	Each Uncoated tablet contains:-				
		Fluconazole	IP	150	mg	5/15/2015
		Excipients		q.s		5/15/2015
		Approved Colour used in Tablet				
280	Doxycycline Hyclate	Each FilmCoated tablet contains:-				
	Tablets USP	Doxycycline Hyclate	IP			
		eq. to Doxycycline		100	mg	5/15/2015
		Excipients		q.s		
		Approved Colour used in Coating				
281	Bisacodyl Tablets IP	Each Enteric Coated tablet contains:-			<u> </u>	
201	Disacouyi Tablets Ir	Bisacodyl	IP	5	ma	
		Excipients	п	q.s	mg	5/15/2015
		Approved Colour used in Coating		415		
				1		
282	Cefuroxime Axetil	Each Filmcoated tablet contains:-	ID			
	Tablets IP	Cefuroxime Axetil	IP	250		5/15/2015
		eq.to Cefuroxime Excipients		250	mg	5/15/2015
		Approved colour used in Coating		q.s		
283	Cefuroxime Axetil	Each Filmcoated tablet contains:-				
200	Tablets IP	Cefuroxime Axetil	IP			
		eq.to Cefuroxime		500	mg	5/15/2015
		Excipients		q.s	0	
		Approved colour used in Coating				
284	Loperamide Capsules	Each Hard Gelatin Capsules Contains:-				
		Loperamide HCl.	IP	2	mg	5/15/2015
		Excipients		qs		5/15/2015
		Approved colour used in Capsule shell				
285	Methylcobalamin,	Each hard gelatin Capsule contains:-				
-50	Alpha Lipoic Acid, Biotin,	Methylcobalamin	IP	1500	mcg	
	Pyridoxine & Folic Acid	Alpha Lipoic Acid	USP	200	mcg	
	Capsules	Biotin	BP	30	mcg	E /1 E /0.01 -
		Pyridoxine	IP	3	mg	5/15/2015
				1500		
		Foilc Acid	IP	1500	mcg	
		Foilc Acid Excipients Approved colour used in Capsule shell.	IP	1500 q.s	mcg	

	List of Retention Product having license No. FORM25:N	NO.HFW-H(DRUGS)279/0' ILY WELFARE DEPARTMENT, H its Approved to be Manufactured by MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the per IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	IIMACI y : Boffi ^{iod from 01.}	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
286	Benzoyl Peroxide Cream IP	Composition:-				
	-	Benzoyl Peroxide	IP	2.5%	w/w	5/15/2015
		Cream Base		q.s		
287	Clindamycin Phosphate &	Composition	1	I	· · ·	
207	Adapalene Gel	Clindamycin Phosphate	IP			
	Adapatelle Gel	eq.to Clindamycin	ш	1%	w/w	5/15/2015
		Adapalene		0.1%	w/w	5/15/2012
		In Gel base		q.s	w/w	
				1		
288	Fusidic Acid Cream IP	Composition:-				
		Fusidic Acid	IP	2%	\mathbf{W}/\mathbf{W}	
		Potassium Sorbate	BP	0.275%	w/w	5/15/2015
		(As a Preservative)				
		Cream Base		q.s		
289	Tacrolimus Cream	Composition:-				
207	racioninus cream	Tacrolimus	USP	0.03%	w/w	
		Chlorocresol	IP	0.1%	w/w	5/15/2015
		(As preservative)		0.170	**/ **	5/15/201
		Cream Base		q.s		
				1		
290	Itraconazole Capsules BP	Each Hard gelatin Capsule Contains:-				
		Itraconazole	BP	100	mg	
		(In the form of Pellets)				5/15/2015
		Excipients		q.s		
		Approved colour used in Capsule Shell				
291	Telmisartan Tablets IP	Each Uncoated Tablets Contains:-				
271	Tennisarun Tublets II	Telmisartan	IP	20	mg	
		Excipients		qs	mg	6/18/2015
		Approved colour used in Tablets		1-		
			T	I		
292	Etoricoxib Tablets IP	Each Uncoated tablet contains:-				
		Etoricoxib	IP	60	mg	6/18/2015
		Excipients		q.s		
293	Etoricoxib Tablets IP	Approved colour used in Tablets Each Uncoated tablet contains:-			┝──┨	
293	Etoricoxid Tablets IP	Etoricoxib	IP	90	ma	
		Excipients	11*		mg	6/18/2015
		Approved colour used in Tablets		q.s		
		Each Uncoated tablet contains:-			┝─┨	
294	Etoricoxib Tablets IP	one one of the contains.	IP	100	ma	
294	Etoricoxib Tablets IP	Etoricoxib		120	mg	
294	Etoricoxib Tablets IP		- 11	-	mg	6/18/2015
294	Etoricoxib Tablets IP	Etoricoxib Excipients Approved colour used in Tablets	п 	q.s	ing	6/18/2015
294	Etoricoxib Tablets IP	Excipients Approved colour used in Tablets		-	ing	6/18/2015
	Atorvastatin Calcium	Excipients Approved colour used in Tablets Each Uncoated Tablets Contains:-		-		6/18/2015
		Excipients Approved colour used in Tablets Each Uncoated Tablets Contains:- Atorvastatin Calcium	IP	q.s		
294	Atorvastatin Calcium	Excipients Approved colour used in Tablets Each Uncoated Tablets Contains:-		-	mg	6/18/2015

NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945								
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED		
296	Telmisartan &	Each Uncoated Tablet Contains:-						
	Amlodipine Besilate	Telmisartan	IP	80	mg			
	Tablets IP	Amlodipine Besilate	IP		0			
		eq. to Amlodipine		5	mg	5/8/2015		
		Excipients		qs				
		Approved colour used in Tablets		-				
297	Diclofenac sodium &	Each Enteric coated tablet contains:-						
227	Serratiopeptidase	Diclofenac sodium	IP	50	mg			
	Tablets	Serratiopeptidase	IP	10	mg			
	(Not for Veterinary Use)	(eq. to 20,000 Enzymatic units)			8	5/8/2015		
	(Excipients		q.s				
		Approved colour used in Coating		1				
200					-			
298	Aceclofenac,	Composition	m	1.50/	1			
	Methyl salicylate,	Aceclofeanc	IP IP	1.5%	w/w			
	Menthol, Linseed Oil &	Methyl salicylate Menthol	IP IP	10%	W/W			
	Capsaicin Gel	Linseed Oil	BP	5% 3%	w/w w/w	5/8/2015		
		capsaicin	USP	0.025%	w/w w/w	3/8/2013		
		Benzyl alcohol	IP	1%	w/w w/w			
		(As a Preservative)	11	1 70	W/W			
		In Gel base		q.s				
299	Aceclofenac(SR) &	Each Hard Gelatin capsule contains:-						
	Rabeprazole sodium(EC)	Aceclofenac	IP	200	mg			
	Capsules	(As Sustained Release Pellets)						
		Rabeprazole sodium	IP	20	mg	5/8/2015		
		(As Enteric coated pellets)						
		Excipients		q.s				
		Approved Colour used in Capsule shell						
300	Rosuvastatin Tablets IP	Each Uncoated tablet contains:-						
		Rosuvastatin Calcium	IP					
		Rosuvastatin		5	mg	8/20/2015		
		Excipients		q.s				
		Approved colour used in Tablets						
301	Cefixime & Ofloxacin							
301	Cefixime & Ofloxacin Tablets	Approved colour used in Tablets Each Uncoated tablet contains:- Cefixime	IP					
301		Each Uncoated tablet contains:- Cefixime	IP	100	mg			
301		Each Uncoated tablet contains:-	IP IP	100	mg	8/20/2015		
301		Each Uncoated tablet contains:- Cefixime eq. to Anhydrous Cefixime Ofloxacin		100	-	8/20/2015		
301		Each Uncoated tablet contains:- Cefixime eq. to Anhydrous Cefixime			-	8/20/2015		
	Tablets	Each Uncoated tablet contains:- Cefixime eq. to Anhydrous Cefixime Ofloxacin Excipients Approved colour used in Tablets	IP	100 q.s	mg	8/20/2015		
301		Each Uncoated tablet contains:- Cefixime eq. to Anhydrous Cefixime Ofloxacin Excipients Approved colour used in Tablets Ibuprofen		100	-	8/20/2015		
	Tablets	Each Uncoated tablet contains:- Cefixime eq. to Anhydrous Cefixime Ofloxacin Excipients Approved colour used in Tablets Ibuprofen Preservative :-	IP IP	100 q.s 15%	mg			
	Tablets	Each Uncoated tablet contains:- Cefixime eq. to Anhydrous Cefixime Ofloxacin Excipients Approved colour used in Tablets Ibuprofen	IP	100 q.s	mg	8/20/2015 9/22/2015		

	HEALTH AND FAMI List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/0 LY WELFARE DEPARTMENT, A Approved to be Manufactured b NB/07/642 AND MB/07/643 28:S-MB/07/643 For the pu EE AS PER SCHEDULE-P-1 OF DRUGS & COSMETI	HIMACI y:Boffi riod from 01.	n Biotec	h Pvt.		
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED	
303	Miconazole Nitrate Cream IP	Miconazole Nitrate	IP	2%	w/w		
		Chlorocresol (As Preservative)	IP	0.1%	w/w	9/22/2015	
		Cream Base		q.s.			
20.4			1	1	1		
304	Tamsulosin (MR) &	Each Uncoated Tablet contains:-	m	0.4			
	Dutasteride Tablets	Tamsulosin (MR)	IP	0.4	mg	11/07/0015	
		Dutasteride	IP	0.5	mg	11/27/2015	
		Excipients	-	q.s			
205	T-1	Approved colour used in Tablets.					
305	Telmisartan	Each Uncoated Tablets Contains:-	m	80			
	Tablets IP	Telmisartan	IP	80	mg	11/27/2015	
		Excipients Approved colour used in Tablets		qs			
		Approved colour used in Tablets					
306	Telmisartan &	Each Uncoated Tablet contains:-					
500	Metoprolol succinate(ER)	Telmisartan	IP	40	mg		
	Tablets	Metoprolol succinate (ER)	IP	50	mg	11/27/2015	
	Tublets	Excipients		q.s	mg	11/2//2010	
		Approved colour used in Tablets.		4.5			
307	Telmisartan &	Each Uncoated Tablet contains:-					
	Hydrochlorothiazide	Telmisartan	IP	80	mg		
	Tablets IP	Hydrochlorothiazide	IP	12.5	mg	11/27/2015	
		Excipients		q.s	0		
		Approved colour used in Tablets.					
308	Terbinafine Tablets IP	Each Uncoated tablet Contains:-					
		Terbinafine HCl	IP				
		Eq. to Terbinafine		250	mg	11/27/2015	
		Excipients		q.s			
		Approved colour used in Tablets					
200	Nimesulide &	Each Uncoated Tablet Contains:-					
309	Paracetamol Tablets	Nimesulide	DD	100	ma		
	(Not for Below 12years	Paracetamol	BP IP	100 325	mg	11/27/2015	
	age of Children)	Excipients	11'		mg	11/2//2013	
	age of clindren)	Approved colour used in Tablets		q.s			
		rippioved colour used in Tublets					
310	Metformin HCl &	Each Uncoated tablet contains:-					
	Voglibose Tablets	Voglibose	IP	0.3	mg		
		Metformin HCl	IP	500	mg	11/27/2015	
		Excipients		q.s	0		
		Approved colour used in Tablet		1			
311	Metoprolol succinate	Each Uncoated Extended Release Tablet	s contains				
	Extended Release Tablets IP	Metoprolol succinate	IP	25	mg	11/27/2015	
		Excipients		q.s		11/27/2015	
		Approved Colour used in Tablets					
312	Metoprolol succinate	Each Uncoated Extended Release Tablet	s contains				
	Extended Release Tablets IP	Metoprolol succinate	IP	50	mg	11/27/2015	
		Excipients		q.s		11/2//2013	
		Approved Colour used in Tablets				1	

	List of Retention Produc having license No. FORM25:M	LY WELFARE DEPARTMENT,H ts Approved to be Manufactured by NB/07/642 AND MB/07/643 28:S-MB/07/643 For the per NB/07/642 AND MB/07/643 28:S-MB/07/643 For the per ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	y : Boffi iod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
313	Metoprolol succinate	Each Uncoated Extended Release Tablets	contains			
	Extended Release Tablets IP	Metoprolol succinate	IP	100	mg	
		Excipients		q.s	0	11/27/201
		Approved Colour used in Tablets		4		
314	Gliclazide &	Each Uncoated tablet Contains:-				
511	Metformin HCl.	Gliclazide	IP	80	mg	
	Tablets	Metformin HCl.	IP	500	mg	11/27/201
	Tublets	Excipients		q.s		11/2//201
		Approved colour used in Tablets		4 .5		
21.5						
315	Febuxostat Tablets	Each Filmcoated Tablets contains	Ĩ	40		
		Febuxostat		40	mg	11/27/201
		Excipients		q.s		
		Approved Colour used in Coating				
316	Febuxostat Tablets	Each Filmcoated Tablets contains		-	-	
		Febuxostat		80	mg	11/27/201
		Excipients		q.s		11/27/201
		Approved Colour used in Coating				
217	Cilnidipine Tablets IP	Each Filmcoated Tablets Contains:-		1		
317	Clinicipine Tablets IP	Cumapine	IP	5	mg	
		Excipients		qs	0	11/27/201
		Approved colour used in Coating				
318	Cilnidipine Tablets IP	Each Filmcoated Tablets Contains:-		1		
516	Chindiphie Tablets Ir	Cilnidipine	IP	10	ma	
			IP		mg	11/27/201
		Excipients		qs		
		Approved colour used in Coating				
319	Doxofylline(SR) &	Each Uncoated Tablet Contains:-				
	Montelukast Sodium Tablets	Doxofylline (SR)	IP	400	mg	
		Montelukast Sodium	IP			11/27/201
		eq. to montelukast		10	mg	11/27/201
		Excipients		q.s		
		Approved colour used in Tablets				
320	S-Amlodipine Besilate &	Each Uncoated Tablet Contains:-				
	Atenolol Tablets	S-Amlodipine Besilate	IP			
		eq. to Amlodipine		5	mg	
		Atenolol	IP	50	mg	11/27/201
		Excipients		q.s	8	
		Approved colour used in Tablets		1		
321	Levosulpiride (SR) &	Each Hard Gelatin capsule contains:-				
	Rabeprazole sodium(EC)	Levosulpiride		75	mg	
	Capsules	(As Sustained Release Pellets)		-	0	
	·	Rabeprazole sodium	IP	20	mg	11/27/201
		(As Enteric coated pellets)				
		Excipients		q.s		
		Approved Colour used in Capsule shell	1	<u> </u>		

	HEALTH AND FAMI List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/0 LY WELFARE DEPARTMENT, J is Approved to be Manufactured b NB/07/642 AND MB/07/643 28:S-MB/07/643 For the pa 25 AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	HIMACI oy:Boffi eriod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
322	Albendazole Tablets IP	Each Uncoated Tablets contains Albendazole Excipients Approved colour used in Tablets	IP	400 qs	mg	11/27/2015
323	Terbinafine Cream IP	Composition:- Terbinafine Hydrochloride Preservative:- Benzyl Alcohol In Cream base	IP IP	1% 1% q.s	w/w w/w	11/27/2015
324	Rosuvastatin & Fenofibrate Tablets IP	Each Film coated tablet contains:- Rosuvastatin Calcium Eq. to Rosuvastatin Fenofibrate Excipients Approved colour used in Coating	IP IP	10 145 q.s	mg mg	12/5/2015
325	Rosuvastatin Tablets IP	Each Film coated tablet contains:- Rosuvastatin Calcium Eq. to Rosuvastatin Excipients Approved colour used in Coating	IP	10 q.s	mg	12/5/2015
326	Rosuvastatin Tablets IP	Each Film coated tablet contains:- Rosuvastatin Calcium eq. to Rosuvastatin Excipients Approved colour used in Coating	IP	5 q.s	mg	12/5/2015
327	Telmisartan & Hydrochlorothiazide Tablets IP	Each Film coated Tablet contains:- Telmisartan Hydrochlorothiazide Excipients Approved colour used in Coating	IP IP	40 12.5 q.s	mg mg	12/5/2015
328	Fexofenadine HCl.Tablets IP	Each Filmcoated tablet contains:- Fexofenadine HCl. Excipients Approved Colour used in Coating	IP	120 q.s	mg	12/5/2015
329	Esomeprazole Gastro Resistant Tablets IP	Each enteric coated tablets contains:- Esomeprazole Magnesiun Trihydrate Eq. to Esomeprazole Excipients Approved colour used in Coating	IP	40 q.s.	mg	12/5/2015
330	Thiocolchicoside and Etoricoxib Tablets	Each film coated tablet contains- Thiocolchicoside Etoricoxib Excipients Colour: Approved colour used	IP IP	4 60 q.s.	mg mg	1/23/2016

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/ ILY WELFARE DEPARTMENT ts Approved to be Manufactured INB/07/642 AND MB/07/643 28:S-MB/07/643 For the ZE AS PER SCHEDULE-P-1 OF DRUGS & COSME	,HIMACI by : Boffi period from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
331	Thiocolchicoside and	Each film coated tablet contains-				
	Ketoprofen Tablets	Thiocolchicoside	IP	4	mg	1/02/2016
		Ketoprofen	IP	50	mg	1/23/2016
		Excipients Colour: Approved colour used		q.s.		
				1	-	
332	Thiocolchicoside and	Each film coated tablet contains-	m	8		
	Ketoprofen Tablets	Thiocolchicoside	IP	8 100	mg	1/22/2016
		Ketoprofen	IP		mg	1/23/2016
		Excipients		q.s.		
		Colour: Approved colour used				
333	Serratiopeptidase Tablets IP	Each enteric coated tablet contains:-				
		Serratiopeptidase	IP	5	mg	1/23/2016
		(as 10,000 enzymatic units of serratiopeptidase)				1/23/2010
334	Piroxicam Tablets	Each uncoated tablet contains:-		20		
		Piroxicam	IP	20	mg	1/23/2016
		Excipients		q.s.		
		Colour: Approved colour used				
335	Pregabalin(SR) and	Each film coated tablet contains:-				
555	Methylcobalamin Tablets	Pregabalin (SR)	IP	75	mg	
	Wethyleobalannin Tablets	Methylcobalamin	IP	1500	mcg	1/23/2016
		Excipients	11	q.s.	meg	1/25/2010
		Colour: Approved colour used		4		
336	Fluconazole Tablets IP	Each uncoated tablet contains:-				
		Fluconazole	IP	200	mg	
		Excipients		q.s.	0	1/23/2016
		Approved Colour used in Tablet		-		
337	Nitazoxanide and	Each film coated tablet contains:-				
	Ofloxacin Tablets	Nitazoxanide		500	mg	
		Ofloxacin	IP	200	mg	1/23/2016
		Excipients		q.s.	-	
		Colour: Approved colour used		-		
220						
338	Montelukast and Fexofenadine Hydrochloride	Each film coated tablet contains:- Montelukast Sodium	IP			
	r exorenadine rrydroemoride	Wontelukast Soulum	11			
	Tablets	Eq. to Montelukast		10	mg	1/23/2016
		Fexofenadine Hydrochloride	IP	120	mg	
		Excipients		q.s.		
		Colour: Approved colour used				
339	Fluconazole Tablets IP	Each uncoated tablet contains:-				
557	i incontazore i abreto n	Fluconazole	IP	400	mg	
		Excipients		q.s.		1/23/2016
		Colour: Approved colour used		.1		1
340	Etoricoxib and	Each uncoated tablet contains:-				

		NO.HFW-H(DRUGS)279/0' ILY WELFARE DEPARTMENT,H cts Approved to be Manufactured by	IIMACI			
	having license No. FORM25:	MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the per SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	iod from 01.	12.2022 to 30.	11.2027	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATED
	Paracetamol Tablets	Etoricoxib	IP	60	mg	
		Paracetamol	IP	325	mg	1/23/2016
		Excipients		q.s.		
		Colour: Approved colour used				
		-				
341	Etodolac and	Each film coated tablet contains:				
	Paracetamol Tablets	Etodolac	IP	400	mg	
		Paracetamol	IP	325	mg	1/23/201
		Excipients		q.s.		
		Colour: Approved colour used				
342	Etodolac and	Each film coated tablet contains:				
	Thiocolchicoside Tablets	Etodolac	IP	400	mg	
		Thiocolchicoside	IP	4	mg	1/23/201
		Excipients		q.s.		
		Colour: Approved colour used				
343	Compound Sodium	Each uncoated tablet contains:-		200		
	Bicarbonate Tablets IP	Sodium bicarbonate	IP	300	mg	
		Pippermint Oil		q.s		1/23/201
		Excipients		q.s		
344	Lycopene, Vitamin A	Each hard gelatin capsule contains:-				
544	Vitamin C,	Lycopene 10%	USP	2	mg	
	Vitamin E, Zinc Sulphate	Vitamin A	IP	2500	IU	
	and Selenium Capsules	(as acetate)		2300	10	
	and Selemun Capsules	Vitamin C	IP	50	mg	
		Vitamin E	IP	10	IU	
		(as Tocopheryl acetate)		10	10	1/23/201
		Zinc Sulphate	IP	27.5	mg	
		Selenium		70	mcg	
		(as sodium selenate)				
		Excipients		a 2		
		Approved colour used in empty capsule		q.s.	$\left \right $	
345	Acebrophylline Capsules	Each hard gelatin capsule contains:-				
545	Accorophynnie Capsules	A ashronhulling		100	mσ	

Acebrophylline

Methylcobalamin

Approved colour used in empty capsule

Approved colour used in empty capsule

Each hard gelatin capsule contains:-

Excipients

Pregabalin

Vitamin B6

Benfothiamine

Folic Acid

Excipients

shells

shells

346 Methylcobalamin,

Pregabalin,

Vitamin B6, Folic Acid

and Benfotiamine Capsules

100

q.s.

750

75

1.5

750

7.5

q.s.

IP

IP

IP

IP

mg

mcg

mg

mg

mcg

mg

1/23/2016

1/23/2016

	List of Retention Produc having license No. FORM25:N	NO.HFW-H(DRUGS)279/07 ILY WELFARE DEPARTMENT,H ets Approved to be Manufactured by ANB/07/642 AND MB/07/643 28:S-MB/07/643 For the per	IMACI Solution : : : : : : : : : : : : : : : : : : :	n Biotecl	h Pvt.	
S. No.	PACK S DOSAGE FORM, GENERIC NAME/BRAND NAME	IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
347	Omeprazole Gastro -	Each hard gelatin capsule contains:-				
	resistant	Omeprazole	IP	40	mg	
	capsules IP	(as Gastro-resistant pellets)				1/23/2016
		Excipients		q.s.		
		Approved colour used in empty capsule				
348	Esomeprazole and	Each hard gelatin capsule contains:-				
	Domperidone DSR	Esomeprazole Magnesium Trihydrate	IP			
	Capsules	Eq. to Esomeprazole		20	mg	
		(as enteric coated pellets)				
		Domperidone maleate	IP			
		Eq. to Domperidone		30	mg	1/23/2016
		(as sustained release pellets)				l
		Excipients		q.s.		
		Approved colour used in empty capsule		-		
		shells				
349	Trioxsalen Tablets USP	Each uncoated tablet contains:				
549	Thoxsalen Tablets USP	Trioxsalen	USP	5	ma	
			USP	5	mg	2/17/2016
		Excipients Approved Colour used in Tablets			q.s.	
350	Trioxsalen Tablets USP	Each uncoated tablet contains:				
		Trioxsalen	USP	25	mg	2/17/2016
		Excipients			q.s.	
351	Metaxalone and Diclofenac	Each uncoated tablet contains:				
	Potassium Tablets (Not for	Metaxalone		400	mg	2/17/2016
	Veterinary Use)	Diclofenac Potassium	IP	50	mg	
		Excipients			q.s.	
352	LevetiracetamTablets USP	Each uncoated tablet contains:				
		Levetiracetam	USP	500	mg	2/17/2016
		Excipients			q.s.	
353	Citicoline Tablets IP	Each uncoated tablet contains:				
		Citicoline Sodium	IP			
		Eq. to Citicoline		500	mg	2/17/2016
		Excipients			q.s.	
		Colour: Approved colour used				
354	Citicoline and Piracetam	Each uncoated tablet contains:				
	Tablets	Citicoline Sodium	IP			
		Eq. to Citicoline	_	500	mg	2/17/2016
		Piracetam	IP	400	mg	
		Excipients			q.s.	
		~				
355	Ketoconazole Cream	Composition	m	201	<i>,</i>	0/10/001 -
		Ketoconazole	IP	2%	w/w	
		In a cream base			q.s.	

	having license No. FORM25:MI	S Approved to be Manufactured b NB/07/642 AND MB/07/643 28:S-MB/07/643 For the per ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	riod from 01.			2000
. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATED
	Domperidone DSR Capsules	Esomeprazole Magnesium Trihydrate	IP			
		Eq. to Esomeprazole		40	mg	
		(as enteric coated pellets)			-	2/17/2016
		Domperidone Maleate	IP			
		Eq. to Domperidone		30	mg	
		(as sustained release pellets)				
		Excipients		q.s.		
357	Mometasone Furoate	Commerciation				
557		Composition: Mometasone Furoate	USP	0.1%	w/v	2/17/2016
	Topical Solution USP	Lotion base	USP	0.1%		2/17/2010
		Louon base			q.s.	
358	Sertaconazole and Zinc	Composition				
	Pyrithione Shampoo	Sertaconazole	BP	2%	W/V	2/17/2016
		Zinc Pyrithione		1%	w/v	2/17/2010
		Shampoo base			q.s.	
359	Sucralfate, Metronidazole and	Composition				
	Povidone Iodine Ointment	Each gram contains:				
		Sucralfate	USP	70	mg	2/17/2016
		Metronidazole	IP	10	mg	2/17/2010
		Povidone Iodine	IP	50	mg	
		Cream base			q.s.	
260	Dominuil and	Each uncoated tablet contains:				
360	Ramipril and		m	25		
	Hydrochlorothiazide Tablets	Ramipril Hydrochlorothiazide	IP IP	2.5 12.5	mg mg	2/26/2016
		Excipients	п	12.5	q.s.	
		Excipients			q. 3.	
361	Ramipril and	Each uncoated tablet contains:				
	Hvdrochlorothiazide Tablets	Ramipril	IP		mg	
	,	··· r		5	0	2/26/2016
		Hydrochlorothiazide	IP	25	mg	
		Excipients			q.s.	
362	Methylprednisolone Tablets IP	Each uncoated tablet contains:				
		Methylprednisolone	IP	8	mg	2/26/2016
		Excipients			q.s.	
262						
363	Methylcobalamin Tablets	Each film coated tablet contains:	IP	500		
		Methylcobalamin Excipients	IP	500	mcg	2/26/2016
		Colour: Approved colour used			q.s.	
	1	colour rippiored colour used				
364	Glimepiride and Metformin	Each uncoated tablet contains:				
	Hydrochloride (SR) Tablets	Glimepiride	IP	2	mg	g 2/26/2016
		Metformin Hydrochloride	IP		mg	
		(As Sustained Release)		500	Ũ	
		Excipients			q.s.	

NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH

List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

	Ö								
	PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945								
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED			
	ParacetamolTablets (Not for	Diclofenac Potassium	BP	50	mg	2/26/2016			
	Veterinary Use)	Paracetamol	IP	325	mg	2/20/2010			
		Excipients			q.s.				

366	Bisoprolol Fumarate Tablets	Each film coated tablet contains:				
	USP	Bisoprolol Fumarate	USP	2.5	mg	2/26/2016
		Excipients			q.s.	
		Colour: Approved colour used				
	Bisoprolol Fumarate Tablets	Each film coated tablet contains:				
367						
	USP	Bisoprolol Fumarate	USP	5	mg	2/26/2016
		Excipients			q.s.	
		Colour: Approved colour used				

368	Methylcobalamin and	Each hard gelatin capsule contains:				
	Pregabalin Capsules IP	Methylcobalamin	IP	750	mcg	
		Pregabalin	IP	75	mg	2/26/2016
		Excipients			q.s.	
		Colour: Approved colour used				

369	Lignocaine Hydrochloride	Composition:				
	Gel IP	Lignocaine Hydrochloride	IP			
		Eq. to Ahnydrous Lignocaine		2%	w/w	
		Hydrochloride				2/26/2016
		Methyl Paraben	IP	0.061%	w/w	2/20/2010
		Propyl Paraben	IP	0.027%	w/w	
		Water soluble Gel Base in Purified	IP		q.s.	
		Water				

370	Roxithromycin Tablets IP	Each uncoated tablet contains:				
		Roxithromycin	IP	150	mg	3/16/2016
		Excipients			q.s.	

371	Ondansetron Mouth	Each un coated mouth dissolving tablet co				
	Dissolving Tablets IP	Ondansetron Hydrochloride	IP			
		Eq. to Ondansetron		4	mg.	3/16/2016
		Excipients			q.s.	
		Colour: Approved colour used				

Γ	372	Glipizide and Metformin	Each un coated tablet contains:				
		Hydrochloride Tablets	Glipizide	IP	5	mg	
			Metformin Hydrochloride	IP	500	mg	3/16/2016
			Excipients			q.s.	

	PACK SIZ	E AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC		12.2022 to 30.		
5. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATEI
	Serratiopeptidase Tablets (Not	Diclofenac Potassium	IP	50		
	for Veterinary Use)	Serratiopeptidase	IP	10	mg	3/16/2016
		(eq. to 20,000 enzymatic units				5/10/2010
		Excipients			q.s.	
		Colour: Approved colour used				
374	Betamethasone Tablets IP	Each un coated tablet contains:				
-		Betamethasone	IP	1	mg	0.11.6.10.0.1
		Excipients			q.s.	3/16/2016
		Approved colour used in Tablets			Ĺ	
375	Pantoprazole (as enteric	Each hard galatin cancula contains:				
515	coated pellets) and	Each hard gelatin capsule contains: Pantoprazole Sodium	IP			
	Domperidone	Eq. to Pantoprazole	<u> </u>	40	mg.	
	(as sustained release	(as enteric coated pellets)			g.	
	pellets)Capsules IP	Domperidone	IP	10	mg	3/16/2016
	penets)eupstiles il	(as sustained release pellets)			8	
		Excipients			q.s.	
		Colour: Approved colour used			1	
		T		1		
376	Methylcobalamin, Calcium,	Each hard gelatin capsule contains:				
	Calcitriol,Folic Acid,	Methylcobalamin	IP	500	mcg	
	Pyridoxine Hydrochloride	Calcium Carbonate	IP			
	and Zinc Capsule	Eq. to elemental Calcium		250	mg	
		Calcitriol	IP	0.25	mcg	
		Folic Acid	IP	1.5	mg	3/18/2010
		Pyridoxine Hydrochloride	IP	3	mg	
		Zinc (as Zinc Sulphate)	IP	7.5	mg	
		Excipients			q.s.	
		Approved colour used in empty capsule shells				
377	Fluconazole Tablets IP	Each un coated tablet contains:		50		
		Fluconazole	IP	50	mg	3/18/2016
		Excipients			q.s.	
		I		1		
378	Calcitriol, Calcium and	Each hard gelatin capsule contains:	m	0.25		
	Zinc Capsules	Calcitriol	IP	0.25	mcg	
		Calcium Carbonate	IP	200		
		Eq. to elemental Calcium	ID	200	mg	3/18/2016
		Zinc(as Zinc Sulphate)	IP	7.5	mg	
		Excipients			q.s.	
		Approved colour used in empty capsule				
379	Tacrolimus Ointment	Composition				
	0.1%w/w (NFI)	Tacrolimus	USP	0.1%	w/w	0.110.200
	Ň Ź	Ointment base	1	i	q.s.	3/18/201

	List of Retention Produc having license No. FORM25:M	ILY WELFARE DEPARTMENT ts Approved to be Manufactured INB/07/642 AND MB/07/643 28:S-MB/07/643 For the ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMB	by : Boffi period from 01.	n Biotec	h Pvt.	
5. No.	PACK S DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVE ON DATE
	Tablets IP	Olmesartan Medoxomil	IP	40	mg	
		Excipients			q.s.	4/6/2010
		Colour: Approved colour used				
381	Isosorbida Mononitrata Tablet	s Each un coated tablet contains:				
501	IP	Diluted Isosorbide Mononitrate	IP			
		Eq. to Isosorbide Mononitrate		20	· mg	4/6/2010
		Excipients		20	q.s.	
382	Domperidone Tablets IP	Each un coated tablet contains:		10		
		Domperidone	IP	10	mg.	4/6/201
		Excipients			q.s.	
		l		<u> </u>		
383	Itraconazole Capsule BP	Each hard gelatin capsule contains:	~~~	T		
		Itraconazole Pellets	BP			4/6/201
		Eq. to itraconazole		200	mg.	
		Excipients			q.s.	
384	Tranexamic Acid and	Each film coated tablet contains:				
-	Mefenamic Acid Tablets	Tranexamic Acid	IP	500	mg	
		Mefenamic Acid	IP	250	0	5/24/201
		Excipients			q.s.	
		Colour: Approved colour used			<u>`</u>	
385	Mefenamic acid and	Each uncoated tablet contains:				
365	Dicyclomine Hydrochloride	Mefenamic acid	IP	250	ma	
	Tablets IP	Dicyclomine Hydrochloride	IP	230	mg	5/24/201
	Tublets II	Excipients	IP	20	mg	3/24/201
		Approved Colour used in Tablets	_		q.s.	
	-	• • •		-		
386	Mefenamic Acid and	Each film coated tablet contains:				
	Drotaverine	Drotaverine Hydrochloride	IP	80	mg.	
	HydrochlorideTablets	Mefenamic Acid	IP	250	mg	5/24/201
		Excipients Colour: Approved colour used	_		q.s.	
	1	colour rippiored colour used				
387	Glimepiride and Metformin	Each uncoated tablet contains:				
	Hydrochloride (SR) Tablets	Glimepiride	IP	1	mg	
		Metformin Hydrochloride	IP		mg	5/24/201
		(As Sustained Release)	_	500		
		Excipients			q.s.	
	l	I		I	I	
388	Finasteride Tablets IP	Each un coated tablet contains:		-		
		Finasteride	IP	5	mg	5/24/201
		Excipients			q.s.	

389Diclofenac PotassiumEach film coated tablet contains:
--

	HEALTH AND FAMIL List of Retention Product	NO.HFW-H(DRUGS)279/(LY WELFARE DEPARTMENT, s Approved to be Manufactured h NB/07/642 AND MB/07/643 28:S-MB/07/643 For the p	HIMACI by : Boffi	n Biotec	h Pvt.	
	PACK SIZ	E AS PER SCHEDULE-P-1 OF DRUGS & COSMET	C ACT 1945			
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Paracetamol	Diclofenac Potassium	BP	50	mg	
	and Serratiopeptidase Tablets	Paracetamol	IP	325	mg	
	(NOT FOR VETERINARY	Serratiopeptidase	IP	15	mg	5/24/2016
	USE)	(As enteric coated granules				5/24/2010
		30,000 units of enzymatic activity of				
		Excipients			q.s.	
		Colour: Approved colour used				
200	4 1111 D: 11					
390	Amoxicillin Dispersible	Each uncoated dispersible tablet contain	s:	-		
	Tablets IP	Amoxycillin Trihydrate	IP			5/24/2016
		Eq. to Amoxycillin		125	mg	0/2//2010
		Excipients			q.s.	
201						
391	Aceclofenac, Paracetamol and Serratiopeptidase Tablets	Each film coated tablet contains:	ID	100		
	Serradopeptidase Tablets	Aceclofenac	IP	325	mg	
		Paracetamol	IP IP		mg	
		Serratiopeptidase (As enteric coated granules	IP	10	mg	5/24/2010
		20,000 units of enzymatic activity of				5/24/2010
		Serratiopeptidase)				
		Excipients			q.s.	
		Colour: Approved colour used			q.s.	
392	Aceclofenac, Paracetamol and	Each film coated tablet contains:				
	Serratiopeptidase Tablets	Aceclofenac	IP	100	mg	
		Paracetamol	IP	325	mg	
		Serratiopeptidase	IP	15	mg	
		(As enteric coated granules				5/24/2010
		30,000 units of enzymatic activity of				
		Serratiopeptidase)				
		Excipients			q.s.	
		Colour: Approved colour used				
0.00						
393	Pantoprazole Sodium Tablets	Each enteric coated tablet contains:	-			
	IP	Pantoprazole Sodium	IP	20		C/15/201
		Eq. to Pantoprazole	_	20	mg	6/15/2010
		Excipients		qs		
204	Levocarnitine Tablets USP	Colour: Approved colour used				
394	Levocarinulle Tablets USP	Each film coated tablet contains: Levocarnitine	USP	200	ma	
		Excipients	USP	qs	mg	6/15/2010
		Colour: Approved colour used		<u> </u>		
395	Diclofenac Sodium and	Each film coated tablet contains:		1		
275	Serratiopeptidase Tablets (Not	Diclofenac Sodium	IP	50	mg	
	for Veterinary Use)	Serratiopeptidase	IP	10	mg	
	• /	as enteric coated granules)				
		(20,000 enzymatic units of				6/15/2010
		Serratiopeptidase)	1			
		Excipients	—	qs		
		Colour: Approved colour used	+	1		

	List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/07 LY WELFARE DEPARTMENT,H is Approved to be Manufactured by NB/07/642 AND MB/07/643 28:S-MB/07/643 For the peri ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	IMACI V : Boffi iod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
396	Calcium Pantothenate Tablets	Each film coated tablet contains:		8		
	IP	Calcium Pantothenate	IP	100	mg	6/15/2016
		Excipients		qs		0/13/2010
		Colour: Approved colour used				
397	Pantoprazole and	Each hard gelatin capsule contains:				
371	Levosulpiride Capsules	Pantoprazole Sodium	IP			
	Levosulpinde Capsules	Eq. toPantoprazole	п	40	mg	
		Levosulpiride		75	mg	6/15/2016
		Excipients			8	
		Colour: Approved colour used		qs		
		**				
398	Rifaximin Tablets	Each film coated tablet contains:				
		Rifaximin	BP	400	mg	7/27/2016
		Excipients		qs		//2//2010
		Colour: Approved colour used				
200						
399	Paracetamol, Phenylephrine Hydrochloride, Caffeine and	Each un coated tablet contains: Paracetamol	IP	325	mg	
	Diphenhydramine	Phenylephrine Hydrochloride	IP	5	mg	
	Hydrochloride Tablets	Caffeine (anhydrous)	IP	30	mg	7/27/2016
		Diphenhydramine Hydrochloride	IP	25	mg	//2//2010
		Excipients:		qs		
		Approved colour used in Tablet		-		1
		· · · ·				
400	Olmesartan Medoxomil	Each film coated tablet contains:				
	Tablets 20mg	Olmesartan Medoxomil	IP	20	mg	7/27/2016
		Excipients		qs		//2//2010
		Colour: Approved colour used				
		-				
401	Labetalol Hydrochloride	Each film coated tablet contains:		100		
	Tablets IP	Labetalol Hydrochloride	IP	100	mg	7/27/2016
		Excipients		qs		
		Colour: Approved colour used				
402	Finasteride Tablets IP	Each film coated tablet contains				
402	i masteride Tablets fi	Finasteride	IP	5	mg	
		Excipients		qs	mg	7/27/2016
		Colour: Approved colour used		1		
403	Diclofenac Potassium and	Each film coated tablet contains:				
	Paracetamol Tablets	Diclofenac Potassium	BP	50	mg	
	(NOT FOR VETERINARY	Paracetamol	IP	325	mg	7/27/2016
	USE)	Excipients		qs		
		Colour: Approved colour used				
404	Orlistat Capsule USP	Each hard gelatin capsule contains:	LICD	100		
		Orlistat	USP	100	mg	
		Excipients		qs	7/27/20	7/27/2016
		Approved colour used in empty capsule				

	HEALTH AND FAMI List of Retention Product having license No. FORM25:MN	NO.HFW-H(DRUGS)279 LY WELFARE DEPARTMEN s Approved to be Manufacture VB/07/642 AND MB/07/643 28:S-MB/07/643 For th	T,HIMACI d by : Boffi he period from 01.	n Biotecl	h Pvt.	
	PACK SIZ DOSAGE FORM, GENERIC	E AS PER SCHEDULE-P-1 OF DRUGS & COSM	SPECIFI			APPROVE
. No.	NAME/BRAND NAME	COMPOSITION	CATION	QUANTITY	UNIT	ON DATEI
105	Simvastatin Tablets IP 5mg	Each film coated tablet contains:				
		Simvastatin	IP	5	mg	8/31/201
		Excipients		qs		0/31/201
		Colour: Approved colour used				
06	Montelukast Tablets IP	Each film coated tablet contains:				
		Montelukast Sodium	IP			
		Eq. to Montelukast		10	mg	8/31/201
		Excipients		qs	Ŭ	
		Colour: Approved colour used				
07	Levetiracetam Tablets USP	Each un coated tablet contains:				
	Levenueean rabits USI	Levetiracetam	USP	250	mg	8/31/201
		Excipients	0.01	qs		5,51/201
	1		1	.1.		
08	Etodolac Tablets IP	Each film coated tablet contains:				
		Etodolac	IP	400	mg	8/31/201
		Excipients		qs		8/31/201
		Colour: Approved colour used	-	-		
09	Duloxetine Tablets	Each film coated contains:		1		
		Duloxetine Hydrochloride	IP	10		8/31/201
		Eq. to Duloxetine Excipients		qs	mg	
		Colour : Approved colour used		4 5		
10	Cyanocobalamin, Chromium	Each film coated tablet contains:				
	Picolinate, Folic	Cyanocobalamin	IP	15	mcg	
	Acid,Nicotinamide, Pyridoxine	Chromium Picolinate	USP	250	mcg	
	Hydrochloride, Selenius Acid	Folic Acid	IP	1500	mcg	
	and Zinc Sulphate	Nicotinamide	IP	100	mg	
	Monohydrate Tablets	Pyridoxine Hydrochloride	IP	3	mg	8/31/201
		Selenius Acid	USP	100	mcg	
		Zinc Sulphate Monohydrate	IP	61.8	mg	
		Eq. to elemental Zinc		22.5	mg	
		Excipients		qs		
		Colour: Approved colour used				
11	Cefixime and Lactic acid	Each film coated tablet contains:				
	bacillus Tablets	Cefixime	IP			
		Eq. to Anhydrous Cefixime		200	mg	0/01/22
		Lactic acid bacillus			Million	8/31/201
				60	spores	
		Colour: Approved colour used				
12	Fenbendazole Tablets	Each uncoated tablet contains:				
+12	rendendazoie radiets	Fenbendazole	IP(vet.)	150	ma	
		Excipients	II (vec.)	qs	mg	8/31/201
		Encipiono		77	1	

HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945								
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED		
	Terbinafine Cream	Mometasone Furoate	IP	0.1%	\mathbf{W}/\mathbf{W}	9/21/2016		
		Terbinafine Hydrochloride	IP	1%	\mathbf{W}/\mathbf{W}	8/31/2016		
		Water soluble base		qs				
414	Sildenafil Tablets IP 25mg	Each film coated tablet contains:						
		Sildenafil Citrate	IP			2/21/2017		
		Eq. to Sildenafil		25	mg			
		Excipients			qs			
		Colour: Approved colour used						
415	Olmesartan Medoxomil and	Each film coated tablet contains:						
	Hydrochlorothiazide Tablets	Olmesartan Medoxomil	IP	40	mg	2/21/2017		
	IP	Hydrochlorothiazide	IP	12.5	mg	2/21/2017		
		Excipients			qs			
		Colour: Approved colour used						

416	Methylcobalamin and	Each film coated tablet contains:				
	Gabapentin Tablets	Methylcobalamin	IP	500	mcg	
		Gabapentin	IP	300	mg	2/21/2017
		Excipients			qs	
		Colour: Approved colour used				

417	Drotaverine Hydrochloride	Each film coated tablet contains:				
	Tablets IP 80mg	Drotaverine Hydrochloride	IP	80	mg	2/21/2017
		Excipients			qs	2/21/2017
		Colour: Approved colour used				

418	Tolperisone Hydrochloride and	Each uncoated tablet contains:				
	Paracetamol Tablets	Tolperisone Hydrochloride		150	mg	2/23/2017
		Paracetamol	IP	325	mg	2/23/2017
		Excipients		qs		

419	Telmisartan Tablets IP 40mg	Each film coated tablet contains:				
		Telmisartan	IP	40	mg	2/23/2017
		Excipients		qs		2/23/2017
		Colour: Approved colour used				

420	Nortriptyline Hydrochloride	Each film coated tablet contains:				
	Tablets IP 10mg	Nortriptyline Hydrochloride Eq. to Nortriptyline	IP	10	mg	2/23/2017
		Excipients			qs	
		Colour: Approved colour used				

421	Moxifloxacin Tablets 400mg	Each film coated tablet contains:				
		Moxifloxacin Hydrochloride Eq. to Moxifloxacin	IP	400	mg	2/23/2017
		Excipients			qs	
		Colour: Approved colour used				

NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945 APPROVED DOSAGE FORM, GENERIC SPECIFI S. No. COMPOSITION QUANTITY UNIT NAME/BRAND NAME CATION ON DATED Tablets IP 10mg Levocetirizine Hydrochloride IP 10 mg 2/23/2017 Excipients qs Colour: Approved colour used 423 Ketoconazole Tablets IP Each un coated tablet contains: 200mg 200 IP Ketoconazole mg 2/23/2017 Excipients qs Colour: Approved colour used Amlodipine Tablets IP 10mg Each uncoated tablet contains: 424 IP Amlodipine Besilate 2/23/2017 Eq. to Amlodipine 10 mg Excipients qs 425 Tamsulosin Hydrochloride Each film coated tablet contains: Tamsulosin Hydrochloride 0.4 Tablets 0.4mg IP mg (Modified release) (as modified release) 4/26/2017

426	Levocetirizine Hydrochloride	Each film coated tablet contains:				
	and Ambroxol Hydrochloride	Levocetirizine Hydrochloride	IP	5	mg	
	Tablets	Ambroxol Hydrochloride	IP	30	mg	4/26/2017
		Excipients		qs		
		Colour: Approved colour used				

Colour: Approved colour used

qs

Excipients

427	Clobetasol Propionate,	Composition:				
	Gentamycin, Tolnaftate,	Clobetasol Propionate	IP	0.05%	W/W	
	Iodochlorhydroxyquinolin and	Gentamycin Sulphate	IP			
	Clotrimazole Cream	Eq. to Gentamycin		0.1%	W/W	4/26/2017
		Tolnaftate	IP	1%	w/w	4/20/2017
		Iodochlorhydroxyquinoline	IP	1%	w/w	
		Clotrimazole	IP	1%	w/w	
		In a cream base		qs		

428	Stanozolol Tablets USP	Each uncoated tablet contains:				
		Stanozolol	USP	2	mg	5/25/2017
		Excipients		qs		5/25/2017
		Colour: Approved colour used				
429	Levocetirizine Hydrochloride	Each film coated tablet contains:				
	and Ambroxol Hydrochloride	Levocetirizine Hydrochloride	IP	5	mg	
	Tablets	Ambroxol Hydrochloride	IP	60	mg	5/25/2017
		Excipients		qs		
		Colour: Approved colour used				
430	Cefixime dispersible Tablets IP	Each uncoated dispersible tablet contains:				
		Cefixime	IP			
		Eq. to Anhydrous Cefixime		50	mg	5/25/2017
		Excipients		q.s		
		Colour: Approved colour used				

	HEALTH AND FAMI List of Retention Product having license No. FORM25:MP	NO.HFW-H(DRUGS)279/(LY WELFARE DEPARTMENT, s Approved to be Manufactured I NB/07/642 AND MB/07/643 28:S-MB/07/643 For the p	HIMACI by : Boffi eriod from 01.	n Biotec	h Pvt.	
S. No.	PACK SIZ DOSAGE FORM, GENERIC NAME/BRAND NAME	E AS PER SCHEDULE-P-1 OF DRUGS & COSMET COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
431	Clobetasol Propionate,	Composition:-Each gram contains:-				
	Gentamycin Tolnaftate,	Clobetasol Propionate	IP	0.5	mg	
	Iodochlorhydroxyquinoline	Gentamycin Sulphate	IP			
	and Ketoconazole Cream	Eq. to Gentamycin		1	mg	5/25/2017
		Tolnaftate	IP	10	mg	5/25/2017
		Iodochlorhydroxyquinoline	IP	10	mg]
		Ketoconazole	IP	20	mg	
		In a cream base		qs		
(22						
432	Acetaminophen Tablets	Each uncoated tablet contains:		500	-	
		Acetaminophen	IP	500	mg	5/25/2017
		Excipients	_	qs		
		Colour: Approved colour used				
433	Potassium Nitrate,	Composition:-Each gram contains:-				
	Sodium monofluorophosphate	Potassium Nitrate	BP	5%	w/w	
	and Triclosan Paste	Sodium Monofluorophosphate	USP	0.7%	w/w	5/25/2017
		Triclosan	USP	0.3%	w/w	
		Presently Flavoured Paste Base	0.01	qs	••• / ••	
				1~		
434	Amoxycillin Capsules IP	Each hard gelatin capsule contains:				
		Amoxycillin Trihydrate	IP			
		Eq. to Amoxycillin		250	mg	1/24/2018
		Excipients		q.s		
		Approved colour used				
435	Amoxycillin Capsules IP	Each hard gelatin capsule contains:	-			
		Amoxycillin Trihydrate	IP	7 00		
		Eq. to Amoxycillin	_	500	mg	1/24/2018
		Excipients		q.s		
		Approved colour used				
436	Cephalexin Capsules IP	Each hard gelatin capsule contains:				
+50	Cophaickin Capsules IF	Cephalexin	IP			
		Eq. to Anhydrous Cephalexin		250	mg	1/24/2018
		Excipients		q.s	8	1,27,2010
		Approved colour used		-12		
		FF				
437	Cephalexin Capsules IP	Each hard gelatin capsule contains:				
	- •	Cephalexin	IP			
		Eq. to Anhydrous Cephalexin		500	mg	1/24/2018
		Excipients		q.s		
		Approved colour used				
1.2						
438	Ampicillin Capsules IP	Each hard gelatin capsule contains:	ID	r		
		Ampicillin Trihydrate	IP			1/04/2010
		Eq. to Ampicillin		500	mg	1/24/2018
		Excipients		q.s		
		Approved colour used				

	HEALTH AND FAMI List of Retention Product having license No. FORM25:MD	NO.HFW-H(DRUGS)279/0 LY WELFARE DEPARTMENT, s Approved to be Manufactured b NB/07/642 AND MB/07/643 28:S-MB/07/643 For the pe te AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	HIMACI y:Boffi riod from 01.	n Biotecl	ı Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
439	Ampicillin Capsules IP	Each hard gelatin capsule contains:				
.05		Ampicillin Trihydrate	IP			
		Eq. to Ampicillin		250	mg	1/24/2018
		Excipients		q.s		
		Approved colour used				
440	Amoxycillin Oral Suspension	Each 5ml of reconstituted suspension cor	ntains:		-	
	IP	Amoxycillin Trihydrate	IP			
		Eq. to Amoxycillin		125	mg	1/24/2018
		In a flavoured suspension base		q.s		
		Approved colour used				
441	Amoxycillin Oral Suspension	Each 5ml of reconstituted suspension con			-	
	IP	Amoxycillin Trihydrate	IP	250		1/01/0010
		Eq. to Amoxycillin		250	mg	1/24/2018
		In a flavoured suspension base		q.s		
		Approved colour used				
442	Ampicillin Oral Suspension IP	Each 5ml of reconstituted suspension cor	ntains.			
442	Amplemin Oral Suspension II	Ampicillin Trihydrate	IP			
		Eq. to Ampicillin	- 11	125	mg	1/24/2018
		In a flavoured suspension base		q.s	mg	1/24/2010
		Approved colour used		4 .5		
443	Cefixime Oral Suspension IP	Each 5ml of reconstituted suspension cor	ntains:			
	1	Cefixime Trihydrate	IP			
		Eq. to Anhydrous Cefixime		100	mg	1/24/2018
		In a flavoured suspension base		q.s		
		Approved colour used				
444		Each 5ml of reconstituted suspension cor				
	IP	Cefpodoxime proxetil	IP			
		Eq. to Cefpodoxime		50	mg	1/24/2018
		In a flavoured suspension base		q.s		
		Approved colour used				
			•			
445	Cefpodoxime Oral Suspension	Each 5ml of reconstituted suspension con	-	1	-	
	IP	Cefpodoxime proxetil	IP	100		1/04/2010
		Eq. to Cefpodoxime		100	mg	1/24/2018
		In a flavoured suspension base		q.s		
116	Democratemal Decidiotaria Oral	Approved colour used Each 5ml contains:				
446	Paracetamol Paediatric Oral Suspension IP	Paracetamol	IP	125	ma	
	Suspension II	Excipients	11*		mg	1/24/2018
		Approved colour used	1	q.s		
447	Paracetamol Paediatric Oral	Each 5ml contains:				
,	Suspension IP	Paracetamol	IP	250	mg	
	1	Excipients	<u> </u>	q.s		1/24/2018
		Approved colour used	1	1.2		

	List of Retention Product	NO.HFW-H(DRUGS)279 LY WELFARE DEPARTMENT ts Approved to be Manufactured NB/07/642 AND MB/07/643 28:S-MB/07/643 For th	Г,НІМАС l by : Boffi	n Biotecl	h Pvt.		
	~	ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMI	<u> </u>	.12.2022 to 50.	11.2027		
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVE ON DATEI	
448	Levocetirizine Hydrochloride	Each 5ml contains:					
	Syrup IP	Levocetirizine Hydrochloride	IP	2.5	mg	1 10 1 10 1 1	
		Excipients		q.s	Ũ	1/24/2018	
		Approved colour used		1			
449	Levocetirizine Hydrochloride	Each 5ml contains:					
	and Montelukast Suspension	Levocetirizine Hydrochloride	IP	2.5	mg		
	Ĩ	Montelukast Sodium	IP		8		
		Eq. to Montelukast		4	mg	1/24/201	
		Excipients		q.s			
		Approved colour used		1.~			
450	Cetirizine Hydrochloride	Each 5ml contains:					
	Syrup IP	Cetirizine Hydrochloride	IP	5	mg	1/04/00:	
		Excipients		q.s	8	1/24/201	
		Approved colour used		1.~			
		11					
451	Cefixime Oral Suspension IP	Each 5ml of reconstituted suspension	contains:				
-51	Certaine Oral Suspension II	Cefixime Trihydrate	IP		1		
		Eq. to Anhydrous Cefixime	11	50	mg	6/4/2018	
		In a flavoured suspension base			mg		
		in a navoured suspension base		q.s			
452	Azithromycin oral Suspension	Composition: Each 5ml contains:					
432	(For Paediatric use)	Azithromycin dihydrate	IP		1		
	(FOI Faculatile use)	Eq. to Anhydrous Azithromycin	11	100	ma	6/4/2018	
		Colour: Approved Colour Used		100	mg		
		Colour. Approved Colour Osed					
453	Azithromycin oral	Composition: Each 5ml contains:					
455	Suspension IP	Azithromycin dihydrate	IP	1			
	(For Paediatric use)	Eq. to Anhydrous Azithromycin		200	mg	6/4/2018	
	(i of i dedidate use)	Colour: Approved Colour Used		200	mg		
454	Piracetam Tablets	Each uncoated Tablet contains :-					
		Piracetam	IP	800	mg		
		Excipients		qs		7/23/201	
		Colour:- Approved colour used		1			
455	Pantoprazole Sodium (EC) &	Each hard gelatin Capsule contains :					
	Levosulpiride (SR) Capsule	Pantoprazole Sodium	IP				
		Eq. to Pantoprzole		40	mg		
		(Enteric Coated Pellets)			Ŭ		
		Levosulpiride		75	mg	7/23/201	
		(Sustained Release Pellets)			Ŭ		
		Excipients		qs			
456	Phenylenhrine HCl	Approved Colour Used in Empty Cap	sule Shell				
456	Phenylephrine HCl, Paracetamol	Approved Colour Used in Empty Cap Each 5ml contains:		5	mσ		
456	Paracetamol,	Approved Colour Used in Empty Cap Each 5ml contains: Phenylephrine HCl	IP	5	mg		
456	Paracetamol, Chlorpheniramine	Approved Colour Used in Empty Cap Each 5ml contains: Phenylephrine HCl Paracetamol	IP IP	125	mg	7/23/201	
456	Paracetamol, Chlorpheniramine Maleate, Sodium Citrate &	Approved Colour Used in Empty Cap Each 5ml contains: Phenylephrine HCl Paracetamol Chlorpheniramine Maleate	IP IP IP	125 0.5	mg mg	7/23/201	
456	Paracetamol, Chlorpheniramine	Approved Colour Used in Empty Cap Each 5ml contains: Phenylephrine HCl Paracetamol	IP IP	125	mg	7/23/201	

	having license No. FORM25:N	Ets Approved to be Manufactured ANB/07/642 AND MB/07/643 28:S-MB/07/643 For the IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMI	e period from 01.			
. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATEI
457	Ambroxol Hydrochloride,	Each 5ml contains:				
	Salbulamol Sulphate,	Ambroxol Hydrochloride	IP	15	mg	
	Guaiphenesin and	Guaiphenesin	IP	50	mg	7/23/201
	Menthol Syrup	Salbutamol Sulphate	IP	1	mg	//20/2010
		Menthol	IP	1	mg	
		Colour: Approved Colour Used				
458	Ambroxol Hydrochloride,	Each 5ml contains:				
	Terbutaline Sulphate,	Ambroxol hydrochloride	IP	15	mg	
	Guaiphenesin and	Terbutaline Sulphate	IP	1.25	mg	7/22/201
	Menthol Syrup	Guaiphenesin	IP	50	mg	7/23/201
		Menthol	IP	2.5	mg	
		Colour: Approved Colour Used				
459	Benzoic acid &	COMPOSITION				
1.57	salicylic acid Ointment IP	Benzoic acid	IP	6%	w/w	7/23/2018
		salicylic acid	IP	3%	w/w	
		Ointment base		qs	,	
				1		
160	Luliconazole Cream.	Composition:-				
		Luliconazole		1%	W/W	
		Preservative:-				7/23/2018
		Benzyl Alcohol	IP	1%	W/W	
		Cream Base		q. s.		
461	White Petroleum	COMPOSITION				
	Jelly IP	White Petroleum Jelly	IP	100%	w/w	w 7/23/2018
462	Norfloxacin	Each film coated tablet contains :-		400	-	
	Tablets IP	Norfloxacin	IP	400	mg	10/1/201
		Excipients		qs		
		Approved colour used in coating				
463	Norfloxacin &	Each film coated tablet contains :-				
	Tinidazole Tablets	Norfloxacin	IP	400	mg	
		Tinidazole	IP	600	mg	10/1/201
		Excipients		q.s		
		Approved colour used in coating				
464	Hydroxychloroquine	Each film coated tablet contains :-				
	Tablets IP	Hydroxychloroquine Sulphate	IP	200	mg	10/1/201
		Excipients		qs		10/1/2018
		Approved colour used in coating				
465	Hydroxychloroquine	Each film coated tablet contains :-				
	Tablets IP	Hydroxychloroquine Sulphate	IP	300	mg	
		Excipients		qs		10/1/201
		Approved colour used in coating	1	1		

	List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/ LY WELFARE DEPARTMENT ts Approved to be Manufactured NB/07/642 AND MB/07/643 28:S-MB/07/643 For the ZE AS PER SCHEDULE-P-1 OF DRUGS & COSME	,HIMACI by : Boffi period from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Tablets IP	Hydroxychloroquine Sulphate	IP	400	mg	10/1/2010
		Excipients		qs		10/1/2018
		Approved colour used in coating				
467	Atorvastatin &	Each film coated tablet contains :-				
	Fenofibrate Tablets IP	Atorvastatin Calcium	IP	10		
		Eq. to Atorvastatin		10	mg	10/1/2018
		Fenofibrate	IP	145	mg	
		Excipients		qs		
		Approved colour used in coating				
468	Fluoxetine Hydrochloride Capsules IP	Each hard gelatin capsule shell contain Fluoxetine Hydrochloride eq. to Fluoxetine	s :- IP	20	mg	10/1/2018
		Approved colour used in Capsule shell				
			-			
469	Albendazole Oral Suspension	Each 5ml Contains:				
	IP (Vet.)	Albendazole	IP	125	mg	10/1/2010
	VETERINARY USE	In a syurpy Base		q.s.		10/1/2018
	NOT FOR HUMAN USE	Colour:Approved colour used				
470	Lactulose Solution USP	Each 15ml contains:				
		Lactulose Concentrate	USP			10/1/2018
		Eq. to Lactulose		10	gm	10/1/2010
		Colour: Approved colour used				
471	Cymechantadina	Each 5ml contains:				
4/1	Cyproheptadine Hydrochloride Syrup IP	Cyproheptadine Hydrochloride	IP	2	ma	10/1/2018
	Trydroemonde Syrup Ir	Colour: Approved colour used	Ir	Z	mg	10/1/2018
		Colour. Approved colour used				
472	Aluminium Hydroxide,	Each 5ml. contains:				
.,2	Magnesium Hydroxide and	Aluminium Hydroxide	IP	250	mg	
	Simethicone Suspension. IP	Magnesium Hydroxide	IP	250	mg	10/1/2018
	······································	Simethicone	IP	50	mg	
		Colour: Approved colour used	•		. 0	
	-					
473	Albendazole Oral	Each 5ml contains:				
	Suspension IP	Albendazole	IP	200	mg	10/1/2018
		Colour: Approved colour used				
474	Mefenamic Acid &	Each Uncoated Tablet Contains		-		
	Paracetamol Tablet	Mefenamic Acid	IP	250	mg	
		Paracetamol	IP	325	Mg	3/5/2021
		Excipients		q.s.		
1=-		Colour: Approved Colour used				
475	Albendazole &	Each Uncoated Chewable Tablet Conta		400		
	Ivermectin Tablet	Albendazole	IP	400	mg	21512021
		Ivermectin	IP	6	Mg	3/5/2021
		Excipients		q.s.		
		Colour: Approved Colour used				

	List of Retention Production having license No. FORM25:	NO.HFW-H(DRUGS)279 IILY WELFARE DEPARTMEN cts Approved to be Manufactured MNB/07/642 AND MB/07/643 28:S-MB/07/643 For th	T,HIMACI d by : Boffi he period from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC	SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSM COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED
170	NAME/BRAND NAME	Each Uncoated Chewable Tablet Cor				ON DATED
476	Albendazole & Ivermectin Tablet	Albendazole	IP	400	ma	
	Ivermectini Tablet	Ivermectin	IP	12	mg Mg	3/5/2021
		Excipients		q.s.	wig	3/3/2021
		Colour: Approved Colour used		q.s.		
477	Sucralfate Oral Suspension	Each 10ml contains:				
		Sucralfate	IP	1000	mg	3/5/2021
		In a flavoured syrup base		q.s.		5/5/2021
		Colour: Sunset Yellow Supra				
478	Sucralfate &	Each 10ml Contains:		-		
	Oxetacaine Oral	Sucralfate	IP	1000	mg	
	suspension	Oxetacaine	BP	20	mg	3/5/2021
		In a flavoured syrup base			q.s.	
		Colour: Approved Colour				
470	Dhamada nhain a	East with a state of the				
479	Phenylephrine	Each ml contains:	ID	25		
	& Chlorpheniramine	Phenylephrine Hydrochloride	IP	2.5	mg	3/5/2021
	Maleate Oral Drops	Chlorpheniramine Maleate	IP	1	mg	3/3/2021
		In a Flavoured Syrup Base Colour:Approved colour used		q.s.		
		Colour.Approved colour used				
480	Phenylephrine &	Each 5ml contains:				
400	Chlorpheniramine	Phenylephrine Hydrochloride	IP	5	mg	
	Maleate Syrup IP	Chlorpheniramine Maleate	IP	2	mg	3/5/2021
	F	In a Flavoured Syrup Base		q.s.	8	
		Colour:Approved colour used		.1		
		-				
481	Mefenamic Acid &	Each 5ml contains				
	Paracetamol	Mefenamic Acid	IP	50	mg	
	Suspension	Paracetamol	IP	125	Mg	3/5/2021
		In a flavoured syrup base		q.s.		
		Colour: Approved Colour Used				
40.2						
482	Ibuprofen & Paracetamol	Each 5ml contains	T	100	r	
	Suspension	Ibuprofen	IP	100	mg	2/5/2021
		Paracetamol	IP	162.5	mg	3/5/2021
		In a flavoured syrupy base		q.s.		
		Colour: Approved Colour Used				
483	Ferric Ammonium Citrate,	Each 10 ml contains:				
-05	Folic Acid &	Ferric Ammonium Citrate	IP	160	ma	
	Cyanocobalamin	Folic Acid	IP IP	100	mg mg	
	Syrup	Cyanocobalamin	IP IP	7.5	mg	3/5/2021
	Syrup	In a Flavoured Syrup Base			mcg	5/5/2021
	1	in a mayoured Syrup Dase		q.s.		
		Colour:Approved colour used				

	List of Retention Produce having license No. FORM25:N	NO.HFW-H(DRUGS)279 ILY WELFARE DEPARTMENT ets Approved to be Manufactured MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the DIZE AS PER SCHEDULE-P-1 OF DRUGS & COSME	,HIMACI by : Boffi period from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Gel, Magnesium	Dried Aluminium Hydroxide Gel	IP	291	mg	
	Hydroxide &	Magnesium Hydroxide	IP	98	mg	2/5/2021
	Oxetacaine Suspension	Oxetacaine	BP	10	mg	3/5/2021
		In a flavoured syrup base		q.s.		
		Colour: approved colour added				
485	Diphenhydramine HCL,	Each 5 ml contains				
	Ammonium Chloride,	Diphenhydramine Hydrochloride	IP	14.08	mg	
	Sodium Citrate &	Ammonium Chloride	IP	138	mg	
	Menthol Syrup	Sodium Citrate	IP	57.03	mg	3/5/2021
		Menthol	IP	1.14	mg	
		In a Flavoured Syrup Base		q.s.		
		Colour:Approved colour used				
486	Albendazole &	Each 5ml Contains	-			
	Ivermectin Suspension	Albendazole	IP	200	mg	
		Ivermectin	IP	3	mg	3/5/2021
		In a flavoured Suspension Base		q.s.		
		Colour: Approved Colour used				
487	Albendazole &	Each 5ml Contains		-		
	Ivermectin Suspension	Albendazole	IP	200	mg	
		Ivermectin	IP	1.5	mg	3/5/2021
		In a flavoured Suspension Base		q.s.		
		Colour: Approved Colour used				
488	CyproheptadineHCl &	Each 5ml contains:				
	Tricholine Citrate Syrup	Cyproheptadine HCL	IP	2	mg	
		TricholineCitrate(65%)	IP	275	mg	3/5/2021
		In a Flavoured Sorbitol Base		q.s.		
	~	Colour:Approved colour used				
489	Cetirizine	Each 5 ml contains:			-	
	Hydrochloride,	Cetirizine Hydrochloride	IP	2	mg	
	Phenylephrine	Phenylephrine Hydrochloride	IP	5	mg	3/5/2021
	Hydrochloride	Paracetamol	IP	125	mg	
	&Paracetamol	In a Flavoured Syrup Base		q.s		
	Suspension	Colour: Approved Colour				
400	Chaling Calin-1-t-	Composition				
490	Choline Salicylate	Composition:	חת			
	, Lignocaine Hydrochloride Gel	Choline Salicylate Solution Eq. to Choline Salicylate	BP	8 700/	· · · · ·	
	Hydrochloride Gel	1	TD	8.70%	w/w	3/5/2021
		Lignocaine Hydrochloride Benzalkonium Chloride Solution	IP ID	2%	w/w	
		In a pleasant flavoured Gel base	IP	0.01%	w/w	
		In a pleasant havoured Gel base		q.s.		
491	Ciprofloxacin.	Composition:				
771	Cipionozaciii.		m	r – –		
	Metronidazole	Ciproflovacin Hydrochlorida				
	Metronidazole, Terbinafine	Ciprofloxacin Hydrochloride	IP	1 0004	xx/xx7	
	Terbinafine	Eq. to Ciprofloxacin		1.00%	w/w	
	Terbinafine Hydrochloride &	Eq. to Ciprofloxacin Metronidazole Benzoate	IP			
	Terbinafine Hydrochloride & Clobetasol Propionate	Eq. to Ciprofloxacin Metronidazole Benzoate Eq. to Metronidazole	IP	1.00%	w/w	3/5/2021
	Terbinafine Hydrochloride &	Eq. to Ciprofloxacin Metronidazole Benzoate Eq. to Metronidazole Terbinafine Hydrochloride	IP IP	1.00% 1.00%	w/w w/w	3/5/2021
	Terbinafine Hydrochloride & Clobetasol Propionate	Eq. to Ciprofloxacin Metronidazole Benzoate Eq. to Metronidazole Terbinafine Hydrochloride Clobetasol Propionate	IP IP IP	1.00% 1.00% 0.05%	w/w w/w w/w	3/5/2021
	Terbinafine Hydrochloride & Clobetasol Propionate	Eq. to Ciprofloxacin Metronidazole Benzoate Eq. to Metronidazole Terbinafine Hydrochloride	IP IP	1.00% 1.00%	w/w w/w	3/5/2021

	List of Retention Produc having license No. FORM25:N	NO.HFW-H(DRUGS)279/07 ILY WELFARE DEPARTMENT, H its Approved to be Manufactured by INB/07/642 AND MB/07/643 28:S-MB/07/643 For the per	IIMACI y : Boffi iod from 01.	n Biotecl	h Pvt.	
S. No.	PACK S DOSAGE FORM, GENERIC NAME/BRAND NAME	IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATED
492	Clobetasol Propionate	Composition:				
	& Salicylic Acid Cream	Clobetasol Propionate	IP	0.05%	w/w	
		Salicylic acid	IP	3%	w/w	3/5/2021
		Ointment Base		q.s.		
	•		8			
493	Clobetasol Propionate,	Composition:				
	Gentamicin, Miconazole	Clobetasol Propionate	IP	0.05%	w/w	
	Nitrate & Zinc oxide	Gentamicin Sulphate	IP			
	Cream	Eq. to Gentamicin		0.20%	\mathbf{w}/\mathbf{w}	3/5/2021
		Miconazole Nitrate	IP	2%	W/W	3/3/2021
		Zinc Oxide	IP	0.10%	w/w	
		Chlorocresol (as preservative)	IP	0.10%	w/w	
		Cream Base		q.s.		
494	Fusidic Acid & Clobetasol	Composition:				
	Propionate	Fusidic Acid	IP	2%	w/w	3/5/2021
	Cream	Clobetasole Propionate	IP	0.05%	w/w	
		Cream Base		q.s.		
10.5						
495	Fusidic Acid, Clobetasol	Composition:	ID	20/		
	Propionate & Clotrimazole Cream	Fusidic Acid	IP	2%	w/w	2/5/2021
	Clotrimazole Cream	Clobetasole Propionate Clotrimazole	IP IP	0.05%	w/w	3/5/2021
		Cream Base	IP	1% q.s.	w/w	
		Cream Base		q. 3.		
496	Fusidic Acid,	Composition:				
., 0	Beclomethasone	Fusidic Acid	IP	2%	w/w	
	Dipropionate &	BeclomethasoneDipropionate	IP	0.025%	w/w	3/5/2021
	Chlorocresol Cream	Chlorocresol	IP	0.10%	w/w	
		Cream Base		q.s.		
497	Gamma Benzene	Composition:		1	-	
	Hexachloride &	Gamma BenzeneHexachloride	IP	1%	w/w	
	Cetrimide Lotion	Cetrimide	IP	0.10%	w/w	3/5/2021
		In a Lotion Base		q.s.		
	•	•				
498	Ketoconazole & Zinc	Composition:				
	Pyrithione Anti	Ketoconazole	IP	2%	\mathbf{W}/\mathbf{W}	
	Dandruff Topical	Zinc Pyrithione		1%	w/w	3/5/2021
	Lotion Shampoo	Anti Dandruff Topical Lotion Shampoo		q.s.		
		Base				
499	Ketoconazole, Neomycin,	Composition:				
	Tolnaftate,	Ketoconazole	IP	2.00%	w/w	
	Iodochlorhydroxyquinoline,	Neomycin Sulphate	IP	0.10%	w/w	
	& Clobetasol Propionate	Eq. to Neomycin		1.0-		3/5/2021
	Cream.	Tolnaftate	IP	1.00%	w/w	
		Iodochlorhydroxyquinoline	IP	1.00%	w/w	
		Clobetasol Propionate	IP	0.05%	w/w	
		In a cream base		q.s.		

500 Mupirocin & Fluticasone

Composition:

I

		ANB/07/642 AND MB/07/643 28:S-MB/07/643 For the IZE AS PER SCHEDULE-P-1 OF DRUGS & COSME				
. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATED
	Propionate Ointment	Mupirocin	IP	2%	\mathbf{W}/\mathbf{W}	3/5/2021
		Fluticasone Propionate	IP	0.005%	w/w	5/5/2021
		In a Ointment Base		q.s.		
501	Mupirocin &	Composition:				
/01	Beclomethasone	Mupirocin	IP	2%	w/w	
	Dipropionate Ointment	BeclomethasoneDipropionate	IP	0.025%	w/w	3/5/2021
		In a Ointment Base		q.s.		
502	Mupirocin & Sucralfate	Composition:				
502	Ointment	Mupirocin	IP	2%	w/w	
	Untillent	Sucralfate	IP IP	2% 7%	w/w w/w	3/5/2021
		In a Ointment Base	11	7% q.s.	w/w	
503	Ofloxacin, Ornidazole, Itraconazole & Clobetasol	Composition:	v~-	0.77		
	Propionate Cream	Ofloxacin Ornidazole	IP IP	0.75%	w/w w/w	
	ropionale cream	Itraconazole	BP	1.00%	w/w	
		Clobetasol Propionate	IP	0.05%	w/w	3/5/2021
		Methyl Paraben	IP	0.20%	w/w	
		Propyl Paraben	IP	0.02%	w/w	
		In a cream base		q.s.		
504	Ampicillin Trihydrate	Each Hard Gelatin Capsules contains		1		
	& Dicloxacillin Sodium	Ampicillin Trihydrate	IP	250	mg	
	Capsules	Eq. to Ampicillin				
		Dicloxacillin Sodium	IP	250	mg	3/5/2021
		Eq. to Dicloxacillin				
		Excipents		q.s.		
		Approved Colour Used in empty capsu	ules Shell			
505	Thiocolchicoside &	Each Film Coated Tablet contains:				
	Lornoxicam Tablet	Thiocolchicoside	IP	4	mg	
		Lornoxicam		8	mg	3/15/2021
		Excipients		q.s.		
		Colour:Approved colour used				
506	Terbutaline Sulphate,	Each Uncoated Tablet Contains:				
	Ambroxol	Terbutaline Sulphate	IP		mg	
	Hydrochloride &	Eq. to Terbutaline		2.5	8	
	Guaiphenesin Tablet	Ambroxol Hydrochloride	IP	30	mg	3/15/2021
		Guaiphenesin	IP	100	mg	
		Excipients		q.s.		
		Colour: Approved colour Used				
507	Piracetam & Citicoline	Each Film Coated Tablet contains:				
	Sodium Tablet	Piracetam	IP	800	mg	
		Citicoline Sodium	IP	500	mg	
		Eq. to Citicoline				3/15/2021
		Excipients		q.s.		
		Colour:Approved colour used		-	\vdash	

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/ ILY WELFARE DEPARTMENT ts Approved to be Manufactured INB/07/642 AND MB/07/643 28:S-MB/07/643 For the	,HIMACI by : Boffi period from 01.	n Biotecl	h Pvt.	
S. No.	PACK S DOSAGE FORM, GENERIC NAME/BRAND NAME	ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Sodium Tablet	Piracetam	IP	1200	mg	
		Citicoline Sodium	IP	500	mg	
		Eq. to Citicoline			0	3/15/2021
		Excipients		q.s.		
		Colour:Approved colour used		_		
509	CefpodoximeProxetil&	Each Filmcoated Tablet contains:				
	Ofloxacin Tablet	CefpodoximeProxetil	IP	100	mg	
		Eq. to Cefpodoxime				2/15/2021
		Ofloxacin	IP	100	mg	3/15/2021
		Excipients		q.s.		
		Colour:Approved colour used				
510	CefpodoximeProxetil&	Each Filmcoated Tablet contains:				
010	Ofloxacin Tablet	CefpodoximeProxetil	IP		mg	
		Eq. to Cefpodoxime		200		
		Ofloxacin	IP	200	mg	3/15/2021
		Excipients		q.s.	0	
		Colour:Approved colour used				
511	Cofining Trillouter 9			1		
511	CefiximeTrihydrate & Ofloxacin Tablet	Each Uncoated Tablet contains:	ID	50		
	Ofloxacin Tablet	CefiximeTrihydrate	IP		mg	
		Eq. to (Anhydrous)Cefixime Ofloxacin	ID	50		3/15/2021
			IP		mg	
		Excipients Colour:Approved colour used	_	q.s.		
			1			
	Doxycycline Hydrochloride &	Each Hard Gelatin Capsule contains:				
512						
512	Lactic Acid Bacillus	Doxycycline Hydrochloride	IP	100	mg	
512	Lactic Acid Bacillus Capsules	Doxycycline Hydrochloride Eq. to Doxycycline	IP	100	mg	
512			IP	100 5	mg spores	3/15/2021
512		Eq. to Doxycycline Lactic Acid Bacillus Excipients	IP		Ŭ	3/15/2021
512		Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard	IP	5	Ŭ	3/15/2021
512		Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell	IP	5	Ŭ	3/15/2021
512		Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell Each Uncoated Bolus contains:	IP	5	Ŭ	3/15/2021
	Capsules	Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell	IP IP	5	Ŭ	
	Capsules Albendazole Bolus IP VETERINARY USE	Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell Each Uncoated Bolus contains: Albendazole Excipients		5 q.s.	spores	
	Capsules Albendazole Bolus IP	Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell Each Uncoated Bolus contains: Albendazole		5 q.s. 600	spores	3/15/2021 3/15/2021
	Capsules Albendazole Bolus IP VETERINARY USE	Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell Each Uncoated Bolus contains: Albendazole Excipients		5 q.s. 600	spores	
513	Capsules Albendazole Bolus IP VETERINARY USE NOT FOR HUMAN USE	Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell Each Uncoated Bolus contains: Albendazole Excipients Colour:Approved colour used Each Uncoated Bolus contains:		5 q.s. 600 q.s.	spores mg	3/15/2021
513	Capsules Albendazole Bolus IP VETERINARY USE NOT FOR HUMAN USE Albendazole Bolus IP	Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell Each Uncoated Bolus contains: Albendazole Excipients Colour:Approved colour used Each Uncoated Bolus contains: Albendazole		5 q.s. 600 q.s. 1500	spores	3/15/2021
513	Capsules Albendazole Bolus IP VETERINARY USE NOT FOR HUMAN USE	Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell Each Uncoated Bolus contains: Albendazole Excipients Colour:Approved colour used Each Uncoated Bolus contains:		5 q.s. 600 q.s.	spores mg	3/15/2021
513	Capsules Albendazole Bolus IP VETERINARY USE NOT FOR HUMAN USE Albendazole Bolus IP VETERINARY USE NOT FOR HUMAN USE	Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell Each Uncoated Bolus contains: Albendazole Excipients Colour:Approved colour used Each Uncoated Bolus contains: Albendazole Excipients Colour:Approved colour used		5 q.s. 600 q.s. 1500	spores mg	3/15/202
513	Capsules Albendazole Bolus IP VETERINARY USE NOT FOR HUMAN USE Albendazole Bolus IP VETERINARY USE NOT FOR HUMAN USE Fenbendazole Bolus	Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell Each Uncoated Bolus contains: Albendazole Excipients Colour:Approved colour used Each Uncoated Bolus contains: Albendazole Excipients Colour:Approved colour used Each Uncoated Bolus contains:		5 q.s. 600 q.s. 1500 q.s.	spores mg mg	3/15/2021
513	Capsules Albendazole Bolus IP VETERINARY USE NOT FOR HUMAN USE Albendazole Bolus IP VETERINARY USE NOT FOR HUMAN USE	Eq. to Doxycycline Lactic Acid Bacillus Excipients Approved colour used in empty hard gelatin Capsules Shell Each Uncoated Bolus contains: Albendazole Excipients Colour:Approved colour used Each Uncoated Bolus contains: Albendazole Excipients Colour:Approved colour used		5 q.s. 600 q.s. 1500	spores mg	

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279 ILY WELFARE DEPARTMEN ts Approved to be Manufacture INB/07/642 AND MB/07/643 28:S-MB/07/643 For the	T,HIMACI d by : Boffi he period from 01.	n Biotec	h Pvt.	
S. No.	PACK SI DOSAGE FORM, GENERIC NAME/BRAND NAME	ZE AS PER SCHEDULE-P-1 OF DRUGS & COSM COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
516	Ivermectin Tablets IP	Each Uncoated Tablet contains:				
		Ivermectin	IP	80	mg	3/15/2021
	VETERINARY USE	Excipients		q.s.		5/15/2021
	NOT FOR HUMAN USE	Colour:Approved colour used				
517	Ivermectin & Praziquantel	Each Uncoated Tablet contains:		1		
017	Tablets	Ivermectin	IP	2	mg	
	1 401045	Praziquantel	IP	50	mg	3/15/2021
	VETERINARY USE	Excipients		q.s.		
	NOT FOR HUMAN USE	Colour:Approved colour used		1		
510	Malariana D. (10	East Uses and D. 1				
518	Meloxicam, Paracetamol &	Each Uncoated Bolus contains: Meloxicam	IP	100		
	Serratiopeptidase Bolus	Paracetamol	IP IP	100 2000	mg	
		Serratiopeptidase	IP IP	2000	mg	
		(As Enteric coated granules)	Ir	15	mg	3/15/2021
		Eq. to 150,000 Enzymatic Units				
	VETERINARY USE	Excipients		q.s.		
	NOT FOR HUMAN USE	Colour:Approved colour used		4.5.		
		<u> </u>			1 1	
519	Metronidazole, Furazolidone					
		Each Uncoated Bolus contains:		1000		
	& Loperamide Bolus	Metronidazole	IP	1000	mg	2/15/2021
		Furazolidone	IP ID	500	mg	3/15/2021
	VETERINARY USE	Loperamide HCl Excipients	IP	7.5	mg	
	NOT FOR HUMAN USE	Colour:Approved colour used		q.s.		
	NOT FOR HOMAN USE	Colour.Approved colour used				
520	Oxytetracycline Hydochloride	Each Uncoated Bolus contains:				
	Bolus	Oxytetracycline Hydochloride	IP	500	mg	3/15/2021
	VETERINARY USE	Excipients		q.s.		
	NOT FOR HUMAN USE	Colour:Approved colour used				
521	Sucralfate&Oxetacaine	Each 10ml Contains:				
	Oral suspension	Sucralfate	IP	1000	mg	
		Oxetacaine	BP	10	mg	3/15/2021
		In a flavoured syrup base		q.s.		
		Colour: Approved Colour		q.s.		
522	Terbutaline Sulphate,	Each 5 ml contains				
522	Bromhexine	Terbutaline Sulphate	IP	1.25	mg	
	Hydrochloride,	Bromhexine Hydrochloride	IP	4	mg	
	-	Guaiphenesin	IP	50	-	3/15/2021
	Guaiphenesin&	-			mg	5/15/2021
	Menthol Syrup	Menthol In a Flavoured Syrupy Base	IP	1 q.s.	mg	4

	List of Retention Product having license No. FORM25:N	NO.HFW-H(DRUGS)279/0 ILY WELFARE DEPARTMENT, its Approved to be Manufactured b INB/07/642 AND MB/07/643 28:S-MB/07/643 For the pu IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETI	HIMACI y:Boffi eriod from 01.	n Biotec	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Bromhexine	Terbutaline Sulphate	IP	1.25	mg	
	Hydrochloride,	Bromhexine Hydrochloride	IP	2	mg	
	Guaiphenesin&	Guaiphenesin	IP	50	mg	3/15/2021
	Menthol Syrup	Menthol	IP	0.5	mg	
	, I	In a Flavoured Syrupy Base		q.s.	0	
		Colour:Approved colour used				
		· · · ·				
524	Roxithromycin Oral	Each 5ml contains:				
	Suspension IP	Roxithromycin	IP	50	mg	3/15/2021
		In a Flavoured Syrupy Base		q.s.		5/15/2021
		Colour:Approved colour used				
525	Salbutamol Sulphate	Each ml contains				
	,Guaiphenesin &	Salbutamol Sulphate	IP	0.5		
	Ambroxol	Eq. to Salbutamol			mg	
	Hydrochloride Syrup	Guaiphenesin	IP	12.5	mg	3/15/2021
		Ambroxol Hydrochloride	IP	7.5	mg	
		In a Flavoured Syrupy Base		q.s.		
		Colour:Approved colour used				
526	Paracetamol,	Each 5ml contains:				
	Phenylephrine HCl &	Paracetamol	IP	250	mg	
	Cetirizine Dihydrochloride	Phenylephrine HCl	IP	5	mg	3/15/2021
	suspension	Cetirizine Dihydrochloride	IP	2	mg	5/15/2021
		Flavoured syrupy base		q.s.		
		Colour:Approved colour used				
527	Ondansetron Hydrochloride	Each 5ml contains:				
	Oral Solution IP	Ondansetron Hydrochloride	IP	2		
		Eq. to Ondansetron			mg	3/15/2021
		In a Flavoured Syrupy Base		q.s.		
		Colour:Approved colour used				
528	Paracetamol Paediatric	Each ml contains:	_			
	Oral Suspension IP	Paracetamol	IP	100	mg	3/15/2021
		In a Flavoured Syrupy Base		q.s.		0/10/2021
		Colour:Approved colour used				
529	Mefenamic Acid &	Each 5ml contains	-			
	Paracetamol	Mefenamic Acid	IP	100	Mg	
	Suspension	Paracetamol	IP	250	Mg	3/15/2021
		In a flavoured syrup base		q.s.		
		Colour: Approved Colour Used				
530	Ofloxacin Oral	Each 5ml contains:				
	Suspension IP	Ofloxacin	IP	50	mg	3/15/2021
		In a Flavoured Syrupy Base		q.s.		
		Colour:Approved colour used				

	List of Retention Produc	NO.HFW-H(DRUGS)279/ ILY WELFARE DEPARTMENT ts Approved to be Manufactured INB/07/642 AND MB/07/643 28:S-MB/07/643 For the	,HIMACI by : Boffi	n Biotecl	h Pvt.	
		ZE AS PER SCHEDULE-P-1 OF DRUGS & COSME				
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
531	Levosalbutamol Sulphate	Each 5 ml contains				
	, Ambroxol	Levosalbutamol Sulphate	IP			
	Hydrochloride &	Eq. to Levosalbutamol		1	Mg	
	Guaiphenesin Syrup	Ambroxol Hydrochloride	IP	30	Mg	3/15/2021
		Guaiphenesin	IP	50	Mg	
		In a Flavoured Syrupy Base		q.s.		
		Colour:Approved colour used				
532	Aceclofenac&Paracetamol	Each 5ml contains		-		
	Suspension	Aceclofenac	IP	50	mg	
		Paracetamol	IP	125	mg	3/15/202
		In a flavoured syrupy base		q.s.		
		Colour: Approved Colour Used		q.s.		
533	Calcium Carbonate	Each 5ml contains				
	& Vitamin D3	Calcium Carbonate IP 625mg	IP	250	mg	
	Suspension	Eq. to Elemental Calcium				
		Vitamin D3	IP	125	IU	3/15/202
		In a flavoured syrupy base		q.s.		
		Colour: Approved Colour Used				
		For Therapeutic use				
534	Cetirizine Hydrochloride,	Each 5 ml contains:				
	Phenylephrine	Cetirizine Hydrochloride	IP	2.5	mg	
	Hydrochloride &	Phenylephrine Hydrochloride	IP	5	mg	3/15/202
	Dextromethorphan	Dextromethorphan Hydrobromide	IP	10	mg	0/10/202
	HydrobromideSyrup	In a Flavoured Syrup Base		q.s		
		Colour: Approved Colour				
535	Clobetasol Propionate,	Composition:		0.07	<u> </u>	
	Gentamicin Sulphate,	Clobetasol Propionate	IP	0.05%	w/w	
	Miconazole Nitrate &	Gentamicin Sulphate IP	IP	0.10%		
	Clotrimazole Cream	Eq. to Gentamicin			w/w	3/15/202
		Clotrimazole	IP	1%	w/w	
		Miconazole Nitrate	IP	2%	w/w	
		Cream Base		q.s		
536	Chlorpheniramine Maleate &	Each 5ml contains		. .		
	Dextromethorphan	Chlorpheniramine Maleate	IP	4	mg	0/15/000
	Hydrobromide Syrup	Dextromethorphan Hydrobromide	IP	10	mg	3/15/202
		In a flavoured syrupy base		q.s.		
	~	Colour: Approved Colour Used		q.s.		
537	Chlorpheniramine Maleate,	Each 5 ml contains:				
	Phenylephrine	Chlorpheniramine Maleate	IP	1	mg	
	Hydrochloride &	Phenylephrine Hydrochloride	IP	2.5	mg	3/15/202
	Paracetamol	Paracetamol	IP	125	mg	
	Suspension	In a Flavoured Syrup Base		q.s		
		Colour: Approved Colour				
- C	Chlorpheniramine Maleate,	Each 5 ml contains:	-	-		
538	-		IP	2	mg	y 5
538	Phenylephrine	Chlorpheniramine Maleate			_	
538	Phenylephrine Hydrochloride &	Phenylephrine Hydrochloride	IP	5	mg	3/15/202
538	Phenylephrine	-			_	3/15/202

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/07 ILY WELFARE DEPARTMENT,H ts Approved to be Manufactured by INB/07/642 AND MB/07/643 28:S-MB/07/643 For the per ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	IMACI V : Boffi iod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
539	Dextromethorphan Hydrobromide,	Each 5ml Contains: Dextromethorphan Hydrobromide	IP	5		
	Phenylephrine	Phenylephrine Hydrochloride	IP	5	mg	
	Hydrochloride &	Chlorpheniramine Maleate	IP	2	mg mg	3/15/2021
	Chlorpheniramine	In a flavoured Syrupy base	11	q.s.	mg	
	Maleate Syrup	Colour: Approved colour Used		q .5.		
540	Dicyclomine Hydrochloride	Each ml contains:				
	& Activated	Dicyclomine Hydrochloride	IP	10	mg	
	Dimethicone	Activated Dimethicone	IP	40	mg	3/15/2021
	Suspension	In a Flavoured Syrupy Base		q.s.		
		Colour:Approved colour used				
<i>C</i> 4 1		P 15 1 4		1		
541	Diphenhydramine HCl,	Each 5ml contains: Diphenhydramine HCl	IP	12.5	-	
	Terpin Hydrate, Ammonium Chloride &	Terpin Hydrate	USP	7.5	mg	
	Sodium Citrate Syrup	Ammonium Chloride	IP	125	mg mg	3/15/2021
	Sourum Chrace Syrup	Sodium Citrate	IP	55	mg	5/15/2021
		Flavoured Mentholated syrupy base		q.s.	mg	
		Colour:Approved colour used		-1		
		▲ ▲ ▲				
542	Disodium Hydrogen	Each 5ml contains:		-		
	Citrate Syrup	Disodium Hydrogen Citrate	BP	1.25	gm	3/15/2021
		In a flavoured syrup base		q.s.		
		Colour: Approved Colour Used				
543	Disodium Hydrogen	Each 5ml contains:				
545	Citrate Syrup	Disodium Hydrogen Citrate	BP	1.41	gm	
	Cidate Syrap	In a flavoured syrup base	ы	q.s.	5	3/15/2021
		Colour: Approved Colour Used		4 .5.		
544	Domperidone Oral	Each ml contains:				
	Suspension IP	Domperidone	IP	1	mg	3/15/2021
		In a Flavoured Syrupy Base		q.s.		5/15/2021
		Colour:Approved colour used				
E 4 E	D' 141 '' II 1 '1					
545	Dried Aluminium Hydroxide	Each 10ml contains: Dried Aluminium Hydroxide Gel	ID	250	ma	
	Gel, Magnesium Hydroxide &	Magnesium Hydroxide Gel	IP IP	250 200	mg	
	Simethicone	Simethicone	IP IP	200 50	mg	
	Suspension IP	Sorbitol Solution (Non Crystallizing)	IP	 q.s	mg	3/15/2021
	supportion in	(iton crysunizing)		4.5		
		In a flavoured syrup base		q.s.		
		Colour: Approved Colour Used				
546	Ferric Ammonium Citrate,	Each 10ml contains				
	Foilc Acid &	Ferric Ammonium Citrate	IP	160	mg	
	Cyanocobalamin Syrup	Foilc Acid	IP	1.5	mg	
		Cyanocobalamin (Vitamin B12)	IP	15	mcg	3/15/2021
		In a flavoured syrupy base		q.s.		
		Colour: Approved Colour Used		ļ		
		For Therapeutic use				

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/0 ILY WELFARE DEPARTMENT, J ts Approved to be Manufactured b INB/07/642 AND MB/07/643 28:S-MB/07/643 For the pr ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIN	HIMACI y:Boffi eriod from 01.	n Biotec	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
547	Ketoconazole,	Composition:	8			
	Iodochlorhydroxy-quinoline,	Ketoconazole	IP	2.00%	W/W	
	Clobetasol Propionate,	Iodochlorhydroxyquinoline	IP	1.00%	W/W	
	Gentamicin Sulphate &	Clobetasol Propionate	IP	0.05%	w/w	3/15/2021
	Chlorocresol Cream.	Gentamicin Sulphate	IP	0.10%	\mathbf{W}/\mathbf{W}	
		Chlorocresol	IP	0.10%	\mathbf{W}/\mathbf{W}	
		In a cream base		q.s.		
548	C					
548	Sertaconazole Nitrate Cream	Composition: Sertaconazole Nitrate	חח	20/		
	Nitrate Cream		BP IP	2%	w/w	3/15/2021
		Preservative : Benzyl Alcohol In a Cream Base	IP	1%	w/w	
		iii a Creaiii Base		q.s		
549	Thiocolchicoside,	Composition:				
	DiclofenacDiethylamine,	Thiocolchicoside	IP	0.125%	w/w	
	Linseed Oil, Methyl	DiclofenacDiethylamine	IP	1.16%	w/w	
	Salicylate & Menthol Gel	(Eq to Diclofenac Sodium 1.0% w/w)				3/15/2021
		Linseed Oil	BP	3%	w/w	
		Methyl Salicylate	ID	10%	w/w	
		Menthol	IP	5%	w/w	
		Gel Base		q.s.		
550	Telmisartan,	Each Uncoated Tablet contains:-				
	Chlorthalidone &	Telmisartan	IP	40	mg	
	Amlodipine Tablets	Chlorthalidone	IP	12.5	mg	
		Amlodipine Besilate	IP	_		3/23/2021
		eq. to Amlodipine		5	mg	
		Excipients Approved colour used in Tablets.		q.s		
		Approved colour used in Tablets.				
551	Telmisartan &	Each Uncoated Tablet contains:-				
	Chlorthalidone	Telmisartan	IP	40	mg	
	Tablets	Chlorthalidone	IP	12.5	mg	3/23/2021
		Excipients		q.s		
		Approved colour used in Tablets.				
550	Donitiding UCI Tablata ID	Each Eilmanated Tablet contained				
552	Ranitidine HCl Tablets IP	Each Filmcoated Tablet contains: Ranitidine HCl	IP			
			11'	150	ma	3/23/2021
		eq. to Ranitidine Excipients			mg	3/23/2021
		Colour:Approved colour used		q.s.		
553	Ranitidine HCl Tablets IP	Each Filmcoated Tablet contains:				
		Ranitidine HCl	IP			
		eq. to Ranitidine		300	mg	3/23/2021
		Excipients		q.s.		
		Colour:Approved colour used				
554	PrednisoloneTablets IP	Each Filmcoated Tablet contains:				
		Prednisolone	IP	5	mg	3/23/2021
		Excipients		q.s.		5,25,2021
		Colour:Approved colour used				

	PACK SI	ZE AS PER SCHEDULE-P-1 OF DRUGS & COSME	TIC ACT 1945			
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATEI
555	PrednisoloneTablets IP	Each Filmcoated Tablet contains:				
		Prednisolone	IP	10	mg	3/23/202
		Excipients		q.s.		5/25/202
		Colour:Approved colour used				
556	IvermectinTablets IP	Each Uncoated Tablet contains:		1		
000		Ivermectin	IP	3	mg	
		Excipients		q.s.	0	3/23/202
		Colour:Approved colour used		1		
	1			1		
557	Hydroxyzine HCl Tablets IP	Each Filmcoated Tablet contains:				
		Hydroxyzine HCl	IP	10	mg	3/23/202
		Excipients		q.s.	0	
		Colour:Approved colour used		1		
				1		
558	Paracetamol	Each Uncoated tablet contains:			\mid	
	Chlorpheniramine Maleate &	Paracetamol	IP	325	mg	
	Phenylephrine HCl	Chlorpheniramine Maleate	IP	2	mg	3/23/202
	Tablets	Phenylephrine HCl	IP	5	mg	
		Excipients		q.s.		
		Colour:Approved colour used				
559	Paracetamol &	Each Uncoated tablet contains:				
	Ibuprofen Tablets IP	Paracetamol	IP	325	mg	
		Ibuprofen	IP	400	mg	3/23/202
		Excipients		q.s.		
		Colour:Approved colour used				
560	MetronidazoleTablets IP	Each Filmcoated Tablet contains:				
500	Wiedomadzole Lablets II	Metronidazole Benzoate	IP			
		eq. to Metronidazole		200	mg	3/23/202
		Excipients		q.s.	0	
		Colour:Approved colour used				
		· · · · · · · · · · · · · · · · · · ·				
561	MetronidazoleTablets IP	Each Filmcoated Tablet contains:		ļ	\mid	
		Metronidazole Benzoate	IP	10-		0.00.00
		eq. to Metronidazole		400	mg	3/23/202
		Excipients		q.s.		
		Colour:Approved colour used			╞──┨	
562	Diclofenac Potassium,	Each Uncoated tablet contains:			╞──┨	
	Paracetamol,	Diclofenac Potassium	BP	50	mg	
	Cetirizine HCl &	Paracetamol	IP	325	mg	
	Magnesium Trisilicate	Cetirizine HCl	IP	5	mg	3/23/202
	Tablets	Magnesium Trisilicate	IP	100	mg	
		Excipients		q.s.		
		Colour:Approved colour used				
		-				

		NO.HFW-H(DRUGS)279, ILY WELFARE DEPARTMENT	,HIMACI			
		ts Approved to be Manufactured				Ltd.
	č	INB/07/642 AND MB/07/643 28:S-MB/07/643 For the ZE AS PER SCHEDULE-P-1 OF DRUGS & COSME		12,2022 to 30	.11.2027	
5. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVE ON DATE
	Methyl Sulfonyl Methane &	Diacerein	IP	50	mg	
	Glucosamine Tablets	Methyl Sulfonyl Methane		250	mg	
		Glucosamine Sulphate			U	3/23/202
		Sodium Chloride	IP	750	mg	
		Excipients		q.s.		
		Colour:Approved colour used				
564	Combikit of Azithromycin, I	Fluconazole & Secnidazole Tablets				
	A. Azithromycin	Each Filmcoated tablet contains:				
	Tablets IP 1000mg	Azithromycin Dihydrate	IP			
		Eq. to Anhydrous Azithromycin		1000	mg	
		Excipients		qs.		
		Colour:Approved colour used				
	B. Fluconazole	Each uncoated tablet contains:				3/23/202
	Tablets IP 150 mg	Fluconazole	IP	150	mg	51251202
		Excipients		qs.		
		Colour:Approved colour used				
	C. 2 Secnidazole TabletsIP	Each Filmcoated tablet contains:		1000		
		Secnidazole	IP	1000	mg	
		Excipients		qs.		
		Colour:Approved colour used				
565	N - off	East Unanted Datas and income		1		
303	Norfloxacin Tinidazole &	Each Uncoated Bolus contains:- Norfloxacin	ID	1200		
	Lactic Acid Bacillus Bolus	Tinidazole	IP IP	1200 1800	mg	
	Lacue Acid Bacillus Bolus	Tillidazole	IP	1800	mg million	3/23/202
		Lactic Acid Bacillus		100	spores	
	(For animal use only)	Excipients		q.s		
	(Not for human use)	Approved colour used in Bolus				
	1			-		
566	Ranitidine HCl Oral	Each 5ml contains:				
	Solution IP	Ranitidine HCl	IP			
		eq. to Ranitidine		75	mg	3/23/202
		Excipients		q.s.		
		Colour:Approved colour used				
	Ofloxacin & Metronidazole	Each 5 ml contains:				
567			IP	50	ma	
567					mg	
567	Suspension	Ofloxacin Metropidazole Benzoate				
567		Metronidazole Benzoate	IP		ma	3/23/202
567		Metronidazole Benzoate eq. to Metronidazole		100	mg	3/23/202
567		Metronidazole Benzoate eq. to Metronidazole In a flavoured syrup base			mg	3/23/202
567		Metronidazole Benzoate eq. to Metronidazole		100	mg	3/23/202
	Suspension	Metronidazole Benzoate eq. to Metronidazole In a flavoured syrup base Colour:Approved colour used		100	mg	3/23/202
	Suspension Magaldrate & Activated	Metronidazole Benzoate eq. to Metronidazole In a flavoured syrup base Colour:Approved colour used Each 10 ml contains:		100 q.s.		3/23/202
	Suspension Magaldrate & Activated Dimethicone	Metronidazole Benzoate eq. to Metronidazole In a flavoured syrup base Colour:Approved colour used Each 10 ml contains: Magaldrate (Anhydrous)	IP	100 q.s. 480	mg	
567	Suspension Magaldrate & Activated	Metronidazole Benzoate eq. to Metronidazole In a flavoured syrup base Colour:Approved colour used Each 10 ml contains:	IP IP IP IP	100 q.s.		3/23/202 3/23/202

569	Dried Aluminium Hydroxide			
	Gel	Each 10 ml contains:		

	NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945									
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED				
	Magnesium Hydroxide	Magnesium Hydroxide	IP	185	mg					
	Simethicone	Sodium Carboxymethylcellulose	IP	100	mg					
	&Sodium Carboxymethylcellulose	Simethicone	IP	50	mg	3/23/2021				
	&Sodium Carboxymethylcellulose	Dried Aluminium Hydroxide Gel	IP	830	mg					
		In a flavoured syrup base		q.s.						
	Suspension	Colour:Approved colour used								

570	Disodium Hydrogen Citrate &					
		Each 5 ml contains:				
		Disodium Hydrogen Citrate				
	Dipotassium Hydrogen Citrate		BP	625	mg	3/23/2021
	Syrup	Dipotassium Hydrogen Citrate	BP	625	mg	
		In a flavoured syrup base		q.s.		
		Colour:Approved colour used				

571	Chlorhexidine Gluconate	Chlorhexidine Gluconate Solution	IP	1.5%	v/v	
	Solution & cetrimide	Cetrimide Solution	BP			
	Antiseptic Liquid	eq. to Cetrimide		3%	v/v	3/23/2021
		purified water	IP	qs		
		Approved Colour used				
572	Luliconazole Lotion	Composition:-				
		Luliconazole		1%	w/v	3/23/2021

573	Povidone Iodine	Povidone Iodine	IP	5%	w/v	
	Solution IP	eq. to Available Iodine (0.5% w/w)				3/23/2021
		purified water	IP	qs		5/25/2021
		Colour:Approved colour used				

q. s.

Lotion Base

574	Povidone Iodine	Povidone Iodine	IP	7.5%	W/V	
	Solution IP	eq. to Available Iodine (0.75% w/w)				3/23/2021
		purified water	IP	qs		3/23/2021
		Colour:Approved colour used				

575	Povidone Iodine	Povidone Iodine	IP	10%	w/v	
	Solution IP	eq. to Available Iodine (1.0% w/w)				3/23/2021
		purified water	IP	qs		5/25/2021
		Colour:Approved colour used				

576	Povidone Iodine &	Povidone Iodine	IP	5%	w/w	v
	Ornidazole	eq. to Available Iodine (0.5% w/w)				3/23/2021
	Ointment	Ornidazole	IP	1%	W/W	
		Water Soluble Ointment Base				

577	Amoxycillin Tryhydrate,	Each hard geletin capsule contains:-		
	Cloxacillin Sodium&	Amoxycillin Tryhydrate	IP	

	List of Retention Product having license No. FORM25:M	LY WELFARE DEPARTMENT,H s Approved to be Manufactured by NB/07/642 AND MB/07/643 28:S-MB/07/643 For the per E AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	y : Boffi iod from 01.	n Biotecl	h Pvt.	
5. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVE ON DATE
	Lactic Acid bacillus Capsules	Eq.to Amoxycillin		250	mg	
	1	Cloxacillin Sodium	IP			
		Eq.to Cloxacillin		250	mg	3/23/202
		Lactic Acid Bacillus		2	Billion spores	
		Excipients		qs	-F	
		Approved colour used in empty capsule s	hell	45		
			-			
578	Amoxycillin Tryhydrate,	Each hard geletin capsule contains:-				
	Lactic Acid bacillus Capsules	Amoxycillin Tryhydrate	IP			
		Eq.to Amoxycillin		125	mg	
		Lactic Acid Bacillus		1.66	Billion spores	3/23/202
		Excipients		qs		
		Approved colour used in empty capsule s	hell	40		
			-			
579	Amoxycillin Tryhydrate,	Each hard geletin capsule contains:-				
	Lactic Acid bacillus Capsules	Amoxycillin Tryhydrate	IP			
		Eq.to Amoxycillin		250	mg	2 12 2 12 12
		Lactic Acid Bacillus		1.66	Billion spores	3/23/202
		Excipients		qs		
		Approved colour used in empty capsule s	hell	45		
	•					
580	Amoxycillin Tryhydrate,	Each hard geletin capsule contains:-				
	Lactic Acid bacillus Capsules	Amoxycillin Tryhydrate	IP			
		Eq.to Amoxycillin		500	mg	2/22/20/
		Lactic Acid Bacillus		1.66	Billion spores	3/23/202
		Excipients		qs		
		Approved colour used in empty capsule s	hell	-		
	-					
581	Doxycycline & Ambroxol HCl					
		Each Hard Gelatin Capsule contains:				
	Capsule	Doxycycline Hydrochloride	IP			
		Eq. to Doxycycline		100	mg	3/23/202
		Ambroxol HCl	IP	7.5	mg	
		Excipients	aula Shi i	q.s.		
	1	Colour:Approved colour used Empty Cap	sule Shel	1		
582	Trypsin - Chymotrypsin with	Each Film Coated Tablet Contains				
	Jr Shijinou jpom with					
	Paracetamol and Aceclofenac	50,000 Armour units enzymatic activity				
	Tablets	(supplied by a purified concentrate				
		which has specific Trypsin &				
		Chymotrypsin activity in a ratio of				3/26/202
		approximately six to one)				5,20,20
		(As enteric coated granules)		10-		
		Aceclofenac	IP	100	mg	
		Paracetamol	IP	325	mg	
		Excipients Colour:Approved colour used		q.s.		
		IL OLOUF, Approved colour lised	1	1	1	

	NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945								
		LE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	ACT 1945	1					
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED			
	Rutoside Trihydrate Tablets	Trypsin							
			BP	96	mg				
		Bromelain		180	mg	3/26/2021			
		Rutoside Trihydrate	BP	200	mg				
		Excipients		q.s.					
		Colour:Approved colour used							

584	Trypsin, Bromelain,	Each Enteric Coated Tablet Contains				
	Rutoside Trihydrate and	Trypsin	BP	48	mg	
	Diclofenac Sodium Tablets	Bromelain		90	mg	
		Rutoside Trihydrate	BP	100	mg	3/26/2021
		Diclofenac Sodium	IP	50	mg	
		Excipients		q.s.		
		Colour:Approved colour used				

585	Thiocolchicoside,					
	Aceclofenac	Each Film Coated Tablet Contains				
	and Paracetamol Tablets	Thiocolchicoside	IP	4	mg	
		Aceclofenac	IP	100	mg	3/26/2021
		Paracetamol	IP	325	mg	
		Excipients		q.s.		
		Colour:Approved colour used				

586	Rifaximin Tablets 550mg	Each film coated tablet contains				
		Rifaximin Ph. Eur.	IP	550	mg	3/26/2021
		Excipients		q.s.		3/20/2021
		Colour:Approved colour used				

587	Paracetamol, Phenylephrine	Each uncoated tablet contains				
	Hydrochloride, Caffeine and	Paracetamol				
			IP	500	mg	
	Chlorpheniramine Maleate	Phenylephrine Hydrochloride	IP	12.5	mg	2/26/2021
	Tablets	Caffeine (Anhydrous)	IP	30	mg	3/26/2021
		Chlorpheniramine Maleate	IP	2	mg	
		Excipients		q.s.		
		Colour:Approved colour used				

588	Ranitidine HCl &	Each Filmcoated Tablet contains:				
	Domperidone	Ranitidine HCl	IP			
	Tablets	eq. to Ranitidine		150	mg	3/26/2021
		Domperidone	IP	10	mg	3/20/2021
		Excipients		q.s.		
		Colour:Approved colour used				

589	Rifaximin Tablets 200mg	Each film coated tablet contains				
		Rifaximin Ph. Eur.	IP	200	mg	3/26/2021
		Excipients		q.s.		3/20/2021
		Colour:Approved colour used				

	HEALTH AND FAMI	NO.HFW-H(DRUGS)279/0 LY WELFARE DEPARTMENT,I s Approved to be Manufactured b	HIMAC			
	having license No. FORM25:MI	NB/07/642 AND MB/07/643 28:S-MB/07/643 For the po E AS PER SCHEDULE-P-1 OF DRUGS & COSMETI	eriod from 01.			200
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
590	Levocetirizine, Montelukast and	Each UnCoated bilayered Tablet Contain	26			
		Levocetirizine Dihydrochloride	115			
	Ambroxol HCl (SR) Tablets	Levoceurizine Dinydrochioride	IP	5	ma	
		Montelukast Sodium	IP	5	mg	
		eq. to Anhydrous Montelukast	ш	10	mg	3/26/2021
		Ambroxol Hydrochloride	IP	75	mg	
		(as sustained release)		15	mg	
		Excipients		q.s.		
		Colour:Approved colour used		q .5.		
		colour.Approved colour used				
591	Glucosamine,	Each film coated tablet contains:				
571	,	Glucosamine Sulphate Potassium		1		
	Methyl Sulfonyl Methane &	Chloride	USP	750	mg	
	Diacerein Tablets	Equivalent to Glucosamine	0.51	446	mg	
		Methylsulfonylmethane	USP	250	mg	3/26/2021
		Diacerein	IP	50	mg	
		Excipients		q.s.		
		Colour:Approved colour used		4.5.		
		11				
592	Gabapentin and Nortriptyline	Each Film Coated Tablet Contains				
	Tablets	Gabapentin	IP	400	mg	
		Nortriptyline Hydrochloride	IP		Ū	0.000.0000
		equivalent to Nortriptyline		10	mg	3/26/2021
		Excipients		q.s.	Ū	
		Colour:Approved colour used		-		
593	Ferrous Ascorbate, Folic Acid					
		Each Film Coated Tablet Contains				
	and Zinc Tablets	Ferrous Ascorbate				
		equivalent to elemental iron		100	mg	
		Folic Acid	IP	1.5	mg	3/26/2021
		Zinc Sulphate monohydrate	IP			
		equivalent to elemental zinc		22.5	mg	
		Excipients		q.s.		
		Colour:Approved colour used				
594	Doxofylline Tablets IP 400mg					
		Each uncoated tablet contains				
		Doxofylline	IP	400	mg	3/26/2021
		Excipients	_	q.s.		
		Colour:Approved colour used	_			
595	Ferrous Ascorbate, Folic Acid					
		Each Film Coated Tablet Contains				
	Zinc and Adenosylcobalamin	Ferrous Ascorbate		100		
	Tablets	equivalent to elemental iron		100	mg	
		Folic Acid	IP	1.5	mg	3/26/2021
		Zinc Sulphate monohydrate	IP	_		
		equivalent to elemental zinc		5	mg	
		Adenosylcobalamin		500	mcg	3
		Excipients		q.s		
		Colour:Approved colour used				

		ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	ACT 1945	I		
5. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
596	Dried Aluminium Hydroxide,	Each UnCoated Chewable Tablet Contain	_			
	Magnasium Aluminium		8			
	Magnesium Aluminium Silicate	Dried Aluminium Hydroxide	IP	300	mg	
	Hydrate, Magnesium Hydroxide	Magnesium Aluminium Silicate Hydrate		50	mg	3/26/2021
	and Simethicone	Magnesium Hydroxide	IP	25	mg	
	Chewable Tablets	Simethicone	IP	25	mg	
	Chewable Tablets	Excipients	п	-	mg	
		Colour:Approved colour used		q.s.		
		Colour.Approved colour used				
597	Disulfiram tablets IP	Each uncoated tablet contains				
,,,		Disulfiram	IP	500	mg	
		Excipients	1	q.s.	mg	3/26/2021
		Colour:Approved colour used		4 .5.		
		colour.reproved colour used				
598	Cinnarizine Tablets IP	Each uncoated tablet contains				
,,0		Cinnarizine	IP	10	mg	
		Excipients	п	q.s.	mg	3/26/2021
		Colour:Approved colour used		q .o.		
		colour.rpploved colour used				
599	Cefpodoxime Proxetil	Each film coated tablet contains				
,,,	and Potassium	Cefpodoxime Proxetil	IP			
	Clavulanate Tablets	equivalent to Cefpodoxime	п	200	mg	
	Clavulanate Tablets	Potassium Clavulanate Diluted	IP	200	mg	3/26/2021
		equivalent to Clavulanic Acid	п	125	mg	5/20/2021
		Excipients		q.s.	mg	
		Colour:Approved colour used		4 .5.		
600	Cefixime and Potassium	Each film coated tablet contains				
500	Clavulanate Tablets	Cefixime Trihydrate	IP			
	Clavulanate Tablets	Eq. to Anhydrous Cefixime	1	200	mg	
		Potassium Clavulanate Diluted	IP	200	mg	3/26/2021
		equivalent to Clavulanic Acid	1	125	mg	5/20/2021
		Excipients		q.s.	mg	
		Colour:Approved colour used		q .s.		
	1	colour approved colour used		1		
501	Pre & Pro Biotic Capsules	Each hard gelatin capsule contains:				
	cerro Bione Cuponeo	Streptococcus faecalis		30	million	
		Clostridium butyricum		2	million	
		Bacillus mesentericus		1	million	
		Lactic acid bacillus (lactobacillus sporogenes)		50	million	3/26/2021
		Excipients		q.s.	minon	
		Approved colours used in empty hard		4.5.		
		gelatin capsule shells				
	1	y 1 a b b		1		
502	Biotin and Folic Acid Tablets	Each Film Coated Tablet Contains				
502	broth and rone refu radiets	Biotin	USP	5	mg	
		Folic Acid	IP	5	mg	3/26/2021
		Excipients		q.s.		5,20,2021
		Colour:Approved colour used		4.5.		

	PACK SIZ	E AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	ACT 1945			
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Alpha Lipoic Acid , Folic Acid	Pregabalin				
			IP	75	mg	
	and Pyridoxine Hydrochloride	Mecobalamin	IP USP	750 100	mcg	3/26/2021
	Capsules	Alpha Lipoic Acid Folic Acid	IP	1.5	mg	5/20/2021
		Pyridoxine Hydrochloride	IP	3	mg mg	
		Excipients		q.s.	0	
		Colour:Approved colour used				
604	Racecadotril Capsules IP	Each hard gelatin capsule contains				
001		Racecadotril	IP	100	mg	
		Excipients		q.s.	8	3/26/2021
		Colour:Approved colour used		1		
605			1			
605	Cefixime and Ofloxacin for Oral Suspension	Each 5ml of the Reconstituted suspension Contains				
	Ural Suspension	Cefixime Trihydrate	IP			
		eq. to Anhydrous Cefixime	- 11	50	mg	3/26/2021
		Ofloxacin	IP	50	mg	
		Excipients		q.s.	mg	
		Colour:Approved colour used		q .s.		
606	Ambroxol Hydrochloride,	Each 5ml Contains				
	Guaiphenesin and Terbutaline	Ambroxol Hydrochloride				3/26/2021
			IP	15	mg	
	Sulphate Syrup	Guaiphenesin	IP	50	mg	3/26/2021
		Terbutaline Sulphate	IP	1.5	mg	
		Mentholated syrupy base Colour:Approved colour used		q.s.		
		Colour.Approved colour used				
607	Fexofenadine HCl	Each 5 ml contains:				
	suspension	Fexofenadine HCl	IP	30	mg	2/26/2021
		In a flavoured syrup base		q.s.		3/26/2021
		Colour:Approved colour used				
(00	Chlashani dina Chasanata	Comparition of				
608	Chlorhexidine Gluconate, Sodium Fluoride & Zinc	Composition :- Chlorhexidine Gluconate Solution	IP			
	Sodium Fluonde & Zinc	Eq. to Chlorhexidine Gluconate	IF			
	Chloride Solution Mouthwash	Eq. to Chlomexiume Oluconate		0.20%	w/v	
		Sodium Fluoride	IP	0.05%	w/v	3/26/2021
		Zinc Chloride	IP	0.09%	w/v	
		In a pleasantly flavoured aqueous base		q.s.	, .	
		Colour:Approved colour used		1		
609	Paracetamol &	Each Un Coated tablet contains:				
	Caffeine	Paracetamol	IP	500	mg	2/20/2023
	Tablets IP	Caffeine (Anhydrous)	IP	50	mg	3/30/2021
		Excipients		q.s.		
	1	Colour:Approved colour used	1			

S. No. DOSAGE FORM GENERIC NAMERBAND NAME COMPOSITION craws Control outsite PIROVE ON DATE and Minerals Tablets Biotin USP 10 mg And Minerals Tablets Biotin USP 10 mg Calcium Pantohenate IP 100 mg Galax Fig. to Elemental Sciencia IP 100 mg Edg. to Elemental Sciencia IP 100 mg 326/202 Calcium Pantohenate IP 100 mg 326/202 Galax Edg. to Elemental Sciencia 1P 100 mg Fig. to Elemental Copper 3 mg 326/202 Galax Ecolomethasone Sertaconazole Nitrate BP 236 w/w Sectaconazole Nitrate & Beclomethasone Diproprionate IP 0.025% w/w Folic Acid Each film Coated Tablet Contains: P 100 10 Vitamin D3, Vitamin B1, Vitamin B2 IP 200 10 Vitamin B2, Vitamin B6, Vitamin B2 IP 2 mg Vitamin B2, Vitamin B6,		List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/(LY WELFARE DEPARTMENT, ts Approved to be Manufactured I NB/07/642 AND MB/07/643 28:S-MB/07/643 For the p ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	HIMACI by : Boffi eriod from 01.	n Biotec	h Pvt.	
611 Sertaconazole Nitrate Economic Dipropionate IP 100 mg 611 Sertaconazole Nitrate & Colour. Approved colour used IP 22,5 mg 611 Sertaconazole Nitrate & Colour. Approved colour used IP 22,5 mg 611 Sertaconazole Nitrate & Colour. Approved colour used IP 22,5 mg 612 Vitamin A (as Acetate) BP 2% w/w 7 Beclomethasone Dipropionate IP 0.025% w/w 7 Beclomethasone Dipropionate IP 0.025% w/w 7 Vitamin A (as Acetate) IP 200 IU 7 Vitamin B (as Acetate) IP 200 IU 7 Vitamin B (as Acetate) IP 2 mg 8 Vitamin B (as Acetate) IP 2 mg <th>S. No.</th> <th>DOSAGE FORM, GENERIC</th> <th></th> <th>SPECIFI</th> <th>QUANTITY</th> <th>UNIT</th> <th>APPROVED ON DATED</th>	S. No.	DOSAGE FORM, GENERIC		SPECIFI	QUANTITY	UNIT	APPROVED ON DATED
611 Section Partorbenate IP 100 mg 611 Section Partorbenate IP 100 mg 612 Vitamin A Colour: Approved colour used IP 1 613 Sectoonazole Nitrate & Beclomethasone Dipropionate Cream IP Each of Im Cost of Colour: Approved colour used IP 20.00000000000000000000000000000000000		and Minerals Tablets	Biotin	USP	10	mg	
Sodium Selenite Image: Sodium Seleni			N-Acetylcysteine	USP	50	mg	
Eq. to Elemental Selenium 65 neg Gupric Oxide 1 1 1 Fq. to Elemental Copper 3 neg Zinc Oxide IP 1 1 Equivalent to Elemental Copper 3 neg 1 Equivalent to Elemental Copper 9,8 1 1 611 Sertaconazole Nitrate & Conposition: 1 1 1 1 Beclomethasone Dipropionate IP 0.025% w/w 3/26/202 612 Vitamin A (as Acetate) Each film Coated Tablet Contains: 1 4,8 1 Vitamin D3, Vitamin B1, Vitamin B1 Vitamin B1 Vitamin B1 IP 200 IU Vitamin C and Folic Acid Vitamin B2 IP 200 IU 1 Vitamin C and Folic Acid Vitamin B2 IP 2 neg 1 Niacinamide, Vitamin B2 IP 2 neg 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 <t< td=""><td></td><td></td><td>Calcium Pantothenate</td><td>IP</td><td>100</td><td>mg</td><td></td></t<>			Calcium Pantothenate	IP	100	mg	
611 Software Software </td <td></td> <td></td> <td>Sodium Selenite</td> <td></td> <td></td> <td></td> <td></td>			Sodium Selenite				
$ \left \begin{array}{c c c c c c c c } & Cupic Oxide & 1 & 1 & 1 \\ \hline Eq. i to Elemental Copper & 3 & ng \\ Zinc Oxide & 1P & 4 \\ \hline Equivalent to Elemental Zinc & 22.5 & ng \\ Excipients & -4 & 4.8 \\ \hline Colour:Approved colour used & -4 & -4 \\ \hline Colour:Approved colour used & -4 $			Eq. to Elemental Selenium		65	mcg	3/26/2021
Zinc OxideIPIEquivalent to Elemental Zinc 22.5 ngEquivalent to Elemental Zinc 22.5 ng611Sertaconazole Nitrate &Conposition:BeclomethasoneComposition: $4.8.$ Dipropionate Cream IPEach Film Coated Tablet Contains: $4.8.$ 612Vitamin A (as Acetate)IP 0.025% w/w613Vitamin B1,Vitamin B1IP 2500 IUVitamin B2, Vitamin B6,Vitamin B1IP 22.5 ngVitamin B2, Vitamin B6,Vitamin B1IP 2 ngVitamin C and Folic AcidVitamin B6IP 0.5 ngTabletsVitamin CIP 2 ngFolic Acid andVitamin CIP 0.2 ngColour:Approved colour usedIP 0.2 ng614Sodium Feredetate,Folic AcidIP 0.2 ngFolic Acid andColour:Approved colour used $ -$ 614Sodium Feredetate,Folic AcidIP 1.5 ngFolic Acid andColour:Approved colour used $ -$ 614Sodium Feredetate,Folic AcidIP 1.5 ngFolic Acid andColour:Approved colour used $ -$ 615Sodium Feredetate,Each Film Coated Tablet Contains : $ -$ 616Sodium FeredetateBP 231 ng617Sodium Feredetate,Colour:Approved colour used <td></td> <td></td> <td>1</td> <td></td> <td></td> <td></td> <td>3/20/2021</td>			1				3/20/2021
Becker in the interval of the interval					3	mg	
Excipients q.s. G 611 Sertaconazole Nitrate & Beclomethasone Colour:Approved colour used Image: Colour Approved Colour Used				IP			
Colour:Approved colour used Image: Colour:Approved colour used <thimage: colour="" colour:approved="" th="" used<=""> Ima</thimage:>			-		22.5	mg	
611 Sertaconazole Nitrate & Beclomethasone Dipropionate Cream IP Composition:- Sertaconazole Nitrate BP 2% W/W 612 Vitamin A (as Acetate) IP 0.025% W/W 612 Vitamin A (as Acetate) IP 0.025% W/W 612 Vitamin A (as Acetate) IP 0.025% W/W 612 Vitamin D3, Vitamin B1, Vitamin B2, Vitamin B6, Calcium Pantotheanate, IP 200 IU Vitamin C and Folic Acid Tablets Vitamin B6 Vitamin B2 IP 2 mg Vitamin C and Folic Acid Vitamin B6 Vitamin B2 Niacinamide IP 1 mg Vitamin C and Folic Acid Vitamin B2 Vitamin B2 IP 0.5 mg Vitamin C and Folic Acid IP 0.5 mg mg Niacinamide IP 0.5 mg Folic Acid and Colour:Approved colour used IP 0.5 mg Mg No2020 614 Sodium Feredetate, Folic Acid and Cyanocobalamin Tablets Each Film Coated Tablet Contains : Im Im Mg No2020 614 Sodium Feredetate, Folic A			1		q.s.		
Beclomethasone Dipropionate Cream IPSertaconazole Nitrate Beclomethasone DipropionateBP2% W/W W/W3/26/202612Vitamin A (as Acetate)IP0.025% W/WW/W613Vitamin A (as Acetate)IP2500IUVitamin D3, Vitamin B1, Calcium Pantotheanate, Witamin C and Folic AcidVitamin B1IP200IUVitamin C and Folic Acid TabletsVitamin B2IP2mgVitamin C and Folic Acid TabletsVitamin B6IP0.05mgVitamin C and Folic Acid TabletsIP25mgVitamin C and Folic Acid TabletsIP25mgFolic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :		~					
Dipropionate Cream IPBeclomethascone DipropionateIP0.025%w/w3726/202612Vitamin A (as Acetate)Ia a Cream Baseq.s.q.s.q.s.1612Vitamin D3, Vitamin B1,Vitamin A (as Acetate)IP2500IUVitamin B2, Vitamin B6,Vitamin D3IP2000IUCalcium Pantotheanate,Vitamin B1IP2mgNiacinamide,Vitamin B1Vitamin B1IP2mgVitamin C and Folic AcidVitamin B6IP0.5.5mgTabletsVitamin CIP5.0mgFolic Acid andCalcium PantotheanateIP1mgFolic Acid andCalcium PantotheanateIP0.2.2mgCyanocobalamin TabletsEach Film Coated Tablet Contains :	611				201	,	
612 Vitamin A (as Acetate) Each film Coated Tablet Contains: - - 612 Vitamin D3, Vitamin B1, Vitamin A (as Acetate) IP 2500 IU Vitamin B2, Vitamin B4, Vitamin B1 IP 200 IU Calcium Pantotheanate, Vitamin B2 Vitamin B2 mg Niacinamide , Vitamin B2 Vitamin B2 mg Vitamin C and Folic Acid Vitamin B6 IP 0.5 mg Tablets Calcium Pantotheanate IP 2.5 mg Vitamin C IP 50 mg Folic Acid IP 0.2 mg Vitamin C IP 50 mg Folic Acid and Colour:Approved colour used - - 613 Sodium Feredetate, Each Film Coated Tablet Contains : - - Folic Acid and Cyanocobalamin Tablets - - - - 614 Sodium Feredetate, Each Film Coated Tablet Contains : - - - Folic Acid and Cyanocobalamin Tablets - - - -<			~				3/26/2021
612 Vitamin A (as Acetate) Each film Coated Tablet Contains: I I I 612 Vitamin D3, Vitamin B1, Vitamin A (as Acetate) IP 2500 IU Vitamin B2, Vitamin B1, Vitamin B1 IP 200 IU IIP 200 IU Niacinamide, Vitamin B1 IP 2 mg mg mg Vitamin C and Folic Acid Vitamin B6 IP 0.5 mg mg Calcium Pantotheanate IP 0.5 mg mg Nacinamide IP 0.5 mg Tablets Vitamin B6 IP 0.5 mg mg Nacinamide IP 0.2 mg Folic Acid IP 0.2 mg Macinamide IP 0.2 mg Folic Acid IP 0.2 mg Macinamide IP 0.2 mg Colour:Approved colour used IP 0.2 mg Mg Mg Mg/202 613 Sodium Feredetate, Each Film Coated Tablet Contains : IP 1.5 mg Mg/202 Mg/202 Mg/202		Dipropionate Cream IP		IP		W/W	
Vitamin D3, Vitamin B1, Vitamin B2, Vitamin B6, Calcium Pantotheanate, Niacinamide, Vitamin C and Folic Acid TabletsVitamin B1 Vitamin B2IP 200IU Vitamin B1200IU P 2mg mg mg Mianiamide, Vitamin B1IP 2mg mg mg3/30/202613Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains : Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains : Sodium Feredetate, Folic Acid Colour:Approved colour usedIP 1.5 mg 3/30/2023/30/202614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains : Sodium Feredetate Colour:Approved colour usedII614Sodium Feredetate, Folic Acid and 	(12)	XIII A (A)			q. s.		
Vitamin B2, Vitamin B6, Calcium Pantotheanate, Niacinamide, Vitamin C and Folic Acid TabletsVitamin B1IP200IU reg reg mg Vitamin B2IP200IU mg reg mg Vitamin B2IP200IU mg reg mg Vitamin B3IP200IU mg reg mg Vitamin B4IP2mg mg reg3/30/202730/202TabletsCalcium Pantotheanate Calcium PantotheanateIP1mg mg reg3/30/202731TabletsCalcium PantotheanateIP1mg reg3/30/202613Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains : Sodium FeredetateIP1.5mg reg614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains : Sodium FeredetateIP1.5mg reg614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains : Sodium FeredetateIP1.5mg reg614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains : Sodium FeredetateIP1.5mg reg615Ranitidine HCl, Magaldrate and SimethiconeEach Film Coated Tablet Contains : Ranitidine HClIP5mg reg615Ranitidine HCl, Magaldrate and SimethiconeRanitidine HClIP1mg reg616Ranitidine HClIP1IP11617Ranitidine HCl <td< td=""><td>612</td><td></td><td></td><td>ID</td><td>2500</td><td>пт</td><td></td></td<>	612			ID	2500	пт	
Calcium Pantotheanate, Niacinamide ,Vitamin B1IP2ngNiacinamide , Vitamin C and Folic Acid TabletsVitamin B6IP0.5ngCalcium PantotheanateIP1ngNiacinamideIP25ngVitamin CIP25ngVitamin CIP50ngVitamin CIP0.2ngVitamin CIP0.2ngFolic AcidIP0.2ngExcipients-q.s.Colour:Approved colour used613Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :-614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :-614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :-614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :-614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :-615Ranitidine HCI, Magaldrate and SimethiconeEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate and SimethiconeEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate and SimethiconeIP200ng Simethicone3/30/202615Ranitidine HCI, Magaldrate and SimethiconeIP200<			. ,			-	
Niacinamide , Vitamin C and Folic AcidVitamin B2IP2ng Calcium Pantotheanate3/30/202TabletsVitamin CIP0.5mg Calcium PantotheanateIP1mg mgNiacinamideIP25mg Vitamin CIP50mg Folic AcidIP0.2mg mgfolic AcidIP0.2mg Folic AcidIP0.2mg Folic AcidIP0.2mg mgfolic AcidIP0.2mg Folic AcidIP0.2mg Folic AcidIP0.2mg mgfolic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :IP1mg Folic AcidMg Folic AcidMg<							
Vitamin C and Folic Acid TabletsVitamin B6IP0.5mg mg (Acid)3/30/202Vitamin C and Folic Acid TabletsVitamin B6IP0.5mg mgNiacinamideIP1mg S0mgVitamin C CIP50mg Folic AcidIP0.2mg mgFolic AcidIP0.2mg Excipientsq.sColour:Approved colour used613Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate and SimethiconeEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate (as Anhydrous)IP200mg a616Ranitidine HCI Magaldrate (as Anhydrous)IP200mg a617Ranitidine HCI Magaldrate (as Anhydrous)IP200mg a618Ranitidine HCI Magaldrate (as Anhydrous)IP200mg a619 <td< td=""><td></td><td><i>,</i></td><td></td><td></td><td></td><td>Ŭ</td><td></td></td<>		<i>,</i>				Ŭ	
TabletsCalcium PantotheanateIP1mg mg Niacinamide3/30/202NiacinamideIP2.5mg Vitamin CIP5.0mg Polic AcidIP0.2mg Polic Acid613Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :		,			_	Ū	
InitialNiaciananideIP2mgNiaciananideIP25mgVitamin CIP50mgFolic AcidIP0.2mgExcipients-q.s.Colour:Approved colour used613Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate and SimethiconeEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate and SimethiconeEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate and SimethiconeEach Film Coated Tablet Contains :616Ranitidine HCI, Magaldrate (as Anhydrous)IP200mg617Ranitidine HCI, Magaldrate (as Anhydrous)IP200mg618Ranitidine HCI, Magaldrate (as Anhydrous)IP200mg619Ranitidine HCI, Magaldrate (as Anhydrous)IP200mg610E						Ŭ	3/30/2021
Vitamin CIP50mg mgFolic AcidIP0.2mg a.s.ExcipientsColour:Approved colour used613Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate and SimethiconeEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate and SimethiconeEach Film Coated Tablet Contains :7abletseq. to Ranitidine HCI Magaldrate (as Anhydrous)IP200mg a.g.3/30/202					-	Ŭ	
Folic AcidIP0.2mgExcipients613Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :613Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate and SimethiconeEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate and SimethiconeEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate (as Anhydrous)IP200mg mg Simethicone616Each Film Coated Tablet Contains :617Ranitidine HCI, Magaldrate (as Anhydrous)IP20					-	Ŭ	
Excipients613Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :613Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :615Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate and Simethicone TabletsEach Film Coated Tablet Contains :615Ranitidine HCI, Magaldrate (as Anhydrous)IP200mg mg Magaldrate (as Anhydrous)IP200mg mg Magaldrate (as Anhydrous)IP200mg mg Magaldrate (as Anhydrous)						Ŭ	
Colour:Approved colour usedImage: Colour and the contains is in the contain is integrated in the contain is						8	
Folic Acid and Cyanocobalamin TabletsSodium Feredetate eq. to Elemental IronBP2.31mg reg.Folic AcidIP1.5mg reg.3/30/202Folic AcidIP1.5mg reg.3/30/202CyanocobalaminIP1.5mg reg.3/30/202614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :					1		
Folic Acid and Cyanocobalamin TabletsSodium Feredetate eq. to Elemental IronBP2.31mg reg.Folic AcidIP1.5mg reg.3/30/202Folic AcidIP1.5mg reg.3/30/202CyanocobalaminIP1.5mg reg.3/30/202614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :	(10			-			
Cyanocobalamin Tabletseq. to Elemental Iron33mg Folic AcidJ330/202Folic AcidIP1.5mg CyanocobalaminJ330/202CyanocobalaminIP1.5mg Folic AcidJ330/202614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :Image: Cyanocobalamin TabletsImage: Cyanocobalamin Ta		,		DD	021		
Folic AcidIP1.5mg mcg (yanocobalamin3/30/202614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :				BP		Ŭ	
CyanocobalaminIP15mcgExcipientsq.s.Q.s.Colour:Approved colour used00614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :11Folic Acid and Cyanocobalamin TabletsSodium FeredetateBP231mgFolic Acid and Cyanocobalamin TabletsSodium FeredetateBP231mgFolic AcidIP1.5mg330/202Folic AcidIP1.5mg330/202Folic AcidIP1.5mg330/202Colour:Approved colour usedq.s.11615Ranitidine HCl, Magaldrate and SimethiconeEach Film Coated Tablet Contains :11Tabletseq. to Ranitidine150mg330/202Magaldrate (as Anhydrous)IP200mg3/30/202SimethiconeIP200mg3/30/202SimethiconeIP200mg3/30/202SimethiconeIP200mg3/30/202SimethiconeIP200mg3/30/202SimethiconeIP200mg3/30/202SimethiconeIP200mg3/30/202SimethiconeIP200mg3/30/202SimethiconeIP200mg3/30/202SimethiconeIP200mg3/30/202SimethiconeIP200mg3/30/202SimethiconeIP </td <td></td> <td>Cyanocobalamin Tablets</td> <td>*</td> <td>ID</td> <td></td> <td>-</td> <td>3/30/2021</td>		Cyanocobalamin Tablets	*	ID		-	3/30/2021
Excipientsq.s.Colour:Approved colour usedq.s.614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :Image: Colour Sodium Feredetate (Sodium Feredetate)BP231mg614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :Image: Colour Sodium Feredetate (Sodium Feredetate)BP231mg615Ranitidine HCI, Magaldrate and SimethiconeEach Film Coated Tablet Contains :Image: Colour: Approved colour usedImage: Colour: Approved colour							5/50/2021
OrderColour:Approved colour usedI614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :I614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :BP231mgeq. to Elemental Iron33mgJ3/30/202Folic AcidIP1.5mgCyanocobalaminIP5mcgExcipientsq.s.IColour:Approved colour usedII615Ranitidine HCl, Magaldrate and SimethiconeEach Film Coated Tablet Contains :ITabletseq. to RanitidineIP200mgMagaldrate (as Anhydrous)IP200mgSimethiconeIP20mgExcipientsq.s.4.8.				Ir		meg	
614Sodium Feredetate, Folic Acid and Cyanocobalamin TabletsEach Film Coated Tablet Contains :Image: Contains :Imag			1		4 .5.		
Folic Acid and Cyanocobalamin TabletsSodium FeredetateBP231mgeq. to Elemental Iron33mgFolic AcidIP1.5mgFolic AcidIP1.5mgCyanocobalaminIP5mcgExcipientsq.s.q.s.Colour:Approved colour used615Ranitidine HCl, Magaldrate and SimethiconeEach Film Coated Tablet Contains :Tabletseq. to RanitidineIP150mgMagaldrate (as Anhydrous)IP200mgSimethiconeIP20mgExcipientsq.s.q.s.3/30/202			consum approved corour used	1	1		
Folic Acid and Cyanocobalamin TabletsSodium FeredetateBP231mgeq. to Elemental Iron33mgFolic AcidIP1.5mgFolic AcidIP1.5mgCyanocobalaminIP5mcgExcipientsq.s.q.s.Colour:Approved colour used615Ranitidine HCl, Magaldrate and SimethiconeEach Film Coated Tablet Contains :Tabletseq. to RanitidineIP150mgMagaldrate (as Anhydrous)IP200mgSimethiconeIP20mgExcipientsq.s.q.s.3/30/202	614	Sodium Feredetate.	Each Film Coated Tablet Contains :				
Cyanocobalamin Tabletseq. to Elemental Iron33mgFolic AcidIP1.5mgCyanocobalaminIP5mcgCyanocobalaminIP5mcgExcipientsq.s.q.s.Colour:Approved colour usedIPI615Ranitidine HCl, Magaldrate and SimethiconeEach Film Coated Tablet Contains :IPTabletseq. to RanitidineIP150mgMagaldrate (as Anhydrous)IP200mgSimethiconeIP20mgExcipientsq.s.q.s.				BP	231	mg	
Folic AcidIP1.5mgCyanocobalaminIP5mcgCyanocobalaminIP5mcgExcipientsq.s.q.s.0Colour:Approved colour used00615Ranitidine HCl, Magaldrate and SimethiconeEach Film Coated Tablet Contains :00Tabletseq. to Ranitidine150mg3/30/202Magaldrate (as Anhydrous)IP200mg3/30/202SimethiconeIP20mg3/30/202Excipientsq.s.150mg3/30/202						-	
Cyanocobalamin IP 5 mcg Excipients q.s. q.s. q.s. Colour:Approved colour used III IIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII		-		IP		-	3/30/2021
615 Ranitidine HCl, Each Film Coated Tablet Contains : Image: Colour: Approved colour used 615 Ranitidine HCl, Each Film Coated Tablet Contains : Image: Colour: Approved colour used 615 Magaldrate and Simethicone Each Film Coated Tablet Contains : Image: Colour: Approved colour used Image: Colour: Approved colour used 615 Magaldrate and Simethicone Each Film Coated Tablet Contains : Image: Colour: Approved colour used Image: Colour: Approved colour used Tablets eq. to Ranitidine Ifp Image: Colour: Approved colour used Image: Colour used <			Cyanocobalamin	IP	5	mcg	
615 Ranitidine HCl, Each Film Coated Tablet Contains : Image: Colour: Approved colour used 615 Ranitidine HCl, Each Film Coated Tablet Contains : Image: Colour: Approved colour used 615 Magaldrate and Simethicone Each Film Coated Tablet Contains : Image: Colour: Approved colour used Image: Colour: Approved colour used 615 Magaldrate and Simethicone Each Film Coated Tablet Contains : Image: Colour: Approved colour used Image: Colour: Approved colour used Tablets eq. to Ranitidine Ifp Image: Colour: Approved colour used Image: Colour used <					q.s.		
615 Ranitidine HCl, Magaldrate and Simethicone Each Film Coated Tablet Contains : Image:							
IPIPeq. to Ranitidine150mgMagaldrate (as Anhydrous)IP200mgSimethiconeIP20mgExcipientsq.s.q.s.	615	Ranitidine HCl,					
Tabletseq. to Ranitidine150mgMagaldrate (as Anhydrous)IP200mgSimethiconeIP20mgExcipientsq.s.1		Magaldrate and Simethicone	Ranitidine HCl				
Magaldrate (as Anhydrous)IP200mgSimethiconeIP20mgExcipientsq.s.		Tableta	ag to Donitidin-	IP	150		
SimethiconeIP20mgExcipientsq.s.		1 adlets		TD			3/30/2021
Excipients q.s.				_		Ŭ	
· · · · · ·				IP		mg	
			Excipients Colour:Approved colour used	_	q.s.		

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/(ILY WELFARE DEPARTMENT, ts Approved to be Manufactured I INB/07/642 AND MB/07/643 28:S-MB/07/643 For the p ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	HIMACI by:Boffi eriod from 01.	n Biotec	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
616	Paracetamol &	Each Un Coated tablet contains:		250		
	Caffeine	Paracetamol	IP	250	mg	2/20/2021
	Tablets IP	Caffeine (Anhydrous)	IP	25	mg	3/30/2021
		Excipients Colour:Approved colour used		q.s.		
		colour.Approved colour used				
617	Paracetamol &	Each Un Coated tablet contains:				
	Caffeine	Paracetamol	IP	650	mg	
	Tablets IP	Caffeine (Anhydrous)	IP	50	mg	3/30/2021
		Excipients		q.s.		
		Colour:Approved colour used				
618	Paracetamol Tablets IP	Each Un Coated tablet contains:				
		Paracetamol	IP	250	mg	3/30/2021
		Excipients		qs		
		Colour:Approved colour used				
619	Paracetamol Tablets IP	Each Un Coated tablet contains:				
019	rafacetanior radiets ir	Paracetamol	IP	1000	mg	
		Excipients	11	qs	mg	3/30/2021
		Colour:Approved colour used		4 3		
620	Norfloxacin &	Each Film Coated Tablet contains:-				
	Tinidazole Tablets	Norfloxacin	IP	400	mg	
		Tinidazole	IP	600	mg	3/30/2021
		(with Betacyclodextrin)				3/30/2021
		Excipients		q.s		
		Approved colour used		q.s		
				1		
621	Metronidazole, Furazolidone					
	9. Disuslamina Tablata	Each Uncoated Tablets contains: Metronidazole	IP	200		
	& Dicyclomine Tablets	Furazolidone	IP IP	200 50	mg	3/30/2021
		Dicyclomine HCl	IP	10	mg mg	3/30/2021
		Excipients		q.s.	mg	
		Colour:Approved colour used		4.5.		
		FI THE COLUMN	L	L		
622	Loperamide HCl and	Each UnCoated Tablet Contains :				
	Lactic Acid Bacillus	Loperamide HCl		2	mg	
		Lactic Acid Bacillus			Million	3/30/2021
	Tablet			100	spores	3/30/2021
		Excipients		q.s.		
		Colour:Approved colour used				
	Ix			1		
623	Levocarnitine,	Each Film Coated Tablet Contains :	LICD	0.50		
	Methylcobalamin and	Levocarnitine	USP	250	mg	
	Folic Acid Tablets	Methylcobalamin Folio Agid	IP ID	1500	mcg	3/30/2021
		Folic Acid Excipients	IP	1.5	mg	
		Colour:Approved colour used	+	q.s.	\vdash	
	1	Colour.Approved colour used		I	1	

5. No. NAME/BR. 524 Biotin Tablets 525 L-Carnitine L-7 Folic acid Table 526 Ibuprofen, Para Chlorpheniram Tablets 527 Dicyclomine H Oxetacaine and Tablets 528 Dicyclomine H Oxetacaine and Tablets 529 Dicyclomine H Oxetacaine and Tablets 529 Dicyclomine H Oxetacaine, Ma Simethicone Ta 530 Cetirizine Hydr Ambroxol Hyd Tablets	HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945									
625 L-Carnitine L-T Folic acid Table 626 Ibuprofen, Para Chlorpheniram Tablets 627 Dicyclomine H Oxetacaine and Tablets 628 Dicyclomine H Oxetacaine and Tablets 628 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets	RM, GENERIC AND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATEI				
625 L-Carnitine L-T Folic acid Table 626 Ibuprofen, Para Chlorpheniram Tablets 627 Dicyclomine H Oxetacaine and Tablets 628 Dicyclomine H Oxetacaine and Tablets 628 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets		Each Film Coated Tablet Contains								
Folic acid Table Folic acid Table 626 Ibuprofen, Para Chlorpheniram Tablets 627 Dicyclomine H Oxetacaine and Tablets 628 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets		Biotin	USP	10	mg					
Folic acid Table Folic acid Table 626 Ibuprofen, Para Chlorpheniram Tablets 627 Dicyclomine H Oxetacaine and Tablets 628 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets		Excipients	0.51	q.s.	mg	3/30/2021				
Folic acid Table Folic acid Table 626 Ibuprofen, Para Chlorpheniram Tablets 627 Dicyclomine H 628 Dicyclomine H 628 Dicyclomine H 629 Dicyclomine H 629 Dicyclomine H 0xetacaine and Tablets 629 Dicyclomine H 0xetacaine, Ma Simethicone Ta 630 Cetirizine Hydra Ambroxol Hyd Tablets		Colour:Approved colour used		4.5.						
Folic acid Table Folic acid Table 626 Ibuprofen, Para Chlorpheniram Tablets 627 Dicyclomine H 628 Dicyclomine H 628 Dicyclomine H 629 Dicyclomine H 629 Dicyclomine H 0xetacaine and Tablets 629 Dicyclomine H 0xetacaine, Ma Simethicone Ta 630 Cetirizine Hydra Ambroxol Hyd Tablets	Tartrate and	Each Film Coated Tablet Contains :								
626 Ibuprofen, Para Chlorpheniram Tablets 627 Dicyclomine H Oxetacaine and Tablets 628 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets		L-Carnitine L-Tartrate								
 Chlorpheniram Tablets Dicyclomine H Oxetacaine and Tablets Dicyclomine H Oxetacaine and Tablets Dicyclomine H Oxetacaine, Ma Simethicone Ta G30 Cetirizine Hydr Ambroxol Hydr Tablets 		eq. to L-Carnitine		500	mg	2/20/2021				
 Chlorpheniram Tablets Dicyclomine H Oxetacaine and Tablets Dicyclomine H Oxetacaine and Tablets Dicyclomine H Oxetacaine, Ma Simethicone Ta G30 Cetirizine Hydr Ambroxol Hydr Tablets 		Folic Acid	IP	1.5	mg	3/30/2021				
 Chlorpheniram Tablets Dicyclomine H Oxetacaine and Tablets Dicyclomine H Oxetacaine and Tablets Dicyclomine H Oxetacaine, Ma Simethicone Ta G30 Cetirizine Hydr Ambroxol Hydr Tablets 		Excipients		q.s.	0					
Tablets 627 Dicyclomine H Oxetacaine and Tablets 628 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets		Colour:Approved colour used								
 Chlorpheniram Tablets Dicyclomine H Oxetacaine and Tablets Dicyclomine H Oxetacaine and Tablets Dicyclomine H Oxetacaine, Ma Simethicone Ta G30 Cetirizine Hydr Ambroxol Hydr Tablets 	acetamol &	Each Un Coated Tablet Contains :								
627 Dicyclomine H Oxetacaine and Tablets 628 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets		Ibuprofen	IP	400	mg					
628 Dicyclomine H 628 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hydr Tablets		Paracetamol	IP	325	mg	2/20/2021				
628 Dicyclomine H 628 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hydr Tablets		Chlorpheniramine Maleate	IP	2	mg	3/30/2021				
628 Dicyclomine H 628 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hydr Tablets		Excipients		q.s.						
628 Dicyclomine H 628 Dicyclomine H 0xetacaine and Tablets 629 Dicyclomine H 0xetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hydr Tablets		Colour:Approved colour used								
628 Dicyclomine H 628 Dicyclomine H Oxetacaine and Tablets 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hydr Tablets	vdrochloride									
 Tablets Dicyclomine H Oxetacaine and Tablets Dicyclomine H Oxetacaine, Ma Simethicone Ta Cetirizine Hydr Ambroxol Hydr Tablets 	.,,	Each UnCoated Dispersible Tablet Con	tains :							
 Tablets Dicyclomine H Oxetacaine and Tablets Dicyclomine H Oxetacaine, Ma Simethicone Ta Cetirizine Hydr Ambroxol Hydr Tablets 	l Magaldrate	Dicyclomine Hydrochloride	IP	10	mg					
 Oxetacaine and Tablets Dicyclomine H Oxetacaine, Ma Simethicone Ta Cetirizine Hydr Ambroxol Hydr Tablets 	U	Oxetacaine	BP	5	mg	3/30/2021				
 Oxetacaine and Tablets Dicyclomine H Oxetacaine, Ma Simethicone Ta Cetirizine Hydr Ambroxol Hydr Tablets 		Magaldrate (as Anhydrous)	IP	400	mg					
 Oxetacaine and Tablets Dicyclomine H Oxetacaine, Ma Simethicone Ta Cetirizine Hydr Ambroxol Hydr Tablets 		Excipients		q.s.						
 Oxetacaine and Tablets Dicyclomine H Oxetacaine, Ma Simethicone Ta Cetirizine Hydr Ambroxol Hydr Tablets 		Colour:Approved colour used								
 Tablets Dicyclomine H Oxetacaine, Ma Simethicone Ta Cetirizine Hydr Ambroxol Hydr Tablets 	-	Each UnCoated Dispersible Tablet Con	tains :							
 629 Dicyclomine H Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hydr Tablets 	l Magaldrate	Dicyclomine Hydrochloride	IP	10	mg					
Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets		Oxetacaine	BP	5	mg	3/30/2021				
Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets		Magaldrate (as Anhydrous)	IP	540	mg					
Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets		Excipients		q.s.						
Oxetacaine, Ma Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets	vdrochloride	Colour:Approved colour used								
Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets	ly di ocilioni de,	Each Film Coated Tablet Contains :								
Simethicone Ta 630 Cetirizine Hydr Ambroxol Hyd Tablets	agaldrate and	Dicyclomine Hydrochloride	IP	10	mg					
630 Cetirizine Hydr Ambroxol Hyd Tablets	-	Oxetacaine	BP	10						
Ambroxol Hyd Tablets	ablet	Magaldrate (as Anhydrous)	IP	400	mg mg	3/30/2021				
Ambroxol Hyd Tablets		Simethicone	IP	25	mg					
Ambroxol Hyd Tablets		Excipients		q.s.	mg					
Ambroxol Hyd Tablets		Colour:Approved colour used		4.5.						
Ambroxol Hyd Tablets	rochloride &	Each Film Coated tablet contains:								
Tablets		Cetirizine Hydrochloride	IP	5	mg	3/30/2021				
		Ambroxol Hydrochloride	IP	60	mg					
631 Ambroxol Hyd		Excipients		q.s.	6					
631 Ambroxol Hyd		Colour:Approved colour used								
obi millionon mil	lrochloride,	Each Un Coated Tablet Contains :								
Guaiphenesin a		Ambroxol Hydrochloride	IP	15	mg	5				
Salbutamol Sul		Guaiphenesin	IP	100	mg	2/20/2021				
	_	Salbutamol Sulphate	IP	2	mg	- 5/30/202				

List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Lt having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945									
. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVE ON DATE			
		Colour:Approved colour used							
532	L- Carnitine, Coenzyme Q10,		1	1					
552	L- Camune, Coenzyme Q10,	Each Hard Gelatin Capsule Contains:							
	Vitamin K2 -7, Astaxanthin,	L-Carnitine	-						
	vitanini K2 -7, Astaxantinii ,	L-Califiune	USP	500	mg				
	Magnesium Sulphate and	Coenzyme Q 10	USP	100	mg				
	Zinc Sulphate Monohydrate	Vitamin K2 -7	0.01	50	mcg				
	Capsules	Astaxanthin	USP	8	mg	3/30/202			
	Cupsules	Magnesium Sulphate	IP	50	mg				
		Zinc Sulphate Monohydrate	IP		8				
		eq. to elemental zinc		7.5	mg				
		Excipients		q.s.	0				
		Colour:Approved colour used		1					
533	Amoxicillin Trihydrate and	Each 5ml of Constituted Suspension Cor	tains :						
	Potassium Clavulanate	Amoxicillin Trihydrate	IP						
	Suspension	eq. to Amoxicillin		200	mg				
		Potassium Clavulanate	IP			3/30/202			
		eq. to Clavulanic acid		28.5	mg				
		Excipients		q.s.					
		Colour:Approved colour used							
534	Amoxicillin Trihydrate and	Each 5ml of Constituted Suspension Cor	toing						
554	Potassium Clavulanate	Amoxicillin Trihydrate	IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII						
	Suspension	eq. to Amoxicillin	- 11	400	mg				
	Suspension	Potassium Clavulanate	IP	400	mg	3/30/202			
		eq. to Clavulanic acid		57	mg	5/50/202			
		Excipients		q.s.	mg				
		Colour:Approved colour used		4.5.					
535	Dextromethorphan	Each 5ml Contains:							
	Hydrobromide, Phenylephrine	Dextromethorphan Hydrobromide	IP	10	mg				
	Hydrochloride	Phenylephrine Hydrochloride	IP	5	mg				
	&Chlorpheniramine Maleate	Chlorpheniramine Maleate	IP	2	mg	3/30/202			
	Syrup	In a flavoured Syrupy base		q.s.					
		Colour: Approved colour Used							
536	Cyproheptadine HCl &	Each ml Contains :							
	Tricholine Citrate Drops	Cyproheptadine Hydrochloride	IP	1.5	mg				
		Tricholine Citrate	IP	55	mg	3/30/202			
		In A Flavoured Sarbitol Base		q.s.					
		Colour:Approved colour used							
537	Ambroxol Hydrochloride.	Each 5ml Contains							
	Guaiphenesin and	Ambroxol Hydrochloride	IP	15	mg				
	Levosalbutamol Sulphate	Guaiphenesin	IP	50	mg				
	Syrup	Levosalbutamol Sulphate		0.7		3/30/202			
		Eq. to Levosalbutamol	IP	0.5	mg				
		Mentholated syrupy base	+	q.s.					
		Colour:Approved colour used							
(20		Each Gram Contains :-	1	1					
538	Nimesulide, Methyl		DD	10					
538	Salicylate, Menthol and	Nimesulide	BP	10	mg				
538	-		BP IP IP	10 100 50	mg mg mg	3/30/202			

	HEALTH AND FAMI List of Retention Product	NO.HFW-H(DRUGS)279/ LY WELFARE DEPARTMENT is Approved to be Manufactured	,HIMACI bv : Boffi	n Biotecl	h Pvt.	
		NB/07/642 AND MB/07/643 28:S-MB/07/643 For the TE AS PER SCHEDULE-P-1 OF DRUGS & COSME		12.2022 to 30.	11.2027	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
		In a gel base		q.s.		
		Colour:Approved colour used		-		
639	Ferric Ammonium Citrate,	Each 5ml oral liquid contains:				
	Folic Acid , L- Lysine	Ferric Ammonium Citrate	IP	160	mg	
	Monohydrochloride,	Folic Acid	IP	1	mg	
	Vitamin B12, Niacinamide,	L-Lysine Monohydrochloride	USP	12	mg	
	and Zinc Sulphate oral liquid	Vitamin B12	IP	7.5	mcg	3/30/2021
		Niacinamide	IP	15	mg	
		Zinc Sulphate	IP	10	mg	
		In a flavoured syurpy base		q.s.	Ŭ	
		Colour:Approved colour used				
640	Diclofenac Diethylamine,	Each 1 ml of Liniment Contains :				
	Mephenesin, Capsaicin,	Diclofenac Diethylamine	BP	17.4	mg	
	Menthol and	eq. to Diclofenac Sodium		15	mg	
	Camphor Liniment	Mephenesin	IP	50	mg	
		Capsaicin Powder 95%	USP	0.02	mg	3/30/2021
		Menthol	IP	70	mg	
		Camphor	USP	10	mg	
		In a liniment liquid base		q.s.		
		Colour:Approved colour used				
641	Diclofenac Diethylamine,	Each 1 ml of Liniment Contains :				
	Methyl Salicylate,	Diclofenac Diethylamine	BP	17.4	mg	
	Menthol and	eq. to Diclofenac Sodium		15	mg	
	Camphor Liniment	Methyl Salicylate	IP	100	mg	3/30/2021
		Menthol	IP	70	mg	3/30/2021
		Camphor	USP	10	mg	
		In a liniment liquid base		q.s.		
		Colour:Approved colour used				
642	Diclofenac Diethylamine,	Composition				
	Methyl Salicylate,	Diclofenac Diethylamine	BP	1.16%	w/w	
	Mephenesin, Linseed Oil,	eq. to Diclofenac Sodium		1.00%	w/w	
	Menthol and Chlorocresol gel	Methyl Salicylate	IP	5.00%	w/w	
		Mephenesin	IP	10.00%	w/w	
		Linseed Oil	BP	3.00%	w/w	3/30/2021
		Menthol	IP	5.00%	w/w	
		Capsaicin	USP	0.025%	w/w	
		Chlorocresol (as preservative)	IP	0.10%	w/w	
		In a gel base		q.s.		
		Colour:Approved colour used				
				0.77	· · · ·	
643	Thymol, Ichthammol,	Thymol	IP	0.50%	w/w	
	Menthol & Lignocaine	Ichthammol	BP	0.20%	w/w	
	Hydrochloride	Menthol	IP	1.00%	w/w	3/30/2021
	Ointment	Lignocaine Hydrochloride	IP	1.00%	w/w	
		In a Ointment Base		qs		
644	Ubidecarenone and	Composition :				
	Betacarotene gel	Ubidecarenone	BP	0.10%	w/w	
		Betacarotene 30% despersion		0.10%	w/w	3/30/2021
		In a gel base		q.s.		
		Colour:Approved colour used		-1		
		used				

	PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945								
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED			

645	Troxerutin,Calcium	Troxerutin	BP	2%	w/w	
	Dobesilate Monohydrate,	Calcium Dobesilate Monohydrate	IP			
		Eq. to Anhydrous Calcium Dobesilate				
	Lignocaine Hcl,			0.25%	\mathbf{W}/\mathbf{W}	
	Hydrocortisone Acetate,	Lignocaine Hydrochloride	IP	3%	w/w	3/30/2021
	Zinc Oxide & Phenylephrine	Hydrocortisone Acetate	IP	0.25%	w/w	5/50/2021
	HCl Cream	Zinc Oxide	IP	5%	w/w	
		Phenylepherine Hydrochloride	IP	0.10%	W/w	
		In a cream base		q.s.		
		Colour:Approved colour used				

646	Vildagliptin & Metfromin HCl	Each film coated tablets contains:				
	Tablets	Vildagliptin		50	mg	4/12/2021
		Metfromin HCl	IP	500	mg	4/12/2021
		Excipients		q. s.		
		Colour :- Approved colour used				

64′	7 Vildagliptin & Metfromin HCl	Each film coated tablets contains:				
	Tablets	Vildagliptin Metfromin HCl	IP	50 850	mg mg	4/12/2021
		Excipients		q. s.		
		Colour :- Approved colour used				

648	Vildagliptin & Metfromin HCl	Each film coated tablets contains:				
	Tablets	Vildagliptin Metfromin HCl	IP	50 1000	mg mg	4/12/2021
		Excipients		q. s.		
		Colour :- Approved colour used				

649	Vitamin D3 (Cholecalciferol)	Each Uncoated Tablet Contains:				
	& Vitamin K2-7 Tablets	Vitamin D3 (Cholecalciferol)	IP	2000	IU	4/12/2021
		Vitamin K2-7	IP	50	mcg	4/12/2021
		Excipients		q.s		
		Colour :- Approved colour used				

650	Vitamin B1 mononitrate	Each Film Coated Tablet Contains:				
	Vitamin B2, Vitamin B6	Vitamin B1 mononitrate	IP	5	mg	
	Vitamin B12, Niacinamide,	Vitamin B2	IP	5	mg	
	Folic Acid,	Vitamin B6	IP	3	mg	
	Calcium D-Panththenate,	Vitamin B12	IP	15	mcg	
	Vitamin C,	Niacinamide	IP	50	mcg	
	Glutamic Acid and	Folic Acid	IP	1	mg	4/12/2021
	Zinc Oxide Tablets	Calcium D-Panththenate	IP	10	mg	
		Vitamin C	IP	75	mg	
		Glutamic Acid		50	mg	
I		Zinc Oxide	IP	20	mg	

	having license No. FORM25:M	ts Approved to be Manufactured b INB/07/642 AND MB/07/643 28:S-MB/07/643 For the p ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETI	eriod from 01.	n Blotec 12.2022 to 30.	n PVt. 11.2027	Lta.
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVE ON DATEI
		Excipients		q.s.		
		Colour:Approved colour used				
651				1		
651	Trypsin & Chymotrypsin Tablets	Each gastro-resistant Tablet Contains 1,00,000 Armour units of enzymatic				
	1 adiets					4/12/202
		Excipients Colour:Approved colour used		q.s.		
		Colour.Approved colour used				
652	Trypsin, Bromelain and	Each Enteric Coated Tablet Contains				
	Rutoside Trihydrate Tablets	Trypsin				
			BP	48	mg	
		Bromelain		90	mg	4/12/202
		Rutoside Trihydrate	BP	100	mg	
		Excipients		q.s.		
		Colour:Approved colour used				
653	Terbinafine HCL Tablets IP	Each Film Coated tablets contains:				
033	Terdinarine HCL Tablets IP	Terbinafine HCL	IP	500	ma	
			п		mg	4/12/202
		Excipients Colour :- Approved colour used		q. s.	I	
		colour . Approved colour used				
654	Telmisartan & Chlorthalidone	Each Film Coated tablet contains:				
	Tablets	Telmisartan	IP	80	mg	
		Chlorthalidone	IP	12.5	mg	4/12/202
		Excipients		q. s.		
		Colour :- Approved colour used				
				1		
655	Salbutamol Tablets IP	Each Uncoated Tablet Contains:	TD			
		Salbutamol Sulphate	IP	2		4/12/202
		eq. to Salbutamol Excipients		2	mg	4/12/202
		Colour: Approved colour Used		q.s.		
656	Salbutamol Tablets IP	Each Uncoated Tablet Contains:				
000		Salbutamol Sulphate	IP			
		eq. to Salbutamol	1	4	mg	4/12/202
		Excipients		q.s.		
		Colour: Approved colour Used				
657	Roxithromycin Tablets IP	Each uncoated tablet contains:	-	-		
		Roxithromycin	IP	300	mg	4/12/202
		Excipients			q.s.	
658	Rosuvastatin & Telmisartan	Each Film Coated tablets contains:	ID	10		
	Tablets	Rosuvastatin calcium	IP	10	mg	
		eq to Rosuvastatin Telmisartan	IP	40	ma	4/12/202
		Excipients	Ir.	40 q. s.	mg	
		Colour :- Approved colour used		ч. <i>э</i> .		
659	Rosuvastatin & Aspirin Tablets	Each Uncoated tablets contains:				
	-					
		Rosuvastatin calcium	IP	10	mg	
		eq to Rosuvastatin		1		4/12/202

	PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945									
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED				
		Aspirin	IP	150	mg					
		Excipients		q. s.						
		Colour :- Approved colour used								

660	Rosuvastatin & Aspirin Tablets	Each Uncoated tablets contains:				
		Rosuvastatin calcium	IP	5	mg	
		eq to Rosuvastatin				4/12/2021
		Aspirin	IP	75	mg	4/12/2021
		Excipients		q. s.		
		Colour :- Approved colour used				

661	Rosuvastatin & Aspirin Tablets	Each Uncoated tablets contains:				
		Rosuvastatin calcium eq to Rosuvastatin	IP	10	mg	4/12/2021
		Aspirin	IP	75	mg	
		Excipients		q. s.		
		Colour :- Approved colour used				

662	Paracetamol & Ibuprofen	Each Uncoated Dispersible tablets contains:				
	Tablets	Ibuprofen	IP	100	mg	
		Paracetamol	IP	125	mg	4/12/2021
		Excipients		q. s.		
		Colour :- Approved colour used				

663	Paracetamol &	Each Uncoated Tablet Contains				
	Mefenamic Acid Tablets	Mefenamic Acid	IP	500	mg	
		Paracetamol	IP	325	Mg	4/12/2021
		Excipients		q.s.		
		Colour: Approved Colour used				

664	Paracetamol &	Each Uncoated tablets contains:				
	Dicyclomine HCl Tablets	Paracetamol	IP	500	mg	
		Dicyclomine HCl	IP	20	mg	4/12/2021
		Excipients		q. s.		
		Colour :- Approved colour used				

665	Ondansetron orally	Each un coated orally Disintegrating table	et contain	s:		
	Disintegrating Tablets IP	Ondansetron Hydrochloride	IP			
		Eq. to Ondansetron		8	mg.	4/12/2021
		Excipients			q.s.	
		Colour: Approved colour used				

666	Nebivolol Hcl & Telmisartan	Each Uncoated tablets contains:				
	Tablets	Nebivolol Hcl	IP	5	mg	4/12/2021
		Telmisartan	IP	40	mg	4/12/2021
		Excipients		q. s.		
		Colour :- Approved colour used				
667	Nortriptyline HCl Tablets IP	Each Filmcoated tablet contains:-				
		Nortriptyline HCl	IP			

	~	INB/07/642 AND MB/07/643 28:S-MB/07/643 For the ZE AS PER SCHEDULE-P-1 OF DRUGS & COSME	IC ACT 1945			
5. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVE ON DATE
		eq. to Nortriptyline		25	mg	4/12/202
		Excipients		q.s		
		Approved colour used in Tablets				
668	Magaldrate, Dicyclomine	Each film coated tablets contains:				
	Hydrochloride, Dimethicone	Magaldrate	IP	540	mg	
	Tablets	Dicyclomine Hydrochloride	IP	20	mg	4/12/202
		Dimethicone	IP	20	mg	4/12/202
		Excipients		q. s.		
		Colour :- Approved colour used				
669	Loperamide HCl and	Each Uncoated Tablet Contains:				
	Simethicone Tablets	Loperamide HCl	IP	2	mg	
		Simethicone	IP	125	mg	4/12/202
		Excipients		q.s.		
		Colour:Approved colour used				
670	Levofloxacin	Each Film Coated tablet Contains:-		1		
070	Tablets IP	Levofloxacin Hemihydrate	IP			
		eq. to Levofloxacin		750	mg	4/12/202
		Excipients		q.s		., 12, 201
		Approved colour used in Coating		4		
C7 1				1		
671	Ibuprofen Tablets IP	Each Uncoated Tablet Contains:	m	200		
		Ibuprofen Excipients	IP		mg	4/12/202
		Colour: Approved colour Used		q.s. q.s.		
	•		1			
672	Ibuprofen Tablets IP	Each Uncoated Tablet Contains:				
		Ibuprofen	IP	400	mg	4/12/202
		Excipients		q.s.		
		Colour: Approved colour Used		q.s.		
673	Griseofulvin Tablets IP	Each Uncoated Tablet Contains:				
		Griseofulvin	IP	125	mg	4/12/202
		Excipients		q.s.		+/12/2U2
		Colour: Approved colour Used		q.s.		
674	Griseofulvin Tablets IP	Each Uncoated Tablet Contains:				
		Griseofulvin	IP	250	mg	4/12/202
		Excipients		q.s.		
C75	Crissofulnin T-11 (D	Colour: Approved colour Used		q.s.	$\left - \right $	
675	Griseofulvin Tablets IP	Each Uncoated Tablet Contains:	т	500		
		Griseofulvin Excipients	IP	500	mg	4/12/202
		Colour: Approved colour Used		q.s.	$\left - \right $	
676	Glimepiride & Metformin	Each Uncoated tablets contains:		q.s.	L	
570	Hydrochloride Tablets	Glimepiride	IP	2	mg	
		Metformin Hydrochloride	IP	850	mg	4/12/202
		Excipients		q. s.	0	
		Colour :- Approved colour used				

N.N. NAME/BRAND NAME CONPOSITION C.Tros QLASTRY ESR ox Glibenclamide IP 5 mg 4/ Excipients IP 5 mg 4/ 578 Gliclazide Tablets Each Uncoated tablets contains: IP 40 mg 610 Each Uncoated tablets contains: IP 40 mg 630 Each Clour: - Approved colour used IP 40 mg 631 Colour: - Approved colour used IP 40 mg 634 Each Film Coated tablets contains: IP 4/ 6359 Gabapentin USP 300 mg Methylcobalamin IP 500 mg Alpha Lipoic Acid Tablets Each Film Coated tablets contains: IP 100 mg 630 Folic Acid & Riboflavin , Each Uncoated tablets contains: IP 10 mg 840 Folic Acid & Riboflavin , Each Film Coated tablet contains: IP 10 mg 851 Etodolac & Thiocolchicoside Each Film Coated tablet contains: IP 4/<	
Excipients q.s. 4/ Colour: Approved colour Used 1 4/ 678 Gliclazide Tablets Each Uncoated tablets contains: Metformin Hydrochloride IP 500 mg 678 Gliclazide IP 40 mg 4/ 679 Gabapentin , & Alpha Lipoic Acid Tablets Each Film Coated tablets contains: Gabapentin USP 300 mg 679 Gabapentin , & Alpha Lipoic Acid Tablets Each Film Coated tablets contains: Gabapentin USP 300 mg 680 Folic Acid & Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 1.5 mg 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Folic Acid IP 300 mg 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 683 Escomeprazole Magnesium & Colour :- Approved colour used 4/ 684 Epalrestat & Methylcobalamin Bercipients IP 20 mg 684 Epalrestat & Methylcobalamin Each Film Coated Su	PPROVEI N DATEE
Excipients q.s. Colour: Approved colour Used 1 578 Gliclazide Tablets &Metformin Hydrochloride Each Uncoated tablets contains: Metformin Hydrochloride IP Gilclazide IP Gabapentin , Each Film Coated tablets contains: Gabapentin , Each Gabapentin Wethylcobalamin IP Alpha Lipoic Acid Tablets Gabapentin Excipients q.s. Colour :- Approved colour used	/12/2021
678 Gliclazide Tablets & Metformin Hydrochloride IP 500 mg 678 Gliclazide IP 40 mg 679 Gabapentin q. s. Colour :- Approved colour used 679 Gabapentin , & Alpha Lipoic Acid Tablets Each Film Coated tablets contains: Gabapentin USP 300 mg 680 Folic Acid Tablets Each Film Coated tablets contains: Gabapentin IP 500 mg 680 Folic Acid & Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 1.5 mg 681 Etodolac & Thiocolchicoside Tablets Each Film Coated tablets contains: Folic Acid IP 1.5 mg 682 Etodolac & Thiocolchicoside Tablets Each Film Coated tablet contains: 4/ 683 Etodolac & Thiocolchicoside Excipients IP 300 mg 684 Epalestat & Methylcobalamin IP 8 mg 685 Etodolac & Thiocolchicoside Excipients IP 8 mg 686 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 4/ 686 <	12,2021
&Metformin Hydrochloride IP 500 mg Gliclazide IP 40 mg Colour :- Approved colour used q.s. 47 679 Gabapentin , Each Film Coated tablets contains: mg Alpha Lipoic Acid Tablets Each Film Coated tablets contains: mg Alpha Lipoic Acid USP 300 mg Alpha Lipoic Acid USP 100 mg Excipients q.s. Colour :- Approved colour used	
Gliclazide IP 40 mg Gliclazide IP 40 mg Colour : Approved colour used q. s. colour : Approved colour used 679 Gabapentin , & Alpha Lipoic Acid Tablets Each Film Coated tablets contains: Gabapentin USP 300 mg 680 Folic Acid & Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 1.5 mg 680 Folic Acid & Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 1.5 mg 681 Etodolac & Thiocolchicoside Tablets Each Film Coated tablet contains: Colour : Approved colour used 4/ 682 Etodolac & Thiocolchicoside Tablets Each Film Coated tablet contains: Colour : Approved colour used 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Film Coated tablet contains: Colour : Approved colour used 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Film Coated tablets contains: Colour : Approved colour used 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 1P 20 mg 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release	
Gliclazide IP 40 mg Excipients Q. s. Colour : Approved colour used 679 Gabapentin , & Alpha Lipoic Acid Tablets Each Film Coated tablets contains: Gabapentin USP 300 mg Methylcobalamin IP 100 mg Alpha Lipoic Acid USP 100 mg Alpha Lipoic Acid USP 100 mg Alpha Lipoic Acid USP 100 mg Kalonamide IP 10 mg Kalonamide IP 10 mg Niacinamide Tablets Folic Acid IP 10 mg Niacinamide Tablets Each Hilm Coated tablets contains: Folic Acid IP 10 mg Niacinamide Tablets Each Film Coated tablet contains: Folic Acid IP 300 mg Kalpha Lipoic Acide Each Film Coated tablet contains: Folic Acid IP 300 mg Statianamide IP 300 mg Maintainamide IP 300 mg Tablets Each Film Coated tablet contains: IP 300 </td <td>/12/2021</td>	/12/2021
Colour :- Approved colour used 679 Gabapentin USP 300 mg Alpha Lipoic Acid Tablets Gabapentin USP 300 mg Alpha Lipoic Acid USP 100 mg Alpha Lipoic Acid USP 100 mg Alpha Lipoic Acid USP 100 mg Kalpha Lipoic Acid USP 100 mg Colour :- Approved colour used (a.s.) (b.s.) (b.s.) 680 Folic Acid & Riboflavin , Each Uncoated tablets contains: (b.s.) (b.s.) Folic Acid & Riboflavin , Each Tablets Each Time Coated tablets contains: (b.s.) (b.s.) 680 Folic Acid & Riboflavin , Each Film Coated tablet contains: (b.s.) (b.s.) (b.s.) 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: (b.s.) (b.s.) (c.s.) 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: (c.s.) (c.s.) (c.s.) 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: (c.s.) (c.s.) (c.s.) <td>/12/2021</td>	/12/2021
679 Gabapentin , & Alpha Lipoic Acid Tablets Each Film Coated tablets contains: Gabapentin USP 300 mg 679 Gabapentin , & Alpha Lipoic Acid Tablets Each Film Coated tablets contains: Gabapentin IP 500 mcg 680 Folic Acid & Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 1.5 mg 680 Folic Acid & Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 1.5 mg 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used q. s. Colour :- Approved colour used 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Enteric coated tablets contains: Esomeprazole Magnesium & Someprazole Magnesium eq. To Esomeprazole Magnesium eq. To Esomeprazole Magnesium eq. To Esomeprazole IP 20 mg 684 Epalrestat & Methylcobalamin Each Film	
& Alpha Lipoic Acid Tablets Gabapentin USP 300 mg Methylcobalamin IP 500 mcg 4/ Alpha Lipoic Acid USP 100 mg Alpha Lipoic Acid USP 100 mg Excipients q.s. Golour :- Approved colour used 9, s. 4/ 680 Folic Acid & Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 1.5 mg Riboflavin IP 10 mg 10 mg Riboflavin IP 10 mg 4/ 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ Tablets Etodolac IP 8 mg 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ Colour :- Approved colour used 683 Someprazole Magnesium 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	
& Alpha Lipoic Acid Tablets Gabapentin USP 300 mg Methylcobalamin IP 300 mg Alpha Lipoic Acid USP 100 mg Alpha Lipoic Acid USP 100 mg Kathylcobalamin IP 100 mg Alpha Lipoic Acid USP 100 mg Kathylcobalamin IP 100 mg Kathylcobalamin IP 10 mg Kathylcobalamin IP 1.5 mg Kathylcobalamin IP 1.5 mg Kathylcobalamin IP 10 mg Niacinamide IP 10 mg Niacinamide IP 10 mg Katholac IP 0 mg Colour :- Approved colour used 4/ Colour :- Approved colour used 4/ 682 Etodolac & Thiocolchicoside IP 8 mg Tablets Etodolac IP 200 mg Thiocolchicoside IP 4 mg	
Alpha Lipoic Acid USP 100 mg Excipients q. s. Q. s. Colour :- Approved colour used 680 Folic Acid & Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 1.5 mg Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 10 mg Riboflavin , Niacinamide Excipients q. s. q. s. 4/ 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium & Domperidone Each Enteric coated tablets contains: 4/ 684 E	
Alpha Lipoic Acid USP 100 mg Excipients q. s. Colour :- Approved colour used q. s. Colour :- Approved colour used 680 Folic Acid & Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 1.5 mg Riboflavin , Niacinamide Each Chicoated tablets contains: IP 10 mg 4/ 680 Folic Acid & Riboflavin , Niacinamide Each Film Coated tablet contains: IP 10 mg 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: IP 300 mg 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: IP 8 mg 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: IP 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: IP 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Enteric coated tablets contains: IP 20 mg 683 Esomeprazole Magnesium & Domperidone Each Enteric coated tablets contains: IP 20 mg 684 Epalrestat & Methylcob	/12/2021
Colour :- Approved colour used 680 Folic Acid & Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 1.5 ng Riboflavin IP 1.5 ng Riboflavin 4/ 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Tablets 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 683 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Enteric coated tablets contains: Esomeprazole 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	
680 Folic Acid & Riboflavin , Niacinamide Tablets Each Uncoated tablets contains: Folic Acid IP 1.5 mg Riboflavin IP 10 mg Miacinamide 4/ 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 4/ 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Tablets IP 300 mg Miacinamide 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Colour :- Approved colour used 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Enteric coated tablets contains: Esomeprazole Magnesium & Colour :- Approved colour used 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Enteric coated tablets contains: Esomeprazole Magnesium eq. To Esomeprazole Magnesium eq. To Esomeprazole IP 15 mg Miacinamic 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	
Niacinamide Tablets Folic Acid IP 1.5 mg Riboflavin IP 10 mg 4/ Riboflavin IP 50 mg 4/ Riboflavin IP 300 mg 4/ Riboflavin Etodolac IP 300 mg Tablets Etodolac IP 8 mg Riboflavin IP 8 mg 4/ Riboflavin Etodolac IP 8 mg Tablets Etodolac IP 200 mg Thiocolchicoside Each Film Coated tablet contains: 4/ 4/ Ribets Etodolac IP 4 mg Ribets Etodolac IP 4 mg Ribets Each Enteric coated tablet contains: 4/	
Niacinamide Tablets Folic Acid IP 1.5 mg Riboflavin IP 10 mg 4/ Riboflavin IP 50 mg 4/ Riboflavin IP 300 mg 4/ Riboflavin Etodolac IP 300 mg Tablets Etodolac IP 8 mg Riboflavin IP 8 mg 4/ Riboflavin Etodolac IP 8 mg Tablets Etodolac IP 200 mg Thiocolchicoside Each Film Coated tablet contains: 4/ 4/ Ribets Etodolac IP 4 mg Ribets Etodolac IP 4 mg Ribets Each Enteric coated tablet contains: 4/	
Riboflavin IP 10 mg 4/ Niacinamide IP 50 mg 4/ Excipients q. s. q. s. q. s. 4/ 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ Tablets Etodolac IP 300 mg Tablets Etodolac IP 8 mg Excipients q. s. Colour :- Approved colour used 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 683 Esomeprazole Magnesium Each Film Coated tablets contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	
Niacinamide IP 50 mg 4/ Excipients q. s. Colour :- Approved colour used q. s. 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 1 1 1 Tablets Etodolac IP 300 mg 4/ 681 Etodolac & Thiocolchicoside Etodolac IP 8 mg Tablets Etodolac IP 8 mg 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 1 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	
Colour :- Approved colour used 681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ Tablets Etodolac IP 300 mg Thiocolchicoside IP 8 mg 4/ 682 Etodolac & Thiocolchicoside IP 8 mg 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	/12/2021
681 Etodolac & Thiocolchicoside Each Film Coated tablet contains: IP 300 mg Tablets IP 8 mg 4/ 682 Etodolac & Thiocolchicoside IP 8 mg 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: IP 200 mg 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: IP 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	
Tablets Etodolac IP 300 mg 4/ Thiocolchicoside IP 8 mg 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	
Tablets Etodolac IP 300 mg 4/ Tablets Etodolac IP 8 mg 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	
Thiocolchicoside IP 8 mg 4/ Excipients q. s. q. s. q. s. 4/ Colour :- Approved colour used Q. s. q. s. 4/ 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: 4/ Tablets Etodolac IP 200 mg Thiocolchicoside IP 4 mg 4/ 682 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium Each Enteric coated tablets contains: 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	
Thiocolchicoside IP 8 mg Excipients q. s.	/12/2021
Colour :- Approved colour used 682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: Tablets Etodolac IP 200 mg Thiocolchicoside IP 4 mg Excipients q. s. Colour :- Approved colour used 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Enteric coated tablets contains: 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 10 11	12/2021
682 Etodolac & Thiocolchicoside Each Film Coated tablet contains: IP 200 mg Tablets Etodolac IP 4 mg 4/ Excipients q. s. Colour :- Approved colour used 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Enteric coated tablets contains: 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Enteric coated tablets contains: 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	
Tablets Etodolac IP 200 mg 4/ Thiocolchicoside IP 4 mg 4/ Excipients q. s. Q. s. 4/ Colour :- Approved colour used Q. s. 1 4/ 683 Esomeprazole Magnesium & Domperidone Tablets Each Enteric coated tablets contains: Esomeprazole Magnesium eq. To IP 20 mg Domperidone IP 15 mg 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	
683 Esomeprazole Magnesium &Domperidone Tablets Each Enteric coated tablets contains: Esomeprazole Magnesium eq. To IP 4 mg 4/ 683 Esomeprazole Magnesium &Domperidone Tablets Each Enteric coated tablets contains: Esomeprazole Magnesium eq. To IP 20 mg 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release IP 15 mg 4/	
683 Esomeprazole Magnesium &Domperidone Tablets Each Enteric coated tablets contains: Esomeprazole Magnesium eq. To IP 4 mg 4/ 683 Esomeprazole Magnesium &Domperidone Tablets Each Enteric coated tablets contains: Esomeprazole Magnesium eq. To IP 20 mg 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release IP 15 mg 4/	
Colour :- Approved colour used 683 Esomeprazole Magnesium &Domperidone Tablets Each Enteric coated tablets contains: Esomeprazole Magnesium eq. To Esomeprazole IP 20 mg Domperidone IP 15 mg 4/ Excipients q. s. Colour :- Approved colour used 4/ 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/	/12/2021
683 Esomeprazole Magnesium &Domperidone Tablets Each Enteric coated tablets contains: Esomeprazole Magnesium eq. To Esomeprazole IP 20 mg 683 Esomeprazole Magnesium eq. To Esomeprazole IP 20 mg 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 4/1	
&Domperidone Tablets Esomeprazole Magnesium eq. To IP 20 mg Esomeprazole IP 15 mg Domperidone IP 15 mg Excipients q. s. Colour :- Approved colour used 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release III	
&Domperidone Tablets Esomeprazole Magnesium eq. To Esomeprazole IP 20 mg Domperidone IP 15 mg Excipients q. s. Colour :- Approved colour used 4/1 684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release 684	
Esomeprazole IP 15 mg Domperidone IP 15 mg Excipients q. s. Colour :- Approved colour used	
Domperidone IP 15 mg Excipients q. s. Colour :- Approved colour used	
Excipients q. s. Colour :- Approved colour used 684	/12/2021
684 Epalrestat & Methylcobalamin Each Film Coated Sustained Release	
Epalrestat 150 mg	
Methylcobalamin IP 1500 mcg 4/	/12/2021

NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

		E AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC		12.2022 10 30.	11.2027	
S. No.	S. No. DOSAGE FORM, GENERIC COMPOSITION SPECIFI QUANTITY UNIT					
		Colour :- Approved colour used				

685	Doxycycline Hydrochloride	Each Film Coated Tablet Contains				
	and Ambroxol HCl Tablets	Doxycycline Hydrochloride	IP			
		equivalent to Doxycycline		100	mg	4/12/2021
		Ambroxol Hydrochloride	IP	7.5	mg	4/12/2021
		Excipients		q.s.		
		Colour:Approved colour used				

686	Doxylamine Succinate &	Each Enteric Coated tablets contains:				
	Pyridoxine HCl Tablets	Doxylamine Succinate	USP	10	mg	4/12/2021
		Pyridoxine HCl	IP	10	mg	4/12/2021
		Excipients		q. s.		
		Colour :- Approved colour used				

687	Diclofenac Sodium	Each Uncoated Prolong Release Tablet co	ontains:-			
	Tablets IP	Diclofenac Sodium	IP	100	mg	4/12/2021
	(Not for Veterinary Use)	Excipients		q.s		4/12/2021
		Approved colour used in Coating				

688	Diclofenac Potassium &	Each film coated Tablet Contains:				
	Drotaverine Hcl Tablets	Diclofenac Potassium	BP	50	mg	
		Drotaverine HCl		80	mg	4/12/2021
		Excipients		q.s		
		Colour :- Approved colour used				

689	Cvproheptadine Hvdrochloride	Each uncoated tablet contains				
	Tablets IP 4mg	Cyproheptadine Hydrochloride	IP	4	mg	4/12/2021
		Excipients		q.s.		4/12/2021
		Colour:Approved colour used				

690	Clarithromycin Tablets IP	Each film coated tablet contains				
		Clarithromycin	IP	250	mg	4/12/2021
		Excipients		q.s.		4/12/2021
		Colour:Approved colour used				

691	Chlorpheniramine maleate	Each Uncoated Tablet Contains				
	Phenylephrine Hydrochloride	Chlorpheniramine Maleate				
			IP	4	mg	4/12/2021
	Tablets	Phenylephrine Hydrochloride	IP	2.5	mg	4/12/2021
		Excipients		q.s.		
		Colour:Approved colour used				
692	Cetirizine HCL Tablets IP	Each Uncoated tablets contains:				
		Cetirizine HCL	IP	5	mg	4/12/2021
		Excipients		q. s.		4/12/2021
		Colour :- Approved colour used				

693 Cefixime and Lactic Acid	Each Uncoated Dispersible Tablet Contai	ns:	
Bacillus Dispersible Tablets	Cefixime Trihydrate	IP	

	0	NB/07/642 AND MB/07/643 28:S-MB/07/643 For the j E AS PER SCHEDULE-P-1 OF DRUGS & COSMET				
. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATEI
		eq. to Anhydrous Cefixime		200	mg	
		Lactic Acid Bacillus		60	Million spores	4/12/2021
		Excipients		q.s.		
		Colour:Approved colour used				
				1		
594	Cefixime	Each Uncoated Tablets Contains:-	ID			
	Tablets IP	Cefixime Trihydrate	IP	400		4/10/2021
		Eq. to Anhydrous Cefixime	_	400	mg	4/12/2021
		Excipients		q.s		
		Approved colour used in Tablets				
695	Cefadroxil Tablets IP	Each Uncoated tablet contains:-				
595	Celadioxii Tablets II	Cefadroxil Monohydrate	IP			
		eq. to Anhydrous Cefadroxil		500	mg	4/12/2021
		Excipients			mg	4/12/2021
		Approved colour used in Tablets		q.s		
696	Cefadroxil Tablets IP	Each Uncoated tablet contains:-				
090	Celadioxii Tablets Ir	Cefadroxil Monohydrate	IP			
		eq. to Anhydrous Cefadroxil	IF	125	ma	4/12/2021
		Excipients		-	mg	4/12/2021
		Approved colour used in Tablets		q.s		
697	Cefadroxil Tablets IP	Each Uncoated tablet contains:-				
097	Celadioxii Tablets Ir		IP			
		Cefadroxil Monohydrate	IP	250		4/12/2021
		eq. to Anhydrous Cefadroxil Excipients		250	mg	4/12/2021
		Approved colour used in Tablets		q.s		
		Approved colour used in Tablets				
698	Baclofen Tablets IP	Each uncoated tablet contains				
		Baclofen	IP	5	mg	
		Excipients		q.s.	8	4/12/2021
		Colour:Approved colour used		4		
699	Baclofen Tablets IP	Each uncoated tablet contains				
		Baclofen	IP	10	mg	4/10/0001
		Excipients		q.s.		4/12/2021
		Colour:Approved colour used				
700	Baclofen Tablets IP					
		Each uncoated tablet contains				
		Baclofen	IP	20	mg	4/12/2021
		Excipients		q.s.		
		Colour:Approved colour used				
701	Atenolol & Chlorthalidone	Each Uncoated tablet contains:				
/01	Tablets IP	Atenolol	IP	50	ma	
	rablets IP		-		mg	4/12/2021
		Chlorthalidone Excinionta	IP	12.5	mg	4/12/2021
		Excipients		q. s.	<u> </u>	
702	Amoyyaillin Tribydrata	Colour :- Approved colour used Each Film Coated Tablet Contains:				
702	Amoxycillin Trihydrate,					
	Potassium Clavulanate Diluted	Amoxycillin Trihydrate	ID			
			IP	1	1	

	List of Retention Produc having license No. FORM25:N	NO.HFW-H(DRUGS)279/0 ILY WELFARE DEPARTMENT, E its Approved to be Manufactured by 1/Bb/07/642 AND MB/07/643 28:S-MB/07/643 For the per IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	IIMACI y:Boffi iod from 01.	n Biotecl	ı Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATEI
	Tablets	Potassium Clavulanate Diluted	IP			4/12/202
		eq. to Clavulanic Acid		125	mg	
		Lactic Acid Bacillus		60	M.S	
		Excipients		q.s.		
		Colour:Approved colour used				
702	Atenolol & Chlorthalidone	Each Uncoated tablet contains:				
703	Tablets IP	Atenolol	IP	25	mg	
	Tablets II	Chlorthalidone	IP	12.5	mg	4/12/202
		Excipients	- 11	q. s.	mg	7/12/202
		Colour :- Approved colour used	1	q. s.	L	
704	Aspirin & Prasugrel HCL	Each Enteric coated tablets contains:				
	Tablets	Aspirin	IP	75	mg	
		Prasugrel HCL		10	mg	4/12/202
		Excipients		q. s.		
		Colour :- Approved colour used				
705	Tetracycline HCl	Each hard geletin capsule contains:-				
	Capsule IP	Tetracycline HCl	IP	500	mg	
	cupoure n	Excipients		qs		4/12/202
		Approved colour used in empty capsule s	hell	1		
	1		T	I		
706	Tetracycline HCl	Each hard geletin capsule contains:-		2.50		
	Capsule IP	Tetracycline HCl	IP	250	mg	4/12/202
		Excipients Approved colour used in empty capsule s	hell	qs		
		Approved colour used in empty capsule s	licii			
707	Ferrous Fumarate, Folic Acid					
		Each Hard Gelatin Capsule Contains				
	and Vitamin B12 Capsules	Ferrous Fumarate	IP	300	mg	
		Folic Acid	IP	1.5	mg	4/12/202
		Vitamin B12	IP	15	mcg	
		Excipients		q.s.		
		Colour:Approved colour used in empty ca	apsule she	ell		
708	Lansoprazole	Each hard geletin capsule contains:-				
.00	Capsule IP	Lansoprazole	IP	15	mg	
	Cupsule II	As enteric coated pellets		15	mg	4/12/202
		Excipients		qs		
		Approved colour used in empty capsule s	hell	1		
			1			
709	Lansoprazole	Each hard geletin capsule contains:-				
	Capsule IP	Lansoprazole	IP	30	mg	
		As enteric coated pellets				4/12/202
		Excipients		qs		
		Approved colour used in empty capsule s	hell			
710	Phenylephrine (Sustained	Each Hard Gelatin Capsule Contains:		l		
	Release) &	Phenylephrine Hydrochloride	IP	20	mg	
	Chlorpheniramine Maleate	(as sustained release pelletes)		1	-	

	PACK SI	ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	CACT 1945			
5. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVE ON DATEI
	(Sustained Release) Capsules	Chlorpheniramine Maleate	IP	8	mg	4/12/2021
		(as sustained release pelletes)		0	mg	
		Excipients		q.s.		
		Colour:Approved colour used		.1		
711	Phenylephrine (Sustained	Each Hard Gelatin Capsule Contains:				
/11	Release) &	Phenylephrine Hydrochloride	IP	10	mg	
	Chlorpheniramine Maleate	(as sustained release pelletes)		10	mg	
	(Sustained Release) Capsules	Chlorpheniramine Maleate				4/10/202
		1	IP	4	mg	4/12/202
		(as sustained release pelletes)				
		Excipients		q.s.		
		Colour:Approved colour used				
712	Amlodipine & Atenolol	Each Uncoated tablets contains:				
	Tablets	Amlodipine	IP	5	mg	
		Atenolol	IP	250	mg	4/12/2021
		Excipients		q. s.		
		Colour :- Approved colour used				
				1		
713	Indomethacin (EC) and	Each Hard Geletin Capsule Contains:-				
	Paracetamol Capsules	Indomethacin	IP	25	mg	
		As Enteric Coated Granules Paracetamol	IP	325	ma	4/12/2021
		Excipients	п	q.s.	mg	
		Colour:Approved colour used in empty c	apsule she			
714	Cephalexin Monohydrate and	Each Hard Gelatin Capsule Contains:				
	Bromhexine HCl Capsules	Cephalexin Monohydrate	IP			
	Dioninexine rier cupsules	eq. to Cephalexin	п	250	mg	4/12/202
		Bromhexine HCl	IP	4	mg	
		Excipients		q.s.		
		Colour:Approved colour used in empty c	apsule she	ell		
71 -			1	-		
715	Cephalexin Monohydrate and	Each Hard Gelatin Capsule Contains:				
	Bromhexine HCl Capsules	Cephalexin Monohydrate	IP		L	
	bronnexine rier capsules	eq. to Cephalexin		500	mg	4/12/202
		Bromhexine HCl	IP	8	mg	
		Excipients		q.s.		
		Colour:Approved colour used		-		
/16	Chloramphenicol	Each hard geletin capsule contains:-				
	Capsule IP	Chloramphenicol	IP	250	mg	
	·	Excipients		qs	-	4/12/202
		Approved colour used in empty capsule s	shell			

NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

	PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945						
S. No.	S. No. DOSAGE FORM, GENERIC NAME/BRAND NAME COMPOSITION SPECIFI CATION QUANTITY UNIT APPROVED ON DATED						
		Excipients		qs		4/12/2021	
	Approved colour used in empty capsule shell						

718	Amoxycillin Tryhydrate,	Each hard geletin capsule contains:-				
	Cloxacillin Sodium&	Amoxycillin Tryhydrate	IP			
	Lactic Acid bacillus Capsules	Eq.to Amoxycillin		250	mg	
	1	Cloxacillin Sodium	IP		0	
		Eq.to Cloxacillin		250	mg	4/12/2021
		1			Million	
		Lactic Acid Bacillus		90	spores	
		Excipients		qs		
		Approved colour used in empty capsule s	hell			
	-					
719	Albendazole and	Each 30ml Contains				
	Ivermectin Oral Suspension	Albendazole	IP	750	mg	
	_	Ivermectin (Vet.)	IP	25	mg	4/12/2021
	(For Animal Use Only)	In a flavoured syurpy base		q.s.		
	(Not For Human Use)	Colour:Approved colour used				
	-					
720	Ivermectin Bolus	Each Uncoated Bolus Contains:				
		Ivermectin (Vet.)	IP	100	mg	4/12/2021
	(For Animal Use Only)	Excipients		q.s.		4/12/2021
	(Not For Human Use)	Colour:Approved colour used				
721	Meloxicam Bolus BP	Each Uncoated Bolus Contains:				
		Meloxicam	BP	100	mg	4/12/2021
	(For Animal Use Only)	Excipients		q.s.		., 12, 2021
	(Not For Human Use)	Colour:Approved colour used				
722	Nimesulide, Paracetamol and	Each Uncoated Bolus Contains:				
	Serratiopeptidase Bolus	Nimesulide	BP	400	mg	
		Paracetamol	IP	1500	mg	
		Serratiopeptidase	IP	60	mg	4/12/2021
		(as enteric coated granules)				
	(For Animal Use Only)	Excipients		q.s.		
	(Not For Human Use)	Colour:Approved colour used				
723	Trimethoprim and	Each Uncoated Bolus Contains:				
	Sulphadiazine Bolus IP	Trimethoprim	IP	400	mg	
		Sulphadiazine	IP	2000	mg	4/12/2021
	(For Animal Use Only)	Excipients		q.s.		
	(Not For Human Use)	Colour:Approved colour used				

724	Vitamin B1,	Each Hard Geletin Capsule Contains:-				
	Vitamin B2, Vitamin B6,	Vitamin B1	IP	1	mg	
	Vitamin B12,	Vitamin B2	IP	1	mg	
	Folic Acid and	Vitamin B6	IP	0.5	mg	
	Niacinamide Capsules	Vitamin B12	IP	5	mcg	4/12/2021
		Folic Acid	IP	100	mcg	

	PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945						
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED	
		Niacinamide	IP	15	mg		
		Excipients		q.s.			
	Colour:Approved colour used in empty capsule shell						

725	Vitamin B1, Vitamin B2,	Each Hard Gelatin Capsule Contains:				
	Vitamin B6, Vitamin B12,	Vitamin B1	IP	2	mg	
	Folic Acid, Niacinamide,	Vitamin B2	IP	1	mg	
	Lactic Acid Bacillus and	Vitamin B6	IP	1.5	mg	
	Diabasic Calcium Phosphate	Vitamin B12	IP	1	mcg	
	Capsules	Folic Acid	IP	400	mcg	4/12/2021
		Niacinamide	IP	15	mg	
		Lactic Acid Bacillus		100	Million Spores	
		Diabasic Calcium Phosphate	IP	100	mg	
		Excipients		q.s.		
		Colour:Approved colour used in empty ca	psule she	-11		

		1				
726	Cephalexin Monohydrate and	Each 5ml reconstituted Suspension Conta	ins.			
	Bromhexine HCl Suspension	Cephalexin monohydrate				
	Biominexine FICI Suspension	Cephalexin mononyurate	IP			
		eq. to Cephalexin		125	mg	4/12/2021
		Bromhexine HCl	IP			
		eq. to Bromhexine		2	mg	
		In a Flavoured Syrupy Base		q.s.		
		Colour:Approved colour used				
727	Cephalexin Monohydrate and	Each 5ml reconstituted Suspension Conta	ains:			
	Bromhexine HCl Suspension	Cephalexin monohydrate	IP			
		eq. to Cephalexin	- 11	250	mg	4/12/2021
		Bromhexine HCl	IP	250	mg	4/12/2021
		eq. to Bromhexine	- 11	4	mg	
		In a Flavoured Syrupy Base		4.s.	mg	
		Colour:Approved colour used		q .s.		
728	Zinc Sulphate Monohydrate,					
720	Zine Sulphate Wohonydrate,	Each Hard Geletin Capsules Contains:				
	Vitamin B12,	Zinc Sulphate Monohydrate	IP	41.17	mg	
	Calcium Pantothenate,	eq. to elemental Zinc		15	mg	
	Nicotinamide and	Vitamin B12	IP	15	mcg	
	Vitamin C Capsules	Calcium Pantothenate	IP	25	mg	4/12/2021
		Nicotinamide	IP	50	mg	
		Vitamin C	IP	150	mg	
		Excipients		q.s.		
		Colour:Approved colour used in empty ca	apsule she	211		
729	Vitamin B1,	Each 5ml Contains:-				
	Riboflavin sodium Phosphate	Vitamin B1				
			IP	0.5	mg	
	, Vitamin B6 ,	Riboflavin sodium Phosphate	IP	0.5	mg	
	Vitamin B12,	Vitamin B6	IP	0.25	mg	
	Niacinamide, D-Panthenol	Vitamin B12	IP	0.25	mcg	4/12/2021

		ZE AS PER SCHEDULE-P-1 OF DRUGS & COSME	TIC ACT 1945	1		
5. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	and L-lysine HCl Syrup	Niacinamide	IP	7.5	mg	
		D-Panthenol	USP	0.5	mg	
		L-lysine HCl	BP	30	mg	
		In a flavoured syurpy base		q.s.		
		Colour:Approved colour used				
730	Protein Hydrolysate,	Each 15ml Oral Liquid Contains:				
	Vitamin B1, Vitamin B2,	Protein Hydrolysate		1	am	
	Vitamin B6,	Vitamin B1	IP	2.5	gm mg	
	Cyanocobalamin,	Vitamin B2	IP	2.5	mg	
	D-Panthenol.	Vitamin B6	IP	0.75	mg	
	Iron choline Citrate,	Cyanocobalamin	IP	5	mcg	
	L-lysine Monohydrate,	D-Panthenol	USP	5	mg	4/12/2021
	Zinc Sulphate and	Iron Choline Citrate		100	mg	
	Niacinamide Oral Liquid	L-lysine Monohydrate	BP	40	mg	
		Zinc Sulphate	IP	8	mg	
		Niacinamide	IP	25	mg	
		In a flavoured syurpy base		q.s.	mg	
		Colour:Approved colour used		q .5.		
731	Ofloxacin, Metronidazole	Each 5 ml contains:				
	& Simethicone Suspension	Ofloxacin	IP	50	mg	
		Metronidazole Benzoate	IP	120		1g 4/12/2021
		eq. to Metronidazole	m	120	mg	4/12/2021
		Simethicone	IP	10	mg	
		In a flavoured syrup base Colour:Approved colour used		q.s.		
732	Liquid Paraffin ,	Each 5ml Suspension Contains:				
132	Milk of Magnesia and	Liquid Paraffin	IP	1.25	ml	
	Sodium Picosulphate	Milk of Magnesia	IP	3.75	ml	
	Suspension	Sodium Picosulphate	BP	3.33	mg	4/12/2021
	Suspension				mg	
		In a Flavoured Syrupy Base Colour:Approved colour used		q.s.		
	1	Colour approved colour used	1	I		
733	Fexofenadine HCl &	Each 5 ml contains:				
	Montelukast Sodium	Fexofenadine HCl	IP	60	mg	
	suspension	Montelukast Sodium	IP			4/12/2021
		eq. to Montelukast		4	mg	
		In a flavoured syrup base		q.s.		
		Colour:Approved colour used				
734	Calcium Gluconate,	Each 5ml Contains:	m			
	Calcium Lactate,	Calcium Gluconate	IP IP	20	mg	
	Cyanocobalamin ,Vitamin D3	Calcium Lactate	IP	40	mg	
	and Niacinamide Syrup	Cyanocobalamin	IP ID	2.5	mcg	4/12/202
		Vitamin D3	IP ID	200	IU	
		Niacinamide	IP	22.5	mg	
		In a flavoured syurpy base	_	q.s.		
707		Colour: Approved colour used				
735	Calcium Gluconate,	Each 5ml oral liquid contains:				

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/0 ILY WELFARE DEPARTMENT, ts Approved to be Manufactured b NB/07/642 AND MB/07/643 28:S-MB/07/643 For the pe ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	HIMACI y:Boffi riod from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Vitamin B12 and	Cholecalciferol	IP	400	IU	
	Ferric Ammonium Citrate	Vitamin B12	IP	3.5	mcg	4/12/2021
	Oral Liquid	Ferric Ammonium Citrate	IP	45	mg	
		In a flavoured syurpy base		q.s.		
		Colour:Approved colour used				
			I			
736		Calamine	IP	1.5%	w/w	
	Zinc Oxide, Cetrimide &	Zinc Oxide	IP	7.5%	w/w	
	Dimethicone ointment	Cetrimide	IP	1.125%	w/w	4/12/2021
		Dimethicone	IP	20.0%	w/w	
		In a Ointment Base		q.s		
		Colour:Approved colour used				
737	Calamine,	Calamine	IP	5.0%	w/w	
	Phenylephirine HCl &	Phenylephirine HCl	IP	0.1%	w/w	
	Lignocaine HCl Cream	Lignocaine HCl	IP	3.0%	w/w	
	8	Chlorocresol	IP	0.1%	w/w	4/12/2021
		As a Preservatives				
		In a Cream Base		q.s		
		Colour:Approved colour used				
738	Calamine,	Calamine	IP	8.0%	w/v	
	Aloe Vera Gel &	Light Liquid Paraffin	IP	10.0%	w/v	
	Light Liquid Paraffin Lotion	Aloe Vera Gel	IP	10.0%	w/v	4/12/2021
		In a Lotion Base		q.s		
		Colour:Approved colour used				
739	Chlorhexidine Mouthwash IP	Chlorhexidine Gluconate Solution				
/39	Chiornexidine Wouthwash IP	Chiornexidine Gluconate Solution	IP			
		Eq. to Chlorhexidine Gluconate	11	0.20%	w/v	4/12/2021
		In a pleasantly flavoured aqueous base		q.s.	vv / v	4/12/2021
		Colour:Approved colour used		q.s.		
		colour reproved colour used				
740	Vitamin - E Cream	Composition:				
		Vitamin E Acetate	IP	0.50%	w/w	
	With Aloe Vera	Moisturizing Cream Base with Aloe				4/12/2021
		Vera		q.s.		
		Colour:Approved colour used				
741	Povidone - Iodine Gargle	Composition:		2 0.004	,	
		Povidone-iodine	IP	2.00%	w/v	
		(Available Iodine 0.2% w/v)		0.200/		4/12/2021
		Absolute Alcohol Content		8.38%	v/v	
		In a mint flavour aqueous base Colour:Approved colour used				
		Colour.Approved colour used	1			
742	Atorvastatin	Each film coated tablet contains :-				
742	Atorvastatin , Fenofibrate & Ezetimibe	Each film coated tablet contains :- Atorvastatin Calcium	IP			
742		Atorvastatin Calcium	IP	10	mg	
742	Fenofibrate & Ezetimibe	Atorvastatin Calcium Eq. to Atorvastatin	IP BP	10 160	mg mg	4/22/2021
742	Fenofibrate & Ezetimibe	Atorvastatin Calcium			mg mg mg	4/22/2021

	List of Retention Produce having license No. FORM25:N	NO.HFW-H(DRUGS)279// ILY WELFARE DEPARTMENT cts Approved to be Manufactured MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the p	HIMACI by : Boffi period from 01.	n Biotecl	ı Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
		Approved colour used in coating				
743	Betahistine	Each Uncoated Tablets Contains:-				
	Hydrochloride Tablets IP	Betahistine Hydrochloride	IP	24	mg	4/22/2021
		Excipients		qs		4/22/2021
		Approved colour used in Tablets				
744	Betahistine	Each Uncoated Tablets Contains:-				
	Hydrochloride Tablets IP	Betahistine Hydrochloride	IP	48	mg	4/22/2021
		Excipients		qs		
		Approved colour used in Tablets				
745	Cefaclor Tablets IP	Each Film Coated Tablet Contains:-			_	
		Cefaclor Monohydrate	IP			
		Eq. to Cefaclor		125	mg	4/22/2021
		Excipients		q.s		
		Approved colour used in Coating				
746	Cefaclor Tablets IP	Each Film Coated Tablet Contains:-				
		Cefaclor Monohydrate	IP			
		Eq. to Cefaclor		250	mg	4/22/2021
		Excipients		q.s		
		Approved colour used in Coating				
747	Cefadroxil & Lactic Acid	Each Filmcoated tablet Contains:-				
747	Bacillus Tablets	Cefadroxil Monohydrate	IP	1		
	Bacillus Tablets	eq. to Anhydrous Cefadroxil	Ir	250	ma	
		Lactic Acid Bacillus		60	M.S	4/22/2021
		Excipients				
		Approved colour used in Coating		q.s		
				•		
748	Clarithromycin Tablets IP	Each Film Coated Tablet Contains:-				
		Clarithromycin	IP	500	mg	4/22/2021
		Excipients		q.s		4/22/2021
		Approved colour used in Coating				
749	Betacarotine,	Each Film coated Tablet Contains:-				
	Vitamin B1,	Betacarotine 30% dispersion		10	mg	
	Vitamin B2,	Vitamin B1	IP	10	mg	
	Vitamin B6,	Vitamin B2	IP	10	mg	
	Vitamin C,	Vitamin B6	IP	3	mg	
	Mecobalamin,	Vitamin C	IP	75	mg	
	Folic Acid,	Mecobalamin	IP	500	mcg	
	Lycopene,	Folic Acid	IP	1	mg	
	Inositol,	Lycopene 6 %		2000	mcg	
	DL-Methionine,	Inositol	USP	25	mg	
	Calcium Pantothenate,	DL-Methionine	USP	25	mg	
	Nicotinamide,	Calcium Pantothenate	IP	12.5	mg	4/22/2021
	Vitamin E,	Nicotinamide	IP	50	mg	4/22/2021
	Copper,	Vitamin E Acetate	IP	25	mg	
	Zinc,	Copper Sulphate Anhydrous	BP			
	Potassium &	eq. to Elemental Copper		40	mcg	
	Manganese Tablets	Zinc Sulphate Monohydrate	IP			
		eq. to Elemental Zinc		22.5	mg	
	1	Manganese Sulphate	USP			

List of Retention Products Approved to be Manufactured by : Boffin Biotech	Pvt. Ltd.
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.1	1.2027

	PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945								
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED			
		eq. to Elemental Manganese		2	mg				
		Potassium Sulphate	USP						
		eq. to Elemental Potassium		1	mg				
		Excipients		qs					
		Approved colour used in Coating							

750	Combikit of 2 Clarithromyc	in Tablets IP 500 mg ,2 Pantoprazole 7	Fablets 1	P 40 mg	& 2	
	A. 2 Clarithromycin Tablets					
	IP 500 mg	Each Filmcoated tablet contains:				
		Clarithromycin	IP	500	mg	
		Excipients		qs.		
		Colour:Approved colour used in coating				
	B. 2 Pantoprazole Tablets IP					
	40 mg	Each Enteric coated tablet contains:				
		Pantoprazole Sodium	IP			4/22/2021
		Pantoprazole		40	mg	1,22,2021
		Excipients		qs.		
		Colour:Approved colour used in coating				
	C. 2Amoxycillin Tablets IP	Each Filmcoated tablet contains:				
		Amoxycillin Trihydrate	IP			
		Eq. to Amoxycillin		750	mg	
		Excipients		qs.		
		Colour:Approved colour used in coating				

751	Combikit of 3 Artesunate Ta	blets IP & 6 Mefloquine HCl Tablets				
	A. 3 Artesunate Tablets IP					
		Each uncoated tablet contains:				
		Artesunate	IP	200	mg	
		Excipients		qs.		
		Colour:Approved colour used				4/22/2021
	B. 6 Mefloquine HCl					
	Tablets	Each uncoated tablet contains:				
		Mefloquine HCl	IP			
		Eq. to Mefloquine		250	mg	
		Excipients		qs.		
		Colour:Approved colour used				

752	Combikit of 1 Biotin Table	ts & 1 Finasteride Tablets				
	A. 1 Biotin Tablets	Each Filmcoated tablet contains:				
		Biotin	BP	5	mg	
		Excipients		qs.		
		Colour:Approved colour used in coating				4/22/2021
	B. 1 Finasteride Tablets	Each Filmcoated tablet contains:				
		Finasteride	IP	1	mg	
		Excipients		qs.		
		Colour:Approved colour used in coating				

S. No. DOSAGE FORM, GENERIC NAME/BRAND NAME COMPOSITION SPECIFI CATION QUANTITY UNIT APPROVED ON DATED	PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945								
	S. No.		COMPOSITION		QUANTITY	UNIT			

	A. 30 Calcium, Vitamin-D3	Each Filmcoated tablet contains:				
	& Zinc Tablets	Calcium Carbonate	IP	1250	mg	
		Eq. to Elemental Calcium		500	mg	
		Vitamin-D3 (As Stabilised)	IP	500	IU	
		Zinc sulphate Monohydrate	IP			
	Eq. to Elemental Zinc		7.5	mg		
				qs.		4/22/2021
		Excipients				4/22/2021
		Colour:Approved colour used in Coating				
	B 1 Ibandronic Acid Tablets					
		Each Filmcoated tablet contains:				
		Ibandronate Sodium Monohydrate	IP			
		Eq. to Ibandronic Acid		150	mg	
		Excipients		qs.		
		Colour:Approved colour used in Coating				
4	Deflazacort Tablets	Each Uncoated tablet contains:-				

Deflazacort Tablets	Each Uncoated tablet contains:-				
	Deflazacort		1	mg	4/22/2021
	Excipients		q.s		4/22/2021
	Approved colour used in Tablets				
	Deflazacort Tablets	Excipients	Deflazacort Excipients	Deflazacort1Excipientsq.s	Deflazacort1mgExcipientsq.s

755	Deflazacort Tablets	Each Uncoated tablet contains:-			
		Deflazacort	12	mg	4/22/2021
		Excipients	q.s		4/22/2021
		Approved colour used in Tablets			

756	Deflazacort Tablets	Each Uncoated tablet contains:-			
		Deflazacort	18	mg	4/22/2021
		Excipients	q.s		4/22/2021
		Approved colour used in Tablets			

757	Deflazacort Tablets	Each Uncoated tablet contains:-			
		Deflazacort	30	mg	4/22/2021
		Excipients	q.s		4/22/2021
		Approved colour used in Tablets			

758	Dosulepin Tablets IP	Each Filmcoated tablet contains:-				
		Dosulepin Hydrochloride	IP	25	mg	4/22/2021
		Excipients		q.s		4/22/2021
		Approved colour used in Coating				
759	Dosulepin Tablets IP	Each Filmcoated tablet contains:-				
		Dosulepin Hydrochloride	IP	50	mg	4/22/2021
		Excipients		q.s		4/22/2021
		Approved colour used in Coating				
760	Erythromycin stearate	Each Film Coated Tablet Contains:-				
	& Lactic Acid Bacillus	Erythromycin stearate	IP			

| S.N. NAMEBRAND NAME CONTONTION CNON ON DATE Tablets eq to Erythronycin 500 mg 4/22.20. Lactic Acid Bacillus 60 sporse q.s 4/22.20. Tablets eq to Erythronycin g.s q.s 4/22.20. Tablets Each Film Coated Tablet Contains:- q.s q.s 4/22.20. Tablets Each Film Coated Tablet Contains:- q.s q.s 4/22.20. Tablets Each Film Coated Tablet Contains:- q.s q.s 4/22.20. Tablets Gimeprinde Tablet IP Each Uncoated tablets contains: q.s q.s 4/22.20. Tablets Fungal Diastase (1 : 800),
Papain &
Activated Charcoal Tablets Each Uncoated Tablets contains: q.s 4/22.20. Tablets Each Uncoated Tablets Contains:- q.s. q.s. 4/22.20. Tablet IP Each Uncoated Tablets Contains:- q.s. q.s. 4/22.20. Tablet IP Each Uncoated Tablets Contains:- q.s. q.s. 4/22.20. Tablet IP Each Uncoated Tablets Contains:- q.s. q.s. 4/22.20.

 | | List of Retention Produc | NO.HFW-H(DRUGS)279/
ILY WELFARE DEPARTMENT
ats Approved to be Manufactured | HIMACI
by : Boffi | n Biotec | h Pvt. | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

--
--|--------|---------------------------------|---|----------------------|----------|---------|----------------------
--
--
--
--|-----|--|--|--|---|--|--|---|-----|---|-------------------------|----|-----|----|--|---|--|----------------------------|-------------------------|----|-----|----|-----------|--|--|----------------------------|---|----|----|----|-----------|--|--|--|---|----|-------|----|-----------|--|--|--|--------------------------------|--|-------|--|--|--|-----|-----------------------|---------------------------------|--|---|--|--
--|-----|-----------------------|---------------------------------|----|---|----|--|--|-----|--|---|----|---|----|-----------|--|--|--|---|--|-----|----|-----------|--|-----|-----------------------|---|--|-----|--|--|--|-----|-----------------------|--|----|---|----|--
---|--|-------|---|----|-----|----|-----------|---|--|--|---|--|-----|---|-----------|---|-----|---------------------------|---|----|--|--|--|---|-----|---------------------------|---|----|---|----|--|--|--|--------------------------|-------------------------|----|---|----|-----------|--|--|---------------------|-----------------------------|----|-----|----|-----------
--|--|--|-----------------------------|--|-----|------|--|--|--|--|------------|--|--|------|--|---|-----|--|--|--|--|--|--|--|-----|-----------------------|--|---|---|----|--|--|--|-----------------------|--|----|-----|----|-----------|---|--|--|--|----|----------|----|-----------|---|--|--|--|--|----------|--|--|--|--|--|--------------------------------|--|-------|--|--|--|-----|-------------------------|---------------------------------|--|--|--|--|--|-----|-------------------------|---------------------------------|----|---|----|--|--|-----|------------------------|--|----|---|----|--|--|--|------------------------|--|---|------|----|-----------|------------------|--|--|--|---|------|----|-----------|--------------------------------|--|--|--------------------------------|---|------|--|--|--------------------------------|--|--|--------------------------------|---|------|--|--|
| S. No. DOSAGE FORM GENRIC
NAME/BRAND NAME COMPOSITION SECON
OPENITY OPENITY Tablets eq to Erythromycin 500 mg. 4/22/20. Lactic Acid Bacillus 600 super-
section and provide colour used in Coating 4/22/20. 761 Erythromycin stearate
& Lactic Acid Bacillus Each Film Coated Tablet Contains:- IP - 762 Fungal Diastase (1 : 800),
Papain &
Activated Charcoal Tablets Each Chronoted Tablets contains:- - - 763 Glimepiride Tablet IP Each Uncoated tablets contains:- - - - 764 Glimepiride Tablet IP Each Uncoated tablets contains:- - - - 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - <

 | | | | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Image: Constraint of the second se

 | S. No. | DOSAGE FORM, GENERIC | | SPECIFI | QUANTITY | UNIT | APPROVED
ON DATED |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Image: Text is the second s

 | | Tablets | eq to Erythromycin | | 500 | mg | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Image: constraint of the second se

 | | | | | | Million | 4/22/2021 |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Approved colour used in Coating Image: Content of Con

 | | | Lactic Acid Bacillus | | 60 | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 761 Erythromycin stearate
& Lactic Acid Bacillus Each Film Coated Tablet Contains:- IP IP 7ablets Each Film Coated Tablet Contains:- IP IP IP 7ablets Eythromycin stearate
eq to Erythromycin IP IP IP 7ablets Each Gacillus IP IP IP 7ablets Each Chacola I actic Acid Bacillus IP IP IP 7ablets Approved colour used in Coating IP IO IP 7ablets Fungal Diastase (1 : 800). IP IO IP

 | | | Excipients | | q.s | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| & Lactic Acid BacillusErythromycin stearateIPITabletseq to Erythromycin250 mgLactic Acid Bacillus60 mgExcipientsq.sApproved colour used in Coatingq.s762Fungal Diastase (1 : 800),
Papain &
Activated Charcoal TabletsEach Uncoated tablets contains:
Papain at the straight of the straight

 | | | Approved colour used in Coating | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| & Lactic Acid BacillusErythromycin stearateIPITabletseq to Erythromycin250 mgLactic Acid Bacillus60 mgExcipientsq.sApproved colour used in Coatingq.s762Fungal Diastase (1 : 800),
Papain &
Activated Charcoal TabletsEach Uncoated tablets contains:
PapainIP763Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Colour :- Approved colour usedIP3 mg
4/22/20:
4/22/20:763Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Colour :- Approved colour usedIP3 mg
4/22/20:764Glimepiride Tablet IPEach Uncoated Tablets Contains:-
GlimepirideIP4765Glimepiride and Metformin
Hydrochloride (IP)Each Uncoated Tablets Contains:-
GlimepirideIP4766Glimepiride AttributesEach Uncoated Tablets contains:-
GlimepirideIP4766Glimepiride & Metformin
Hydrochloride (IP)IP4mg
4/22/20:
4/22/20:766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:-
GlimepirideIP4mg
4/22/20:
4/22/20:766Glimepiride & Metformin
Hydrochloride TabletsIP1mg
4/22/20:
4/22/20:4/22/20:
4/22/20:767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
4/22/20:
4/22/20:767Glimepiride & Metformin
Hydrochloride TabletsIP1mg
4/22/20:
4

 | | | | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Tablets eq to Erythromycin 250 mg Lactic Acid Bacillus 60 sperse 4/22/20 Excipients q.s Approved colour used in Coating q.s 762 Fungal Diastase (1 : 800),
Papain &
Activated Charcoal Tablets Each Uncoated tablets contains:
Fungal Diastase (1 : 800) IP 100 mg Activated Charcoal Tablets Each Uncoated Tablets Contains:
Fungal Diastase (1 : 800) IP 75 mg 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4/22/20: 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each Uncoated tablets contains:-
Glimepiride IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:-
Glimepiride IP 4 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:-
Glimepiride IP 1 mg

 | 761 | | Each Film Coated Tablet Contains:- | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 762 Fungal Diastase (1 : 800),
Papain &
Approved colour used in Coating 9,8 4/22/20. 762 Fungal Diastase (1 : 800),
Papain &
Activated Charcoal Tablets Each Uncoated tablets contains:
Fungal Diastase (1 : 800) 1P 100 mg
Activated Charcoal Tablets 4/22/20. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Colour :- Approved colour used 9,8 4/22/20. 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride 1P 3 mg
Activated Charcoal 4/22/20. 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride 1P 4 mg
Activated Tablet IP 4/22/20. 764 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each Uncoated Tablets Contains:-
Glimepiride 1P 4 mg
Activated Charcoal Tablet 4/22/20. 766 Glimepiride & Metformin
Hydrochloride Tablets IP Each Uncoated tablets contains:-
Glimepiride 1P 4 mg
Activated release form) 4/22/20. 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used 1P 1 mg
Activated release form) 4/22/20. 767 Glimepiride & Metformin
Hydrochloride Tablets <td></td> <td></td> <td></td> <td>IP</td> <td></td> <td></td> <td></td>

 | | | | IP | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 44/22/20 Image: Provide and Provide Colour used in Coating 900 spress 44/22/20 762 Fungal Diastase (1 : 800),
Papain &
Activated Charcoal Tablets Each Uncoated tablets contains:
Fungal Diastase (1 : 800) IP 100 ng 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Colour :- Approved colour used IP 3 ng 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4/22/20 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4/22/20 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4/22/20 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each Uncoated Bilaycred tablet contains:-
Glimepiride IP 4 766 Glimepiride & Metformin
Hydrochloride Tablets IP 1 ng 766 Glimepiride & Metformin
Hydrochloride Tablets IP 1 ng 767 Glimepiride & Metformin
Hydrochloride Tablets IP 1 ng 766 Glimepiride & Metformin
Hydrochloride Tablets IP 1 ng 767 Glimepiride & Metformin
Hydrochloride Tablets IP 1 ng 767 Glimepiride & Metformin
Hydrochloride Tabl

 | | Tablets | eq to Erythromycin | | 250 | mg | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Approved colour used in Coating i i 762 Fungal Diastase (1 : 800),
Papain &
Activated Charcoal Tablets Each Uncoated tablets contains:
Fungal Diastase (1 : 800) IP 100 mg 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Colour : Approved colour used IP 3 mg 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Colour : Approved colour used IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4/22/20: 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4 mg 765 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains:
Hydrochloride Tablets 4/22/20: 765 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg 767 Glimepiride & Metformin
Hydrochloride T

 | | | Lactic Acid Bacillus | | 60 | | 4/22/2021 |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Approved colour used in Coating i i 762 Fungal Diastase (1 : 800),
Papain &
Activated Charcoal Tablets Each Uncoated tablets contains:
Fungal Diastase (1 : 800) IP 100 mg 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Colour : Approved colour used IP 3 mg 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Colour : Approved colour used IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4/22/20: 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4 mg 765 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains:
Hydrochloride Tablets 4/22/20: 765 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg 767 Glimepiride & Metformin
Hydrochloride T

 | | | | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 762 Fungal Diastase (1 : 800),
Papain &
Activated Charcoal Tablets Each Uncoated tablets contains:
Fungal Diastase (1 : 800) IP 100 mg
Papain 4/22/20: 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Colour :- Approved colour used IP 3 mg
Papain 4/22/20: 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4 mg
Papain 4/22/20: 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:-
Glimepiride IP 4 mg
Papain 4/22/20: 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each Uncoated tablets contains:-
Glimepiride IP 4 mg
Activation I Hydrochloride 4/22/20: 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:-
Glimepiride IP 4 mg
Activation Papea 4/22/20: 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:-
Glimepiride IP 1 mg
Activation Papea 4/22/20: 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:-
Glimepiride IP 2 mg
Activation Papea 4/22/20: 767 <t< td=""><td></td><td></td><td>Excipients</td><td></td><td>q.s</td><td></td><td></td></t<>

 | | | Excipients | | q.s | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Papain &
Activated Charcoal TabletsFungal Diastase (1 : 800)IP100mg
mg
Activated CharcoalIP100mg
mg
Mativated Charcoal4/22/201763Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP3mg
4/22/201764Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP4mg
4/22/201764Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP4mg
4/22/201765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach Uncoated tablets contains:
GlimepirideIP4mg
4/22/201766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
4/22/201767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
4/22/201767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
4/22/201 <tr <td="">4/22/201<td></td><td></td><td>Approved colour used in Coating</td><td></td><td></td><td></td><td></td></tr> <tr><td>Papain &
Activated Charcoal TabletsFungal Diastase (1 : 800)IP100mg
mg
Activated CharcoalIP100mg
mg
Mativated Charcoal4/22/201763Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP3mg
4/22/201764Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP4mg
4/22/201764Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP4mg
4/22/201765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach Uncoated tablets contains:
GlimepirideIP4mg
4/22/201766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
4/22/201767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
4/22/201767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
4/22/201<tr <td="">4/22/201<td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Activated Charcoal Tablets Papain IP 60 mg Activated Charcoal IP 75 mg 4/22/20. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 766 Glimepiride and Metformin Each Uncoated Bilayered tablet contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin</td><td>762</td><td></td><td></td><td></td><td>-</td><td></td><td></td></tr><tr><td>Activated Charcoal IP 75 ng
Excipients 4/22/20: 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- -</td><td></td><td>1</td><td>Fungal Diastase (1:800)</td><td>IP</td><td>100</td><td>mg</td><td></td></tr><tr><td>Activated Charcoal IP 75 mg
q. s. Excipients q. s. q. s. Colour :- Approved colour used q. s. q. s. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- </td><td></td><td>Activated Charcoal Tablets</td><td>1</td><td></td><td></td><td>mg</td><td>4/22/2021</td></tr><tr><td>Color :- Approved colour used 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 4/22/20: 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg</td><td></td><td></td><td></td><td>IP</td><td>75</td><td>mg</td><td>172272021</td></tr><tr><td>763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4/22/20: 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 1 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride</td><td></td><td></td><td>1</td><td></td><td>q. s.</td><td></td><td></td></tr><tr><td>Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: -</td><td></td><td></td><td>Colour :- Approved colour used</td><td></td><td></td><td></td><td></td></tr><tr><td>Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated
tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: -</td><td>763</td><td>Glimeniride Tablet IP</td><td>Fach Uncoated Tablets Contains:</td><td></td><td>1</td><td></td><td></td></tr><tr><td>Final State Image: State</td><td>105</td><td></td><td></td><td>IP</td><td>3</td><td>mσ</td><td></td></tr><tr><td>Approved colour used in Tablet Image: Color of the second sec</td><td></td><td></td><td>·</td><td></td><td>-</td><td>mg</td><td>4/22/2021</td></tr><tr><td>764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Image: Contains:- <</td><td></td><td></td><td>1</td><td></td><td>4.5</td><td></td><td></td></tr><tr><td>GlimepirideIP4mgApproved colour used in TabletIP44/22/203765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIPmg4/22/203766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg7</td><td>764</td><td>Glimepiride Tablet IP</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Excipientsq.s4/22/20.765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
(As Prolonged Release form)IP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiri</td><td></td><td>· · ·</td><td></td><td>IP</td><td>4</td><td>mg</td><td></td></tr><tr><td>Approved colour used in TabletImage: Colour used in Tablet<!--</td--><td></td><td></td><td>·</td><td></td><td>q.s</td><td>U</td><td>4/22/2021</td></td></tr><tr><td>Hydrochloride (Prolonged
Release) Tablets IPGlimepiride
Metformin Hydrochloride
(As Prolonged Release form)IP4mg
mg
5004/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
4/22/2024/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202768Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Release) Tablets IPMetformin Hydrochloride
(As Prolonged Release form)IPng4/22/201766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP34/22/201767Glimepiride & Metformin
HydrochlorideIP850mg4/22/201767Glimepiride & Metformin
HydrochlorideIP850mg4/22</br></br></br></br></br></br></td><td>765</td><td>Glimepiride and Metformin</td><td>Each uncoated Bilayered tablet contains</td><td>s:</td><td></td><td></td><td></td></tr><tr><td>766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
q.s. 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride IP 4/22/202</td><td></td><td>Hydrochloride (Prolonged</td><td>Glimepiride</td><td>IP</td><td>4</td><td>mg</td><td></td></tr><tr><td>Excipients Image: Contract of the section of the s</td><td></td><td>Release) Tablets IP</td><td>Metformin Hydrochloride</td><td>IP</td><td></td><td>mg</td><td>4/22/2021</td></tr><tr><td>766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 2 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Excipients Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202</td><td></td><td></td><td>(As Prolonged Release form)</td><td></td><td>500</td><td></td><td></td></tr><tr><td>Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 850 mg Excipients q. s. IP 1 mg Colour :- Approved colour used IP 850 mg 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Excipients q. s. 1 1</td><td></td><td></td><td>Excipients</td><td></td><td></td><td>q.s.</td><td></td></tr><tr><td>Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 4/22/202 Excipients q. s. IP Colour :- Approved colour used IP 2 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Metformin Hydrochloride IP 850
 mg Metformin Hydrochloride IP 850 mg Keripients q. s. 4/22/202</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Metformin Hydrochloride IP 850 mg 4/22/202 (in sustained release form) </td><td>766</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(in sustained release form) 4/22/20. Excipients q. s. Colour :- Approved colour used 767 Glimepiride & Metformin Hydrochloride Tablets Each Uncoated tablets contains: Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form) </td><td></td><td>Hydrochloride Tablets</td><td></td><td>_</td><td>1</td><td>mg</td><td></td></tr><tr><td>767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride
(in sustained release form) IP 850 mg 4/22/202 Ketropients IP 850 mg 1/22/202 1/22/202</td><td></td><td></td><td></td><td>IP</td><td>850</td><td>mg</td><td>4/22/2021</td></tr><tr><td>Colour :- Approved colour used 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 (in sustained release form)
Excipients q. s. 9 9 4/22/202</td><td></td><td></td><td></td><td></td><td> </td><td></td><td></td></tr><tr><td>767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form) Excipients q. s. 4/22/202</td><td></td><td></td><td></td><td></td><td>q. s.</td><td></td><td></td></tr><tr><td>Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form)</td><td></td><td></td><td>Colour :- Approved colour used</td><td></td><td></td><td></td><td></td></tr><tr><td>Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form)</td><td>767</td><td>Climonirida & Mattannin</td><td>Each Uncosted tablets contains:</td><td></td><td></td><td></td><td></td></tr><tr><td>Metformin HydrochlorideIP850mg(in sustained release form)4/22/202Excipientsq. s.</td><td>/0/</td><td>-</td><td></td><td>ID</td><td>2</td><td>ma</td><td></td></tr><tr><td>(in sustained release form)4/22/20.Excipientsq. s.</td><td></td><td>riyurochioriue radiets</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Excipients q. s.</td><td></td><td></td><td></td><td>ш</td><td>0.50</td><td>mg</td><td>4/22/2021</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>0. S</td><td></td><td></td></tr><tr><td>Colour :- Approved colour used</td><td></td><td></td><td>Colour :- Approved colour used</td><td>8</td><td>4.5.</td><td></td><td></td></tr></td></tr> | | | Approved colour used in Coating | | | | | Papain &
Activated Charcoal TabletsFungal Diastase (1 : 800)IP100mg
mg
Activated CharcoalIP100mg
mg
Mativated Charcoal4/22/201763Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP3mg
4/22/201764Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP4mg
4/22/201764Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP4mg
4/22/201765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach Uncoated tablets contains:
GlimepirideIP4mg
4/22/201766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
4/22/201767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
4/22/201767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
4/22/201 <tr <td="">4/22/201<td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>Activated Charcoal Tablets Papain IP 60 mg Activated Charcoal IP 75 mg 4/22/20. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 766 Glimepiride and Metformin Each Uncoated Bilayered tablet contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin</td><td>762</td><td></td><td></td><td></td><td>-</td><td></td><td></td></tr> <tr><td>Activated Charcoal IP 75 ng
Excipients 4/22/20: 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- -</td><td></td><td>1</td><td>Fungal Diastase (1:800)</td><td>IP</td><td>100</td><td>mg</td><td></td></tr> <tr><td>Activated Charcoal IP 75 mg
q. s. Excipients q. s. q. s. Colour :- Approved colour used q. s. q. s. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- </td><td></td><td>Activated Charcoal Tablets</td><td>1</td><td></td><td></td><td>mg</td><td>4/22/2021</td></tr> <tr><td>Color :- Approved colour used 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 4/22/20: 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg</td><td></td><td></td><td></td><td>IP</td><td>75</td><td>mg</td><td>172272021</td></tr> <tr><td>763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4/22/20: 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 1 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets
contains:
Glimepiride</td><td></td><td></td><td>1</td><td></td><td>q. s.</td><td></td><td></td></tr> <tr><td>Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: -</td><td></td><td></td><td>Colour :- Approved colour used</td><td></td><td></td><td></td><td></td></tr> <tr><td>Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: -</td><td>763</td><td>Glimeniride Tablet IP</td><td>Fach Uncoated Tablets Contains:</td><td></td><td>1</td><td></td><td></td></tr> <tr><td>Final State Image: State</td><td>105</td><td></td><td></td><td>IP</td><td>3</td><td>mσ</td><td></td></tr> <tr><td>Approved colour used in Tablet Image: Color of the second sec</td><td></td><td></td><td>·</td><td></td><td>-</td><td>mg</td><td>4/22/2021</td></tr> <tr><td>764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Image: Contains:- <</td><td></td><td></td><td>1</td><td></td><td>4.5</td><td></td><td></td></tr> <tr><td>GlimepirideIP4mgApproved colour used in TabletIP44/22/203765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIPmg4/22/203766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg7</td><td>764</td><td>Glimepiride Tablet IP</td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>Excipientsq.s4/22/20.765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
(As Prolonged Release form)IP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiri</td><td></td><td>· · ·</td><td></td><td>IP</td><td>4</td><td>mg</td><td></td></tr> <tr><td>Approved colour used in TabletImage: Colour used in Tablet<!--</td--><td></td><td></td><td>·</td><td></td><td>q.s</td><td>U</td><td>4/22/2021</td></td></tr> <tr><td>Hydrochloride (Prolonged
Release) Tablets IPGlimepiride
Metformin Hydrochloride
(As Prolonged Release form)IP4mg
mg
5004/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
4/22/2024/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202768Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>Release) Tablets IPMetformin Hydrochloride
(As Prolonged Release form)IPng4/22/201766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP34/22/201767Glimepiride & Metformin
HydrochlorideIP850mg4/22/201767Glimepiride & Metformin
HydrochlorideIP850mg4/22</br></br></br></br></br></br></td><td>765</td><td>Glimepiride and Metformin</td><td>Each uncoated Bilayered tablet contains</td><td>s:</td><td></td><td></td><td></td></tr> <tr><td>766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
q.s. 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride IP 4/22/202</td><td></td><td>Hydrochloride (Prolonged</td><td>Glimepiride</td><td>IP</td><td>4</td><td>mg</td><td></td></tr> <tr><td>Excipients Image: Contract of the section of the s</td><td></td><td>Release) Tablets IP</td><td>Metformin Hydrochloride</td><td>IP</td><td></td><td>mg</td><td>4/22/2021</td></tr> <tr><td>766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 2 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets
Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Excipients Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202</td><td></td><td></td><td>(As Prolonged Release form)</td><td></td><td>500</td><td></td><td></td></tr> <tr><td>Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 850 mg Excipients q. s. IP 1 mg Colour :- Approved colour used IP 850 mg 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Excipients q. s. 1 1</td><td></td><td></td><td>Excipients</td><td></td><td></td><td>q.s.</td><td></td></tr> <tr><td>Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 4/22/202 Excipients q. s. IP Colour :- Approved colour used IP 2 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Metformin Hydrochloride IP 850 mg Metformin Hydrochloride IP 850 mg Keripients q. s. 4/22/202</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>Metformin Hydrochloride IP 850 mg 4/22/202 (in sustained release form) </td><td>766</td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>(in sustained release form) 4/22/20. Excipients q. s. Colour :- Approved colour used 767 Glimepiride & Metformin Hydrochloride Tablets Each Uncoated tablets contains: Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form) </td><td></td><td>Hydrochloride Tablets</td><td></td><td>_</td><td>1</td><td>mg</td><td></td></tr> <tr><td>767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride
(in sustained release form) IP 850 mg 4/22/202 Ketropients IP 850 mg 1/22/202 1/22/202</td><td></td><td></td><td></td><td>IP</td><td>850</td><td>mg</td><td>4/22/2021</td></tr> <tr><td>Colour :- Approved colour used 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 (in sustained release form)
Excipients q. s. 9 9 4/22/202</td><td></td><td></td><td></td><td></td><td> </td><td></td><td></td></tr> <tr><td>767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form) Excipients q. s. 4/22/202</td><td></td><td></td><td></td><td></td><td>q. s.</td><td></td><td></td></tr> <tr><td>Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form)</td><td></td><td></td><td>Colour :- Approved colour used</td><td></td><td></td><td></td><td></td></tr> <tr><td>Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form)</td><td>767</td><td>Climonirida & Mattannin</td><td>Each Uncosted tablets contains:</td><td></td><td></td><td></td><td></td></tr> <tr><td>Metformin HydrochlorideIP850mg(in sustained release form)4/22/202Excipientsq. s.</td><td>/0/</td><td>-</td><td></td><td>ID</td><td>2</td><td>ma</td><td></td></tr> <tr><td>(in sustained release form)4/22/20.Excipientsq. s.</td><td></td><td>riyurochioriue radiets</td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>Excipients q. s.</td><td></td><td></td><td></td><td>ш</td><td>0.50</td><td>mg</td><td>4/22/2021</td></tr> <tr><td></td><td></td><td></td><td></td><td></td><td>0. S</td><td></td><td></td></tr> <tr><td>Colour :- Approved colour used</td><td></td><td></td><td>Colour :- Approved colour used</td><td>8</td><td>4.5.</td><td></td><td></td></tr> | | | | | | | | Activated Charcoal Tablets Papain IP 60 mg Activated Charcoal IP 75 mg 4/22/20. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 766 Glimepiride and Metformin Each Uncoated Bilayered tablet contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin | 762 | | | | - | | | Activated Charcoal IP 75 ng
Excipients 4/22/20: 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - | | 1 | Fungal Diastase (1:800) | IP | 100 | mg | | Activated Charcoal IP 75 mg
q. s. Excipients q. s. q. s. Colour :- Approved colour used q. s. q. s. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- | | Activated Charcoal Tablets | 1 | | | mg | 4/22/2021 | Color :- Approved colour used 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1
 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 4/22/20: 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg | | | | IP | 75 | mg | 172272021 | 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4/22/20: 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 1 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride | | | 1 | | q. s. | | | Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - | | | Colour :- Approved colour used | | | | | Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - | 763 | Glimeniride Tablet IP | Fach Uncoated Tablets Contains: | | 1 | | | Final State Image: State | 105 | | | IP | 3 | mσ | | Approved colour used in Tablet Image: Color of the second sec | | | · | | - | mg | 4/22/2021 | 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Image: Contains:- < | | | 1 | | 4.5 | | | GlimepirideIP4mgApproved colour used in TabletIP44/22/203765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIPmg4/22/203766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg7 | 764 | Glimepiride Tablet IP | | | | | | Excipientsq.s4/22/20.765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
(As Prolonged Release form)IP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiri | | · · · | | IP | 4 | mg | | Approved colour used in TabletImage: Colour used in Tablet </td <td></td> <td></td> <td>·</td> <td></td> <td>q.s</td> <td>U</td> <td>4/22/2021</td> | | | · | | q.s | U | 4/22/2021 | Hydrochloride (Prolonged
Release) Tablets IPGlimepiride
Metformin Hydrochloride
(As Prolonged Release form)IP4mg
mg
5004/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
4/22/2024/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202768Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202 | | | | | | | | Release) Tablets IPMetformin Hydrochloride
(As Prolonged Release form)IPng4/22/201766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:

 | 765 | Glimepiride and Metformin | Each uncoated Bilayered tablet contains | s: | | | | 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
q.s. 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride IP 4/22/202 | | Hydrochloride (Prolonged | Glimepiride | IP | 4 | mg | | Excipients Image: Contract of the section of the s | | Release) Tablets IP | Metformin Hydrochloride | IP | | mg | 4/22/2021 | 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 2 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Excipients Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 | | | (As Prolonged Release form) | | 500 | | | Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 850 mg Excipients q. s. IP 1 mg Colour :- Approved colour used IP 850 mg 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Excipients q. s. 1 1 | | | Excipients | | | q.s. | | Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 4/22/202 Excipients q. s. IP Colour :- Approved colour used IP 2 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Metformin Hydrochloride IP 850 mg Metformin Hydrochloride IP 850 mg Keripients q. s. 4/22/202 | | | | | | | | Metformin Hydrochloride IP 850 mg 4/22/202 (in sustained release form) | 766 | | | | | | | (in sustained release form) 4/22/20. Excipients q. s. Colour :- Approved colour used 767 Glimepiride & Metformin Hydrochloride Tablets Each Uncoated tablets contains: Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form) | | Hydrochloride Tablets | | _ | 1 | mg | | 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride
(in sustained release form) IP 850 mg 4/22/202 Ketropients IP 850 mg 1/22/202 1/22/202 | | | | IP | 850 | mg | 4/22/2021 | Colour :- Approved colour used 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 (in sustained release form)
Excipients q. s. 9 9 4/22/202 | | | | | | | | 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form) Excipients q. s. 4/22/202 | | | | | q. s. | | | Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form) | | | Colour :- Approved colour used | | | | | Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form) | 767 | Climonirida & Mattannin | Each Uncosted tablets contains: | | | | | Metformin HydrochlorideIP850mg(in sustained release form)4/22/202Excipientsq. s. | /0/ | - | | ID | 2 | ma | | (in sustained release form)4/22/20.Excipientsq. s. | | riyurochioriue radiets | | | | | | Excipients q. s. | | | | ш | 0.50 | mg | 4/22/2021 | | | | | | 0. S | | | Colour :- Approved colour used | | | Colour :- Approved colour used | 8 | 4.5. | | |
|

 | | Approved colour used in Coating | | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Papain &
Activated Charcoal TabletsFungal Diastase (1 : 800)IP100mg
mg
Activated CharcoalIP100mg
mg
Mativated Charcoal4/22/201763Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP3mg
4/22/201764Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP4mg
4/22/201764Glimepiride Tablet IPEach Uncoated Tablets Contains:-
Glimepiride Tablet IPIP4mg
4/22/201765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach Uncoated tablets contains:
GlimepirideIP4mg
4/22/201766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
4/22/201767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
4/22/201767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
4/22/201 <tr <td="">4/22/201<td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>Activated Charcoal Tablets Papain IP 60 mg Activated Charcoal IP 75 mg 4/22/20. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 766 Glimepiride and Metformin Each Uncoated Bilayered tablet contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin</td><td>762</td><td></td><td></td><td></td><td>-</td><td></td><td></td></tr> <tr><td>Activated Charcoal IP 75 ng
Excipients 4/22/20: 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- -</td><td></td><td>1</td><td>Fungal Diastase (1:800)</td><td>IP</td><td>100</td><td>mg</td><td></td></tr> <tr><td>Activated Charcoal IP 75 mg
q. s. Excipients q. s. q. s. Colour :- Approved colour used q. s. q. s. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- </td><td></td><td>Activated Charcoal Tablets</td><td>1</td><td></td><td></td><td>mg</td><td>4/22/2021</td></tr> <tr><td>Color :- Approved colour used 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 4/22/20: 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg</td><td></td><td></td><td></td><td>IP</td><td>75</td><td>mg</td><td>172272021</td></tr> <tr><td>763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4/22/20: 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 1 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride</td><td></td><td></td><td>1</td><td></td><td>q. s.</td><td></td><td></td></tr> <tr><td>Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: -</td><td></td><td></td><td>Colour :- Approved colour used</td><td></td><td></td><td></td><td></td></tr> <tr><td>Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: -</td><td>763</td><td>Glimeniride Tablet IP</td><td>Fach Uncoated Tablets Contains:</td><td></td><td>1</td><td></td><td></td></tr> <tr><td>Final State Image: State</td><td>105</td><td></td><td></td><td>IP</td><td>3</td><td>mσ</td><td></td></tr> <tr><td>Approved colour used in Tablet Image: Color of the second sec</td><td></td><td></td><td>·</td><td></td><td>-</td><td>mg</td><td>4/22/2021</td></tr> <tr><td>764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Image: Contains:- <</td><td></td><td></td><td>1</td><td></td><td>4.5</td><td></td><td></td></tr> <tr><td>GlimepirideIP4mgApproved colour used in TabletIP44/22/203765Glimepiride and Metformin
Hydrochloride (Prolonged
Release)
Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIPmg4/22/203766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg7</td><td>764</td><td>Glimepiride Tablet IP</td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>Excipientsq.s4/22/20.765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
(As Prolonged Release form)IP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiri</td><td></td><td>· · ·</td><td></td><td>IP</td><td>4</td><td>mg</td><td></td></tr> <tr><td>Approved colour used in TabletImage: Colour used in Tablet<!--</td--><td></td><td></td><td>·</td><td></td><td>q.s</td><td>U</td><td>4/22/2021</td></td></tr> <tr><td>Hydrochloride (Prolonged
Release) Tablets IPGlimepiride
Metformin Hydrochloride
(As Prolonged Release form)IP4mg
mg
5004/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
4/22/2024/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202768Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>Release) Tablets IPMetformin Hydrochloride
(As Prolonged Release form)IPng4/22/201766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP34/22/201767Glimepiride & Metformin
HydrochlorideIP850mg4/22/201767Glimepiride & Metformin
HydrochlorideIP850mg4/22</br></br></br></br></br></br></td><td>765</td><td>Glimepiride and Metformin</td><td>Each uncoated Bilayered tablet contains</td><td>s:</td><td></td><td></td><td></td></tr> <tr><td>766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
q.s. 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride IP 4/22/202</td><td></td><td>Hydrochloride (Prolonged</td><td>Glimepiride</td><td>IP</td><td>4</td><td>mg</td><td></td></tr> <tr><td>Excipients Image: Contract of the section of the s</td><td></td><td>Release) Tablets IP</td><td>Metformin Hydrochloride</td><td>IP</td><td></td><td>mg</td><td>4/22/2021</td></tr> <tr><td>766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 2 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Excipients Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202</td><td></td><td></td><td>(As Prolonged Release form)</td><td></td><td>500</td><td></td><td></td></tr> <tr><td>Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 850 mg Excipients q. s. IP 1 mg Colour :- Approved colour used IP 850 mg 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Excipients q. s. 1 1</td><td></td><td></td><td>Excipients</td><td></td><td></td><td>q.s.</td><td></td></tr> <tr><td>Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 4/22/202 Excipients q. s. IP Colour :- Approved colour used IP 2 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Metformin Hydrochloride IP 850 mg Metformin Hydrochloride IP 850 mg Keripients q. s. 4/22/202</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>Metformin Hydrochloride IP 850 mg 4/22/202 (in sustained release form) </td><td>766</td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>(in sustained release form) 4/22/20. Excipients q. s. Colour :- Approved colour used 767 Glimepiride & Metformin Hydrochloride Tablets Each Uncoated tablets contains: Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form) </td><td></td><td>Hydrochloride Tablets</td><td></td><td>_</td><td>1</td><td>mg</td><td></td></tr> <tr><td>767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride
(in sustained
release form) IP 850 mg 4/22/202 Ketropients IP 850 mg 1/22/202 1/22/202</td><td></td><td></td><td></td><td>IP</td><td>850</td><td>mg</td><td>4/22/2021</td></tr> <tr><td>Colour :- Approved colour used 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 (in sustained release form)
Excipients q. s. 9 9 4/22/202</td><td></td><td></td><td></td><td></td><td> </td><td></td><td></td></tr> <tr><td>767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form) Excipients q. s. 4/22/202</td><td></td><td></td><td></td><td></td><td>q. s.</td><td></td><td></td></tr> <tr><td>Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form)</td><td></td><td></td><td>Colour :- Approved colour used</td><td></td><td></td><td></td><td></td></tr> <tr><td>Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form)</td><td>767</td><td>Climonirida & Mattannin</td><td>Each Uncosted tablets contains:</td><td></td><td></td><td></td><td></td></tr> <tr><td>Metformin HydrochlorideIP850mg(in sustained release form)4/22/202Excipientsq. s.</td><td>/0/</td><td>-</td><td></td><td>ID</td><td>2</td><td>ma</td><td></td></tr> <tr><td>(in sustained release form)4/22/20.Excipientsq. s.</td><td></td><td>riyurochioriue radiets</td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>Excipients q. s.</td><td></td><td></td><td></td><td>ш</td><td>0.50</td><td>mg</td><td>4/22/2021</td></tr> <tr><td></td><td></td><td></td><td></td><td></td><td>0. S</td><td></td><td></td></tr> <tr><td>Colour :- Approved colour used</td><td></td><td></td><td>Colour :- Approved colour used</td><td>8</td><td>4.5.</td><td></td><td></td></tr> | | | | | | | | Activated Charcoal Tablets Papain IP 60 mg Activated Charcoal IP 75 mg 4/22/20. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 766 Glimepiride and Metformin Each Uncoated Bilayered tablet contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin

 | 762 | | | | - | | | Activated Charcoal IP 75 ng
Excipients 4/22/20: 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- | | 1 | Fungal Diastase (1:800) | IP | 100 | mg | | Activated Charcoal IP 75 mg
q. s. Excipients q. s. q. s. Colour :- Approved colour used q. s. q. s. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- | | Activated Charcoal Tablets | 1 | | | mg | 4/22/2021 | Color :- Approved colour used 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 4/22/20: 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg | | | | IP | 75 | mg | 172272021 | 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4/22/20: 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 1 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride
 IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride | | | 1 | | q. s. | | | Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - | | | Colour :- Approved colour used | | | | | Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - | 763 | Glimeniride Tablet IP | Fach Uncoated Tablets Contains: | | 1 | | | Final State Image: State | 105 | | | IP | 3 | mσ | | Approved colour used in Tablet Image: Color of the second sec | | | · | | - | mg | 4/22/2021 | 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Image: Contains:- < | | | 1 | | 4.5 | | | GlimepirideIP4mgApproved colour used in TabletIP44/22/203765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIPmg4/22/203766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg7 | 764 | Glimepiride Tablet IP | | | | | | Excipientsq.s4/22/20.765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
(As Prolonged Release form)IP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiri | | · · · | | IP | 4 | mg | | Approved colour used in TabletImage: Colour used in Tablet </td <td></td> <td></td> <td>·</td> <td></td> <td>q.s</td> <td>U</td> <td>4/22/2021</td> | | | · | | q.s | U | 4/22/2021 | Hydrochloride (Prolonged
Release) Tablets IPGlimepiride
Metformin Hydrochloride
(As Prolonged Release form)IP4mg
mg
5004/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
4/22/2024/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202768Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202 | | | | | | | | Release) Tablets IPMetformin Hydrochloride
(As Prolonged Release form)IPng4/22/201766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
 | 765 | Glimepiride and Metformin | Each uncoated Bilayered tablet contains | s: | | | | 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
q.s. 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767
Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride IP 4/22/202 | | Hydrochloride (Prolonged | Glimepiride | IP | 4 | mg | | Excipients Image: Contract of the section of the s | | Release) Tablets IP | Metformin Hydrochloride | IP | | mg | 4/22/2021 | 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 2 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Excipients Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 | | | (As Prolonged Release form) | | 500 | | | Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 850 mg Excipients q. s. IP 1 mg Colour :- Approved colour used IP 850 mg 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Excipients q. s. 1 1 | | | Excipients | | | q.s. | | Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 4/22/202 Excipients q. s. IP Colour :- Approved colour used IP 2 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Metformin Hydrochloride IP 850 mg Metformin Hydrochloride IP 850 mg Keripients q. s. 4/22/202 | | | | | | | | Metformin Hydrochloride IP 850 mg 4/22/202 (in sustained release form) | 766 | | | | | | | (in sustained release form) 4/22/20. Excipients q. s. Colour :- Approved colour used 767 Glimepiride & Metformin Hydrochloride Tablets Each Uncoated tablets contains: Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form) | | Hydrochloride Tablets | | _ | 1 | mg | | 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride
(in sustained release form) IP 850 mg 4/22/202 Ketropients IP 850 mg 1/22/202 1/22/202 | | | | IP | 850 | mg | 4/22/2021 | Colour :- Approved colour used 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 (in sustained release form)
Excipients q. s. 9 9 4/22/202 | | | | | | | | 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form) Excipients q. s. 4/22/202 | | | | | q. s. | | | Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form) | | | Colour :- Approved colour used | | | | | Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form) | 767 | Climonirida & Mattannin | Each Uncosted tablets contains: | | | | | Metformin HydrochlorideIP850mg(in sustained release form)4/22/202Excipientsq. s. | /0/ | - | | ID | 2 | ma | | (in sustained release form)4/22/20.Excipientsq. s. | | riyurochioriue radiets | | | | | | Excipients q. s. | | | | ш | 0.50 | mg | 4/22/2021 | | | | | | 0. S | | | Colour :- Approved colour used | | | Colour :- Approved colour used | 8 | 4.5. | | | | | | | | | | |
|

 | | | | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Activated Charcoal Tablets Papain IP 60 mg Activated Charcoal IP 75 mg 4/22/20. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 765 Glimepiride and Metformin Each Uncoated Tablets Contains:- Imp 4/22/20. 766 Glimepiride and Metformin Each Uncoated Bilayered tablet contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 766 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin Each Uncoated tablets contains: Imp 4/22/20. 767 Glimepiride & Metformin

 | 762 | | | | - | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Activated Charcoal IP 75 ng
Excipients 4/22/20: 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:-

 | | 1 | Fungal Diastase (1:800) | IP | 100 | mg | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Activated Charcoal IP 75 mg
q. s. Excipients q. s. q. s. Colour :- Approved colour used q. s. q. s. 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:-

 | | Activated Charcoal Tablets | 1 | | | mg | 4/22/2021 |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Color :- Approved colour used 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 1 4/22/20: 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg

 | | | | IP | 75 | mg | 172272021 |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 763 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 3 mg 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4/22/20: 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- IP 4 mg 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 4 mg 766 Glimepiride & Metformin
Hydrochloride Tablets IP 1 mg 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 1 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride

 | | | 1 | | q. s. | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: -

 | | | Colour :- Approved colour used | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Glimepiride IP 3 mg Approved colour used in Tablet q.s 4/22/201 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - Glimepiride Tablet IP Each Uncoated Tablets Contains:- - - - 765 Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IP Each uncoated Bilayered tablet contains: - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: - - - - 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: -

 | 763 | Glimeniride Tablet IP | Fach Uncoated Tablets Contains: | | 1 | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Final State Image: State

 | 105 | | | IP | 3 | mσ | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Approved colour used in Tablet Image: Color of the second sec

 | | | · | | - | mg | 4/22/2021 |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 764 Glimepiride Tablet IP Each Uncoated Tablets Contains:- Image: Contains:- <

 | | | 1 | | 4.5 | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| GlimepirideIP4mgApproved colour used in TabletIP44/22/203765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIPmg4/22/203766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg7

 | 764 | Glimepiride Tablet IP | | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Excipientsq.s4/22/20.765Glimepiride and Metformin
Hydrochloride (Prolonged
Release) Tablets IPEach uncoated Bilayered tablet contains:
GlimepirideIP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
(As Prolonged Release form)IP4mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s.4/22/20.767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg767Glimepiri

 | | · · · | | IP | 4 | mg | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Approved colour used in TabletImage: Colour used in Tablet </td <td></td> <td></td> <td>·</td> <td></td> <td>q.s</td> <td>U</td> <td>4/22/2021</td>

 | | | · | | q.s | U | 4/22/2021 |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hydrochloride (Prolonged
Release) Tablets IPGlimepiride
Metformin Hydrochloride
(As Prolonged Release form)IP4mg
mg
5004/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
4/22/2024/22/202766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg
mg
(a.s.4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202768Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg
mg
(in sustained release form)4/22/202

 | | | | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Release) Tablets IPMetformin Hydrochloride
(As Prolonged Release form)IPng4/22/201766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg766Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP1mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
Glimepirideq. s767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:
GlimepirideIP2mg767Glimepiride & Metformin
Hydrochloride TabletsEach Uncoated tablets contains:

 | 765 | Glimepiride and Metformin | Each uncoated Bilayered tablet contains | s: | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
q.s. 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride IP 4/22/202

 | | Hydrochloride (Prolonged | Glimepiride | IP | 4 | mg | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Excipients Image: Contract of the section of the s

 | | Release) Tablets IP | Metformin Hydrochloride | IP | | mg | 4/22/2021 |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 766 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 1 mg
Metformin Hydrochloride IP 850 mg
(in sustained release form) 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Colour :- Approved colour used IP 2 mg
(in sustained release form) 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Excipients Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202

 | | | (As Prolonged Release form) | | 500 | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 850 mg Excipients q. s. IP 1 mg Colour :- Approved colour used IP 850 mg 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Excipients q. s. 1 1

 | | | Excipients | | | q.s. | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 850 mg (in sustained release form) IP 4/22/202 Excipients q. s. IP Colour :- Approved colour used IP 2 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg 4/22/202 Metformin Hydrochloride IP 850 mg Metformin Hydrochloride IP 850 mg Metformin Hydrochloride IP 850 mg Keripients q. s. 4/22/202

 | | | | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Metformin Hydrochloride IP 850 mg 4/22/202 (in sustained release form)

 | 766 | | | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (in sustained release form) 4/22/20. Excipients q. s. Colour :- Approved colour used 767 Glimepiride & Metformin Hydrochloride Tablets Each Uncoated tablets contains: Glimepiride IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form)

 | | Hydrochloride Tablets | | _ | 1 | mg | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg Metformin Hydrochloride
(in sustained release form) IP 850 mg 4/22/202 Ketropients IP 850 mg 1/22/202 1/22/202

 | | | | IP | 850 | mg | 4/22/2021 |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Colour :- Approved colour used 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains:
Glimepiride IP 2 mg
Metformin Hydrochloride 4/22/202 (in sustained release form)
Excipients q. s. 9 9 4/22/202

 | | | | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 767 Glimepiride & Metformin
Hydrochloride Tablets Each Uncoated tablets contains: IP 2 mg Metformin Hydrochloride IP 850 mg (in sustained release form) Excipients q. s. 4/22/202

 | | | | | q. s. | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form)

 | | | Colour :- Approved colour used | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hydrochloride TabletsGlimepirideIP2mgMetformin HydrochlorideIP850mg(in sustained release form)

 | 767 | Climonirida & Mattannin | Each Uncosted tablets contains: | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Metformin HydrochlorideIP850mg(in sustained release form)4/22/202Excipientsq. s.

 | /0/ | - | | ID | 2 | ma | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (in sustained release form)4/22/20.Excipientsq. s.

 | | riyurochioriue radiets | | | | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Excipients q. s.

 | | | | ш | 0.50 | mg | 4/22/2021 |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|

 | | | | | 0. S | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Colour :- Approved colour used

 | | | Colour :- Approved colour used | 8 | 4.5. | | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

I

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279 ILY WELFARE DEPARTMENT its Approved to be Manufactured INB/07/642 AND MB/07/643 28:S-MB/07/643 For the	Γ,HIMACI l by : Boffi e period from 01.	n Biotecl	h Pvt.	
	PACK S	IZE AS PER SCHEDULE-P-1 OF DRUGS & COSMI	ETIC ACT 1945			
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Metformin Hydrochloride	Glimepiride	IP	3	mg	
	Tablets	Metformin Hydrochloride	IP	850	mg	4/22/2021
		(in sustained release form)				
		Excipients		q. s.		
		Colour :- Approved colour used				
769	Glimepiride & Metformin	Each Uncoated tablets contains:				
	Hydrochloride Tablets	Glimepiride	IP	1	mg	4/22/2021
		Metformin Hydrochloride	IP	1000	mg	
		(in sustained release form)				
		Excipients		q. s.		
		Colour :- Approved colour used		1		
		11				
770	Glimepiride & Metformin	Each Uncoated tablets contains:				
	Hydrochloride Tablets	Glimepiride	IP	2	mg	
		Metformin Hydrochloride	IP	1000	mg	
		(in sustained release form)				4/22/2021
		Excipients		q. s.		
		Colour :- Approved colour used				
771	Glimepiride & Metformin	Each film coated tablets contains:				
//1	Hydrochloride Tablets	Glimepiride	IP	3	mg	
	rigaroemoniae rubieus	Metformin Hydrochloride	IP	1000	mg	
		(in sustained release form)		1000	mg	4/22/2021
		Excipients		q. s.		
		Colour :- Approved colour used in coa	ating	q. s.		
	1	colour - rippiorou colour abou in col				
772	Glimepiride & Metformin	Each film coated tablets contains:				
	Hydrochloride Tablets	Glimepiride	IP	4	mg	
		Metformin Hydrochloride IP 1000 mg	4/22/2021			
		(in sustained release form)				7/22/2021
		Excipients		q. s.		
		Colour :- Approved colour used in coa	ating			

773	Itraconazole & Terbinafine	Each Filmcoated tablet contains:-				
	Tablets	Itraconazole	BP	200	mg	
		Terbinafine HCl	IP			4/22/2021
		Eq. to Terbinafine		250	mg	4/22/2021
		Excipients		q.s		
		Approved colour used in Coating				
774	Itraconazole & Terbinafine	Each Filmcoated tablet contains:-				
774	Itraconazole & Terbinafine Tablets	Each Filmcoated tablet contains:- Itraconazole	BP	100	mg	
774			BP IP	100	mg	4/22/2021
774		Itraconazole		100 250	mg mg	4/22/2021
774		Itraconazole Terbinafine HCl				4/22/2021

		INB/07/642 AND MB/07/643 28:S-MB/07/643 For the ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET				
. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATEE
75	Ketorolac Tromethamine	Each Uncoated Tablet Contains:				
	Tablets IP	Ketorolac Tromethamine	IP	10	mg	4/22/202
		Excipients		q.s.		-1/22/202
		Colour:Approved colour used				
76	Meberevine HCl &	Each Filmcoated tablet contains:-				
	Chlordiazepoxide Tablets	Meberevine HCl	IP	135	mg	
	-	Chlordiazepoxide	IP	5	mg	4/22/202
		Excipients		q.s	Ū	
		Approved colour used in Coating		-		
77	Methylcobalamin and	Each film coated tablet contains:				
	Gabapentin Tablets	Methylcobalamin	IP	500	mcg	
	1	Gabapentin	IP	100	mg	4/22/202
		Excipients	1	1	qs	
		Colour: Approved colour used			- <u>1</u> -*	
78	Metronidazole, Furazolidone					
-	&	Each Un Coated Tablet Contains :				
	Dicyclomine HCl Tablet	Metronidazole	IP	200	mg	
	5	Furazolidone	IP	50	mg	4/22/202
		Dicyclomine Hcl	IP	10	mg	
		Excipients		q.s	8	
		Colour:Approved colour used		-1.~		
Colour.Approved colour used						
79	Ofloxacin Tablets IP	Each Film Coated Tablet Contains:-				
		Ofloxacin	IP	100	mg	4/22/202
		Excipients		q.s		4/22/202
		Approved colour used in Coating				
780	Pirfenidone Tablets IP	Each Film Coated Tablet Contains:-				
		Pirfenidone	IP	200	mg	
		Excipients		q.s	8	4/22/202
		Approved colour used in Coating		1		
				1		
81	Ofloxacin &	Each Filmcoated tablet Contains:-				
	Cefixime Tablets	Ofloxacin	IP	400	mg	
		Cefixime Trihydrate	IP			4/22/202
		eq. to anhydrous Cefixime		400	mg	
		Excipients		q.s		
		Approved colour used in Coating				
82	Paracetamol &	Each Uncoated tablets contains:				
52	Chlorpheniramine Maleate	Paracetamol	IP	325	mg	
	Tablets	Chlorpheniramine Maleate	IP	2	mg	4/22/202
	1 001000	Excipients			mg	7/22/202
		Colour :- Approved colour used		q. s.		
		• • • •				
/83	Rabeprazole Sodium					
	Tablets IP	Rabeprazole Sodium	IP	10	mg	4/22/202
		Excipients		q.s		4/22/202
		Approved colour used in Coating				

List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

	PACK SIZ	E AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	ACT 1945			
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Tablets IP	Rabeprazole Sodium	IP	40	mg	4/22/2021
		Excipients		q.s		4/22/2021
		Approved colour used in Coating				

Rabeprazole Sodium &	Each Enteric Coated tablets contains:				
Domperidone Tablets	Rabeprazole Sodium	IP	20	mg	
	Domperidone	IP	30	mg	4/22/2021
	Excipients		q. s.		
	Colour :- Approved colour used				
Rabeprazole Sodium &	Each Enteric Coated tablet Contains:-				
Ondansetron Tablets	Rabeprazole Sodium	IP	20	mg	
	Ondansetron HCl	IP			4/22/2021
	eq. to Ondansetron		4	mg	4/22/2021
	Excipients		q.s		
	Approved colour used in Coating				
	Domperidone Tablets Rabeprazole Sodium &	Domperidone Tablets Rabeprazole Sodium Domperidone Excipients Colour :- Approved colour used Rabeprazole Sodium & Each Enteric Coated tablet Contains:- Ondansetron Tablets Rabeprazole Sodium Ondansetron HCl eq. to Ondansetron Excipients Excipients	Domperidone Tablets Rabeprazole Sodium IP Domperidone IP Domperidone IP Excipients IP Colour :- Approved colour used IP Rabeprazole Sodium & Each Enteric Coated tablet Contains:- Ondansetron Tablets Rabeprazole Sodium IP Ondansetron HCl IP eq. to Ondansetron Excipients	Domperidone Tablets Rabeprazole Sodium IP 20 Domperidone IP 30 Excipients q. s. Colour :- Approved colour used Rabeprazole Sodium & Each Enteric Coated tablet Contains:- Ondansetron Tablets Rabeprazole Sodium IP 20 Ondansetron HCl IP eq. to Ondansetron 4 Excipients q.s	Domperidone TabletsRabeprazole SodiumIP20mgDomperidoneIP30mgExcipientsq. s.Colour :- Approved colour usedRabeprazole Sodium & Ondansetron TabletsEach Enteric Coated tablet Contains:- Rabeprazole SodiumIP20mgOndansetron HClIP20mgOndansetron HClIP1010eq. to Ondansetron4mg10Excipients11010

787	Telmisartan, Amlodipine	Each Film Coated tablet contains:				
	Besylate &	Telmisartan	IP	40	mg	
	Chlorthalidone Tablets	Amlodipine Besylate	IP			
		eq. to Amlodipine		5	mg	4/22/2021
		Chlorthalidone	IP	6.25	mg	
		Excipients		q. s.		
		Colour:Approved colour used in coating				

788	Telmisartan, Amlodipine Besylate &	Each Film Coated tablet contains:				
	Chlorthalidone Tablets	Telmisartan	IP	80	mg	
		Amlodipine Besylate	IP			4/22/2021
		eq.to Amlodipine		5	mg	4/22/2021
		Chlorthalidone	IP	6.25	mg	
		Excipients		q. s.		
		Colour :- Approved colour used				

789	Telmisartan,	Each Film coated Tablet contains:-				
	Chlorthalidone &	Telmisartan	IP	80	mg	
	Amlodipine Tablets	Chlorthalidone	IP	12.5	mg	
		Amlodipine Besilate	IP			4/22/2021
		eq. to Amlodipine		5	mg	
		Excipients		q.s		
		Approved colour used in Coating				

790	Teneligliptin & Metformin	Each Uncoated Bilayered tablet contains:-				
	HCl Tablets	Teneligliptin hydrobromide hydrate				
		eq. to Teneligliptin		20	mg	
		Metformin HCl	IP	500	mg	4/22/2021
		(As Extended Release)				
		Excipients		q.s		
		Approved colour used in Tablets				

Each Filmcoated tablet contains:-

791 Teneligliptin Tablets

	0	NB/07/642 AND MB/07/643 28:S-MB/07/643 For the p E AS PER SCHEDULE-P-1 OF DRUGS & COSMET		12.2022 to 30.	11.2027	
5. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVEI ON DATED
		Teneligliptin hydrobromide hydrate				
		eq. to Teneligliptin		20	mg	4/22/2021
		Excipients		q.s		
		Approved colour used in Coating				
792	Teneligliptin & Metformin	Each Uncoated Bilayered tablet contains	5:-			
	HCl Tablets	Teneligliptin hydrobromide hydrate				
		eq. to Teneligliptin		20	mg	
		Metformin HCl	IP	1000	mg	4/22/2021
		(As Extended Release)				
		Excipients		q.s		
		Approved colour used in Tablets		-		
702	a a					
793	Sparfloxacin Tablets	Each Filmcoated tablet contains:-	┥──	200		
		Sparfloxacin	-	200	mg	4/22/2021
		Excipients		q.s		
		Approved colour used in Tablets				
794	Terbutaline Sulphate,	Each Uncoated tablet contains:				
	Bromhexine HCL &	Terbutaline Sulphate	IP	1.25	mg	
	Guaiphenesin Tablets	Bromhexine HCL	IP	8	mg	4/22/2021
	-	Guaiphenesin	IP	100	mg	4/22/2021
		Excipients		q. s.		
		Colour :- Approved colour used				
795	Terbutaline Sulphate,	Each Uncoated tablet contains:				
175	Bromhexine HCL &	Terbutaline Sulphate	IP	2.5	mg	
	Guaiphenesin Tablets	Bromhexine HCL	IP	8	mg	
		Guaiphenesin	IP	100	mg	4/22/2021
		Excipients		q. s.	8	
		Colour :- Approved colour used		.1.		
796	T	Each Film Coated tablets contains:				
	Tranexamic Acid & Ethamsylate	Each Film Coated tablets contains:				
	Tablets	Tranexamic Acid	IP	250	mg	1/22/2021
		Etamsylate	IP	250	mg	4/22/2021
		Excipients		q. s.		
		Colour:Approved colour used in coatin	g			
797	Thiamine mononitrate,	Each Film coated Tablet Contains:-	1			
, , , ,	Riboflavin	Thiamine mononitrate	IP	10	mg	
	,Pyridoxine HCl,	Riboflavin	IP	10	mg	
	Cyanocobalamin, Niacinamide,		IP	3	mg	
	Calcium Pantothenate,	Cyanocobalamin Triturate in Geletin			8	4/00/00001
	Tablets	eq. to Cyanocobalamin	IP	15	mcg	4/22/2021
		Niacinamide	IP	45	mg	
		Calcium Pantothenate	IP	50	mg	
		Excipients	1	q.s		
		Approved colour used in Coating	1			

	List of Retention Produc having license No. FORM25:M	NO.HFW-H(DRUGS)279/ ILY WELFARE DEPARTMENT its Approved to be Manufactured MB/07/642 AND MB/07/643 28:S-MB/07/643 For the IZE AS PER SCHEDULE-P-1 OF DRUGS & COSME	,HIMACI by : Boffi period from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
		Etamsylate	IP	250		4/22/2021
		Excipients			q.s.	4/22/2021
		Colour: Approved colour used in			,	
		Coating				
799	Ascorbic Acid,	Each Uncoated Chewable Tablets cont	ains			
())	Sodium Ascorbic	Ascorbic Acid	IP	100	mg	
	& Zinc Citrate	Sodium Ascorbic	IP	450	mg	
	Chewable Tablets	Eq. to Ascorbic Acid		400	mg	
	Chewable Tablets	Zinc Citrate	IP	400	mg	4/22/2021
		Eq. to Elemental Zinc		5	mg	
		Excipients		-	mg	
		Colour:Approved colour used		q.s.		
				1		
800	Rabeprazole Sodium	Each hard geletin capsule contains:-				
	& Domperidone	Rabeprazole Sodium	IP	20	mg	
	Capsule	(As enteric coated pellets)				
		Domperidone	IP	10	mg	4/22/2021
		(As pellets)				
		Excipients		qs		
		Approved colour used in empty capsule	e shell			
001				1	. I	
801	Rabeprazole Sodium	Each hard geletin capsule contains:-		10		
	& Domperidone	Rabeprazole Sodium	IP	40	mg	
	Capsule	(As enteric coated pellets)				
		Domperidone	IP	30	mg	4/22/2021
		(As Sustained release pellets)				
		Excipients		qs		
		Approved colour used in empty capsule	e shell			
802	Oxytetracycline Hydochloride					
	5 5 5	Each Uncoated Bolus contains:				
	Bolus	Oxytetracycline Hydochloride	IP	300	mg	4/22/2021
	VETERINARY USE	Excipients		q.s.	Ŭ	
	NOT FOR HUMAN USE	Colour:Approved colour used		-		
	Cefaclor Oral Suspension IP	Each 5ml of reconstituted suspension c	contains:			
803	-					
		Cefaclor Monohydrate	IP			4/22/2021
		Eq. to Cefaclor	_	125	mg	
		In a flavoured suspension base		q.s		
		Approved colour used				
804	Cefaclor Oral Suspension IP	Each 5ml of reconstituted suspension c	contains:			
004		Cefaclor Monohydrate	IP			
		Eq. to Cefaclor		250	mg	4/22/2021
		In a flavoured suspension base		q.s	8	
		-		4.5		
		Approved colour used				

NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd. having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945 DOSAGE FORM, GENERIC APPROVED SPECIFI S. No. COMPOSITION QUANTITY UNIT NAME/BRAND NAME CATION ON DATED Cefixime Trihydrate IP 4/22/2021 Eq. to Anhydrous Cefixime 25 mg In a flavoured suspension base q.s Approved colour used 806 Cefixime & Each 5ml of reconstituted suspension contains: Lactic Acid Bacillus Cefixime Trihydrate IP Oral Suspension 50 Eq. to Anhydrous Cefixime mg Millio Lactic Acid Bacillus 4/22/2021 Spore 20 In a flavoured suspension base q.s Colour:Approved colour used 807 Cefixime & Each 5ml of reconstituted suspension contains: Lactic Acid Bacillus Cefixime Trihydrate IP Oral Suspension Eq. to Anhydrous Cefixime 100 mg Million Lactic Acid Bacillus 4/22/2021 Spore 20 In a flavoured suspension base q.s Colour:Approved colour used Prednisolone Oral Liquid Each 5ml contains: 808 USP Prednisolone Sodium Phosphate IP 4/22/2021 eq. to Prednisolone 5 mg Flavoured syrupy Base q.s Approved colour used 809 Prednisolone Oral Liquid Each 5ml contains: Prednisolone Sodium Phosphate IP eq. to Prednisolone 4/22/2021 15 mg Flavoured syrupy Base a.s Approved colour used 810 Paracetamol Oral Suspension Each 5ml contains: IP IP 500 Paracetamol mg 4/22/2021 Flavoured syrupy Base q.s Approved colour used Clotrimazole, Menthol, Boric Clotrimazole IP 0.5% 811 w/w Acid, Ichthammol & zinc Menthol IP 1.0% W/WOxide Cream Boric Acid IP 1.0% w/w USP Ichthammol 0.2% w/w 4/22/2021 zinc oxide IP 5% w/w As Preservative:-Phenoxyethanol IP 0.2% w/w Benzyl Alcohol IP 1.0% w/w In cream Base q.s

 812
 Diltiazem Gel 2 % W/W
 Diltiazem HCl
 IP
 2.00%
 w/w
 4/22/2021

	having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027 PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945						
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPRO ON DA	
		In Gel Base		q.s		4/22/2	
	1		1	1			
813	Glycerin & Olive Oil Lotion	Glycerine	IP	15.00%	w/v		
		Olive Oil	BP	0.50%	w/v	4/22/2	
		Lotion Base		q.s			
014			m	11.050/	,		
814	Glycerin,	Glycerine	IP	11.25%	w/w		
	Methyl Paraben & Propyl Paraben Gel	Preservative: Methyl Paraben	IP	0.10%	***/***	4/22/	
	Propyi Paraben Gei	Propyl Paraben	IP	0.10%		W/W	
		Gel Base	п		w/w		
		Ger Base		q.s			
815	ISOPROPYL ALCOHOL	Composition:					
	70% HAND SANITIZER	Isopropyl Alcohol	IP	70%	v/v	4/22/2021	
		Excipients		q.s.			
		Perfumed Solution Base		q.s.			
				4			
816	ISOPROPYL ALCOHOL	Composition:					
	70%HAND SANITIZER	Isopropyl Alcohol	IP	70%	v/v	4/22/202	
		Excipients		q.s.		4/22/	
		Perfumed Gel Base		q.s.			
817	Itraconazole & Terbinafine	Composition :-					
	Cream	Itraconazole	BP	1%	W/W	4/00/	
		Terbinafine HCl	IP			4/22/	
		Eq. to Terbinafine		1%	W/W		
		Cream Base		q.s			
818	Amoxycillin Tryhydrate &	Each hard geletin capsule contains:-					
	Lactic Acid bacillus Capsules	Amoxycillin Tryhydrate	IP				
	.	Eq.to Amoxycillin	1	250	mg	4/00/	
		Lactic Acid Bacillus		60	M.S	4/22/	
		Excipients		qs			
		Approved colour used in empty capsule	shell				
819	Amoxycillin Tryhydrate &	Each hard geletin capsule contains:-					
	Lactic Acid bacillus Capsules	Amoxycillin Tryhydrate	IP				
		Eq.to Amoxycillin		500	mg	mg 4/22/20	
		Lactic Acid Bacillus		60	M.S	4/ <i>22</i> /	
		Excipients		qs			
		Approved colour used in empty capsule	shell				
820	Loratadine 5mg &	Each Film Coated Tablets contains:-				mg	
	Ambroxol 60 mg Tablets	Loratadine	USP	5	mg		
	Ambroxol HCl IP	60	mg	9/22/			
		Excipients		q.s			
		Approved Colours Used Coating	1				

	nuting needse root i oftenine hor		iou iroim oin			
	PACK SIZ	E AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	ACT 1945			
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
821	Cholecalciferol	Each Uncoated Chewable Tablets contains:-				
	Chewable tablets 60000 IU	Cholecalciferol	IP	60,000	IU	9/22/2021
		Excipients		q.s		<i>9122</i> /2021
		Approved Colours Used				

822	L-Methylfolate Calcium	Each Film Coated Tablets contains:-				
	5.6mg, Mecobalamin 2mg,	L-Methylfolate Calcium		5.6	mg	
	Acetylcysteine 600mg tablets	Mecobalamin	IP	2	mg	0 /00 /0001
		Acetylcysteine	BP	600	mg	9/22/2021
		Excipients		q.s.	0	
		Approved Colours Used in coting		1		
823	Diclofenac 50 mg &	Each hard gelatin capsule Contains:-				
	Thiocolchicoside 4 mg	Diclofenac Sodium	IP	50	mg	
	Capsules	Thiocolchicoside	IP	4	mg	9/22/2021
	Ĩ	Excipients		q.s	0	
		Approved colour used in Empty casules	shell	1		
824	Diclofenac 50 mg (E.C.)&	Each hard gelatin capsule Contains:-				
	Thiocolchicoside 8 mg	Diclofenac Sodium	IP	50	mg	
	Capsules	(As Enteric Coated)			8	
	- of other	Thiocolchicoside	IP	8	mg	9/22/2021
		Excipients		q.s		
		Approved colour used in Empty casules	shell	4.5		
825	Diclofenac 100 mg (SR) &	Each hard gelatin capsule Contains:-				
020	Thiocolchicoside 16 mg (SR)	Diclofenac Sodium	IP	100	mg	
	Capsules	(as sustained Release)		100	mg	
	Cupsulos	Thiocolchicoside	IP	16	mg	9/22/2021
		(as sustained Release)	п	10	mg	<i>JI 22/2021</i>
		Excipients		q.s		
		Approved colour used in Empty casules	shell	q .5		
826			shen			
020	Diclofenac Diethylamine,	Composition				
	Peppermint oil, Eucalyptus Oil,	-	IP	2.00%	w/w	
	Methyl salicylate &	Methyl salicylate	IP	10%	w/w	
	Turpentine Oil OIL	Peppermint oil	IP	10%	w/w	
		Turpentine Oil	BP	10%	w/w	9/22/2021
		Eucalyptus Oil	IP	5%	w/w	
		Benzyl alcohol	IP	1%	w/w	
		(As a Preservative)				
		In Oil base				
	-			q.s		
827	Calcium Citrate 1000mg,	Each Film Coated Tablets contains:-				
	vitamin D3 200mcg,	Calcium Citrate	USP	1000	mg	
	_	Calcium Citrate Vitamin D3	USP IP	1000 200	-	
	Methylcobalamin 500mcg,	Vitamin D3	-	200	mcg	0./20./20.01
	_		IP		-	9/22/2021
	Methylcobalamin 500mcg, pyridoxine HCI 10mg,	Vitamin D3 Methylcobalamin	IP IP	200 500	mcg mcg	9/22/2021
	Methylcobalamin 500mcg, pyridoxine HCI 10mg,	Vitamin D3 Methylcobalamin Pyridoxine HCI Folic Acid	IP IP IP	200 500 10 5	mcg mcg mg	9/22/2021
	Methylcobalamin 500mcg, pyridoxine HCI 10mg,	Vitamin D3 Methylcobalamin Pyridoxine HCI	IP IP IP	200 500 10	mcg mcg mg	9/22/2021
828	Methylcobalamin 500mcg, pyridoxine HCI 10mg, folic acid 5mg tablets	Vitamin D3 Methylcobalamin Pyridoxine HCI Folic Acid Excipients Approved Colours Used in coting	IP IP IP	200 500 10 5	mcg mcg mg	9/22/2021
828	Methylcobalamin 500mcg, pyridoxine HCI 10mg,	Vitamin D3 Methylcobalamin Pyridoxine HCI Folic Acid Excipients	IP IP IP	200 500 10 5	mcg mcg mg	9/22/2021

		NO.HFW-H(DRUGS)279/0				
		LY WELFARE DEPARTMENT,				
		ts Approved to be Manufactured h MB/07/642 AND MB/07/643 28:S-MB/07/643 For the p				Lta.
	PACK SI	ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETI	C ACT 1945			
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Pyridoxine HCl 10 mg,	Methylcobalamin	IP	500	mcg	9/22/2021
	Folic Acid 5mg tablets	Pyridoxine HCl	IP	10	mg	9/22/2021
		Folic Acid	IP	5	mg	
		Excipients		q.s.		
		Approved Colours Used in coting				
000				1		
829	Calcium Citrate 1000 mg,	Each Film Coated Tablets contains:-		1000		
	Calcitriol 0.25 mcg,	Calcium Citrate	USP	1000	mg	
	Folic Acid 1.5 mg,	Calcitriol	BP	0.25	mcg	
	Zinc 7.5 mg,	Folic Acid	IP	1.5	mg	
	Methylcobalamin 1500 mcg	Zinc Sulphate monohydrate	IP			
	Vitamin K 27.50 mcg tablets	eq. to elemental Zinc		7.5	mg	9/22/2021
	Vitamin K 27.50 mcg tablets	eq. to elemental Zinc		7.5	mg	
		Methylcobalamin	IP	1500	mcg	
		Phytonadione(Vitamin K)	BP	27.5	mcg	
		Excipients		q.s.		
		Approved Colours Used in coting				
			_			
830	Diclofenac Diethylamine,	Composition				
	Menthol, Eucalyptus Oil,	Diclofenac Diethylamine	IP	1.16%	W/W	
	Methyl salicylate, Camphor	Eq. to Diclofenac Sodium		1.00%	\mathbf{W}/\mathbf{W}	
	& Capsicum Ointment	Methyl salicylate	IP	20%	\mathbf{W}/\mathbf{W}	
		Menthol	IP	10%	\mathbf{W}/\mathbf{W}	
		Camphor	USP	5%	\mathbf{W}/\mathbf{W}	9/22/2021
		Eucalyptus Oil	IP	5%	\mathbf{W}/\mathbf{W}	9/22/2021
		Oleoresin Capsicum				
		Eq. to Capsicum	USP	0.075%	\mathbf{W}/\mathbf{W}	
		Benzyl alcohol	IP	1%	\mathbf{W}/\mathbf{W}	
		(As a Preservative)				
		In Ointment base		q.s		

831	Sucralfate 0.07gm,	Each Gram contains:-				
	Metronidazole 0.01gm,	Sucralfate	USP	0.07	gm	
	Lignocaine 0.04gm Cream	Metronidazole	IP	0.01	gm	9/22/2021
		Lignocaine	IP	0.04	gm	
		Cream Base		q.s.		

832	Pirfenidone Tablets IP 400mg	Each Film Coated Tablet Contains:-				
		Pirfenidone	IP	400	mg	10/25/2021
		Excipients		q.s		10/20/2021
		Approved colour used in Coating				

833	Olmesartan Medoxomil and	Each film coated tablet contains:				
	Hydrochlorothiazide Tablets	Olmesartan Medoxomil	IP	20	mg	
		Hydrochlorothiazide	IP	12.5	mg	10/25/2021
		Excipients			qs	
		Colour: Approved colour used				
834	Mefenamic acid and	Each uncoated tablet contains:				
	Dicyclomine Hydrochloride	Mefenamic acid	IP	500	mg	
	Tablets IP	Dicyclomine Hydrochloride	IP	20	mg	10/25/2021
		Excipients			q.s.	

	HEALTH AND FAMI List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/07 LY WELFARE DEPARTMENT,H ts Approved to be Manufactured by NB/07/642 AND MB/07/643 28:S-MB/07/643 For the per ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC	IMACI 7 : Boffi iod from 01.	n Biotecl	h Pvt.		
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED	
		Approved Colour Used in Tablets					
835	Lornoxicam &	Each Film Coated Tablet Contains:-					
	Paracetamol Tablets	Lornoxicam		4	mg		
		Paracetamol	IP	325	mg	10/25/2021	
		Excipients		q.s			
		Approved colour used in Coating					
836	Calcium Pantothenate Tablets	Each film coated tablet contains:		200		10/05/0001	
	IP	Calcium Pantothenate	IP	200	mg	10/25/2021	
		Colour: Approved colour used					
837	Pregabalin Capsules 75mg IP	Each hard gelatin capsule contains:					
		Descelie	IP	75	ma		
		Pregabalin Excipients	ш	qs	mg	10/25/2021	
		Approved colour used in empty capsule		43			
		shells					
020							
838	Pregabalin Capsules 150mg IP	balin Capsules 150mg IP Each hard gelatin capsule contains:					
		Pregabalin	IP	150	mg	10/25/2021	
		Excipients		qs		10/25/2021	
		Approved colour used in empty capsule					
		shells					
839	Pregabalin and Notriptyline	Each Film Coated Tablet contains:					
	HCL Tablets	Pregabalin	IP	75	mg		
		Notriptyline HCL	IP			11/9/2021	
		Eq. to Notriptyline		10	mg	11/9/2021	
		Excipients		q.s.			
		Colour:Approved colour used in Coating					
840	Clarithromycin Oral	Each 5ml of constituted suspension contain	ins:				
	Suspension USP	Clarithromycin	IP	125	mg		
		Excipients		q.s.		11/9/2021	
		In a flavoured suspension base					
		Approved colour used					
841	Nebivolol Hydrochloride	Each Uncoated tablets contains:					
041	Tablets IP 5mg	Nebivolol Hydrochloride	IP				
	1 ablets IF Shing	eq. to Nebivolol	11'	5	ma	1/10/2022	
		Excipients			mg	1/10/2022	
		Colour :- Approved colour used		q. s.			
842	Nebivolol Hydrochloride	Each Uncoated tablets contains:					
074	Tablets IP 2.5mg	Nebivolol Hydrochloride	IP				
	1 001000 II 2.5111g	eq. to Nebivolol	ш	2.5	mg	1/10/2022	
		Excipients			mg	1/10/2022	
		Colour :- Approved colour used		q. s.	L		
843	Vildagliptin Tablets 50 mg	Each Uncoated tablets contains:					
0-5	, nongripun radicis 50 mg	Vildagliptin		50	ma		
		Excipients		q. s.	mg	1/10/2022	
			-				

		NB/07/642 AND MB/07/643 28:S-MB/07/643 For the ZE AS PER SCHEDULE-P-1 OF DRUGS & COSME				
. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVE ON DATE
844	Rosuvastatin &	Each Film coated tablet contains:-				
	Fenofibrate Tablets IP	Rosuvastatin Calcium	IP			
		Rosuvastatin		10	mg	1/10/202
		Fenofibrate	IP	160	mg	1/10/202
		Excipients		q.s		
		Approved colour used in Coating				
845	Promethazine Theoclate	Each Uncoated Tablet contains:				
	Tablets IP 25mg	Promethazine Theoclate	IP	25	mg	1 11 0 10 00
	C	Excipients		q.s.	0	1/10/202
		Colour:Approved colour used				
246						
846	Methylergometrine Maleate	Each Film Coated Tablets Contains:-	m	0.125		
	Tablets IP	Methylergometrine Maleate	IP	0.125	mg	1/10/202
		Excipients		q.s		
		Approved colour used in Coating				
847	Methylergometrine Maleate	Each Film Coated Tablets Contains:-				
	Tablets IP	Methylergometrine Maleate	IP	0.2	mg	1/10/2022
		Excipients		q.s		
		Approved colour used in Coating				
848	Tacrolimus Capsules IP 1 mg	Each hard geletin capsule contains:-		1		
		Tacrolimus	IP	1	mg	1/10/202
		Excipients		qs	0	
		Approved colour used in empty capsule	e shell			
849	Diclofenac Sodium,	Each Filmcoated Tablet contains:-				
577	Paracetamol &	Diclofenac Sodium	IP	50	mg	
	Chlorzoxazone Tablets	paracetamol	IP	325	mg	
	(Not for Veterinary Use)	Chlorzoxazone	USP	250	mg	2/17/202
		Excipients		q.s	0	
		Approved colour used in Tablets.		1		
050	Atorvastatin &	Each film and dealers				
850	Atorvastatin & Fenofibrate Tablets IP	Each film coated tablet contains :- Atorvastatin Calcium	IP			
	renolibrate rablets IP		IP	10		
		Eq. to Atorvastatin Fenofibrate	IP	160	mg	2/17/202
			Ir		mg	
		Excipients Approved colour used in coating		qs		
851	Calcium with	Each Uncoated Tablet Contains:-				
	& Vitamin D3 Tablets IP	Calcium Carbonate	IP			
		(Derived From Coral Grains)				1/22/22
		eq. to Calcium		500	mg	4/22/202
		Vitamin D3	IP	500	IU	
		Excipients Approved colour used in Tablets		q.s		

	List of Retention Product having license No. FORM25:M	NO.HFW-H(DRUGS)279/ LY WELFARE DEPARTMENT ts Approved to be Manufactured NB/07/642 AND MB/07/643 28:S-MB/07/643 For the ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	,HIMACI by : Boffi period from 01.	n Biotec	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Suspension USP	Cefuroxime axetil	IP			
	-	Eq. to Cefuroxime		125	mg	
		In a flavoured suspension base			U	4/22/2022
		Excipients		q.s		
		Approved colour used				
	1					
853	Loperamide Hydrochloride	Each 5ml contains:		<u> </u>		
	Solution USP	Loperamide Hydrochloride	IP	1	mg	
		Excipients		q.s.		4/22/2022
		In aqueous Non Syrupy Base				
		Colour:Approved colour used				
854	Etodolac Tablets IP 600mg	Each uncoated Extended Release tablet	contains.			
55-т	2.040100 Fublets II 000111g	Etodolac	IP	600	mg	
		Excipients		qs	<u>s</u>	4/22/2022
		Colour: Approved colour used in Table	ts	-1-2		
855	Prochlorperazine maleate and	Each uncoated tablet contains:-				
	Paracetamol Tablets	Prochlorperazine Maleate	IP	5	mg	
		Paracetamol	IP	500	mg	4/22/2022
		Excipients		q.s.		
		Colour: Approved colour used				
856	Luliconazole and Clobetasol	Composition:-	-			
	Propionate Cream	Luliconazole		1%	W/W	
		Clobetasol Propionate	IP	0.05%	w/w	4/22/2022
		Excipients		q.s.		
		Cream Base				
857	Nimesulide, Paracetamol	Each Film Coated Tablet Contains:-				
007	& Serratiopeptidase Tablets	Nimesulide	BP	100	mg	
		Paracetamol	IP	325	mg	
		Serratiopeptidase(as enteric coated	IP	10	mg	5/20/2022
		granules 20000 unitsof peptidase)			8	
		Excipients		q.s		
		Approved colour used in Coating				
858	Azithromycin with Lactic	Each Film Coated Tablet Contains:-		1		
	acid Bacillus Tablets	Azithromycin	IP	ł		
		eq. to anhydrous Azithromycin		250	mg	
		Lactic Acid Bacillus		60	Million Spores	5/20/2022
		Excipients		q.s		
		Approved colour used in Coating				
859	Azithromycin with Lactic	Each Film Coated Tablet Contains:-				
	acid Bacillus Tablets	Azithromycin	IP	<u> </u>		
		eq. to anhydrous Azithromycin		500	mg	E 100 10000
		Lactic Acid Bacillus		60	Spores	5/20/2022
		Excipients		q.s		
		Approved colour used in Coating				
860	Amoxycillin Trihydrate	Each Uncoated Bolus contains:-				
	with Sulbactam Bolus	Amoxycillin Trihydrate	IP	1		
		eq. to Amoxycillin		1250	mg	

	HEALTH AND FAMI List of Retention Product having license No. FORM25:MI	NO.HFW-H(DRUGS)279 LY WELFARE DEPARTMEN' s Approved to be Manufactured \ns/07/642 AND MB/07/643 28:S-MB/07/643 For th TE AS PER SCHEDULE-P-1 OF DRUGS & COSM	T,HIMACI d by : Boffi ne period from 01.	n Biotecl	h Pvt.	
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
		Sulbactam Sodium	USP			5/20/2022
		eq. to Sulbactam		250	mg	
	(For animal use only)	Excipients		q.s		
	(Not for human use)	Approved colour used in Bolus				
861	Etodolac Extended - Release	Each Uncoated Extended-Release tab	let contains:			
	Tablets IP	Etodolac	IP	400	mg	0/20/2022
		Excipients		qs		9/29/2022
		Colour: Approved colour used				
862	Pregabalin, Notriptyline	Each Film Coated Tablet contains:				
	HCL & Methylcobalamin	Pregabalin	IP	75	mg	
	Tablets	Notriptyline HCL	IP	1		
		Eq. to Notriptyline		10	mg	9/29/2022
		Methylcobalamin	IP	1500	mcg	
		Excipients		q.s.		
		Colour:Approved colour used in Coat	ting			
863		Each 5ml contains:				
005	Ambroxol Hcl, Guaiphenesin,	Ambroxol Hydrochloride	IP	15	mg	
	Phenylephrine Hcl,Chlorpheniramine		IP	50	mg	
	Maleate & Menthol Syrup	Phenylephrine Hydrochloride	IP	5	mg	12/24/2022
	inaleate terrentilor Syrup	Chlorpheniramine Maleate	IP	2	mg	
		Menthol	IP	1	mg	
		In flavoured Syrupy base		q.s.	mg	
		Colour:Approved colour used .		4		
		Each 10ml contains:		_		
864	Cyproheptadine &		m	2		
	Tricholine Citrate syrup	Cyproheptadine Hydrochloride	IP	2	mg	
		(Anhydrous)	m	275		12/24/2022
		Tricholine Citrate(65%) In flavoured Sorbitolbase	IP		mg	
		Colour:Approved colour used .		q.s.		
	I					
865	Loratadine Tablets IP 10mg	Each Uncoated tablet contains:		10		
		Loratadine Excinients	IP	10	mg	12/24/2022
		Excipients		qs		12/24/2022
		Colour: Approved colour used				
866	Gabapentin Tablets IP 300mg	Each Film-coated tablet contains:				
		Gabapentin	IP	300	mg	27-02-2023
		Excipients		qs		
0/7		Colour: Approved colour used				
867		Each 5ml contains:	т	100	-	
	Ofloxacin & Metronidazole Benzoate	Ofloxacin Metronidazole Benzoate	IP IP	100	mg	4/25/2023
	Oral Suspension		114	200	ma	
		Eq. to Metronidazole In flavoured Syrupy base		q.s.	mg	
		Colour:Approved colour used .		4.5.		
	1					
868	Esomenrazole(EC) &					
868	Esomeprazole(EC) & Levosulpiride (SR) Capsule	Each Hard Gelatin capsule contains:- Esomeprazole Magnesium Trihydrate	IP			

NO.HFW-H(DRUGS)279/07 HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. Ltd.

having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027								
PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945								
. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED		

s.

	TAME/BRAILD NAME				UNDATED
		(As Enteric Coated Pellets)			4/25/2023
		Levosulpiride	75	mg	4/23/2023
		(As Sustained Release Pellets)			
		Excipients	qs		
		Approved Colour used in Capsule shell			
860	$E_{a} = 1 - (EC) \theta_{a}$	Each Hand Calatin annula anntainn			

869	Esomeprazole(EC) &	Each Hard Gelatin capsule contains:-				
	Domperidone (SR) Capsule	Esomeprazole Magnesium Trihydrate	IP			
		eq. to Esomeprazole		40	mg	
		(As Enteric Coated Pellets)				5/29/2023
		Domperidone	IP	30	mg	3/29/2023
		(As Sustained Release Pellets)				
		Excipients		qs		
		Colour:Approved Colour used in Empty hardgelatinCapsule shells&Pellets				

870		Each Hard Gelatin capsule contains:-				
	Rosuvastatin ,Asprin& Clopidogrel	Rosuvastatin Calcium	IP			
	Capsules	eq. to Rosuvastatin		20	mg	
		(As Un- Coated Pellets)				5/29/2023
		Aspirin	IP	75	mg	3/29/2023
		(As Enteric-coated Pellets)				
		Clopidogrel Bisulphate	IP			
		eq. to Clopidogrel		75	mg	
		(As Un- Coated Pellets)				
		Excipients		qs		
		Colour:Approved Colour used in Empty hardgelatinCapsule s	hells&Pellets			
871		Each Hard Gelatin capsule contains:-				
	Rosuvastatin ,Asprin& Clopidogrel	Rosuvastatin Calcium	IP			
	Capsules	eq. to Rosuvastatin		10	mg	
		(As Un- Coated Pellets)				5/29/2023
		Aspirin	IP	75	mg	5/27/2025
		(As Enteric-coated Pellets)				
		Clopidogrel Bisulphate	IP			
		eq. to Clopidogrel		75	mg	
		(As Un- Coated Pellets)				
		Excipients		qs		
		Colour:Approved Colour used in Empty hardgelatinCapsule s	hells&Pellets			
872	Prochlorperazine Maleate	Each Uncoated Mouth Dissolving table	t contains:			
	Mouth Dissolving Tablets 5mg		IP	5	mg	12/1/2023
		Excipients		qs		12, 1, 2023
		Colour: Approved colour used				

873		Each Uncoated Tablets contains:				
	Paracetamol, Phenylephrine	Paracetamol	IP	500	mg	
	Hydrochloride,Caffeine &	Phenylephrine Hydrochloride	IP	5	mg	
	Diphenhydramine	Caffeine (Anhydrous)	IP	30	mg	12/1/2023
	Hydrochloride Tablets	Diphenhydramine Hydrochloride	IP	25	mg	
		Excipients		q.s.		
		Colour:Approved colour used				

874 Each 5ml contains:
Magaldrate, Simethicone & Magaldrate IP

	HEALTH AND FAMI List of Retention Product having license No. FORM25:MD	NO.HFW-H(DRUGS)279/0 LY WELFARE DEPARTMENT,H s Approved to be Manufactured by NB/07/642 AND MB/07/643 28:S-MB/07/643 For the per	IMACI V: Boffi iod from 01.	n Biotecl	h Pvt.	
S. No.	PACK SIZ DOSAGE FORM, GENERIC NAME/BRAND NAME	E AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC COMPOSITION	ACT 1945 SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED
	Oxetacaine Suspension	Eq.to Anhydrous Magaldrate		540	mg	10/1/2022
	_	Simethicone	IP	50	mg	12/1/2023
		Oxetacaine	BP	10	mg	
		In flavoured Syrupy base		q.s.	mg	
		Colour:Approved colour used .				
875	Fluticasone Cream IP	Fluticasone Propionate	IP	0.05%	w/w	12/1/2023
		In CreamBase		q.s		
076						
876		Each Uncoated Tablet contains:				
	Paracetamol,Phenylephrine	Paracetamol	IP	325	mg	
	Hydrochloride,Guaiphenesin, CetirizineHydrochloride &	Phenylephrine Hydrochloride	IP	5	mg	
	Ambroxol Hydrochloride Tablets	Guaiphenesin	IP	50	mg	12/1/2023
		Cetirizine Hydrochloride	IP	5	mg	
		Ambroxol Hydrochloride	IP	15	mg	
		Excipients		q.s.		
		Colour:Approved colour used				
877		Each hard gelatin Capsule contains :				
0	Methylcobalamin,Alpha Lipoic Acid	0 1	IP	1500	mcg	
	,Pyridoxine Hydrochloride &	Alpha Lipoic Acid	USP	100	mg	12/1/2023
	Folic Acid Capsules	Pyridoxine Hydrochloride	IP	3	mg	12/1/2025
		Folic Acid	IP	1.5	mg	
		Excipients Colour:Approved colour used in hard gelatin Ca	psule shell	q.s.		
878	Pyridoxine Hydrochloride	Each Un-coated tablet contains:		-		
	Tablets IP	Pyridoxine Hydrochloride	IP	40	mg	12/13/2023
		Excipients		qs		12/13/202.
		Colour: Approved colour used				
879		Each Gram contains:-				
01)	Clobetasol Propionate&	Clobetasol Propionate	IP	0.05%	W/W	
	Salicylic Acid Ointment	Salicylic Acid	IP	6%	w/w	12/13/2023
	Salleyne Acid Olitillent	In an Ointment base		q.s.	w/w	
				4 .5.		
880		Each 5ml contains:	-			
	Dextromethorphan HBr,	Dextromethorphan Hydrobromide	IP	15	mg	12/13/2023
	Chlorpheniramine Maleate &	Chlorpheniramine Maleate	IP	2	mg	12/13/202.
	Phenylephrine Hydrochloride Syrup	Phenylephrine Hydrochloride	IP	5	mg	
		In flavoured Syrupy base		q.s.		
		Colour:Approved colour used .				
881		Each 5ml contains:	_			
	Ambroxol HCl, Levocetirizine HCl,	Ambroxol Hydrochloride	IP	15	mg	
	Guaiphenesin & Menthol Syrup	Levocetirizine Hydrochloride	IP	2.5	mg	12/13/2023
		Guaiphenesin	IP	50	mg	
		Menthol	IP	1	mg	
		In flavoured Syrupy base		q.s.		
		Colour:Approved colour used .				
882	Esomeprazole Gastro-resistant	Each Enteric-Coated tablet contains:				
	Tablets IP	Esomeprazole MagnesiumTrihydrate Equivalent to Esomeprazole	IP	20	mg	12/13/202
		1		I	I	

		NO.HFW-H(DRUGS)279/0 ILY WELFARE DEPARTMENT,	HIMAC						
	List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027								
		ZE AS PER SCHEDULE-P-1 OF DRUGS & COSMET	IC ACT 1945	1					
S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFI CATION	QUANTITY	UNIT	APPROVED ON DATED			
		Colour: Approved colour used							
883	Deflazacort Oral Suspension	Each 5ml contains:							
	-	Deflazacort		6	mg				
		In flavoured suspension base		qs	U	12/13/2023			
		Colour: Approved colour used		1					
884		Each 10ml contains:							
001	Lycopene with Multivitamin &	Lycopene 10%	USP	2000	mcg				
	Multimineral Syrup	Niacinamide	IP	25	Ū				
	With this is a syrup		IP IP	1.5	mg	12/13/2023			
		Pyridoxine Hydrochloride	IP IP	1.5	mg				
		Cyanocobalamin			mcg				
		Folic Acid	IP	100	mcg				
		Selenium(as Sodium Selenate)	USP	35	mcg				
		Zinc (as Zinc Gluconate)	USP	3	mg				
		Manganese (asManganese Gluconate)	USP	2	mg				
		Iodine (As PotassiumIodide)	IP	100	mcg				
		Copper (As Cupric Sulphate)	USP	500	mcg				
		In flavoured Syrupy base		q.s.					
		Colour:Approved colour used .							
885		Each Film-coated Tablets contains:							
	Camylofin Dihydrochloride &	Camylofin Dihydrochloride		25	mg				
	Paracetamol Tablets	Paracetamol	IP	300	mg	1/11/2024			
		Excipients		q.s.					
		Colour:Approved colour used							
886		Each Film Coated Tablet contains:	m						
	L-Carnitine L-tartrate,	L-Carnitine L-tartrate	IP	500	ma				
	Methylcobalamin & Folic Acid	Equivalent to L-Carnitine Methylcobalamin	IP		mg mcg	1/11/2024			
	Tablets	Folic Acid	IP	1.5	0				
		Excipients		q.s.					
		Colour:Approved colour used							